The role and regulation of the urokinase receptor in asthma and COPD by Portelli, Michael A.
Portelli, Michael A. (2013) The role and regulation of the 
urokinase receptor in asthma and COPD. PhD thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/13355/1/The_Role_and_Regulation_of_the_Urokinase_recep
tor_in_asthma_and_COPD.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
THE ROLE AND REGULATION OF THE
UROKINASE RECEPTOR IN ASTHMA
AND COPD
By
MICHAEL ANTHONY PORTELLI, B.Pharm. (Hons.) (Melit.)
Thesis submitted to the University of Nottingham for the
degree of Doctor of Philosophy
June 2013
The research work disclosed in this publication is funded by the Strategic
Educational Pathways Scholarship (Malta).
The scholarship is part-financed by the European Union  European Social
Fund (ESF) under Operational Programme II  Cohesion Policy 2007-2013,
Empowering People for More Jobs and a Better Quality of Life
To Nanna Paola, Nanna Esther, Nannu Joseph & Aunty Mary Anne
for your belief and faith in me
To Mum and Dad, for everything
iABSTRACT
The urokinase plasminogen activator receptor (PLAUR) is a membrane anchored
receptor that has been associated with a number of disease states. In these diseases,
elevated receptor levels were associated with increased disease aggressiveness and
higher mortality rates. Through genetic studies PLAUR has been identified as an
asthma susceptibility gene. In these studies, coding and untranslated region single
nucleotide polymorphisms showed association with asthma diagnosis and decline in
lung function. In addition, association with baseline lung function in smokers and
PLAUR SNPs was identified. This suggests that PLAUR plays a role in respiratory
disease.
Work presented in this thesis aimed to i) identify whether serum levels of PLAUR are
associated with obstructive lung disease and lung function parameters, ii) identify
novel regulatory mechanisms determining PLAUR levels, both at the genetic level in
primary bronchial epithelial cells and at the protein level for serum PLAUR, iii) explore
a role for the different isoforms in asthma and COPD and iv) determine novel variation
in the PLAUR gene and 5` and 3` distal regions through next generation sequencing.
Levels of the soluble cleaved form of PLAUR in serum were determined to be
significantly elevated in COPD and asthma subjects compared to a control population.
This identified an association between the soluble cleaved receptor and disease per se.
However, PLAUR levels in serum could not be related to lung function parameters.
With regards to receptor regulation, a genome-wide association study identified a
novel post-translational PLAUR regulatory mechanism. This involved key SNPs in the
human plasma kallikrein gene promoter that directed human plasma kallikrein
enzymatic activity to cleave PLAUR in a post-translational mechanism. PLAUR gene
regulation was also investigated via molecular biology, identifying that in primary
ii
bronchial epithelial cells, PLAUR regulation involves the genes 5 prime and 3 prime
untranslated regions. Investigation of regulation under multiple stimulations pertinent
to respiratory disease identified that cigarette smoke extract selectively elevated the
soluble spliced variant of the receptor through a three prime untranslated region
mechanism. This suggests that bronchial epithelial damage driven by cigarette smoke
may be at least partially mediated by the soluble spliced form of PLAUR.
Overexpression of PLAUR identified that the receptor has an important role in
regulating primary bronchial epithelial cell function, including migration and rate of
mitochondrial activity. Interestingly, results identified isoform specific roles for the
different forms of the receptor suggesting that variant-specific over-expression of
PLAUR could have diverse effects on cell function. Importantly this study was also the
first to define a role for the soluble spliced form of PLAUR.
Investigation into variation in the PLAUR gene and surrounding regions through next
generation sequencing in asthma (n=200) and control (n=200) populations identified a
number of novel variants including 4 variants unique to asthma population.
In summary, the work described in this thesis has identified a novel association
between serum soluble cleaved PLAUR and obstructive lung disease, as well defining
novel genetic and post-translational regulatory mechanisms for PLAUR, importantly
defining isoform specific PLAUR regulation for the first time. This work has also
identified novel isoform specific roles for PLAUR, which have significant modulatory
effects on bronchial epithelial cell function, and has through next generation
sequencing furthered knowledge on universal and asthma specific PLAUR variation.
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The coagulation and fibrinolytic pathways have been shown to play a role in
obstructive lung disease and provide potential novel therapeutic targets for both
asthma and chronic obstructive pulmonary disease (COPD). The fibrinolytic pathway
involves the urokinase plasminogen activator receptor (PLAUR), which has
independently been implicated with asthma and COPD pathogenesis both at the gene
and protein level. The regulation and role of the receptor within the bronchial
epithelium, an important part of the airway involved in airway remodelling, is however
poorly understood. This thesis furthers our understanding of the regulation of different
PLAUR isoforms in the periphery and in bronchial epithelial cells. This allows for
further understanding of the gene architecture with regards to variation, with a focus
on differences in variation between asthmatics and controls, and allows for the
identification of novel roles for different receptor isoforms in bronchial epithelial cells.
1.1 ASTHMA
Asthma is a chronic inflammatory disorder of the airways (Levy et al., 2012) which
results in recurrent episodes of wheezing, breathlessness, chest tightness and cough
which occur particularly at night and in the early morning. These episodes are usually
associated with widespread but variable airway obstruction, which is often reversible
spontaneously or with treatment (Toelle et al., 1992). Asthma induced inflammation
also results in increased airway sensitisation by causing an associated increase in
bronchial hyper-responsiveness (BHR) to a variety of stimuli (Toelle et al., 1992).
Therefore, asthma can be defined as a complex disease involving inflammation, hyper-
responsiveness, and bronchoconstriction (Lowhagen, 2012).
31.1.1 PATHOLOGY OF ASTHMA
The inflammatory cascade in asthma involves infiltration of a number of inflammatory
cells (eosinophils, neutrophils, B- and T-lymphocytes, macrophages, mast cells,
dendritic cells and basophils) into the airway and the release of inflammatory
mediators such a leukotrienes, histamine, cytokines and chemokines by airway
structural cells (epithelial, smooth muscle, endothelial and fibroblast cells) (Fig. 1.1).
However, the degree of inflammation in asthma is not directly related to asthma
severity, suggesting that other factors, such as structural changes in the airway also
play a role in disease modulation and progression (Barnes PJ, 2002). These structural
changes have been termed as airway remodelling and may exist in the presence or
absence of inflammatory mechanisms in the airway (Kermode et al., 2011). Airway
remodelling is further discussed in Section 1.4.
The inflammatory response in asthma is a result of excessive activation of mast cells in
the airway, where in the early response to allergen challenge, degranulation of mast
cells results in the release of a number of pro-inflammatory factors such as IL-4,
leukotrienes and histamine. This causes an immediate hypersensitivity response which
in turn leads to airway bronchoconstriction. The concomitant release of other
inflammatory factors such as cytokines and chemokines from the same mast cells
provides an optimal environment for the recruitment of other inflammatory cells such
as eosinophils, basophils, neutrophils and T-lymphocytes to the airways. Once in the
airways these cells act in tandem with allergen activated macrophages, resulting in
what is termed as the late asthmatic response (occurring at 4 to 8 hours post
challenge). Here, via the release of a number of potent bronchoconstrictors including	Ƚǡ ?ǡ  ?ǡ  ? ? ?ǡ
period longer than 24 hours. Of the inflammatory cells involved in the asthmatic
response, it is the infiltration of eosinophils that is considered to be characteristic of
4the asthmatic phenotype, particularly that of mild/moderate allergic atopic asthma.
Therefore the presence of high levels of eosinophils aids in the differentiation between
the asthmatic airway and the COPD airway, where neutrophilic infiltration is more
prevalent (Barnes, 2000, Lacoste et al., 1993). However, this is not a clear cut
distinction, with increasing neutrophilic infiltration occurring with increasing severity
(Wenzel et al., 1997).
Although inflammation in asthma has been extensively studied, the relationship
between inflammation and clinical symptoms of asthma is still unclear. This may be
partially explained by a study that has shown evidence that inflammation is loosely
related to airway hyper-responsiveness (Brusasco et al., 1998), where the airways
become more susceptible to sensitising agents that would not usually trigger an airway
response, due to the increased release of mediators such as histamine and
leukotrienes, abnormal smooth muscle behaviour and thickening of the airways.
As mentioned above, airway remodelling (see Section 1.4) also plays an important role
in asthma pathogenesis. The airway structural changes characteristic of airway
remodelling occur due to prolonged airway inflammation. Here, prolonged release of
inflammatory factors results in:
x Thickening of the smooth muscle bronchial walls, leading to airway narrowing
x Denudation of the bronchial epithelium
x Hyperplasia and hypertrophy of the airway smooth muscle
x Hyperplasia and hypertrophy of the epithelial goblet cells resulting in the
formation of large mucus plugs that are liable to occlude the airway and
increased airway hyper-responsiveness (Douglas and Elward, 2011).
Airway remodelling also involves changes occurring in the extracellular matrix and its
constituent proteins (collagen I/III/IV, fibronectin and laminin) (Bai et al., 2000) and
5other structural changes such as angiogenesis, vasodilation, increased airway blood
flow (Kumar et al., 1998) and changes in autonomic neurological function (Barnes,
1995).
Asthma is a highly heterogeneous disease consisting of a number of disease variants
such as severity, disease history, disease comorbidities and therapeutic efficacy, with
different underlying pathophysiologies (Lotvall et al., 2011, Wenzel, 2006). Historically
the issue of asthma heterogeneity has been tackled by classifying different forms of
asthma according to the sensitising agents, allowing sub-classification of the disease
into; allergic asthma (triggered by multiple allergens including but not exclusive to
pollen, house dust mite and animal dander), exercise-induced asthma (characterised by
bronchoconstriction and other asthma symptoms that develop during and/or after
exercise) and nocturnal asthma (where the Forced expiratory volume in 1 second
[FEV1] decreases by 15% or more from bedtime to waking up in the morning).
However, this classification is problematic when large cohorts of patients with asthma
are studied as all defining characteristics may overlap or may not all be present. In
order to try and broach this problem, Lötvall et al. have proposed a new classification
sytem based on endotypes, i.e. different subtypes of a condition defined by a distinct
pathophysiological mechanism (Lotvall et al., 2011). Classification spanned a number
of known asthma phenotypes such as eosinophilic asthma, exercise-induced asthma
and adult-onset asthma, splitting the disease into 6 endotypes (Lotvall et al., 2011):
i) Aspirin-Sensitive
ii) Allergic pulmonary mycosis
iii) Allergic
iv) Asthma predictive indices positive (preschool wheezer)
v) Severe late-onset
vi) Asthma in cross country skiers
6Correct identification of the relevant endotype to use in research allows for an
improved approach to asthma research as it provides the basis for the stratification of
a mixed asthma cohort in order to separate datasets based on phenotypes, such as
atopic status, which may confound the investigative outcome. In this thesis the specific
endotype investigated is Allergic asthma which is classified on the basis of atopy, with
non-atopic asthmatics defined as those with negative skin tests and no clinical or
family history of allergy. These patients are usually older than their allergic
counterparts and have onset of symptoms in later life, often with a more severe clinical
course (Rackemann, 1947, Humbert et al., 1999).
7Figure 1.1: The asthma inflammatory cascade . Exposure to allergens; e.g. Dermatophagoides
pteronyssinus 1 (Der p 1), histamine and Dactylis glomerata (Dac g 1) originating from various
sources including pollen, house dust mite and mould, are up taken by dendritic cells,
B-lymphocytes, epithelial cells and Macrophages, which present the antigens to T-lympocytes.
This activates the T-lymphocytes to produce cytokines that regulate immunoglobulin (Ig) E
production by the B-lymphocytes. Bound IgE activates mast cells in the airways. Activated
mast cells initially release a number of factors including IL-4, leukotrienes and histamine that
cause airway hyper-responsiveness and result in the early-response to allergen stimulus via
bronchoconstriction. The concurrent release of cytokines and chemokines from the mast cell
recruits eosinophils, basophiles and T-lymphocytes to the airway. These cells in association
with T-cell activated neutrophils and with antigen stimulated macrophages, release
chemokines and leukotrienes over an extended period of time resulting in the late-response to
allergen stimulus via bronchoconstriction. Prolonged stimulation of the late-response factors
ultimately leads to the airway structural changes such as mucus hypersecretion, myofibroblast
and airway smooth muscle proliferation, which are common to the asthmatic lung.
81.1.2 ASTHMA SEVERITY
Asthma can vary in intensity from mild, where assessment of lung function by
spirometry may be extremely hard, to severe and unremitting (status asthmaticus).
Changes in asthma severity are important for correct patient evaluation, treatment and
research, where correct classification of a subject is essential for accurate phenotype
based investigations. Severe asthma is defined by the World Health Organization
(WHO) as Uncontrolled asthma which can result in risk of frequent severe exacerbations
(or death) and/or adverse reactions to medications and/or chronic morbidity (Bousquet
et al., 2010), and differs from mild asthma in that it exhibits increased neutrophil
infiltration, which may actually be absent in the milder forms of asthma (Jatakanon et
al., 1999, Caramori et al., 2005).
In asthma, the term severity has been variably used to indicate the degree of current
symptoms (such as the frequency of exacerbations and nocturnal awakenings), the
resistance of symptoms to standard treatment (i.e. at which step of the management
scale the patient is), and the future risk of death or exacerbations. Since it is difficult for
any single one of these factors to correctly define asthma on its own, due to the
diseases complex and heterogeneous nature, international guidelines attempt to
define severity based on different combinations of these factors.
In this thesis, the guidelines published by the Global Initiative for Asthma (GINA) were
used to define asthma severity. This severity scale is based on a combination of the
prevalence of day/night time symptoms, airflow limitation and pulmonary function
variability (Table 1.1).
9Symptoms/Day Symptoms/Night PEF or FEV1
PEF
variability
STEP 1
Intermittent
< 1 time a week
Asymptomatic and
normal PEF
between attacks
</= 2 times a
month
>/= 80% < 20%
STEP 2
Mild Persistent
> 1 time a week but
< 1 time a day
Attacks may affect
activity
> 2 times a month >/= 80% 20-30%
STEP 3
Moderate
Persistent
Daily
Attacks affect
activity
> 1 time a week 60%-80% > 30%
STEP 4
Severe
Persistent
Continuous
Limited physical
activity
Frequent </= 60% > 30%
Table 1.1: GINA classification of asthma severity. Here, multiple factors including
prevalence of day/night time symptoms, airflow limitation and pulmonary function variability,
are utilised to place a patient in that category. PEF: Peak Expiratory Flow; FEV1: Forced
Expiratory Volume in 1 second.
1.1.3 DIAGNOSIS AND TREATMENT OF ASTHMA
As described by GINA, asthma diagnosis can be prompted by symptoms such as
episodic breathlessness, wheezing, cough and chest tightness. Episodic symptoms after
allergen exposure, seasonal variability of symptoms and a positive family history of
asthma/atopic disease are also helpful first line diagnostic aides (GINA, 2011).
Clinical testing however plays an important part in correct asthma diagnosis, with
measurements of lung function and demonstration of the reversibility of lung function
abnormalities adding confidence to initial asthma diagnosis. Lung function testing
occurs through spirometry, which is the measurement of the forced expiratory volume
in one second (FEV1) and Forced vital capacity (FVC), or peak expiratory flow (PEF)
testing. Asthma diagnosis regularly makes use of the FEV1/FVC ratio for a more
specific asthma diagnosis, as decreases in FEV1 alone can occur in other lung diseases
(GINA, 2011). For this purpose, a normal FEV1/FVC ratio is considered to be >0.75 to
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0.80, with lower ratios identifying airflow limitation (GINA, 2011). A confirmation of
asthma diagnosis then occurs if the patient provides a minimal 12% or 200ml increase
from pre-bronchodilator readings (Vollmer et al., 1999). This spirometric based
asthma diagnosis can then be confirmed with a 60L/min or 20% reversibility in PEF
from the pre-bronchodilator reading and recording a diurnal variation in PEF of >20%
(GINA, 2011).
In addition to spirometric lung function testing, fractional exhaled nitric oxide (FENO)
has recently emerged as an additional potential diagnostic aide for asthma (Stewart
and Katial, 2012, Schneider et al., 2012, Ludviksdottir et al., 2012), providing additional
information on a number of different aspects, including phenotyping, corticosteroid
response and disease control (Ludviksdottir et al., 2012). However FENO cannot be
used as a standalone diagnostic test for asthma due to its association with the
eosinophilic sub-type of asthma, with guidelines suggesting that its use be limited to
the diagnosis of eosinophilic airway inflammation, determining the likelihood of
steroid responsiveness and to support the diagnosis of asthma in situations where
objective evidence is needed (Dweik et al., 2011).
The therapeutic response to asthma involves multiple drug therapies including long   Ⱦ2-adrenoreceptor agonists, leukotriene receptor antagonists and
inhaled and/or oral corticosteroids. Asthma treatment is based on a step-wise
approach where treatment is started at the step most appropriate to the degree of
asthma severity and increased or decreased as necessary to achieve and maintain
adequate control (Fig. 1.2) (BTS, 2011).
However, although current asthma therapeutics are able to successfully treat 90-95%
of the asthmatic population, there remains 5-10% of patients who do not respond wellǤB? ? ? ?
(Caramori et al., 2008). This, together with the need to move away from chronic
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glucocorticosteriod therapy and its associated side-effects (e.g. adrenal suppression,
osteoporosis and increased risk of infection) in severe asthmatics, highlights the need
for novel therapies targeting new pathways in asthma therapeutics.
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Figure 1.2: Step-wise therapy for asthma. Therapeutics for asthma follows a step-wise approach with the strength and number of medications increasing as
one attempts to achieve control on exacerbation, followed by down-stepping therapy on resolution of symptoms to attempt to achieve control using the minimal  Ǥ           Ⱦ2-adrenoreceptor agonists (bronchodilators) as reliever and preventer ǡ     ȋǦȌǡ  Ⱦ2-agonists and Theophylline (bronchodilators) and oral Leukotriene receptor
antagonists as preventers. Figure obtained from BTS British Guideline on the Management of Asthma (BTS, 2011).
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1.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
COPD is defined by both the American Thoracic Society (ATS) and the European
Respiratory Society (ERS) as a preventable and treatable disease state characterised
by airflow limitation that is not fully reversible (Celli et al., 2004), where the airflow
limitation is progressive resulting from an abnormal inflammatory response of the
lungs to noxious particles and gases such as cigarette smoke (Vestbo et al., 2012).
COPD usually presents in the sixth and seventh decade of life and is generally classified
as a disease of smoking adults, although other sensitizing factors such as air pollution,
poor diet and occupational exposure can substitute cigarette smoke, especially in less
developed countries (Barnes PJ, 2002, Barnes et al., 2003).
1.2.1 PATHOLOGY OF COPD
Pathologically COPD, as asthma, is classified as an inflammatory disease. However, in
reality COPD is a term which includes a number of separate and distinct diseases:
1. Bronchitis: Inflammation of the bronchial mucous membranes, which results in
mucus hyper secretion. In COPD, bronchitis is chronic which usually develops
due to recurrent airway injury caused by inhaled irritants.
2. Emphysema: Destruction of alveolar walls causing the collapse of the small
airways during forced exhalation and resulting in dyspnoea. Inhaled irritants
are once again major causes of emphysema. (Currie, 2007, Barnes et al., 2003)
In addition to the mucus hypersecretion and tissue destruction caused by bronchitis
and emphysema, inflammation in COPD results in the disruption of the normal repair
and defence mechanisms of the airway epithelium causing destruction of the lung
parenchyma, loss of lung elasticity and closure of the small airways (bronchiolitis)
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(Currie, 2007, Barnes et al., 2003). In patients with COPD, emphysema, bronchitis or
bronchiolitis or any combination of the three may be present. However, the relative
contribution of each to the disease process is often difficult to discern.
Inflammation in COPD differs strikingly from that in asthma in that it is characterised
by a predominance of macrophages, cytotoxic (CD8+) T-lymphocytes and neutrophils
(Barnes PJ, 2002). Exposure to cigarette smoke (or other irritants) results in activation
of airway epithelial cells and macrophages, resulting in the release of a number of
chemotactic factors, cytokines and inflammatory mediators such as LTB4, IL-8 and
related CXC chemokines, that attract CD8 T-lymphocytes, monocytes and neutrophils
to the area. The CD8 cells and neutrophils in turn activate airway fibroblasts, resulting
in abnormal airway repair processes and bronchiolar fibrosis (Currie, 2007). Increased
release of proteases such as Cathepsin G, Neutrophil Elastase and matrix
metalloproteinases (MMP)-8 and -9 by neutrophils and macrophages in the airway
results in mucus hypersecretion, ciliary dysfunction and increased alveolar wall
destruction, i.e. airway remodelling (see Section 1.4) (Currie, 2007, Barnes PJ, 2002,
Barnes et al., 2003).
Direct oxidative stress through cigarette smoke (and other irritants) can also affect the
airway through the release of oxidants (free radicals). These oxidants have a dual effect
on the airway; primarily they inhibit anti-proteases that would otherwise regulate the
increased secretion of proteases by macrophages and neutrophils and secondly they
directly cause airway remodelling by causing alveolar wall destruction, ciliary
dysfunction and mucus hypersecretion through squamous metaplasia, increased
proliferation of goblet cells and increased size of bronchial sub-mucosal glands
(Barnes PJ, 2002, Currie, 2007).
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Figure 1.3: The COPD inflammatory cascade. Exposure to airway irritants such as cigarette
smoke results in the release of a number of chemotactic factors (e.g. CCL2, CXCL9/10/11), ȋǤǤ Ǧ ?ǡ Ǧ ?ǡ  ?ȾȌ    ȋǤǤ 	ȽȌ    
epithelial cells and macrophages which recruit T-lymphocytes and neutrophils respectively, to
the airways. Both the neutrophils and the T-lymphocytes activate lung fibroblasts resulting in
abnormal repair and bronchiolar fibrosis. Proteases released from neutrophils result in
alveolar wall destruction (emphysema) which is compounded by oxidants released by
oxidative stress from the inhaled irritant and other Leukocytes recruited to the airways.
Oxidants cause alveolar wall destruction both directly and by inhibiting anti-proteases that
would counter-act the neutrophil released proteases.
1.2.2 COPD SEVERITY
COPD can vary in intensity from almost undetectable (mild COPD) to severe and
unremitting (very severe COPD). As in asthma, changes in disease severity are
important for patient evaluation, treatment and research, where correct classification
of a subject is essential for accurate phenotype based investigations. In the case of
COPD, severity is classified according to the guidelines laid out by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) which utilises post-bronchodilator lung
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function tests (spirometry) to classify increasing COPD severity (Table 1.2) (Vestbo et
al., 2012, GOLD, 2011).
COPD Severity Spirometry
I. Mild
FEV1/FVC < 0.7
FEV1 ? ? ? ?
II. Moderate
FEV1/FVC < 0.7 ? ? ? ?	1 < 80% predicted
III. Severe
FEV1/FVC < 0.7 ? ? ? ?	1 < 50% predicted
IV. Very Severe
FEV1/FVC < 0.7
FEV1 < 30% predicted or
FEV1 < 50% predicted plus chronic
respiratory failure
Table 1.2: GOLD classification of COPD severity. COPD severity diagnosis is based on
spirometry readings utilising the FEV1/FVC ratio in conjunction with FEV1 percentage
predicted.
1.2.3 DIAGNOSIS AND TREATMENT OF COPD
According to GOLD, and as in asthma, the diagnosis of COPD is based on an initial
diagnosis of phenotypic changes, which is then confirmed through spirometry. Initial
phenotypes which may indicate the presence of COPD and which warrant spirometry
testing include dyspnoea, chronic cough, and chronic sputum production, a history of
exposure to risk factors such as tobacco smoke and a family history of COPD. The
detection of a post-bronchodilator FEV1/FVC of <0.70 via spirometry then confirms the
presence of persistent airflow limitation and therefore of COPD (GOLD, 2011). Patients
with severe COPD can additionally present with fatigue, weight loss and anorexia
(Schols et al., 1993).
The first aim of COPD treatment is smoking cessation (or prevention of inhalation of
other irritating substances), usually requiring the aid of nicotine replacement therapy
in various forms such as inhalers, sprays, gum and patches. Direct pharmacological
therapy for COPD is aimed at reducing the symptoms of COPD as well as the frequency
and severity of exacerbations along with improving health status and exercise
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tolerance (GOLD, 2011). At the time of writing, no therapy is available that has
successfully improved the long term decline in lung-function that is symptomatic of
COPD identifying that current therapy is still far from optimal and that further
development of novel COPD therapies is essential for optimal COPD therapy.
Pharmacotherapy in COPD is, as in asthma, also based on exacerbations and the degree
of breathlessness. Therapy involves the use of bronchodilators (e.g. long and short Ⱦ2-agonists, short and long acting anti-muscarinics, methylxanthines),
glucocorticosteroids (anti-inflammatories) as well as the phosphodiesterae-4 inhibitor
Roflumilast for exceptionally severe COPD. Therapy is administered in a step-wise
approach similar to asthma, with different types of medication administered either
alone or in combination (GOLD, 2011) (Table 1.3).
Therapy
ǦȾ2-agonist inhaler or
Short-acting antimuscarinic inhaler
As required
First Symptoms
Long-acting anti-muscarinic inhaler or
ǦȾ2-agonist inhaler FEV1 ? ? ?
ǦȾ2-agonist +corticosteroid
inhaler
	 ? ? ? ?ƬǦȾ2-agonist inhaler
Long-acting anti-muscarinic inhaler or
ǦȾ2-agonist +corticosteroid
inhaler
FEV1d50pp
Long-acting anti-muscarinic inhaler
and
ǦȾ2-agonist +corticosteroid
inhaler
FEV1d50pp and still symptomatic
Oral Theophylline/Aminophylline Still symptomatic
Phosphodiesterae-4 inhibitors
(Roflumilast)
Severe chronic obstructive pulmonary
disease associated with chronic bronchitis
and a history of frequent exacerbations
Table 1.3: Step-wise pharmaceutical therapy in COPD. Management of COPD follows a step-
wise approach with the strength and number of medications increasing as one attempts to
achieve symptomatic control, followed by down-stepping therapy on resolution of symptoms
to attempt to achieve control using the minimal amount of medication. Therapy involves the    ȋ    Ⱦ2-agonists, short and long acting anti-
muscarinics and methylxanthines), inhaled glucocorticosteroids (anti-inflammatory) in   Ǧ Ⱦ2-agonists, while use of the phosphodiesterase-4
inhibitor Roflumilast is limited to severe exacerbations of COPD. Data obtained from the
British National Formulary (BMA., 2012)
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1.3 THE GLOBAL BURDEN OF ASTHMA AND COPD
Both asthma and COPD are global problems. The WHO estimates that asthma affects
around 235 million people worldwide while COPD affects 64 million people worldwide
(2004 figures).
In the UK around 5.4 million people currently receive treatment for asthma (1.1 million
children (1 in 11) and 4.3 million adults (1 in 12)), with 1,131 asthma related deaths
reported in 2009. Asthma cost the UK economy up to 1.1 million working days in
2008/9 and also presents a burden to the NHS, with an estimated 79,794 emergency
hospital admissions occurring in 2008/9 and costing the NHS £1 billion per year for
treatment and care (AsthmaUK, 2012). Currently around 1 million people are known to
suffer from COPD in the UK resulting in approximately 30,000 COPD related deaths per
year, however this may be a gross underestimation as around 2 million people are
thought to be living with the disease but are currently undiagnosed (HSE, 2011, NHS,
2010). The rate of mortality in the UK is double the European average, being the fifth
leading cause of death in the UK. COPD, like asthma, presents a burden to the NHS, with
1 in 8 (circa. 130,000) emergency hospital admissions being for COPD, making it the
second largest cause of emergency admission in the UK, and one of the most costly
inpatient conditions treated by the NHS (BLF, 2008). Economically, the total cost of
COPD to the NHS was estimated, in 2000-01, to be around £500 million for direct costs
and around £1 billion when including indirect costs (NICE, 2010).
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1.4 AIRWAY REMODELLING IN ASTHMA AND COPD
As discussed in Sections 1.1.1 and 1.2.1, the development of both asthma and COPD
results in a degree of airway remodelling, where although an amount of overlap occurs
between both diseases, airway remodelling remains distinct between asthma and
COPD (see below and Table 1.4) (Dournes and Laurent, 2012). The structural changes
that define airway remodelling are an important feature in the airways of asthmatics
and COPD patients (Postma and Timens, 2006), where even in newly diagnosed asthma
patients, a degree of structural changes can be identified on the bronchial wall
(Laitinen et al., 1993). Airway remodelling can be defined as a process of sustained
disruption and modification of structural cells and tissues leading to the development
of a new airway wall morphology (O'Donnell et al., 2002). The main airway structural
changes common to both asthma and COPD are airway fibrosis, elevated smooth
muscle mass, mucous metaplasia and glandular hypertrophy (O'Donnell et al., 2002,
Elias et al., 1999). In both cases, airway remodelling is initiated either through various
inflammatory pathways, highlighting the importance of the inflammatory pathway in
both diseases (Jeffery, 1998), or through bronchial hyper-responsiveness, where
airway remodelling occurs independently of inflammation (Grainge et al., 2011).
Initiation of airway remodelling differs between asthma and COPD, with initiation
stemming from deregulated injury and/or repair mechanisms in the asthmatic airway
leading to permanent changes in the airway physiology. In COPD on the other hand,
initiation is almost an exclusive reaction to the toxic effects of cigarette smoke. The
outcomes of airway remodelling also differ between disease states. In asthma,
structural changes involve the sloughing and denudation of the airway epithelium with
thickening of the sub-epithelial basement membrane, diffuse excess matrix deposition
in the large airways and increased vascularity in the large airway wall. In COPD
however, there is squamous metaplasia of the epithelium and diffuse excess matrix
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deposition in the small airways with no effect on the sub-epithelial basement
membrane and large airway vascularity (O'Donnell et al., 2002). These structural
changes ultimately lead to increased bronchial hyper-reactivity and therefore a
worsening of the disease state (Chetta et al., 1997).
Asthma COPD
Initiation
Deregulated injury/repair
mechanisms
Inhaled Irritants
(e.g. Cigarette Smoke)
Airway smooth muscle Hyperplasia
Mucus layer Hyperplasia and Hypersecretion
Fibrosis Fibrosis of the airway walls
Airway Epithelium Sloughing and denudation Squamous Metaplasia
Extracellular Matrix
Excess deposition in the
large airways
Diffuse excess deposition
Airway Vascular system Increased Vascularity No effect
Basement Membrane Thickening No effect
Table 1.4: Airway structural changes defining airway remodelling in asthma and COPD.
Although certain aspects such as hyperplasia of the airway smooth muscle layer, the presence
of fibrosis on the airways and hyperplasia of epithelial cells resulting in mucus hypersecretion
are common to both asthma and COPD, differences in changes occurring in the airway
epithelium, extracellular matrix, basement membrane and airway vascular system makes
airway remodelling in asthma separate and distinct from that in COPD.
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1.5 GENETICS OF ASTHMA AND COPD
Genetics plays an important role in both asthma and COPD, as identified by the strong
hereditary component present in asthma (approximately 25% of the offspring of an
asthma patient will have asthma (Panhuysen et al., 1998)) and the lack of consistency
between smoking and COPD, i.e. not all smokers contract COPD and not all COPD
sufferers are smokers (Mannino, 2002). Multiple genetic studies have been carried out
in asthma and COPD throughout the years, confirming the role of genetics in asthma
and COPD and identifying and investigating a number of disease relevant genes (see
Table 1.5).
Gene Family Examples
Controlling the development and regulation of the
immune response
GATA3, TBX21, IL4, IL4RA,
STAT6, and IL12B
Involved in inflammation ALOX-5, IL-1825 and IL18R126
Involved in the detection of pathogens and allergens
TLR2, TLR4, TLR6, TLR10, and
NOD1/CARD4
Involved in mediating the response to allergic
inflammation and oxidant stress on the tissue level
ADAM33, COL6A5, DPP10 and
GPRA
Involved in the constriction of the airways PDE4D, CHRNA3/5 and NOS1
Involved in the catalysation of enzymatic reactions AGPHD1, IRES2
Involved in signal cascades CHRNA3, HHIP
Table 1.5: Examples of genes associated with asthma and COPD. Genes known to be
involved with obstructive respiratory disease come from various pathways and regulate
various outcomes. Data obtained from (March et al., 2013, Siedlinski et al., 2013, Cho et al.,
2012).       Ƚ1-antitrypsin (AAT) deficiency to early
onset emphysemia, making it a genetic risk factor for COPD (DeMeo and Silverman, ? ? ? ?ǡ   Ǥǡ  ? ? ? ?ȌǤ    Ƚ ?  
electrophoresis is associated with the development of emphysemia (probably through
an increase in levels of neurophil elastase), with severe pulmonary impairment
expected if the levels of serum AAT go below the protective threshold of 35% of the
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ȋ ? ?Ǥ ?Ȁ ? ? ?ɊȀȌȋǤǡ ? ? ? ?ȌǤ
used clinically as a diagnoistic test, this mutation is only present in around 1-2% of
COPD patients highlighting that obstructive lung disease has multiple genetic
contributions to its development (DeMeo and Silverman, 2004).
Initial genetic studies into asthma and COPD have utilised familial aggregation and twin
studies, studies which are useful in determining whether a trait has a suitable genetic
component. The familial aggregation of asthma and COPD has been described in a
number of early studies (Higgins and Keller, 1975, Sibbald and Turner-Warwick, 1979,
Silverman et al., 1998, McCloskey et al., 2001) as was the higher concordance of asthma
in monozygotic twins when compared to dizygotic twins (Edfors-Lubs, 1971, Duffy et
al., 1990).
Early segregation studies led investigations into whether a major gene affects the
distribution of a given phenotypic trait as well as defining the Mendelian mode of
inheritance. Via these segregation studies, a strong familial component to asthma
(Martinez and Holberg, 1995) and COPD (Wang et al., 2008) was identified, where,
within these studies, the genes for the plasminogen activator (PLAU), the urokinase
plasminogen activator receptor (PLAUR), and thrombospondin (THBS1) were
identified as being genes associated with the obstructive lung diseases. Candidate gene
studies on genes to either have a role in disease (functional) or linked to a region of
interest (positional) provide information on the genetic role in modulating diseaseǡ   Ǥ      Ⱦ ?Ǧ
receptor gene (ADRB2) and on 5-lipoxygenase inhibitors (5LOIs) in asthma (Reihsaus
et al., 1993, Drazen, 1998) and on the MMP1 and IL13 genes in COPD (Joos et al., 2002,
van der Pouw Kraan et al., 2002).
More recent genetic studies have involved the use of genome-wide association studies
(GWAS). This form of analysis allows for a hypothesis free mapping of asthma and
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COPD genes and has identified among others, hits on chromosomes 2, 4, 5, 9, 12 and 15
as novel polymorphisms associated with asthma (CSGA, 1997, Moffatt et al., 2010,
Himes et al., 2013, Hao et al., 2012) and hits on chromosomes 2, 4, 5, 12, 19 and 22 as
novel polymorphisms associated with COPD (Silverman et al., 2002, Palmer et al., 2003,
DeMeo et al., 2004, Soler Artigas et al., 2011). GWAS investigations have also identified
hits on chromosomes 2, 3, 4, 5, 6, 12 and 15 to be associated with changes in lung
function, identifying further potential targets for interventions to alleviate respiratory
disease (Repapi et al., 2010).
Genetic based investigations of asthma and COPD does not only allow for the furthering
of our understanding on diseases function, but also provides a medium for the
detection of novel diagnostic tests and novel therapeutic targets for disease
management. This emphasises the importance of genetics based investigations into the
disease as laid out in this thesis.
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1.6 COAGULATION AND FIBRINOLYSIS IN ASTHMA & COPD
The coagulation pathway describes the laying down of fibrin clots through the
activation of Thrombin via an activation cascade of blood factors, which in turn activate
fibrinogen to form fibrin (Fig. 1.4). The fibrinolysis system is the complementary
degradation pathway to the coagulation system where activation of the enzyme
plasmin from its precursor plasminogen, mainly driven by the urokinase plasminogen
activator and its receptor, results in the digestion of fibrin into fibrin degradation
products (Fig. 1.4).
Figure 1.4: The coagulation/fibrinolysis pathway. These pathways concentrate on the
formation and degradation of fibrin plaques in the body. Activation of thrombin from its
precursor prothrombin via the intrinsic (Factor VII) and extrinsic (Factors V-XIII) coagulation
cascades results in the formation of cross-linked fibrin plaques. These plaques are susceptible
to fibrinolysis by plasmin which is activated from its precursor plasminogen via activated
factors XI and XII as well as by the urokinase plasminogen activator, which is activated via its
receptor (PLAUR). KLKB1: Human Plasma Kallikrein; HK: High molecular weight kininogen.
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Although the respiratory and coagulation/fibrinolysis system have historically been
considered to be separate compartments within the body, the human airways are now
considered as a respiratory organ where plasma exudation from the bronchial
microvasculature occurs (Rogers and Evans, 1992, Persson, 1986) and in which
coagulation and anticoagulation mechanisms can be initiated and regulated locally (de
Boer et al., 2012). This coagulation/fibrinolytic system has been implicated in both
asthma and COPD (Polosa et al., 2011, de Boer et al., 2012) with pro-coagulant activity
and impaired fibrinolysis being described as important early findings in the distal
airspaces of patients with lung injury, predisposing the airways to fibrin deposition
and alveolar epithelial injury (Idell, 2002, Ware et al., 2003). Indeed cardiovascular
events such as deep vein thrombosis and pulmonary emboli have been shown to be a
major cause of morbidity and mortality in COPD and asthma (Curkendall et al., 2006,
Huiart et al., 2005, Sidney et al., 2005).
However, the risk in asthma and COPD due to effects driven by the blood
coagulation/fibrinolysis pathway is not limited to the increased risk in cardiovascular
events. Pulmonary coagulation and fibrinolysis arising from crosstalk between
epithelial, endothelial and inflammatory cells has been shown to have a major impact
on the pathophysiology of both COPD and asthma. In COPD, Polosa et al. identified that
fibrinolytic markers such as von Willebrand factor and prothrombin fragments 1 and 2
were elevated during disease exacerbation (Polosa et al., 2011), while an imbalance
between blood coagulation and anticoagulation factors versus oxidative stress has
been reported in COPD patients suffering from acute exacerbations (Huang et al.,
2011). In asthma, activated Factor X has been shown to be involved in airway
remodelling in an ovalbumin-induced asthma mouse model through the stimulation of
mucin production, regulation of amphiregulin expression and collagen deposition
(Shinagawa et al., 2007), while activated Factor VII has been shown to function in the
26
allergic asthmatic response via stimulating lung eosinophilia and airway hyper-
responsiveness (Shinagawa et al., 2009).
Studies have suggested that the major effects of the coagulation/fibrinolysis pathway
on obstructive airway disease are abnormalities that result in greater fibrin deposition
and/or reduced fibrinolysis. This hypothesis was suggested by Wagers et al. on
discovery that increased fibrin deposition on the luminal surface of the airway
epithelium was apparent in a patient who died in status asthmaticus and that
increasing airway hyper-responsiveness was apparent in wild type mice challenged
with aerosolised fibrinogen and thrombin, with the authors concluding that increased
fibrin in the airways significantly contributed to airway hyper-responsiveness in
asthma (Wagers et al., 2004). This hypothesis was supported by a study carried out by
Brims et al., which identified that severe asthmatics had higher levels of various
components of the coagulation/fibrinolysis pathways in their sputum than control
subjects. These included tissue factor, which activates fibrin deposition, as well as
plasminogen activator inhibitor 1 and thrombin activatable fibrinolysis inhibitor,
which inhibit fibrinolysis (Brims et al., 2009). The discovery that mice deficient in
thrombin activatable fibrinolysis inhibitor, an important regulator of fibrinolysis, had
enhanced airway hyper-responsiveness and lung injury in an ovalbumin-induced
asthma model (Fujiwara et al., 2012) further suggests that deregulation of the
fibrin/fibrinolytic pathways is important to changes occurring within the lung.
Apart from the effects caused by increased fibrin deposition in the airways, the
fibrinolytic system is also able to affect obstructive respiratory disease through its
effect on airway remodelling, which occurs via the molecule plasmin (Kucharewicz et
al., 2003). The effect of plasmin on airway remodelling is driven by direct degradation
of the extracellular matrix (ECM) and indirect degradation through the regulation of a
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number of other molecules such as the activation and inhibited of deactivation of
MMPs (Cho et al., 2000) and the release of leukotriene B4 (Weide et al., 1994).
Therefore, through its effect both on fibrin deposition and airway remodelling the
coagulation/fibrinolytic pathway plays an important role in the development and
modulation of the obstructive airway diseases asthma and COPD. Therefore a better
understanding of different components of these pathways would potentially further aid
our understanding of the development and modulation of asthma and COPD. It could
also potentially identify novel targets for asthma and COPD therapeutics, especially
with regards to airway remodelling, which is not adequately targeted using current
therapeutics. This thesis has focussed on the plasminogen activator receptor (PLAUR;
also known as uPAR, CD87 & MO3), an important receptor involved in the fibrinolysis
pathway through the activation of pro-urokinase to active urokinase, which leads to
the formation of plasmin from its precursor plasminogen and subsequent fibrinolysis
(see Section 1.7.1) (Blasi and Carmeliet, 2002). Apart from its involvement in the
fibrinolytic pathway, selection of PLAUR was based on other supporting evidence
outlined in Section 1.6.
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1.7 PLAUR IN OBSTRUCTIVE RESPIRATORY DISEASE
Apart from the suggested importance of the fibrinolytic pathway in the obstructive
respiratory diseases asthma and COPD (see Section 1.5), interest in PLAUR stems from
work carried out by colleagues in the Therapeutics and Molecular Medicine laboratory,
which identified PLAUR as an asthma susceptibility gene in 587 asthma families
(Barton et al., 2009). The same study identified that single nucleotide polymorphisms
(SNPs) across the PLAUR gene and its 5`UTR and 3`UTR were associated with asthma,
BHR susceptibility, baseline lung function and lung function decline in populations
originating from multiple centres as well as serum levels of PLAUR (Barton et al.,
2009). A follow on study on the same 25 SNPs in a population of 992 smokers
identified association with baseline lung function (Stewart et al., 2009). Association
with an alternate obstructive lung disease, i.e. COPD, was determined in an
independent study by Wang et al., where through gene expression profiling and lung
function studies in 43 COPD subjects, PLAUR was found to be involved in lung tissue
remodelling and repair and was determined to differentially express PLAUR in the
COPD lung when compared to controls (Wang et al., 2008). Interestingly, the
association of PLAUR to COPD was found to be independent of the smoking pack/year
status (Wang et al., 2008).
Further evidence for the role of PLAUR in obstructive lung disease has been published
in a number of in vitro and ex vivo studies. While membrane PLAUR has been shown to
be standardly expressed in the apical membrane of the airway epithelium (Drapkin et
al., 2000), levels were elevated in the inflamed asthmatic epithelium when compared to
healthy controls (Stewart et al., 2012, Beaufort et al., 2007) and in COPD subjects when
compared to controls (Wang et al., 2008) (Fig. 1.5). PLAUR was also elevated in the
lungs of patients who died of status asthmaticus when these were compared to the
airways obtained from 7 lung donors without a diagnosis of asthma (Chu et al., 2006).
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In an in vitro study using normal human bronchial epithelial cells (NHBECs),
mechanical stimulation of cells in order to mimic the process that occurs in the lung
during bronchoconstriction, an important event in both asthma and COPD, resulted in a
16.2 fold increase in the expression of PLAUR mRNA in conjunction with the elevation
of other molecules involved in the fibrinolytic pathway, such as PLAU and PAI-1 (Chu et
al., 2006). This evidence suggests that PLAUR may be involved in asthma and COPD
pathogenesis, where elevated PLAUR levels could cause changes in the airways
synonymous with both asthma and COPD, a hypothesis supported by Brooks et al. who
identify PLAUR as a potential marker of airway disease severity (Brooks et al., 2006).
Figure 1.5: Elevated levels of PLAUR are present in the asthmatic and COPD lung .
Immunohistochemistry identifies elevated levels of PLAUR in the epithelial layer (identified
by the large arrows) of the COPD (Panel B) and asthmatic (Panel D) lung when compared to
their respective controls (Panels A & C). Elevations can also be identified in the lamina propia
(submucosal layer; small arrows Panels B & D). Figure adapted from (Wang et al., 2008,
Stewart et al., 2012).
Although evidence has identified that the expression of PLAUR by structural cells in the
airways is altered in asthma and COPD, it is pertinent to mention that elevated levels of
A B
C D
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the receptor have also been identified in other peripheral cells. In COPD subjects, levels
of membrane bound PLAUR expressed on neutrophils and macrophages were found to
be significantly elevated when compared to controls (Jiang et al., 2010). Interestingly,
this elevation occurred in COPD patients irrespectively of their smoking history, a
result also identified by another group (Wang et al., 2008), suggesting that PLAUR is
not simply elevated due to exposure by disease initiating factors such as cigarette
smoke but rather is likely to play a direct role in disease pathophysiology.
A direct role for PLAUR in obstructive respiratory disease has in fact been suggested by
Wang et al., where the authors identify that PLAUR is involved in lung tissue
remodelling and repair in COPD subjects. This hypothesis that PLAUR is involved
asthma and COPD pathophysiology through a direct role in airway remodelling is
further supported by a number of other studies. Elevated PLAU and PAI-1 in the
airways post injury (Heguy et al., 2007), the discovery that PLAUR is critical for
efficient bronchial wound repair in vitro and that inhalation of PLAU protects against
sub-epithelial fibrosis and airway hyper-responsiveness in an asthma mouse model
(Kuramoto et al., 2009), identifies that the pathway involving PLAUR is likely
important in airway injury. Airway injury and the dysregulation of repair are prevalent
in asthma and COPD and are known to have a role in airway remodelling during
disease development.
Although most studies have concentrated on membrane bound PLAUR, there has also
been interest in the role of the soluble cleaved form of the receptor (see Section 1.8.3.2)
in asthma and COPD. However as of writing, this has been a limited interest, with only
two studies carried out. Both these studies identify elevated soluble cleaved PLAUR
(scPLAUR) in the induced sputum of asthmatic and COPD patients (Xiao et al., 2005,
Jiang et al., 2010), with levels associated with airflow limitation, health status and
exercise tolerance in COPD patients (Jiang et al., 2010). This suggests that identified
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PLAUR dependant effects may be at least partially driven by the soluble cleaved form of
the receptor, a situation previously hypothesised in a human bronchial epithelial cell
population (Stewart et al., 2012).
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1.8 PLAUR ACTIVITY
Since the discovery of PLAUR in 1985 (Vassalli et al., 1985), a substantial amount of
literature has accumulated, identifying a role for the membrane bound and soluble
cleaved form of this protein in a range of biochemical processes. PLAUR is known to
carry out this role through either the regulation of pericellular plasminogen activation
(Ellis et al., 1992) or through various non-proteolytic functions through the interaction
with a number of cell bound processes (Ploug, 2003).
1.8.1 PROTEOLYTIC FUNCTIONS
PLAUR binds the serine protease PLAU or its zymogen pro-PLAU with very high affinity
(1nM) and specificity (Ploug, 2003, Smith and Marshall, 2010, Blasi and Carmeliet,
2002) through utilisation of PLAUs amino-terminal fragment (ATF) (Huai et al., 2006,
Llinas et al., 2005). Binding of PLAU to PLAUR results in the conversion of the inactive
single-chain pro-PLAU into the active two-chain PLAU by a single proteolytic event
(Blasi and Carmeliet, 2002) (Fig. 1.6). Therefore cell functions regulated by PLAU come
under indirect regulation by PLAUR via its proteolytic role on this molecule.
In the lung, PLAU is primarily involved in chemotaxis and airway remodelling through
the activation of the plasminogen activation pathway (Kucharewicz et al., 2003). Once
activated, PLAU converts plasminogen into plasmin (Blasi and Carmeliet, 2002) and so
in turn activates the plasminogen activation system (PAS). Activation of the PAS then
results in:
x Fibrin degradation (Connolly et al., 2010)
x Activation of a number of growth factors and pro-inflammatory cytokines such	ȽǡǦ ?ȽƬǦ ?Ⱦȋǡ ? ? ? ?ǡǤǡ ? ? ? ?Ȍ
x Chemoattraction resulting in neutrophil infiltration (Rijneveld et al., 2002)
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x Remodelling of the extracellular matrix (ECM) through the removal of ECM
glycoproteins
x Activation of MMPs (Behrendt, 2004, Kjaergaard et al., 2008, Kucharewicz et
al., 2003)
x Phagocytic clearance of apoptotic cells (D'Mello et al., 2009, Park et al., 2009)
The activation of the PAS therefore has an important effect on cell and tissue, function
especially in the case of airway remodelling (Kucharewicz et al., 2003), highlighting the
importance of PLAUR in the modulation of asthma and COPD (see Section 1.6).
Figure 1.6: PLAUR activates urokinase from pre-urokinase, which proteolytically cleaves
plasminogen to form plasmin, thereby activating the plasminogen plasmin cascade.
Activation of the plasminogen-plasmin cascade results in a number of downstream functionsǡ 	Ƚǡ ?Ƚ ?Ⱦ       
	Ⱦ1 as well as the regulation of a number of
downstream effects such as fibrinolysis, wound repair, cell proliferation and angiogenesis.
1.8.2 NON-PROTEOLYTIC FUNCTIONS
Since PLAUR is attached to the outer leaflet of the phospholipid bilayer of the cellular
membrane via a glycosylphosphatidylinositol (GPI) anchor, the receptor has no part of
its protein structure exposed to the cellular cytoplasm (Kjaergaard et al., 2008). This
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therefore means that PLAUR a priori is unable to elicit transmembrane responses
without the aid of other cell-membrane bound proteins (Ploug et al., 1991b).
However, PLAUR is still able to elicit other responses independent of the PAS by also
interacting with a number of other cell factors, such as:
x Vitronectin (VN) (Wei et al., 1994, Hoyer-Hansen et al., 1997a)
x ǡȾ1Ⱦ2Ⱦ3ǡ ?ǡȽMȾ2ȽvȾ5 (Wei et al., 1996,
Xue et al., 1997, Xue et al., 1994, Blasi and Carmeliet, 2002)
x G-protein coupled receptors (GPCRs) such as formyl peptide receptor-like 1
(FPRL1) (Resnati et al., 1996, Resnati et al., 2002)
x Epidermal growth factor receptor (EGFR) (Resnati et al., 2002)
x High molecular-weight kininogen (HKa) (Colman et al., 1997, Chavakis et al.,
2000)
The importance of these cell associated factors in relation to PLAUR is twofold.
Primarily the independent activities of these cell factors are regulated by PLAUR, and
secondarily, they also help transduce PLAUR mediated intracellular signal-
transduction pathways that involve cytosolic and transmembrane kinases and
cytoskeletal components among others (Fig. 1.7) (Blasi and Carmeliet, 2002).
PLAUR binding to cell-associated factors leads to important downstream events such         Ƚ5Ⱦ1 integrin (Aguirre
Ghiso et al., 1999) and regulation of the chemotactic activity of the full length receptor
and DII/DIII fragment of PLAUR via FPRL1 (Resnati et al., 2002, Blasi and Carmeliet,
2002). Stimulation of cell signalling pathways plays an important role in the non-
proteolytic function of PLAUR with stimulation of pathways such as ERK1/2 and the
JAK1/STAT1 pathway resulting modulation of cell proliferation (Aguirre Ghiso et al.,
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1999, Koshelnick et al., 1997) and downstream up-regulation of various early response
oncogenes such a c-myc, c-fos and c-jun (Mazar et al., 1999) (Fig.1.7).
Figure 1.7: Cell signalling cascades regulated via PLAUR. PLAUR activates cell signalling
cascades through the interaction of the receptor with a number of cell co-factors including
integrins, GPCRs and high molecular weight kininogen. Activation of these cell signalling
pathways (FAK, ERK, PI3K) results in the regulation of a number of cellular processes such
cytoskeleton dynamics, proliferation and cell survival.
1.8.3 NATURAL PLAUR INHIBITORS
PLAUR has been shown to be regulated by two specific receptor inhibitors, namely
plasminogen activator inhibitor type-1 (PAI-1) and type-2 (PAI-2) (Irigoyen and
Nagamine, 1999, Kruithof, 1988). These are mainly synthesised by the endothelium,
platelets, megakaryocytes, neutrophils, monocytes, mast cells, smooth muscle cells and
fibroblasts (Sillaber et al., 1999, Simpson et al., 1991, Kim et al., 2011, Cho et al., 2004).
Both PAI-1 and PAI-2 are members of the Serpine Family (Loskutoff et al., 1999)
differing in terms of secretion, localisation and stability (Blasi and Verde, 1990, Vassalli
et al., 1991), with PAI-1 having an efficiency 20 to 100 times greater than that of PAI-2
(Kruithof et al., 1986).
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PAI-1 and PAI-2 both inhibit binding of the pro-PLAU zymogen and therefore inhibit
activation of the plasminogen activation pathway and antagonise the proteolytic
function of PLAUR (Kruithof, 1988, Irigoyen and Nagamine, 1999). However, PAI-1 also
regulates other PLAUR mediated cell effects, such as chemotaxis, through the active
competition with VN for its binding site (Stefansson and Lawrence, 1996) and the
promotion of internalisation of the PLAU-PLAUR complex. This internalisation occurs
via the low-density lipoprotein (LDL)-receptor-related protein (LRP) with the resulting
immunoprecipitation of PLAU and recycling of free PLAUR to the cell surface (Czekay
et al., 2001). Therefore the plasminogen activator inhibitors have a dual role in not only
antagonising PLAURs proteolytic functions but also antagonising its non-proteolytic
ones, by making the receptor unavailable to cell bound factors such as GPCRs and
integrins.
The role of PAI-2 however is poorly understood (Lee et al., 2011, Medcalf, 2011).
Studies have been limited to downstream function, identifying that PAI-2 is a
modulator of monocyte adhesion, proliferation and differentiation (Yu et al., 2002)
while protecting cells from cytolysis and apoptosis (Kumar and Baglioni, 1991,
Dickinson et al., 1995, Fish and Kruithof, 2006) and providing a control mechanism for
PLAU dependant ECM degradation (Montemurro et al., 1999).
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1.9 THE UROKINASE PLASMINOGEN ACTIVATOR
RECEPTOR
1.9.1 GENE STRUCTURE AND RECEPTOR SPLICE VARIANTS
PLAUR is encoded by a gene located on chromosome 19q13 and is present on the anti-
sense strand of the human genome (Casey et al., 1994). Its transcriptional start site
(TSS) was determined in a number of cells and tissues and shown to vary between -45
and -69 base pairs relative to the translation start site (ATG) (Wang et al., 1995,
Stewart and Sayers, 2009). The PLAUR gene in its full form consists of 7 exons; of these,
exon 1 encodes the five prime untranslated region (5`UTR) and a signal peptide, while
exons 2-3, 4-5 and 6-7 respectively encode the homologous protein domains DI, DII and
DIII (Casey et al., 1994) (Fig. 1.8).
Various splice variants of the receptor are known to exist. The splice variant causing
the greatest change in protein structure is the relocation of the terminal exon (Exon 7
to form alternate Exon 7b; see Fig. 1.8). While still encoding for a structure containing 3
globular domains, in this splice variant the amino acid sequence from position 254 is
completely different to that of the full length receptor. This translates into a
structurally different terminal domain (DIII) which is different to that of the full-length
membrane PLAUR (mPLAUR). The amino acid sequence is also significantly shorter,
having a full length of 281 amino acids compared to the 335 amino acid length of
mPLAUR. The significantly shorter length of the Exon 7b splice variant means that this
splice variant lacks the GPI anchor (Pyke et al., 1993) and so results in the formation of
an alternate soluble form of the receptor (soluble spliced PLAUR: ssPLAUR). This
soluble spliced receptor is expressed in various human cell lines and tissues (e.g.
human airway smooth muscle cells (HASMs) and NHBECs) and is up-regulated by
phorbol ester in A549 cells (Pyke et al., 1993, Stewart and Sayers, 2009). Alteration of
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one of the receptors globular domains will also affect the PLAUR ligands specific to this
region (Colman et al., 1997). However, by retaining an intact DI region, it is probable
that some PLAU binding activity is retained (Luther et al., 2003), albeit not at the same
affinity as offered by mPLAUR (Blasi and Carmeliet, 2002). At the time of writing work
has been limited on the soluble spliced PLAUR and the function of this receptor
remains relatively unknown.
Figure 1.8: Alternate gene structures for the most common variants of the PLAUR gene
(mPLAUR & ssPLAUR). THE PLAUR gene consists of 7 exons containing one of two terminal
exons (Exon 7). The standard Exon 7 (Exon 7a; 564bp) codes for the membrane bound protein,
while the smaller alternate exon (Exon 7b; 430bp) is located at a further distal region than
Exon 7a and codes for an alternate DIII and 3`UTR. The resulting protein also lacks a GPI
anchor and so forms the soluble spliced form of the receptor ssPLAUR. These two forms were
determined to be the most abundant in the lung (mPLAUR: 24%; ssPLAUR: 57%), in human
airway smooth muscle cells (mPLAUR: 15%; ssPLAUR: 74%) and in human bronchial epithelial
cells (mPLAUR: 7%; ssPLAUR: 77%) (Stewart and Sayers, 2009). Other splice variants exist in
either form, namely Exon 3, Exons 4 & 5, Exon 5 and Exon 6 deletions.
Other identified splice variants include those lacking exon 3, exons 4 & 5, exon 5 and
exon 6 (Stewart and Sayers, 2009, Luther et al., 2003, Casey et al., 1994). The exon 6
deletion variant has been found to be the most common deletion variant, along with
the exon 7b variant, expressed (>5%) in peripheral cells (polymorphonuclear
leukocytes & peripheral blood mononuclear cells) (Stewart and Sayers, 2009). Exon
deletion results in structural changes in the receptor structure, which suggests that
these splice variants have different PLAUR ligand binding affinities and different
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degrees of PLAUR driven chemotaxis when compared to the wildtype receptor.
However, apart from the exon 4/5 deletion variant, which has been identified as a
putative prognostic marker in breast cancer and soft tissue sarcoma patients (Luther et
al., 2003, Kotzsch et al., 2005, Kotzsch et al., 2011), these splice variants have also not
been extensively investigated, with their effect on cellular functions as yet unknown.
1.9.2 MOLECULAR STRUCTURE
The urokinase plasminogen activator receptor is a highly glycosylated GPI anchored
cell membrane protein (Ploug et al., 1991b, Roldan et al., 1990, Plesner et al., 1994a,
Hoyer-Hansen and Lund, 2007) translated from a 1.4kb mRNA (Plesner et al., 1994a,
Behrendt et al., 1991) encoded on chromosome 19q13 (Ploug et al., 1991b, Ploug et al.,
1991a, Sayers et al., 2008). PLAUR is a member of the lymphocyte antigen 6 (Ly-6)
superfamily, which consists of a large group of GPI-anchored, secreted and
transmembrane proteins with a diverse number of biological functions (Ploug, 2003).
The Lys-6 superfamily is characterised by Ly-6 and PLAUR domains (LU-domains),
which are orientated in what is known as the three finger fold (Kjaergaard et al., 2008),  ?     ?Ǧ ?  ȾǦ     ?Ǧ ?
disulphide bonds (Kjaergaard et al., 2008). This protein folding results in the formation
of 3 structurally homologous globular domains, annotated as domain 1 (DI), domain 2
(DII) and domain 3 (DIII), each separated by a 15 residue inter-domain linker sequence
and each covering approximately 80-90 residues including either 8 or 10 cysteine
residues (Fig. 1.9) (Blasi and Carmeliet, 2002, Ploug, 2003, Beaufort et al., 2007,
Behrendt et al., 1991).
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Figure 1.9: The multidomain structure of PLAUR . The two dimensional cartoon of PLAUR
identifies protein folding to form the 3 receptor globular domains (numbered from the NH2-
terminus) that together form the receptors ligand binding site. Black bars identify the
disulphide connections within the protein structure which give rise to the globular domain
loops required for PLAUR ligand binding. The red dotted line identifies the region at which the
amino acid sequence changes in the soluble spliced form of the receptor (ssPLAUR). In
ssPLAUR the amino acid sequence is changed to RSLWGSWLPCKSTTALRPPCCEEAQATHV
which alters the conformation of domain III and does not form the GPI-anchor. Adapted from
(Hansen et al., 2004).
The PLAUR GPI anchor has been found to be extended and able to undergo oscillatory
movements relative to the cell membrane (Chevalier et al., 2006, Chevalier et al., 2005)
resulting in PLAUR being a flexible molecule. This enables the receptor to adopt more
favourable orientations to bind with its ligands and cell-membrane bound factors.
X-ray crystallography has identified that the receptors 3 structural domains pack
together into a concave structure with a large central cleft, presenting residues,
necessary for urokinase (PLAU) binding at its amino-terminal growth factor (ATF)
domain, from all 3 domains (Blasi and Carmeliet, 2002, Liang et al., 2001) with the DI to
DIII domain likely facing towards the cell membrane (Xu et al., 2012) (Fig. 1.10).
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Figure 1.10: The three dimensional structure of PLAUR bound with PLAU. This three
dimensional structure allows for visualisation of the orientation of the membrane bound
globular domains ready to receive the amino terminal fragment (ATF) of the ligand urokinase
and Vitronectin (SMB). The individual domains in PLAUR are colour coded as follows: DI,
orange; DII, magenta; and DIII, green. Structures shown in the stick representation (GPI anchor,
carbohydrates linked to Asn52, Asn162, and Asn200 as well as residues Arg239 and Asp277)
are colour coded according to their atomic elements [nitrogen (blue), oxygen (red), carbon
(white), and phosphor (orange)]. Man, mannose; Etn, ethanolamine; PI-PLC,
phosphatidylinositol phospholipase C. Figure derived from (Xu et al., 2012).
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The structure of PLAUR suggests that all 3 globular domains are required for optimal
ligand binding and that receptor structural integrity is necessary for PLAU driven
effects, based on:
1. The presence of ligand binding sites within each of these distinct structural
globular domains (DI-III  see Fig. 1.10),
2. The dynamic role of a correctly folded DII (regions 130-140) during ligand
loading and unloading (Xu et al., 2012),
3. The close spatial proximity between DI and DIII present in intact PLAUR might
be required for the assembly of the composite binding site (Blasi and Carmeliet,
2002).
The final point is of special importance when considering the structural differences
between ssPLAUR and the alternate soluble form of PLAUR, scPLAUR (see Section
1.8.3.2), where ssPLAUR does not have an intact DIII. This suggests that ssPLAUR may
not fully interact with PLAU and any effects driven by this receptor (as yet undefined)
would be independent of the plasminogen-plasmin pathway.
1.9.3 CLEAVAGE OF PLAUR
PLAUR is susceptible to cleave at multiple sites, including the linkage region between
DI and DII and at the receptors GPI anchor. This gives rise to multiple forms of the
receptor such as a soluble DII/DIII fragment and a full length soluble receptor, of which
some retain some activity such as chemotaxis (DII/DIII fragment) and integrin binding
(soluble cleaved receptor), whilst others such as the soluble DI fragment have, to date,
no known effects.
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1.9.3.1 CLEAVAGE OF THE DOMAIN I/II LINKER
Studies by limited proteolysis clearly identify that the linker region between DIand DII,
corresponding to residues 83 to 89, as being particularly susceptible to enzymatic
hydrolysis by a number of different proteases including Pepsin, MMP-12,
Chymotrypsin, human airway trypsin-like protease (HAT), Cathepsin G and PLAU (Fig.
1.11) (Behrendt et al., 1991, Andolfo et al., 2002, Hoyer-Hansen et al., 1997b, Koolwijk
et al., 2001, Beaufort et al., 2004).
Figure 1.11: PLAUR DI/II cleavage. The PLAUR DI/DII linker sequence indicating the various
protease sensitive sites which results in the loss of globular domain DI. This results in the
formation of a DII/DIII fragment which, provided that the urokinase-sensitive SRSRY sequence
is left intact, has chemotactic activity. Figure adapted from (Fazioli et al., 1997).
This results in the loss of DI (Fig. 1.11) resulting in the loss of the high affinity domain
for PLAU and VN binding (Ploug et al., 1994, Hoyer-Hansen et al., 1997a, Sidenius and
Blasi, 2000). Subsequent studies identified that cleavage in this region also abolished
PLAURs lateral interactions with integrins, its ability to regulate integrin adhesive
functions as well as PLAUR driven effects on cellular proliferation and migration
(Montuori et al., 2002). Cleavage at the DI/DII linker therefore acts as a regulatory
procedure for PLAUR driven processes. Since this is driven by PLAU itself (Hoyer-
Hansen et al., 1997b), it suggests that a PLAUR-PLAU interaction exists whereby PLAU
self-regulates PLAUR levels in a negative-feedback mechanism.
Cathepsin GElastase & MMPs
Cathepsin G
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The resulting DII/DIII fragment however, has been reported to retain a chemotactic
neoepitope that allows the fragment to retain a role in cell migration and stem cell
mobilisation (Resnati et al., 1996, Resnati et al., 2002, Selleri et al., 2005). This
fragment has been detected in vitro and in vivo in monocytes, basophils and ovarian
tumours (Wahlberg et al., 1998, Beaufort et al., 2004, de Paulis et al., 2004).
1.9.3.2 GPI ANCHOR CLEAVAGE
The PLAURs GPI-anchor is also susceptible to glycolytic and lipolytic cleavage, most
significantly by the enzymes phospholipase C and D (Ploug et al., 1991b, Wilhelm et al.,
1999). This results in the release of the entire protein moiety from the cell surface,
forming a soluble form of the receptor (soluble cleaved PLAUR: scPLAUR) (Fig. 1.12).
Figure 1.12: PLAUR cleavage products. PLAUR is a 3 globular domain protein attached to the
cellular membrane. Cleavage occurring on the membrane bound receptor can either be
proteolytic or glyco/lipolytic. Glycolytic and lipolytic cleavage occurs at the GPI anchor by
substances such as Phospholipase C & D, and results in the formation of a soluble form of the
receptor which structurally mirrors the corresponding membrane bound receptor. Proteolytic
cleavage occurs in the linker region between DI and DII and results in the loss of D I to form a
DII/DIII fragment which has chemotactic activity.
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Soluble cleaved PLAUR has been detected in plasma, urine, blood, serum and
cerebrospinal fluid (Sorio et al., 2011, Zimmermann et al., 2012, Haupt et al., 2012,
Terracciano et al., 2011, Sporer et al., 2005). High levels (8002000pg/ml) of scPLAUR
have been recorded in vitro in supernatants from a human bronchial epithelial cell line
(BEAS2B) and a human acute monocytic leukemia cell line (THP1), with lower levels
present in supernatants from HASMs and NHBECs (50-800pg/ml) (Stewart and Sayers,
2009). Cleavage at the GPI anchor allows the protein to retain an intact PLAUR moiety
and therefore scPLAUR is still able to interact with the ligands and cell factors whichǡǡȾ1Ⱦ2
integrins (Hoyer-Hansen et al., 1997a, Behrendt and Dano, 1996, Wei et al., 1996, May
et al., 1998). Interestingly however, scPLAUR lacks the ability to bind with the N-
formyl-methionine-leucine-phenylalanine (fMLP) receptors (Resnati et al., 2002),
identifying that cleavage of the GPI anchor does result in some conformational change
to the receptor and that the function of scPLAUR may not be identical to that of the
membrane bound receptor. Therefore, although scPLAUR may be able to carry out
some functional effects identical to mPLAUR, it may have a role independently of the
membrane bound receptor. This is due to conformational changes in receptor structure
and the ability to interact with co-factors located distally from PLAUR expressing cells.
The soluble cleaved receptor can also function by competing with mPLAUR for
extracellular ligands due to its identical nature to mPLAUR. Here, competition for PLAU
would reduce PLAU driven proteolysis (see Section 1.7.1) and cell adhesion to VN.
Therefore, scPLAUR could be defined as a decoy for these extracellular ligands,
dampening the effect of over expression of the aforesaid ligands (Montuori et al., 2005)
at their target site. However, scPLAUR cannot be solely classified as a decoy receptor as
reports have also identified an active role for scPLAUR due to its ability to bind cell ȋǤǤ Ⱦ1 integrins - see above). This identifies that while increased
production of scPLAUR may reduce PLAURs proteolytic functions by its sink-like
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activities, it will not affect its non-proteolytic ones. Interestingly, it has been suggested
that increased scPLAUR generation may be a way of transferring excess PLAUR from
one cell type to another, where it is then taken up by endocytosis. This process having
already been described to occur between neutrophils and eosinophils (Mizukami and
Todd, 1998, Mustjoki et al., 2000),
Cleavage at the GPI anchor can also release PLAUR that has been previously cleaved at
the DI/DII linker, which interacts in the same fashion as the membrane bound DII/DIII
fragment as discussed in Section 1.8.3.1.
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1.10 PLAUR AND NON-RESPIRATORY DISEASE
Although this thesis specifically deals with asthma and COPD, it is important to note
that PLAUR has a role in other human diseases, especially where disease causes tissue
remodelling (Solberg et al., 2001) and in diseases associated with stress, injury and
inflammation (Smith and Marshall, 2010).
Associations with disease have not been limited to the membrane bound form of the
receptor. Multiple studies have highlighted the importance of the soluble cleaved form
of the receptor either as a biomarker of disease or disease progression or as being
directly involved in disease progression/modulation. Diseases to which PLAUR (and
ergo scPLAUR) have been associated with include various types of cancer,
cardiovascular disease, diabetes, human-immunodeficiency virus (HIV) infected
patients and neuromuscular disease (Eugen-Olsen et al., 2010b). However associations
with other types of diseases have also been reported.
In a multi-disease study, Eugen-Olsen et al. identified elevated levels of scPLAUR in the
blood of disease specific patients, associating baseline scPLAUR to an increased risk of
development of diseases with low grade inflammation, such as cancer, cardiovascular
disease and Type II Diabetes Mellitus. An increased risk of disease-related mortality
was also reported (Eugen-Olsen et al., 2010b). This argues in favour of scPLAUR as a
biomarker of disease, especially with regards to disease involving an inflammatory
cascade, a relationship also identified in chronic liver disease patients (Zimmermann et
al., 2012). The findings from the Eugen-Olsen study where mirrored in a study by
Haupt et al. were scPLAUR levels in plasma were associated with diabetes, cancer,
cardiovascular disease and liver disease as well as an increased degree of mortality in
disease in general (Haupt et al., 2012). The relationship between scPLAUR and disease
risk and mortality was further replicated by Savva et al. and Sidenius et al. in disease
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specific patient cohorts of patients with ventilator-associated pneumonia and sepsis or
HIV (Savva et al., 2011, Sidenius et al., 2000) as well as by Zimmermann et al. who
identified that elevated scPLAUR was associated with higher mortality rates or need
for transplantation in patients suffering from chronic liver disease, while also
identifying a correlation between circulating scPLAUR, liver function, fibrosis markers
and renal function (Zimmermann et al., 2012).
PLAUR has also been of interest in multiple forms of cancer, including but not limited
to breast, lung, colon, gastric and prostate carcinomas (Laufs et al., 2006), with PLAUR
differentially expressed and activated on invading tumour cells (Mazar et al., 1999). A
recent analysis by Andres et al. has identified a correlation between overall PLAUR
levels in breast tissue biopsies and overall survival rates (Andres et al., 2012) and
recently soluble cleaved PLAUR has been found to be involved in chondrosarcoma cell
mobilisation (Bifulco et al., 2011).
The multiple studies highlighting a relationship between the soluble cleaved form of
the receptor and disease prognosis identifies that this form may be independently
important in PLAUR disease modulation apart from it being a useful diagnostic severity
marker in multiple disease states.
The association of PLAUR with multiple diseases may be partially explained through its
effects on the coagulation/fibrinolysis pathway (see Sections 1.5 and 1.7.1). However,
the direct effect of PLAUR on cell homeostasis due to modulation of cell migration,
proliferation, adhesion and differentiation, which would regulate tissue remodelling,
also plays an important role. The effect of PLAUR on cellular homeostasis is described
below.
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1.11 ROLE OF PLAUR IN CELLULAR HOMEOSTASIS
PLAUR is expressed in a wide variety of cells and tissues with only a limited number of
cells identified that do not express the receptor. These include non-activated B- and
T-lymphocytes , CD34+ hematopoietic stem cells (Plesner et al., 1994b) and human
embryonal kidney cells (HEK-293) (Wei et al., 1996). The near universal expression of
PLAUR as well as the potential regulation of a number of different cell functions
through the receptors proteolytic and non-proteolytic functions, suggests that PLAUR
is involved in cellular homeostasis. This hypothesis is strengthened by the
classification of PLAUR as an activation antigen in T-lymphocytes and monocytes,
where its expression appears to be relevant to cell function (Fazioli et al., 1997).
Indeed, PLAUR has been implicated in a number of cellular mechanisms including
cellular adhesion, proliferation and migration, as well as being involved in ECM and
basement membrane proteolysis (Mekkawy et al., 2012). Pathways regulating changes
in these cellular outcomes that are affected by PLAUR tend to overlap between the
different outcomes, suggesting a complex system of cell function regulation. Examples
include the regulation of extracellular signal related kinases/p38 signalling, which
affects cellular migration and proliferation, as well as the PLAUR dependant elevation
of HS-1-associated protein X-1 which augments cellular proliferation, migration and
adhesion (Xue et al., 2009, Mekkawy et al., 2012). Recent studies have also implicated
the MEK/ERK arm of the MAPK signalling pathway in the regulation of PLAUR driven
cell migration and proliferation (Whyte et al., 2012, Nowicki et al., 2011).
PLAUR can also interact with other receptors to influence cell functions. An example of
which is the cooperation with the epidermal growth factor receptor to mediate cellular
mitogenesis (Jo et al., 2005). This is of special interest since increased cellular mitosis
may go part way to explain the PLAUR dependant increase in cellular proliferation.
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1.11.1 CELLULAR INVASION AND MIGRATION
PLAUR plays a central role in tissue invasion via cell migration (Andreasen et al., 2000)
and is strongly associated with cell motility (Lijnen, 2001). This is highlighted by the
strong correlation between cellular invasive and migratory potential with mPLAUR
levels (Ossowski et al., 1991) and by increased PLAUR expression at the leading edge of
re-epithelising wounds (Fig. 1.13) (Romer et al., 1994, Stewart et al., 2012).
Figure 1.13: Elevation of PLAUR at the wound edge of re-epithelising wounds. PLAUR
specific staining identifies a striking elevation in PLAUR expression at the wound edge of a
scratch wound model when compared to the remaining population of primary epithelial cells.
Image obtained from (Stewart et al., 2012).
Other more direct studies have confirmed this association with over-expression of
PLAUR in human pleural mesothelial cells causing an increase in the rate of cell
migration in vitro (Tucker et al., 2010), while PLAUR levels on monocyte cells were
associated with the degree of monocyte migration ex vivo (Chen et al., 2012).
Suppression of PLAUR inhibited the migration of pancreatic and bronchial epithelial
cells (Xue et al., 2009), while the granulocytes and monocytes of PLAUR knockout mice
had severely impeded migratory and chemotactic capacity (May et al., 1998).
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This PLAUR mediated regulation of cell migration is thought to occur through either
the activation of latent growth factors or their release from the ECM, following ECM
degradation through PLAUR activation (Preissner et al., 2000). Examples include the
cleavage of the ECM protein fibronectin (Quigley et al., 1987), activation ofȋ
	ȾȌȋǤǡ ? ? ? ?ȌǦ
hepatocyte growth factor (Naldini et al., 1995).
More recent studies however have suggested alternate methods of PLAUR mediated
cellular migration. Some studies have identified that an interaction between PLAUR
and VN regulates cellular migration (Kjoller and Hall, 2001, Madsen et al., 2007, Smith
et al., 2008) through integrin signalling resulting in p130Cas-Crk and DOCK180
dependant Rac activation (Smith et al., 2008, Kjoller and Hall, 2001). Other studies
have identified a direct method by which PLAUR effects cell migration through its own
innate chemotactic properties. The chemotactic activity is driven by a region located
between DI and DII in the PLAUR globular structure (SRSRY; amino acids 88 to 92),
which happens to also be the protease sensitive region of the receptor that results in
the loss of the DI domain. This epitope drives chemotaxis through the activation of the
p56/p59hck tyrosine kinase and via interaction with GPCRs (Fazioli et al., 1997).
1.11.2 CELLULAR ADHESION
PLAUR is known to affect the adhesion of leukocytes such as neutrophils (Chavakis et
al., 1999, Brooks et al., 2006). It has been proposed that PLAUR modulates cell
adhesion either directly as a cell-linked adhesion protein or counter-receptor, or   ȋǤǤ Ⱦ2 integrins) in association with other cytoskeletal and
signalling proteins (Preissner et al., 2000). The direct method of cell adhesion mainly
refers to VN dependant adhesion, where cells use PLAUR to bind soluble, multimeric        Ƚv-integrins and zinc ions and thus cause cell
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attachment (Wei et al., 1994, Kanse et al., 1996, Chavakis et al., 1999). However, a study
by Brooks et al. have suggested that a multiprotein complex consisting of integrinsȋȽMȾ2Ƚ4Ⱦ1), PLAUR, PLAU and the GPCR fMLP is involved in the promotion of cell
adhesion in leukocytes (Brooks et al., 2006).
The indirect method on the other hand refers to the release of other pro-adhesion
molecules from the cell surface or the ECM through PLAUR driven degradation.
Examples include the activation of plasminogen to plasmin and the activation of cell
signalling cascades through PLAUR-integrin interaction (Preissner et al., 2000).
1.11.3 CELLULAR PROLIFERATION
Over-expression of PLAUR in human pleural mesothelial cells identified an increase in
the rate of cell proliferation in vitro and subsequently the rate of tumour formation in
vivo (Tucker et al., 2010), while suppression of PLAUR was found to inhibit the
proliferation rate of pancreatic cells (Xue et al., 2009).
As in its other cellular activities, PLAUR driven modulation of proliferation occurs
through either a direct (proteolysis dependant) or indirect (proteolysis independent)
method. In the first instance, plasmin activated from plasminogen through the action of
the PLAUR-PLAU complex, can release and activate a number of growth factors from Ǥ   
	Ⱦ   
factor/scatter factor (HGF/SF), both of which are known to increase the rate of
proliferation in epithelial cells (Mazzieri and Blasi, 2005). Independently and through
its proteolytic effect, PLAUR increases cellular proliferation through signalling
cascades. For example, PLAUR constitutively activates the epidermal growth factor
receptor (EGFR) inducing an imbalance between p38 and p42/44 and so shifting the
balance between the proliferation activating ERK1/2 signalling cascade and the pro-
apoptotic p38MAPK signalling cascade towards the ERK1/2, thereby indirectly
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increasing the rate of cellular proliferation (Liu et al., 2002a). However, an increase in
the rate of proliferation of the embryo fibroblasts of PLAUR knockout mice identifies
that the role of PLAUR in cellular proliferation must be cell specific and is more
complex than anticipated (Mazzieri et al., 2006).
1.11.4 CELLULAR GROWTH AND DIFFERENTIATION
PLAUR is involved in the differentiation of mesenchymal stem cells to vascular smooth
muscle cells, the differentiation of monocytes to macrophages and the differentiation of
fibroblasts to myofibroblasts (Vallabhaneni et al., 2011, Bernstein et al., 2007, Blasi and
Carmeliet, 2002). As described above, PLAUR influences cellular growth andȽ5Ⱦ1, which in turn increases ERK
activity, causing an imbalance between the ERKMAPK to p38MAPK ratio, increasing cell
growth (Aguirre-Ghiso et al., 2001).
Interestingly, PLAUR can also affect cellular growth and differentiation via the direct
modulation of gene expression. Here PLAUR undergoes cellular internalization and
nuclear transport in vascular smooth muscle cells, mediated by the platelet-derived
growth factor receptor and SUMOylated RanGAP1. Once in the nuclear region, PLAUR
associates with myocardin, which is then recruited to the promoters of serum response
factor target genes and undergoes proteasome degradation. This then initiates a
change in the vascular smooth muscle phenotype that contributes to adverse vascular
remodelling after injury in vivo (Kiyan et al., 2012).
Remarkably, there is evidence that the shift from full length PLAUR to the DII/DIII
fragment is crucial to the role of PLAUR in fibroblast to myofibroblast differentiation.
Berstein et al. identify that full length PLAUR was down-regulated in myofibroblasts
when compared to fibroblasts, the originating cell type, with retention of the full-length
form appearing to prevent the transition from fibroblast to myofibroblast (Bernstein et
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al., 2007). The authors suggest a model where lack of stimulus by fibroblast growth
factor (FGF2) at the end of wound healing results in a reduction in the recycling of the
DII/DIII cleaved PLAUR to full length PLAUR, which in turn results in increased cellular
adhesion. This increase in cellular adhesion then provides the tension requiredȽǦ
that are characteristic of myofibroblasts.
1.11.5 CELLULAR APOPTOSIS
It has been suggested that PLAUR may confer protection to cells against induced
apoptosis, with a decrease in PLAUR, in conjunction with MMP-9 down-regulation,
shown to increase apoptosis (Gondi et al., 2008, Chetty et al., 2010, Nalla et al., 2010,
Nagaraju et al., 2011). This relationship was further defined by in vivo experiments
carried out in wildtype and p53-, PLAU-, PLAUR-, and PAI-1-deficient mice following
Bleomycin induced acute lung injury (Bhandary et al., 2012).
Regulation of cellular apoptosis occurs through an indirect method via multiple
pathways. These include the MAPK signal pathways, where RNA silencing of the PLAUR
gene results in a decrease in ERK activity and therefore an elevated p38 to pERK  ȋ  Ǥǡ  ? ? ? ?Ȍ    ? 	ǦɈ   ǡ
where RNA silencing of PLAUR andMMP-9 genes inhibited activation of these pathways
through EGFR (Kotipatruni et al., 2012).
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1.12 REGULATION OF PLAUR EXPRESSION
Modification of gene transcription is thought to be the main mediator of PLAUR
expression. In general modification of PLAUR gene transcription can be brought about
by a number of factors and pathways including, but not exclusive to:
i) Epidermal growth factor
ii) 
	Ⱦ ?
iii) Protein kinase C and
iv) The MAPK and JNK-pathways (Laufs et al., 2006).
Indeed, PLAUR gene expression is known to be influenced by:
i) Tumour promoters
ii) Hormones
iii) Growth factors
iv) Cytokines
v) Hypoxia (Ganne et al., 1999, Graham et al., 1998).
1.12.1 PROMOTER TRANSCRIPTIONAL REGULATION
At the gene level, regulation of gene expression is brought about by modulation of gene
transcription through cis- and trans- acting factors (Lewin, 2004). Cis-acting factors are
regulatory elements existing proximally to the gene, which together are commonly
termed as the genes promoter region. Trans-acting factors however are regulatory
elements that are located elsewhere (distally) in the genome, which includes
transcription factors, suppressors and enhancers. These cis- and trans- activating
factors work together in order to regulate expression levels of the gene.
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The promoter for the PLAUR gene was first described simultaneously by two groups in
1994 and 1995 in colon cancer and U937 lymphoma cells (Soravia et al., 1995, Wang et
al., 1994). Both groups identified that the minimal promoter in these cell lines lies
within the first 200bp from the major TSS. Wang et al. identify that this promoter lacks
both TATA and CAAT boxes and contains a GC-rich proximal sequence that contains
multiple Sp-1 consensus elements that regulate basal expression of the gene (Soravia et
al., 1995). Other studies carried out on colon cancer cells confirmed the location of a
minimal promoter within the first 200bp upstream of the TSS, identifying that a region
between 190 to 171 base pairs upstream of the TSS was required for PLAUR
expression via the induction of the MAPK- and JNK-pathways (Lengyel et al., 1997, Gum
et al., 1998). This region contains an AP-1 consensus motif that was bound to the c-Jun,
c-Fos and Fra-1 oncogenes (Lengyel et al., 1996), which when deleted resulted in a
severe reduction of promoter activity (Allgayer et al., 1999). The importance of the
AP-1 transcription factor motif in PLAUR transcription was confirmed by Okan et al,.
where an AP-1 motif at 70bp upstream of the TSS was required for transcription
activation, along with a c-Jun binding motif at 184bp upstream of the TSS (Okan et al.,
2001).
Other transcription factors known to affect PLAUR transcription include PEA3/Ets,	 ?ǡǦ ?ǡ	Ɉǡ	Ǧ ?Ǧ ?ȋǤǡ  ? ? ? ?ǡǤǡ  ? ? ? ?ǡ
al., 2005, Schewe et al., 2003, Wang et al., 2000, Wang et al., 2004, Buchler et al., 2009).
Here, experiments using a negative AP-2 expression construct also inhibited PLAUR
mediated proteolysis as well as inhibiting PLAUR transcription, thereby identifying
that inhibition at the transcriptional level can be applied to suppress and/or modify
PLAUR mediated effects such as proteolysis, cellular invasion and metastasis (Laufs et
al., 2006).
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The PLAUR promoter has also been determined to regulate gene expression through Ǥ 
Ǧ     Ⱦ3 integrin via the promoter region
between 398 and 197 base pairs upstream of the TSS, particularly with the PEA3 motif
located at 248bp upstream of the transcriptional start site (Laufs et al., 2006).
However, although all the above studies suggest that the first 200bp upstream of the
PLAUR TSS is the minimal region required for PLAUR transcription, a study in
transgenic mice has identified that the 1.5kb region upstream of the TSS to be required
for optimal expression, with a region spanning between 1295 and 1192 base pairs
upstream of the TSS proposed as a novel regulatory region (Wang et al., 2003).
Therefore it is suggested that further PLAUR regulatory regions still remain to be
discovered.
1.12.2 POST TRANSCRIPTIONAL MODIFICATION
PLAUR expression can also be regulated through post-transcriptional mechanisms
which alter PLAUR mRNA stability. The first reports of post-transcriptional regulation
of PLAUR expression were published in 1995, where Lund et al. identified thatǦ ? ?Ǧ  ? ?Ǧ ȋȌ  
	Ⱦ ?    
PLAUR through increasing the stability of PLAUR mRNA in addition to their direct
effects on PLAUR transcription (Lund et al., 1995). Further studies were thenǡ     Ǧ     Ⱦ2  Ǧ Ǧ ? ȋȽLȾ2) resulted in PLAUR
stabilisation through a cis-acting AU-rich region present in the 3`UTR of the gene
(Wang et al., 1998). Shetty later identified a novel binding protein (Heterogeneous
nuclear ribonucleoproteins C1/C2 [hnRNPC]) that bound to a 110bp region of the
genes 3`UTR, resulting in increased PLAUR mRNA stability (Shetty, 2005). A second
study identified p53 as a novel protein that bound to a 37bp region of the genes 3`UTR
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that destabilised the PLAUR mRNA (Shetty et al., 2007a), confirming the 3`UTRs
importance in PLAUR regulation through stabilisation and destabilisation functions.
Post-transcriptional regulation of the gene is however not limited to the genes 3`UTR.
Over multiple studies Shetty et al. identified, in mesothelioma (MS-1) and human lung
carcinoma cells, a 50kDa PLAUR binding protein, later identified to be
Phosphoglycerate kinase (PGK), which when selectively bound to a 51bp fragment of
mRNA that corresponded to the PLAUR coding region resulted in destabilisation of
PLAUR mRNA (Shetty et al., 1997, Shetty and Idell, 1999, Shetty et al., 2004) and
thereby reduced the expressed levels of PLAUR. This activity was found to be
independent of PGKs previously known enzymatic activity (Shetty et al., 2005). A later
study then identified PGK regulation of PLAURmRNA stability to be part of a system of
regulation involving hnRNPC and the Tyrosine-protein phosphatase non-receptor type
II (SHP2). Here, inhibition of protein tyrosine phosphatase-mediated
dephosphorylation, partly driven by PLAU, results in SHP2 phosphorylation. This
subsequently increases PLAUR mRNA stability through a decrease in the degree of
interaction between PLAUR and PGK, alongside a simultaneous enhancement of the
interaction of hnRNPC with the PLAUR 3`UTR (Shetty et al., 2007b), a process linked to
Lipopolysaccaride (LPS) induced PLAUR elevations (Bhandary et al., 2009).
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Figure 1.14: Known regulatory mechanisms for PLAUR mechanisms. At the 5`UTR the gene
minimal promoter was determined to be located within the first 200bp upstream of the gene
transcriptional start site. Here, regulation involves an AP-1 and c-Jun motif as well as the c-
Fos, Fra-1, MAPK and JNK pathways. Other transcription factors involved in PLAUR regulation  ?Ȁǡ 	 ?ǡ Ǧ ?ǡ 	ɈȾǡ 	Ǧ ?  Ǧ ?Ǥ     
lies in the first 200bp upstream of the gene, the region up to 1.5kb upstream of the gene has
also been determined to be crucial for optimal gene expression. Here the region at 398bp- ? ? ?       Ⱦ ?    ǡ    
1295-1192bp has been proposed as a novel regulatory region. Post transcriptionally, p53,ǡǡ
	Ⱦ ?ȽȾ ?
ǡ
through interaction within the genes coding region (region not specified) decreases PLAUR
gene stability. Post-transcriptional modification is known to involve the tyrosine-protein
phosphatase non-receptor type 11 (SHP2), where on phosphorylation SHP2 increases
heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNPC) activity while simultaneously
inhibiting phosphoglyserate kinase (PGK) activity, thereby increasing the amount of stable
PLAUR mRNA.
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1.13 AIMS
Although limited studies have been carried out investigating PLAUR regulation and
function in the airways, a more in depth analyses of general PLAUR regulation and
function is still outstanding, especially with regards to the regulation of specific forms
of the receptor and in primary human airway cells, where previous associations with
obstructive lung disease (asthma and COPD) have been described.
Therefore, the aims of the work described in this thesis were:
1. To investigate the relationship between scPLAUR and obstructive lung
disease (asthma & COPD) diagnosis and clinical parameters.
2. To identify novel genetic mechanisms regulating scPLAUR levels.
3. To define the relative contribution of proximal PLAUR regulatory regions in
determining gene expression.
4. To determine the functional role of different PLAUR forms in primary
bronchial epithelial cells.
5. To identify both rare and common genetic variants spanning PLAUR and to
identify which of these are relevant to asthma.
CHAPTER 2:
GENERAL MATERIALS & METHODS
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CHAPTER 2: GENERAL MATERIALS AND METHODS
This Chapter describes methodologies used in multiple Results Chapters. Methodologies specific to
a particular Chapter are explained within that Chapters methodology section.
Room temperature is considered to be an ambient temperature of circa. 25oC.
2.1 MATERIALS
2.1.1 GENERAL MATERIALS
All materials used in this thesis are listed below, except for mammalian cells and their
culture material (see Section 2.1.2) and plasmids (see Sections 4.5.6 & 5.4.2.2).
x Agarose Invitrogen, 15510-027
x Ampicillin Sigma-Aldrich, A9518
x Anti-beta Actin antibody Abcam, ab8227
x Acrylamide (30%) Sigma-Aldrich, A3699
x APS (ammonium persulphate) Promega, V3131
x BigDye® Terminator 3.1 Cycle Sequencing Kit Applied Biosystems, 4337456
x BetterBase Microzone, 3BBR
x ȾǦ    Ǧǡ ? ? ? ?
x Bio-Rad protein assay standard II Bio-Rad 500-0007
x Bovine Serum Albumin (BSA), protease-free Sigma-Aldrich, A3059
x Complete Mini Protease Inhibitor Tablets Roche, 11836153001
x DAPI Sigma-Aldrich, D9542
x DEPC-treated water Invitrogen, 75-0024
x Dithiothreitol Sigma-Aldrich, D9779
x Donkey Anti-Goat HRP R&D, HAF 109
x DMSO Sigma-Aldrich, 154958
x DNA Engine Tetrad 2 Cycler Bio-Rad PTC-240
x DNase I, amplification grade Invitrogen, 18068-015
x dNTP Set Bioline, BIO-39026
x ECL Western blotting Detection Reagents kit GE Healthcare, RPN2209
x EcoRI restriction enzyme Promega, R6011
x EDTA Sigma-Aldrich, ED
x EndoFree® Plasmid Maxi Kit Qiagen, 12362
x Ethanol Sigma-Aldrich, 32221
x Ethidium Bromide Invitrogen, 15585-011
x E-Toxate̻Water (endotoxin-free) Sigma-Aldrich, 2107
x FuGENE® 6 Transfection Reagent Roche, 11814443001
x GeneGenius Gel Doc system
x Glacial acetic acid Fisher Scientific, A/0400/PB17
x Glycerol Fisher Scientific, BPE229-1
x Glycine Sigma-Aldrich, G8790
x Goat Anti-Mouse HRP R&D, HAF 007
x Goat Anti-Rabbit HRP R&D, HAF 008
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x Goat serum Sigma-Aldrich, G6767
x HRP-Streptavidin conjugate Fisher, 43-8323
x Human Duoset ELISA R&D Systems DY807
x Iso-Butanol Fisher, 15828-0010
x IsoPropanol Sigma-Aldrich, 190764
x Kanamycin Sigma-Aldrich, K4378
x Kodak® GBX Developer/Replenisher Sigma-Aldrich, P7042
x Kodak® Fixer Sigma-Aldrich, P8307
x KpnI restriction enzyme Promega, R6341
x LB agar, Miller Fisher Scientific, BPE1425-500
x LB broth, Miller Fisher Scientific, BPE1426-500
x MAX Efficiency® ?Ƚ ?Ǧ ? ǡ ? ? ? ? ?Ǧ ? ? ?
x Methanol Fisher Scientific, M/4000/17
x MTT Sigma-Aldrich, M5655
x NanoDrop Technologies NanoDrop®
ND-1000 Spectophotometer
x NheI restriction enzyme Promega, R6501
x NotI restriction enzyme Promega, R6431
x Orange G dye Sigma-Aldrich, O1625
x PBS (1x) [Sterile] Sigma-Aldrich, D8662
x PBS (Dulbecco A) Oxoid BR0014G
x Photographic film (Hyperfilm) GE Healthcare, 28906837
x Platinum® Taq High Fidelity DNA Polymerase Invitrogen, 11304-011
x Precision Plus kaleidoscope marker Bio-Rad, 161-0375
x Protein Reagent Dye Concentrate Bio-Rad, 500-0006
x PVDF Membrane (Immobilon-P) Millipore, IPVH00010
x QIAPrep® Spin Miniprep Kit Qiagen, 27106
x QIAquick Gel extraction kit Qiagen, 28704
x QIAshredder® Spin Columns Qiagen, 79654
x Restriction Buffer H, 10x Promega, R008A
x Restore Stripping buffer Fisher scientific, 21059
x RNase-Free DNase Set Qiagen, 79254
x RNase ZAP̻ Sigma-Aldrich, R2020
x RNeasy®Mini Kit Qiagen, 74104
x Sodium acetate Sigma-Aldrich, S2889
x Sodium dodecyl sulphate Sigma-Aldrich, L5750
x Superscript̻ First-Strand Synthesis System
for RT-PCR kit Invitrogen, 11904-018
x Sulphuric Acid (2N) Sigma-Aldrich, 35276
x TaqMan® Universal PCR Master Mix (2x) Applied Biosystems, 4304437
x TEMED Sigma-Aldrich, T9281
x TOPO TA Cloning® Kit for Sequencing Invitrogen, K4575-J10
x TOPO XL PCR cloning kit Invitrogen, K4510-20
x TRIS-base Fisher scientific, 15504-020
x Triton X-100 Sigma-Aldrich, 9002-93-1
x Tween® 20 Sigma-Aldrich, P7949
x T4 DNA Ligase (HC) Promega, M180A
x VectaShield̻ Hard+Set Mounting
Media with DAPI Vector Laboratories, H-1500
x XhoI restriction enzyme Promega, R6161
x 1Kb DNA ladder Invitrogen, 15615-016
x 100bp DNA ladder Invitrogen, 15628-019
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2.1.2 MAMMALIAN CELLS AND CELL CULTURE MATERIAL
x BEAS-2BR1 cell line A kind gift from Prof Ray Penn,
University of Maryland,
Baltimore, USA
x BEGM BulletKit Lonza/Clonetics, CC-3170
x Cigarettes (3R4F) University of Kentucky,
Reference Cigarette Program
x DMEM culture medium Sigma-Aldrich, D5796
x Foetal calf serum (FCS) Sigma-Aldrich, F-7524
x HBEC (primary cells; Donors 7F3158 & 7F3206) Lonza/Clonetics, CC-2540
x MRC-5 cell line ECACC, 84101801
x Trypan Blue solution, 0.4% Sigma-Aldrich, T8154
x Trypsin-EDTA solution (1x) Sigma-Aldrich, T3924
x Trypsin Inhibitor Invitrogen, 17075-029
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2.2 MOLECULAR BIOLOGY METHODS
2.2.1 POLYMERASE CHAIN REACTION
A Polymerase Chain Reaction (PCR) is a technique by which a segment of DNA is
exponentially replicated in vitro through a process of denaturation, annealing and
extension. Amplification of the region of interest, using the original strand as a
template, occurs on the addition of oligonucleotides (Primers) complimentary to either
of the terminal ends of the region of interest, along with single nucleotides (dNTPs),
Magnesium and an amplification enzyme. Successive cycles of amplification produce
increasing amounts of the required fragment on an exponential scale.
Primers used for specific amplifications are referenced in their respective Chapters
(see Sections 2.2.12, 4.5.6 & 5.4.2) and were designed according to the standard rules
(Dieffenbach et al., 1993). However, certain primers used in this thesis were larger
than the recommended length of ~20bp. This was due to necessary design elements for
plasmid construction e.g. restriction sites. In general all primers were about 2840bp
long, contained circa 50% GC content to avoid mispriming in GC rich DNA regions and
contained a melting temperature (Tm) between 60oC and 80oC. Palindromes, repeats
and runs were avoided. All primers were designed manually and validated (including
detection of stable hairpins, dimers and cross-dimers) using the online tools
NetPrimer1 and Primer-BLAST2 (Ye et al., 2012).
All PCRs carried out used the amplification enzyme Platinum Taq DNA Polymerase
along with other constituents as outlined in Table 2.1.
1 http://www.premierbiosoft.com/netprimer/index.html
2 http://www.ncbi.nlm.nih.gov/tools/primer-blast
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Reagent
Stock
Concentration
Final
Concentration
Volume
Water 36.75 µl
Enzyme buffer 10 X 1 X 5 µl
Mg
2+
50 mM 2 mM 2 µl
dNTP 5 mM 200 µM 2 µl
Platinum Taq 5 U/µl 0.03 U/µl 0.25 µl
Forward Primer  ? ?ʅD  ? ? ?ђD 1 µl
Reverse Primer  ? ?ʅD 0.2 µM 1 µl
Sample Template 2 µl
Total Volume 50 µl
Table 2.1: Polymerase Chain Reaction mix. This table identifies the constituent materials
required to carry out a PCR as well as the required volume and concentration.
A heated lid DNA Engine Tetrad 2 Cycler was used to carry out all PCRs using cycling
parameters as outlined below.
Initial Denaturation 94°C 1min
Denaturation 94°C 30 sec X 35 cycles
Annealing 55°C 30 sec
Extension 68°C
1 min per kb
(minimum 1min)
Final Extension 72°C 10 min
4°C hold
2.2.2 AGAROSE GEL ELECTROPHORESIS OF DNA
Agarose gel electrophoresis is a process by which DNA fragments are separated
according to the fragments size. DNA is formed of negatively charged nucleotides,
which uniformly migrate towards a positive charge. Fragments separate based on size
due to smaller fragments passing more readily through the gel matrix than larger
fragments. DNA fragments are visualised using the intercalating agent Ethidiumȋ ?Ǥ ?ɊȀȌǤǤ
concentrations were used according to the size of fragment to be resolved. A 1% w/v
gel was used for fragments between 200bp and 1kb while a 1.5% w/v gel was used for
fragments between 1.5kb and 10kb. Gels were created by heating agarose powder
dissolved in 1xTAE buffer (50ml) (from 50X stock  see Appendix I). Samples were
loaded using 6x Orange G loading dye (Appendix I) to a final concentration of 1x, while
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the required DNA ladder(s) (Appendix I)) were included on each gel. Gels were run in
50ml 1x TAE buffer at approximately 80Volts for 30 minutes. Bands of DNA fragments
were visualised under UV light using a Syngene GeneGenius Gel Doc system and
GeneSnap v6.08 software (Syngene).
2.2.3 GEL PURIFICATION OF DNA BANDS
The Qiagen QIAquick Gel extraction kit was used to purify all PCR products. Here a
specialised silica membrane selectively retains DNA and washes clear any
contamination, followed by elution of the DNA with sterile water.
Briefly, the required DNA fragments are excised, using a sterile single-use scalpel, from
the agarose gel while visualised on a Ultra-Violet Transilluminator. The pieces are
dissolved into the DNA extraction buffer by incubation at 50oC for 10 minutes. The
resulting solution is then passed through the silica membrane in microspin cups by
centrifugation. The resulting bound DNA is washed with wash buffer + 50% Ethanol     ? ?Ɋ       ȋ  
minute incubation at room temperature). The extraction procedure is quality
controlled by gel electrophoresis (see Section 2.2.2).
2.2.4 TOPO TA AND TOPO XLCLONING
Both the TOPO TA and the TOPO XL (for fragments >2.5kb) kits have been used to form
large copy numbers of a particular sequence of DNA via cloning (Fonte et al., 2002, Liu
et al., 2002b). This results in the duplication of DNA with a lower degree of error than
that provided by PCR. Cloning involves the use of a single Adenosine overhang
introduced at the terminal end of a PCR fragment by the Taq enzyme. E.coli cells
provided by the kit are then transformed with the kit specific plasmid (Fig. 2.1), where
the bacteria formmultiple copies of the plasmid through their reproduction.
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Figure 2.1: Vectors used in TOPO cloning. The pCR4-TOPO vector (Panel A) was used to
clone all fragments smaller than 1000 base pairs while the pCR-XL-TOPO (Panel B) was used
to clone fragments larger than 1000 base pairs.
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2.2.4.1 TOPO TA CLONING KIT FOR SEQUENCING
The TOPO TA Cloning® kit for Sequencing provides a highly efficient single step cloning
strategy directly for Taq polymerase-amplified PCR products. The protocol involves:
1.       ?Ɋ      ȋ  ?Ǥ ?Ǥ ?Ȍǡ ?Ɋǯ ?ɊǦ ?Ǧ ? ?oC for
five minutes.
2.  ?Ɋ® Cloning reaction into a vial of One Shot® TOP10
Chemically Competent E. coli.
3. Incubation of the mix on ice for thirty minutes.
4. Heat-shocking the cells for thirty seconds at 42°C without shaking and
immediately transferring the tubes to ice.
5.    ? ? ?Ɋ     
followed by shaking the tube horizontally at 200 rpm at 37°C for one hour.
The bacterial broth was then used to culture transformed bacteria to form sizable
colonies that could be used for plasmid prepping (Section 2.2.6). For a detailed
procedure please refer to Section 2.2.5.
2.2.4.2 TOPO XL PCR CLONING KIT
TOPO® XL PCR Cloning is modified for the cloning of long PCR products. This kit differs
from the TOPO TA Cloning® kit in the inclusion of a different plasmid vector (pCR-XL-
TOPO; Fig. 2.1b) and has a kit specific methodology for the gel purification of the PCR
constructs that is different to those outlined in Sections 2.2.2 & 2.2.3. In brief the
procedure is as follows:
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1. Running the gel
Gels were prepared by dissolving 50mg of agarose into 50 mL of 1X TAE buffer and ? ?Ɋ ?ȀǤ ? ?Ɋ   ?Ɋ    ?         ǡ
which was run in 1X TAE buffer. The DNA band should be visible in normal light.
2. Gel Purification
The band was excised using a sterile single-use scalpel and then dissolved in 2.5x
volume of sodium iodide by heating at 50oC. Following the addition of 1.5x volume
of binding buffer the product was passed through the membrane in the filter tubes
by centrifugation and washed with 1x Wash Buffer. Following 1 minute incubation  ǡ         ? ?Ɋ   
through the membrane.
3. TOPO Cloning
ǡ ?Ɋ ?Ɋ   ǦǦ         Ǥ	ǡ ?Ɋ ? ?ǡ
which increased the yield of transformants by an average of 2-fold. The kit then
follows a procedure identical to that for the TOPO TA Cloning kit (see Section
2.2.4.1).
2.2.5 BACTERIAL CELL CULTURE
Bacterial strains cultured in this thesis included the TOP 10 E.coli cells provided in the
TOPO TA and TOPO XL cloning kits as well as the MAX Efficiency® ?Ƚ ?
Cells. Transformation (see Section 2.2.4.1) and culturing procedures were identical for
both types of cells.
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All transformed cells were cultured on Lysogeny Broth (LB) agar plates (Appendix I)   ? ? ?ɊȀ  ȋ100) at 37°C for 16-18 hours, apart from
those containing the pCR-XL-TOPO vector, which were similarly treated but on LB agar    ? ?ɊȀ  ȋ50). Following incubation, single
transformed colonies were propagated in 5ml Amp100 or Kan50 LB broth (Appendix I) in   ? ? ?   ? ?Ǧ ? ?  ? ? ?Ǥ  ? ? ?Ɋ 
broth was used to streak a new Amp100 or Kan50 LB agar plate, with the procedure
described above repeated to form an LB broth with a colony originating from a single
bacterial cell. Broths were then used to either extract plasmid DNA (see Section 2.2.6)
or to form glycerol stocks for long-term storage.

       ? ? ?Ɋ     ȋ ǣ
~3-4.109ȀȌ ? ? ?Ɋ ? ? ?ȀǤ
stored at -80°C.
2.2.6 PURIFICATION OF PLASMID DNA
Plasmid purification was carried out using the QIAprepMiniprep kit unless larger and
endotoxin free stocks of plasmid for mammalian cell transfection were required were
the Endofree Plasmid Purification kit was used. Both kits use alkaline lysis,
neutralisation and solution adjustment to high salt-binding conditions. Plasmid DNA is
then bound to a silica-based membrane, and washed to remove both contaminants and
endonucleases followed by elution under low salt conditions, all via centrifugation.
2.2.6.1 QIAPREP®MINIPREP KIT (YIELDS 5 15MCG DNA)
 ? ? ? ?ȀɊ      ? ?ɊǤ    ? ? ? ?Ɋ     ȋ  ?Ǥ ?Ǥ ?Ȍ 
centrifuged at 6800xg to form a bacterial pellet. The resulting bacterial pellet was
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Ǧ  ? ? ?Ɋ ?ǡ   ? ? ?Ɋ ? ? ? ? ?Ɋ
N3. The resulting mixture was then centrifuged for 10 min at 13,000rpm to form a
compact white pellet consisting of organelles and other cell debris. The supernatant
was then applied to a QIAprep spin column, where the DNA was bound to the silicaǡ ? ? ?Ɋ ? ? ?Ɋ ? ? ? ?Ȁ ? ?ɊǤ
2.2.6.2 ENDOFREE® PLASMID PURIFICATION KIT (YIELDS 300500MCG DNA)
As this kit was solely used for the formation of plasmids to be transfected into
mammalian cells it is important that the solution is endotoxin free. This is since
endotoxins can reduce the transfection efficiency of mammalian cells with plasmid
DNA (Weber et al., 1995), cause nonspecific activation of the immune system, stimulate
cytokine production and induce the characteristic shock syndrome associated with
bacterial infections (Heid et al., 1996).
The principle through which this kit functions is similar to that of the QIAPrep® Spin
Miniprep Kit. Due to the larger scale of this preparation, plasmid DNA is bound to an
anion-exchange resin by gravity flow where it is washed and eluted via centrifugation,
with the resulting DNA pellet concentrated through isopropanol precipitation and re-
pelleted by centrifugation. This resulting pellet was re-suspended in endotoxin-free
water.
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2.2.7 DIDEOXYNUCLEOTIDE TRIPHOSPHATE CHAIN TERMINATOR
SEQUENCING
Also known as the Sanger method, this DNA sequencing method denatures target DNA
and anneals it to an oligonucleotide primer, which causes 5` to 3` chain extension
similar to that in PCR (Section 2.2.1). Addition of the chain-terminating
dideoxynucleotide triphosphates (ddNTPs), which lack a 3 OH group, forms short
DNA chains of varying size (Suzuki et al., 2005). In this way, each nucleotide in the
investigated sequence is presented as a terminal nucleotide in the resulting solution. In
the dye terminator version of this technique, the ddNTPs are labelled with different
fluorescent dyes allowing, following separation based on fragment length by gel
electrophoresis, nucleotide detection on exposure to laser excitation of the relevant
wavelengths. This allows for accurate determination of the DNA sequence.
All ddNTP sequencing was exclusively carried out on plasmids, using the BigDye®
Terminator v3.1 Cycle Sequencing Kit. All utilised sequencing primers are listed below
in Table 2.2.
Plasmid Type Primer Tm Percentage GC
pGL4
Forward CTAGCAAAATAGGCTGTCCC 60 50
Reverse TACCAACAGTACCGGA 68 50
psiCHECK-2 Forward TCAAGAGCTTCGTGGAGCGCG 75 61
TOPO (M13)
Forward GTAAAACGACGGCCAG 49 56
Reverse CAGGAAACAGCTATGAC 42 47
Table 2.2: Sequencing primers utilised in this thesis. Each primer was used individually to
sequence their relative plasmids using dideoxynucleotide triphosphate chain terminator
sequencing. Primers for pGL4 and psiCHECK-2 were designed by the investigator, while the
M13 primers were provided with the TOPO and TOPO XL kits.
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2.2.7.1 SEQUENCING REACTION
The sequencing reaction was carried out in a mastermix set up as shown in Table 2.3.
 ȋɊȌ
Plasmid DNA 0.5 (~100ng)
BigDye premix 0.5
BetterBase 3.5
 ?Ɋ 1.5
Sterile Water 4.0
Table 2.3: Reaction mix for dideoxynucleotide triphosphate chain terminator
sequencing. All sequencing reactions carried out in this thesis utilised the same mix as listed
above.
A heated lid DNA Engine Tetrad 2 Cycler was used to carry out all sequencing reactions
using the template outlined below:
Denaturation 96°C 30 sec X 25 cycles
Annealing 50°C 15 sec
Extension 60°C
4 min
Final Extension 28°C 1 min
10°C hold
2.2.7.2 PURIFICATION AND ANALYSES OF SEQUENCING REACTIONS
The resulting DNA fragments were then precipitated using the following method:
1.  ? ? ?Ɋ ?Ɋ   ?  ǡ   ?Ǥ ?   ?Ɋ   ? ? ?  ȋ  ?Ǥ ?Ȍ 
incubate at 28°C for 15 min.
2.  ? ?Ɋ ? ? ? ? ? ? ? ? ? ? ?Ǥ
3.             ? ? ?Ɋ 
70% ethanol followed by centrifugation for 5 min at 13000xg.
4. Carefully aspirate all of the supernatant and air dry the pellet.
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The resulting pellet was then sent to the Post-Genomic Technologies Facility, School of
Molecular Medical Sciences, University of Nottingham UK, where sequencing was
carried out using an Applied Biosystems 3130 Genetic Analyser.
2.2.7.3 ANALYSIS
DNA sequences were visualised and converted to FASTA format using Chromas Lite
version 2.10 (Technelysium Pty Ltd, Australia). Standard IUPAC DNA ambiguity codes
were assigned.
Sequences were first screened for vector contamination by the online tool VecScreen3
and then aligned using the online sequence alignment tool Nucleotide BLAST4 against
the human genome (Build 37). Any apparent variation on the BLAST output was
investigated in Chromas Lite by chromatogram peak verification at relevant positions.
2.2.8 RESTRICTION DIGEST
Restriction enzymes recognize short DNA sequences and cleave double-stranded DNA
within or adjacent to these sequences allowing for specific extraction of DNA fragments
from a larger DNA sequence. Restriction sites were identified using the online tool
WEBCutter5. The use of restriction enzymes for cloning is outlined in the plasmid
design sections of this thesis (Section 4.5.6 & 5.4.2).
In brief, restriction digests were carried out using Promega UK restriction enzymes and
other constituents as outlined in Table 2.4.
3 http://www.ncbi.nlm.nih.gov/VecScreen/VecScreen.html
4
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Nucleotides&PROGRAM=blastn&BLAST_PROGRA
MS=megaBlast&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on
5 http://rna.lundberg.gu.se/cutter2/
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 ȋɊȌ
BSA 0.2
Restriction Enzyme Buffer 2
Restriction Enzymes 0.5 (total; 0.25x2)
DNA sample 2
Sterile water 8.3
Table 2.4: Reaction mix for restriction digests carried out in this thesis. All digests
utilised the mix as outlined above. Restriction enzyme buffers changed as follows, according to
the enzyme mix; [Promega Multicore: NheI/KpnI] [Promega Buffer D: XhoI/NotI] [Promega
Buffer H: XhoI/EcoRI]
A heated lid DNA Engine Tetrad 2 Cycler was used to incubate the mix at 37oC for 60            ?Ɋ   

loading dye. Resulting fragments were visualised on an agarose gel with undigested
plasmid as a negative control (Section 2.2.2). DNA to be used in ligation procedures
were gel purified as outlined in Section 2.2.3.
2.2.9 T4 LIGATION
Ligation is the process by which two complimentary DNA strands are joined together
through the catalysing of the formation of a phosphodiester bond by a ligase enzyme.
Ligation was carried out using the T4 DNA Ligase kit (Promega, UK), according to theǯ Ǥ  ǡ  ?Ɋ      ȋ ? ? ?Ȍ    ?Ɋ          ?ǣ ?    ȋ ?Ǥ ?Ȍ ? ?Ɋǣ
 ȋɊȌ
Linearized Vector 1
Insert 3 ?ȋ ?ȀɊȌ 1
Ligase 10X Buffer 1
Sterile water 4
Table 2.5: Mix used to carry out T4 ligations. All ligation carried out in this thesis used the
mix as outlined above.
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A heated lid DNA Engine Tetrad 2 Cycler was used to incubate the mix at 22°C for 3
hours, followed by incubation at 4°C for 18 hours, thereby allowing enough time for the
ATP-dependent ligation to occur. Vector- and insert-only ligations were included as
negative controls. One Shot® MAX Efficiency® ?Ƚ ?Ǧ ?
transformed with the ligation mixture as outlined in Section 2.2.5.
2.2.10 TOTAL RNA EXTRACTION
Total RNA extraction was carried out using the Qiagen RNeasy®Mini Kit in conjunction
with the Qiagen QIAShredder Kit as per manufacturers instructions. Here, a specialisedǦ  ? ? ?Ɋ   ? ? ?
bases from disrupted cells to the RNeasy silica membrane. Washes then clear any
contamination, followed by elution of the DNA with sterile water. Selection of RNA
>200 bases excludes 5.8S rRNA, 5S rRNA, and tRNAs from the resulting solution
(Qiagen, 2010).
Briefly, cells cultured in either T25 flasks or 6-well tissue culture plates (area per well
9.60cm2Ǣ ? ? ? ? ? ? ?Ȍ ? ? ?Ɋ
RLT buffer via mechanical scraping, The solution was then homogenised by placing the
lysate directly into a QIAshredder spin column within a 2ml collection tube and passing
the solution through by centrifugation at 13000rpm. The resulting homogenised
solution was then treated with 1X volume 70% ethanol which was then passed through
the silica membrane in a fresh RNeasy spin column by a 15 second centrifugation at ? ? ? ? ?Ǥ ? ? ?Ɋ ?Ǥȋ ? ?Ɋ     ?  ? ?Ɋ   ȏ Ǧ	  ȐȌ  
incubated on the membrane at room temperature for 15 minutes in order to degrade  Ǥ          ? ? ?Ɋ    ? 
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 ? ? ?Ɋ   ? ? ? ? Ȁ Ǥ       ? ?Ɋ  Ǧ
water directly to the spin columnmembrane (x2 elutions).
Presence of RNA in the resulting RNA solutions was then detected using agarose gel
electrophoresis (Section 2.2.2) and quantified using a NanoDrop Technologies
NanoDrop® ND-1000 Spectrophotometer. All RNA samples were stored at -80oC. All
work was carried out in an RNAse free environment set up by the use of RNase ZAP̻.
2.2.11 SYNTHESIS OF COMPLIMENTARY DNA
Single stranded complimentary DNA (cDNA) was synthesised from the extracted total
RNA samples using Invitrogens Superscript̻ First-Strand Synthesis System for RT-
PCR kit. All cDNA synthesis was carried out using the kits random hexamers (6bpȌ ? ? ?ɊǤ
allowed for the priming of multiple random sites on the RNA template. This generated
overlapping cDNA fragments of various sizes, thereby ensuring that the whole RNA
sequence was represented in the resulting cDNA mix. The resulting single-stranded
DNA is treated with RNase in order to remove any RNA template remaining and make
it ready for qPCR. A reverse transcriptase (RT) negative control was carried out for
each sample synthesised, while a general RT positive control was carried out for the
cDNA synthesis experiment per se. All cDNA used for comparative analyses was created
in one experiment in order to limit batch variation.
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Briefly, the following master mix was set up:
 ȋɊȌ
10mM dNTP mix 1.00
Random hexamers 0.50
RNA  ?Ǥ ?Ɋ
DEPC-treated water To 10
Table 2.6: Reaction mix A for reverse transcription PCR. This mix is the first part of the
solution utilised to create cDNA from RNA using the Superscript̻ First-Strand Synthesis
System.
A heated lid DNA Engine Tetrad 2 Cycler was then used to incubate the RNA/primer ? ? ? ?ǡ ?Ǥ ?Ɋ
of the following solution was then added to the solution (Table 2.7):
 ȋɊȌ
RT Buffer 2
MgCl2 4
DTT 2 ?ȋ ? ?ȀɊȌ  ?
Table 2.7: Reaction mix B for reverse transcription PCR. This mix is the second part of the
solution utilised to create cDNA from RNA using the Superscript̻ First-Strand Synthesis
System.	       ǡ  ?Ɋ ȋ ? ? Ȍ  
SuperScript̻ II RT enzyme was added, except in the case of RT negative controls ?ɊǦǤ
at room temperature for 10 minutes followed by incubation at 42°C for 50 minutes and
termination of the reaction at 70°C for 15 minutes using a heated lid DNA Engine  ? Ǥ         ǡ  ?Ɋ 
RNaseH was added (37oC for 20 minutes). Due to the high concentration resulting from
this protocol, the resulting cDNA was diluted 1:10 into sterile water.
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Quality control of the synthesis procedure for both successful synthesis and
contamination was carried out by reverse-transcription PCR (RT-PCR). This involved
carrying out a PCR as described in Section 2.2.1 using primers for Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (see Table 2.8) in all the samples and the RT
negative controls. RT-PCR was not carried out on the RT positive control as this was
based on bacterial RNA and therefore lacked the human GAPDH gene. Bands were
visualised on an agarose gel with positive detection of GAPDH resulting in a band at the
293bp position.
Name Sequence Location
Forward GAPDH
Primer
GGTGAAGGTCGGAGTCAACGGA
Exon 1
12:6644008-6644029
Reverse GAPDH Primer GAGGGATCTCGCTCCTGGAAGA
Exons 3&4
12:6645959-6645969
12:6646099-6646110
Table 2.8: GAPDH primers used in the quality control of qPCR reactions. The reverse
primer was designed to cross over two exons which allowed for selective replication of GAPDH
mRNA.
2.2.12 QUANTITATIVE PCR
Quantitative PCR is the method of choice for mRNA quantification as a measure of gene
activity, addressing the requirement for mRNA quantification in molecular medicine,
biotechnology, microbiology and diagnostics (Nolan et al., 2006). For all work
addressed, the TaqMan® method was used. This technique utilises a fluorescent DNA     ?B?   ?B?    Taq polymerase (Holland et al.,
1991). Here, a designed gene specific oligonucleotide probe, with a reporter      ?B?          ?B? ǡ
hybridises to the accumulating PCR product. Using primers designed to specific gene
exon regions, Taq polymerase is able to cleave the quencher dye during PCR    ?B?   ȋ Ǥǡ  ? ? ? ?Ȍ     
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specificity to the reaction. This results in fluorescence accumulation, which allows for
the quantitation of gene expression with high degree of specificity and sensitivity
(VanGuilder et al., 2008, Suzuki et al., 2005).
The cycle threshold (Ct) can be defined as the point when the degree of fluorescence
becomes exponential and moves into the linear phase of a graph where the number of
cycles (x-axis) is plotted against fluorescence on a logarithmic scale (y-axis). The
relationship between the original concentration of the starting template and the Ct is an
inverse one, with the lower the Ct, the greater the starting quantity of template and
vice-versa. Relative gene expression was calculated using Ct values as previously
described (Livak and Schmittgen, 2001), where a Ct>40 is taken as no cDNA present
(RT-ve). All Ct values were calculated using MxPro̻ QPCR Software v4.01 and
Microsoft Excel 2010.
Variation in cDNA levels between samples was corrected using the hypoxanthine
phosphoribosyltransferase 1 (HPRT) Pre-Developed TaqMan Assay Reagent (PDAR) as
a housekeeping gene. As the PDAR was found to interact with the assays for membrane
and soluble PLAUR (Dr Ceri Stewart; unpublished work), these assays were carried out
in conjunction with the assay for total PLAUR. In this way the PDAR values obtained
from the total PLAUR assay could be utilised in the calculations for the membrane and
soluble PLAUR assays.
The primers and probes (Tables 2.9 & 2.10) used to quantify the starting levels of
mRNA were designed and validated by Dr Ceri Stewart (University of Nottingham)
using Beacon Designer 7.0 software (PREMIER Biosoft International) (Stewart et al.,
2009, Stewart et al., 2012). Each assay was validated through the use of standard
curves. These were produced by assaying a PLAUR expressing plasmid construct
serially diluted 10-fold from 300,000 to 30 copies, as outlined by the Applied
Biosystems guide Creating Standard Curves with Genomic DNA or Plasmid DNA
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Templates for Use in Quantitative PCR. QPCR efficiency rates were determined at
65.3% for the total PLAUR assay, 85.1% for the mPLAUR assay and 72.0% for the
ssPLAUR assay (Fig. 2.2). Assay efficiency was plotted using the MxPro̻ QPCR
Software v4.01 using the formula:
Assay Efficiency (%) = [(10-1/slope-1) x 100]
Assay Target Forward Primer Reverse Primer PDAR
1
Total
PLAUR
PLAUR E1 L258
CTGCTGCTGCTCCACACCT
PLAUR E2 R345
ACTCTTCCACACGGCAATCCC
HPRT
2
Membrane
PLAUR
PLAUR E1 L258
CTGCTGCTGCTCCACACCT
E7V1 R1118
TGGGTGGTTACAGCCACTTT
None
3
Soluble
PLAUR
PLAUR E1 L258
CTGCTGCTGCTCCACACCT
suPAR R1013
TGGCAACCAGCTTCCCCAGAGT
None
All Probe
uPARall
CCAGCCTCTTGGGGCCTGCGGT
Table 2.9: Primers and Probes used in the TaqMan̻ qPCR carried out in this thesis.
While the probe and the forward primer are common to all 3 assays, the reverse primer for
each assay specifically targets either total PLAUR, membrane PLAUR or soluble spliced PLAUR.
Due to interference between the Housekeeper gene HPRT and the assays for membrane and
soluble spliced PLAUR, the housekeeper gene was only multiplexed with the total PLAUR assay
and so the remaining assays had to be carried out at the same time using the HPRT values
from the first assay. PDAR: pre-developed assay reagent, HPRT; hypoxanthine
phosphoribosyltransferase 1. The alphanumeric code present in primer names is an
experimental cross-reference.
Primer Name Sequence Exon Location
PLAUR E1 L258 CTGCTGCTGCTCCACACCT 1 44174226 - 44174245
PLAUR E2 R345 ACTCTTCCACACGGCAATCCC 2 44171775 - 44171796
E7V1 R1118 TGGGTGGTTACAGCCACTTT 7a 44153162 - 44153181
sPLAUR R1013 TGGCAACCAGCTTCCCCAGAGT 7b 44150672 - 44150694
Probe CCAGCCTCTTGGGGCCTGCGGT 2 44171861 - 44171839
Table 2.10: Locations of qPCR primers and probe outlined in Table 2.8. Locations refer to
chromosome 19 build GRCh37.
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Figure 2.2: Standard curves for total (Panel A), membrane bound (Panel B) and soluble
spliced (Panel C) PLAUR qPCR assays. Variation between sample readings and the standard
curve determines the efficiency of that qPCR assay. QPCR efficiency rates for the total PLAUR,
mPLAUR and ssPLAUR assays were determined to be 65.3%, 85.1% and 72.0% respectively.
Data generated in collaboration with Dr Ceri Stewart (University of Nottingham).
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2.2.12.1 TAQMAN REACTION
Quantitative PCR was carried out on 4 wells per sample (3x RT positive; 1x RT
negative) as well as 3 blank wells per assay, as detailed in Table 2.11:
 ȋɊȌ
TaqMan Universal PCR Master Mix 10
cDNA (1:10 dilution) 2 ? ?Ɋ	  ?Ǥ ?ȋ ?Ǥ ?ɊȌ ? ?Ɋ  ?Ǥ ?ȋ ?Ǥ ?ɊȌ ?Ɋ  ?Ǥ ?ȋ ?Ǥ ?ɊȌ
PDAR (HPRT) 1
Sterile Water To make up 20
Table 2.11: TaqMan̻ mastermix for qPCR. This mastermix was used universally for qPCR in
this thesis. Reverse primers varied according to the assay used (Table 2.8) while both probe
and forward primer remained constant (Table 2.8).
Each assay was then run on the Stratagene̻ qPCR machine, collecting data for the
ROX̻, HEX̻ and FAM̻ dyes using the cycling procedures listed below:
Total PLAUR:
Temperature Time
50°C 2 min
95°C 10 min
95°C 15 sec X 40 cycles
60°C 10 min
Membrane and Soluble spliced PLAUR:
Temperature Time
50°C 2 min
95°C 10 min
95°C 20 sec X 40 cycles
55°C 20 sec
65°C 1 min
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2.2.12.2 ANALYSIS
Data analyses were carried out using the MxPro Mx3005P v4.01 software, utilising the
following procedure:
1. The reference dye was set to ROX and selected or unselected according to
which assay had been carried out
2. Data was treated individually, with fluorescence set to dRN
3. Data was visualised as log10 values and thresholds, determined through
manual adjustment of the cycle threshold, were set for each assay:
a. HPRT: 0.02
b. Total PLAUR: 0.03
c. Membrane/Soluble Spliced PLAUR: 0.04
4. The generated data was exported to Microsoft Excel where deltaCt was
calculated by subtracting of the data from each well from the mean HPRT value
for that particular sample triplicate
5. In order to correct for the logarithmic scale to which this data is plotted the
deltaCt value is transformed by [2^(-deltaCt)]. This generates values
representing the original mRNA concentrations.
86
2.3 PROTEIN METHODS
2.3.1 BIO-RAD PROTEIN ASSAY
The Bio-Rad protein assay is based on the Bradford assay for solubilised protein
quantification (Bradford, 1976). This is a simple and accurate procedure that involves
the addition of an acidic dye to a protein solution, where the absorbance spectrum
shifts from 465nm to 595nm on binding to protein. This assay was used to normalise
protein concentrations prior to carrying out any protein based assay.
ǡ ?ǣ ? ? ? ?Ɋ ? ?Ɋ ? ?ǦǤǡǡ ?ȋ ? ? ? ?ɊȀ  ? ?Ǥ ?ɊȀȌ       Ǥ       ? ?ǦǤ ? ? ?Ɋ
was then plated into a new 96-well plate and the degree of absorption at 595nm was
read using a Flexstation 3 microplate reader. Unknown samples can be extrapolated
from the standard curve.
2.3.2 WESTERN BLOTTING
Western Blotting is a procedure that allows for visualisation and quantification of
specific proteins from a mix of total proteins through the use of antibodies raised
against the protein of interest. For the purpose of this thesis, proteins were separated
in a polyacrylamide gel and transferred to a PVDF sheet based on the methodology
outlined by Towbin et al. (Towbin et al., 1979).
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2.3.2.1 CELL LYSATE RECOVERY
Total intracellular protein samples used for western blotting were obtained from cells
cultured in 6-well plates. To collect the protein lysate, the cell monolayer was first    ?  Ǥ        ? ? ?Ɋ   ?
loading dye followed by manual scraping of the cell monolayer and recovering of the
cell lysate to a microfuge tube.
2.3.2.2 SDS PAGE ELECTROPHORESIS
Sodium Dodecyl Sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a method
by which proteins are separated according to their electrophoretic mobility, which is a
value that reflects both the length of a proteins polypeptidechain (i.e. size) and its
charge. Presence of the anionic detergent SDS linearizes the proteins while also
imparting a negative charge to linearized proteins with an even distribution of charge
per unit mass, thereby facilitating the separation of the protein according to
charge/size.
Briefly, 10% Acrylamide resolving gels (resolves 21-100kDa) (constituted as outlined
in Table 2.12) were used with the Bio-Rad Mini-protean III gel electrophoresis
apparatus.
Component Volume
Distilled water 8.0ml
30% Acrylamide 6.6ml
10% SDS  ? ? ?Ɋ
1.5M TRIS-HCL 5.0ml
10% APS  ? ? ?Ɋ  ?Ǥ ?Ɋ
Table 2.12: Reaction mix to create 10% Acrylamide resolving gels. This gel was used to
separate proteins based on their electrophoretic mobility on application of a current as the
first step in Western Blotting.
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Once this gel had set, a 5% stacking gel (constituted as outlined in Table 2.13) was
formed as set out below and placed on the 1cm gap on the top of the stacking gel. A
comb was introduced to the gel and left to set.
Component Volume
Distilled water 6.80ml
30% Acrylamide 1.66ml
10% SDS  ? ? ?Ɋ
1.0M TRIS-HCL 1.26ml
10% APS  ? ? ?Ɋ  ? ?Ɋ
Table 2.13: Reaction mix to create 5% Acrylamide stacking gels. This gel was used to stack
the sample prior to separation on a resolving gel for the Western Blotting procedure.
Samples were loaded onto the gel while submerged in running buffer following
denaturation of the samples by heating at 94oC for 5 minutes. Samples were then
separated by first running the samples through the stacking gel at 100V followed by
the resolving gel at 200V until just before the blue band runs off the bottom of the gel.
2.3.2.3 WESTERN BLOTTING USING THEWET TECHNIQUE
Following successful separation of proteins by SDS-PAGE, proteins are transferred to a
PVDF membrane. Transfer utilises electroblotting, where an electric current attracts
the proteins from the gel into the PVDF membrane while maintaining the organization
they had within the gel. Following protein transfer, non-specific protein binding sites
are blocked by incubation in goat serum or milk. Proteins of interest are then probed
with a primary antibody raised against a specific protein. A labelled (e.g. Horse Radish
Peroxidase [HRP]) polyclonal secondary antibody then binds to the primary antibody
and so amplifies the signal. The secondary antibody is then conjugated to a luminescent
enzyme that allows visualisation of the target protein using photographic film.
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Briefly, following electrophoresis, the resolving gel was equilibrated in 1X transfer
buffer for 15 minutes. At the same time PVDF membrane, activated by dipping in 100%
methanol, and filter paper cut to the dimensions of the resolving gel (~7x9cm) were
also equilibrated in 1X transfer buffer for 15 minutes. The SDS-PAGE separated
proteins were then transferred to the PVDF membrane in ice-cold 1X transfer buffer,
where the protein transfers towards the positive cathode at 100V over a period of 1
hour. The membrane was washed for 10 minutes in PBS+0.1% v/v Tween (PBST) and
blocked using either 10% goat serum in PBST for the anti-PLAUR monoclonal primary
antibody IIIF10, or 10% Marvel̻ milk in PBST for the anti-PLAUR polyclonal primary
antibody BAF807. All blocking was carried out over 4 hours at room temperature. The
primary antibodies (Table 2.14) were diluted in the blocking solution and incubated
with the membrane at 4oC overnight. This was followed, after a 3X wash in PBST, with
incubation with an HRP-conjugated secondary antibody (Table 2.14) diluted in the
respective blocking solution and incubated at room temperature for 60 minutes.
Blocking Agent Primary Antibody Secondary Antibody
10% Goat Serum
IIIF10 monoclonal
(1:400)
Goat Anti-Mouse HRP
(1:1000)
10%v/v Marvel Milk
BAF807 polyclonal
(1:500)
Donkey Anti-Goat HRP
(1:1000)
10%v/v Goat Serum
ȾǦ
(1:1000)
Goat Anti-Rabbit HRP
(1:1000)
Table 2.14: Antibodies used in Western Blotting for PLAUR. Monoclonal antibody IIIF10
specifically binds to PLAUR DI, while BAF807 is a non-specific polyclonal binding to all parts   Ǥ  ȾǦ      ǡ   
variation, based on total protein loaded into the wells.
2.3.2.4 ECL METHOD OFWESTERN BLOT PROTEIN DETECTION
The Enhanced Chemiluminescence (ECL) method of protein detection was used to
detect labelled protein levels. In this method HRP, conjugated to the secondary
antibody, catalyses the oxidation of diacylhydrazide luminol present in the ECL
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solution, to produce excited luminol which decays to ground state via a light-emitting
pathway. Exposure of photographic film to this luminescent blot allows for highly
sensitive (<1pg antigen) quantification of the protein of interest.
In brief, following a 3X wash with PBST, the membrane was incubated for one minute
at room temperature in 1ml of ECL reagent 1 and 1ml of ECL reagent 2 and then
exposed to photographic film (Hyperfilm, GE Healthcare) within a developing cassette.
The exposed film was visualised using a 1:5 dilution of Kodak® Developer.
Development was terminated by washing the film in tap water and immersing it in a
1:5 dilution of Kodak® Fixer until it turned transparent. The film was rinsed in water
and air dried. If a secondary blot was to be carried out on the membrane, primary and
secondary antibodies were stripped off the blot by incubating the blot in warmed
(37oC) Restore Western Blot Stripping Buffer (Fisher Scientific, UK) for 15 minutes at
37oC. The membrane would then be ready for re-blocking and staining.
The relative densities of Western blot bands were calculated using the software Image J ?Ǥ ?ǡ  ȾǦ
cellular protein lysate was used.
2.3.3 SANDWICH ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
Measurement of the concentration of circulating soluble cleaved PLAUR was carried
out using sandwich Enzyme Linked Immunosorbent Assays (ELISAs) (Martins et al.,
2012, Rybakowski et al., 2012, Singh et al., 2012) based on the previous use of
sandwich ELISAs to detect circulating levels of soluble cleaved PLAUR (Andres et al.,
2012, Barton et al., 2009). Sandwich ELISAs capture the protein in between two layers
of antibodies (i.e. capture and detection antibody) using two separate epitopes on the
protein (Fig. 2.3). This gives an advantage over other forms of ELISA due to increased
sensitivity and removing the need for sample purification.
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Figure 2.3: Sandwich ELISA procedure. A capture antibody is left overnight to bind to the
plastic, which is then blocked using 1% solution of BSA in PBS. Sample then specifically binds
to the capture antibody and in turn captures the detection antibody to which the HRP
conjugated streptavidin binds. This then allows activation of the colour solution which can be
read using a plate reader to quantify the amount of soluble protein in solution when data is
read off a standard curve.
The kit used in this thesis was the Human Duoset PLAUR ELISA, detects scPLAUR and
not ssPLAUR (Fig. 2.4).
Figure 2.4: The Duoset sandwich ELISA detects scPLAUR but not ssPLAUR. Supernatant
was taken from a population of Normal Human Bronchial Epithelial cells shown, via Western
Blotting, to be recombinantly over expressing each of the different forms of PLAUR (Panel A)
(P=1.3x10-3). A Duoset Sandwich ELISA on these supernatants was able to identify elevated
levels of scPLAUR originating from the overexpression of the molecule or from excess
shedding due to mPLAUR expression, but was unable to detect overexpression of the soluble
spliced receptor (Panel B) (P<1x10-4). (n=4 over 2 donors; Western Blotting data normalised
to media only control.)
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In brief, a non-sterile 96 well plate was coated overnight with detection antibody
diluted in phosphate buffered saline (PBS). Following removal of the remaining
solution by 3 PBS+0.05% v/v Tween (PBS-T) washes, the rest of the uncoated plate
was blocked with reagent diluent (PBS + 1% w/v BSA) for one hour. Sample, diluted in
reagent diluent as required, was then added in duplicate for a period of two hours. This
was followed by the addition of the capture antibody diluted in reagent diluent with
2% v/v heat-inactivated Goat Serum for two hours, Streptavidin diluted in Reagent
diluent for 20 minutes and Colour Solution. Plates were washed 3 times with PBS-T
before the addition of each new solution. Following a 20 minute incubation in the dark,
stop solution (2N H2SO4) was added and the optical density was read using a
Flexstation 3 microplate reader (reading at 450nm and corrected at 570nm).
Concentration values were then calculated from standard curve that was included into
each plate assay.
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2.4 MAMMALIAN CELL CULTURE AND RELATED METHODS
2.4.1 MAMMALIAN CELL LINES
2.4.1.1 BEAS2BR1 CELLS
Beas2BR1 cells, which were originally derived from the bronchial epithelium of non-
diseased individuals, were transformed with an Adenovirus12-SV40 hybrid virus that    
	ǦȾ  ȋ  Ǥǡ  ? ? ? ?Ȍ ȋ	Ǥ  ?Ǥ ?ȌǤ
Although these cells are routinely used as representative cells of the airway epithelium,
in this thesis their use was limited to proof of principle experiments in light of their
known atypical karyotype (Ohnuki et al., 1996).
Figure 2.5: A light microscope X20 magnification
image of Beas2BR1 cells. Cells are identified to be
generally rounded with slightly tapered edges.
 ? ? ?Ɋ
94
2.4.1.2 MRC-5 CELLS
MRC-5 fibroblast cells were originally derived from the normal lung tissue of a 14 week
old male foetus (Jacobs et al., 1970) (Fig. 2.6). In this thesis these cells were used as
control fibroblast cells for immunostaining experiments.
Figure 2.6: A light microscope X20 magnification image of MRC-5 cells. Cells are identified
to be thin and highly elongated, which is characteristic of fibroblasts.
2.4.1.3 CULTURING CONDITIONS FOR MAMMALIAN CELL LINES
All cell lines were cultured in Dulbeccos Modified Eagles Medium (DMEM)
supplemented with 10% v/v Foetal Calf Serum (FCS). Cells were detached from culture
through trypsinisation, with trypsin de-activated using DMEM+10% FCS.
 ? ? ?Ɋ
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2.4.2 MAMMALIAN PRIMARY CELLS
2.4.2.1 NORMAL HUMAN BRONCHIAL EPITHELIAL CELLS
Primary cells used in this thesis were human bronchial epithelial cells obtained from
the post-mortem lungs of normal male subjects sourced from Lonza (Castleford, UK)
(Fig. 2.7). For further details see Appendix II
Figure 2.7: A light microscope X20 magnification image of normal human bronchial
epithelial primary cells (Donor 7F3158). Cells are identified to be generally rounded with a
rice like shape, which is different to that of Beas2BR1 cells.
2.4.2.2 CULTURING CONDITIONS FOR MAMMALIAN PRIMARY CELLS
Normal human bronchial epithelial cells (NHBECs) are cultured in bronchial epithelial
basal media (BEBM) supplemented with additives and growth factors to formȋ
Ȍȏ ?ɊȀ ǡ  ? ?ɊȀǡ  ?Ǥ ?Ȁ     ǡ  ?Ǥ ?ɊȀǡ  ?Ǥ ?ɊȀ ?ǡ  ? ?ɊȀǡ  ?Ǥ ?Ȁ
and 6.5ng/ml triiodo-L-thyronine (Lonza). Cells were detached from culture through
trypsinisation, with trypsin de-activated using Trypsin Inhibitor. NHBECs were seeded
 ? ? ?Ɋ
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at specific numbers as laid out in Table 2.15 in order to seed at 3500cells/cm2 as
recommended by Clonetics; Manual - Airway Epithelial Systems - Instructions for use.
Culturing Plastic Number of cells to seed at 3500cells/cm2
T75 vented flask 262,500
T25 vented flask 87,500
6-well plate 96,000
48-well plate 7,500
96-well plate 3,200
4-well chamber slide 8,300
Table 2.15: Cell seeding densities for Normal Human Bronchial cells. These cell seeding
densities were used to seed at the recommended density of 3500 cells/cm3, which resulted in
a 90% confluent population after five days of culture.
2.4.3 CRYOPRESERVATION OF CULTURED CELLS
In order to be able to store both cell lines and primary cells long-term, cell expansion
has to be halted whilst maintaining cell viability (Ryan, 2004). Cells were frozen to a
temperature of -180°C by placing them in a cryogenic tank filled with liquid nitrogen.
Prior to freezing, cells were suspended in a 10%v/v solution of DMSO in FCS (Cell
lines) or BEGM (NHBECs). DMSO acts as a cryoprotective agent reducing the rate of
cooling and therefore preventing cell dehydration and the formation of ice crystals that
would otherwise lyse the cells. Primary cells were frozen in freezing medium of
BEGM+10%v/v DMSO at a concentration of 2.5x106 cells/ml (per vial). Cell lines were
frozen in freezing medium of FCS+10% v/v DMSO, with one confluent T75 flask split
into 8 vials (1ml).
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2.4.4 CELL COUNTING
Cell density was determined through cell counting using an improved NeubauerǤ  ? ?Ɋ 
assembled haemocytometer. Cells were visualised under an inverted light microscope
and the average number of cells was counted in the 4 corner squares. This was then
multiplied by 1x104as the volume of each corner square is 0.1mm3.
2.4.5 TRANSIENT TRANSFECTION OF MAMMALIAN CELLS
All transient transfections of mammalian cells were carried out using the lipid based
transfection reagent FuGENE® 6 (Promega, UK)(Uyttersprot et al., 1998) where the
liposome+DNA complex moves into the cell by either endocytosis or fusion with the
plasma membrane via the lipid moieties of the liposome (Gao and Huang, 1995).
FuGENE® 6 was selected based on its very high transfection efficiency, low cytotoxicity
and ability to function equally well in the presence or absence of serum.
Transfection was carried out according to the manufacturers instructions with
transfections carried out when cells achieved 50-80% confluence. Briefly, the FuGENE®
6 Transfection Reagent was first diluted in BEGM, followed by a 5 minute incubation.
Plasmid DNA was then added at an experiment specific ratio, allowed to complex with
the FuGENE® 6 for 15 minutes and then added to the cells.
2.4.6 MANUFACTURE OF CIGARETTE SMOKE EXTRACT
The use of cigarette smoke extract to stimulate bronchial epithelial cells has been
extensively used in the literature to imitate the effect of smoking on the airway
epithelium (Liu et al., 2008, Profita et al., 2011, van der Deen et al., 2007). Cigarette
smoke extract was formulated as previously described (Carp and Janoff, 1978) using
the University of Kentucky Reference Cigarette programme cigarettes version 3R4F
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(Roemer E et al., 2012)(Appendix III), which were sealed and stored at 4°C until use.
Briefly, two 84mm long cigarettes with the filter removed were combusted in a home-
made setup (Fig. 2.8) and the smoke bubbled manually through 15ml of BEBM. The ?Ǥ ? ?Ɋ
bacteria or large contaminating particles. In order to normalise different formulations
of CSE, the absorbance of a set of CSE serial dilutions was determined (0%v/v, 10%v/v,
20%v/v, 50%v/v and 100%v/v CSE) and corrected at 320nm via the NanoDrop
Technologies NanoDrop® ND-1000 Spectophotometer, using its Protein A280 setting. A
CSE dilution that gave an absorbance value of 0.15 was considered to be 100% CSE.
Figure 2.8: In house set-up used to manufacture cigarette smoke extract. Two University
of Kentucky 3R4F cigarettes with their filter removed were attached, via a 3 way valve to a
20ml syringe and 15ml of media. Manually smoke was bubbled through the media until both
cigarettes were spent creating cigarette smoke media that was then filter sterilised and
normalised for use in cell culture.
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In order to identify the maximum CSE concentration that could be used with NHBECs
without causing significant cell death, increasing concentrations of CSE diluted in
BEBM were introduced to NHBECs. NHBECs were then counted using a
haemocytometer (see Section 2.4.4) following dilution of the cells with a 1:10 solution
of Trypan Blue, a dye which is actively excluded from the cytoplasm of viable cells. This
identified a 5% v/v solution of CSE diluted in BEBM as the maximal solution that can be
used in NHBECs (Fig. 2.9).
Figure 2.9: Cell death rates on increasing concentrations of cigarette smoke extract.
Determination of viable cells using Trypan blue exclusion identified that addition of cigarette
smoke extract at a concentration higher than 5%v/v results in substantial cell death (n=3).
***: P<0.001,
All additions of CSE to NHBECs occurred within 30 minutes of original smoke
distillation, in order to prevent precipitation of the dissolved substance.
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2.5 CELLULAR OUTCOMES
2.5.1 SCRATCH-WOUND ASSAY
The scratch-wound assay has been previously used as a model for cell injury and as a
measure of cell migration/proliferation (Wadsworth et al., 2006, Bove et al., 2008, Loo
et al., 2011, Stewart et al., 2012). This assay involves the disruption of a fully confluent
NHBEC monolayer in a 6-well plate by dragging the tip of a sterile P200 pipette tip
vertically across the well and then allowing cells, while under optimal growth
conditions (37oC+5% CO2), to attempt to repair the scratch-wound. The scratch wound
assay was carried out in bronchial epithelial wounding media (BEWM), which consists
of BEGM without Hydrocortisone, Epinephrine or Epithelial growth factor
supplements. These supplements were excluded as they or related molecules have
previously been shown to modulate wound repair (Wadsworth et al., 2006, Sivamani et
al., 2009) and/or PLAUR (the gene under investigation) expression (Baek et al., 2008).
Briefly, 24 hours prior to scratch-wounding, NHBEC culture media was changed to
BEWM. NHBECs grown to >90% confluence were then wounded with a sterile P200
pipette tip to form 3 vertical wounds. The cell monolayer was then washed with
warmed sterile PBS and fed with fresh warmed BEWM. Wounds were then visualised
over 24 hours at 9 sites in each well using a Nikon Diaphot 300 Inverted Phase
Contrast Microscope with the 4x objective lens. Wound areas were calculated using
CellProfiler cell image analysis software (Kamentsky et al., 2011) using a pipeline
specifically designed for NHBECs by Mr Benjamin Willson (University of Nottingham).
Data was presented as percentage wound remaining rather than area healed in order
to compensate for variation in wound size.
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2.5.2 MTT ASSAY
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a
colorimetric assay used to quantify mitochondrial dehydrogenase activity, which
reduces MTT to hydrophobic formazan crystals (Mosmann, 1983). These crystals give a
quantifiable purple colour when dissolved in alcohol (isopropanol). The assay
therefore measures cellular respiration, with the amount of formazan produced being
proportional to the number of living cells present in culture. The rate of cellular
respiration measured by the MTT assay has been previously extrapolated to represent
the rate of cellular proliferation (Mosmann, 1983). However, as this assay is not a true
measure of changes in cell number, the resulting data cannot be used with full certainty
to determine the proliferation rate of NHBECs in cell culture. Therefore, in this thesis,
results from the MTT assay are considered as data relating to mitochondrial activity
that may relate to cellular proliferation rates.
ǡ    
ǡ  ? ? ?Ɋ   ǡ  ?Ǥ ? ?Ɋ ǡ  ?Ǥ ?Ȁ
solution of MTT in BEGM was added to NHBECs cultured in a 96-well plate. The culture
was then incubated at 37oC+5% CO2 for 4 hours, after which the MTT solution was         ? ? ?Ɋ  Ǥ 
solutions were then incubated for 10 minutes at room temperature. The degree of
absorption was then read using a Flexstation 3 microplate reader at a wavelength of
570nm using a background reduction of 690nm. All samples were assayed in
quadruplet and isopropanol only wells were used as negative controls.
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2.5.3 CASPASE-3/7 ASSAY FOR CELLULAR APOPTOSIS
The Apo-ONE® Homogeneous Caspase-3/7 Assay is a sensitive measurement of
caspase-3 and -7 activities (Promega Technical Bulletin # TB295). These members of
the cysteine aspartic acid-specific protease (caspase) family are known to be activated
in the apoptotic cell through extrinsic (death ligand) and intrinsic (mitochondrial)
pathways (Salvesen, 2002, Ghavami et al., 2009). Therefore, these molecules can be
used as a marker of the degree of apoptosis in a cell population. In this assay, a pro-
fluorescent substrate (rhodamine 110, bis-(N-CBZL-aspartyl-L-glutamyl-L-valyl-L-
aspartic acid amide [Z-DEVD-R110]) diluted in an optimized bifunctional cell
lysis/activity buffer (DEVDase) is cleaved by active caspase-3/7. This cleavage results
in loss of the DEVD peptide allowing the rhodamine 110 group to fluoresce on
excitation at 499nm.
The assay was carried out according to manufacturers instructions. Briefly, NHBECs
cultured in a black walled tissue culture plate were cultured in the presence of either ? ? ?Ɋ
ȋȌ ? ? ?Ɋ ? ? ?Ɋ 2O2 in BEGM (stimulated
cells), previously shown to induce NHBEC apoptosis (Bucchieri et al., 2002). Cells were
then incubated at 37oC+5% CO2 for 8 hours, after which they were frozen at -80oCǤ ? ? ?ɊǦ ?Ȁ ?ȋ ?ǣ ? ?
100X Substrate to Buffer) was then added to the cells which were then left to incubate
for 8 hours at 37oC+5% CO2. Using a Flexstation 3 microplate reader, solutions were
mixed and fluorescence read using an excitation wavelength of 485nm and an emission
wavelength of 530nm. All samples were assayed in triplicate and media only wells
were used as negative controls.
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2.5.4 IMMUNFLUORESCENCE
Immunostaining was first described in 1941 by Coons et al. as a method to detect
specific protein in a tissue sample via the use of antibodies (Coons et al., 1941, Coons
and Kaplan, 1950). For the purpose of this thesis, staining was limited to that of
cultured cells, i.e. immunocytochemistry, where primary antibodies bind to specific
peptides or protein antigens within or on the surface of the cultured cells. Visualisation
occurs through the binding of a secondary fluorescent-tagged antibody grown against
the species of the primary antibody which is excited and detected on an Improvision
Spinning Disk Confocal Microscope (PerkinElmer UK).
Briefly, the media was aspirated off NHBECs cultured in 4-well glass chamber slides
and washed (X3) in PBS. Cells were then fixed by incubation at room temperature for
45 minutes in 4% formaldehyde, followed by blocking overnight at 4oC with a PBS
solution containing 10% v/v goat serum with 0.15% v/v Triton X-100 and 1% v/v BSA.
The relevant primary antibody was added and left to incubate overnight at 4oC,
followed by the addition, in the dark, of the relevant secondary fluorescent antibody.
Finally cells were mounted underneath a glass cover-slip using the VectaShield̻
Hard+Set Mounting Media with DAPI. Cells were washed 3 times with PBS between
each step. Fluorescence was visualised using the Improvision Spinning Disk Confocal
Microscope (PerkinElmer UK).
104
2.6 METHODS INVOLVED IN POPULATION GENETICS
2.6.1 STUDY POPULATIONS
2.6.1.1 DUTCH ASTHMA AND CONTROL POPULATION
A cohort of 514 Caucasian Dutch asthma patients and 104 Caucasian spouse controls
were selected from 2 populations consisting of a) 200 families and b) 407 trios, based
on the presence of serum samples. Both populations were ascertained through a
proband characterised using a standardized study protocol, with asthma from the
northern part of the Netherlands and studies with an identical protocol, as previously
described (Koppelman et al., 2009). Control subjects were chosen from spouses of the
asthmatic subjects who had no doctor diagnosed respiratory disease. The controls
were predominantly female (62.5%), >40 years (mean age=50±8.16) and had a
smoking pack-year history mean of 10.50 (±1169). Mean percentage predicted FEV1
(FEV1(%Pred)) was 100% (±13.32), FEV1/VC was 0.82 (±0.04) with a percentage
change in FEV1 post bronchodilator of 3.91% (±4.43). Asthma subjects were evenly
distributed along gender (Female: 55.1%) but were generally younger with a mean age
of 40 (±12.3) and had a smoking pack-year history mean of 4.95 (±9.58). Mean FEV1
(%Pred) was 92.42% (±18.73), FEV1/VC was 0.76 (±0.12) with a percentage change in
FEV1 post bronchodilator of 17.44% (±15.82). Ethical approval was obtained by the
University of Groningen.
2.6.1.2 UK COPD POPULATION
A cohort of 381 British COPD subjects were recruited from 5 UK centres based on
physician and spirometry defined COPD (Stewart et al., 2009). Subjects were
Caucasian, predominantly male (62.7%), > 40 years (mean age=68±8.45) and smokers
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with > 10 pack-year history (mean = 46.87±18.52). Mean FEV1 (%Pred) was 41.87
(±18.52), FEV1/VC was 0.45 (±0.12) with a percentage change in FEV1 post
bronchodilator of 1.16% (±0.15). Ethical approval was obtained from the relevant
ethics committees (Nottingham, Sheffield, Manchester, Leicester and Oxford) and
informed consent from all subjects was obtained. Of the recruited subjects, 161 had a
previous diagnosis of asthma in addition to COPD.
2.6.2 SNP GENOTYPING
All SNP genotyping was outsourced to KBiosciences (Hoddesdon, Hertfordshire, UK),
which carried out genotyping in 96-well DNA plates containing 10ng/ml DNA and 4
water control samples. KBiosciences utilises its own patented allele-specific PCR  ȋ Ǧ   Ȍ
to carry out genotyping. This involves the use of two allele-specific forward primers,
each of which contain a unique unlabelled 5` tail, with a common reverse primer in a
competitive genotyping system using Fluorescent Resonance Energy Transfer (FRET).
Here two unique quencher cassette oligonucleotides (FAM or CAL Fluor Orange 560)         Ǧ  
fluorescent based detection of the SNP genotype. The KASP system allows for the
detection of SNPs without the need for a separation step and has a very high SNP to
assay conversion rate (>90% in comparison to ~60%with Taqman).
2.6.2.1 QUALITY CONTROL OF GENOTYPING DATA
Quality control was initially carried out by KBiosciences using the following criteria:
x Identify whether the genotypes were in distinct genotype clusters for each SNP
x Identify whether all water controls were negative
x Identify if the number of the SNP call was >90% of the genotyped population
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I also completed quality control with genotyping data visualised using the KBioscience
developed software SNPviewer26. An example of the interface can be seen in Fig. 2.10.
Axes correspond to the fluorescence intensity from the two unique quencher cassette
oligonucleotides with different colours used to represent the genotype groups (red,
green and blue), black for the water control and pink for samples that could not be
called by the software. Data was quality controlled by checking that:
x Appropriate clustering was present
x Genotype success rates were >90% of the genotyped population
Any samples that were miscalled and could be identified as a particular genotype with
acceptable accuracy were manually re-called on the output data sheet. Analysis
identified that genotyping success rates were >91% for all SNPs genotyped and >99%
for the majority of the SNPs genotyped.
Figure 2.10: Representative image of SNPViewer2 outlay of KASP genotyping by
KBiosciences. Axes correspond to the fluorescence intensity from the two unique quencher
cassette oligonucleotides with different colours used to represent the genotype groups (red,
green and blue), black for the water control and pink for samples that could not be called.
6 http://www.kbioscience.co.uk/software/SNP%20viewer%20intro.html
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2.6.2.2 HARDY-WEINBERG EQUILIBRIUM
Under Hardy-Weinberg Equilibrium (HWE), both allele and genotype frequencies in a
population remain constant from generation to generation unless specific disturbing
influences are introduced. Deviations from HWE may be due to either genotyping
error, which tends to be the most common cause in genotyping analyses (Cox and
Kraft, 2006, Hosking et al., 2004), non-random mating, small population size, selection
bias, mutation or migration or any combination of the above (Salanti et al., 2005).
HWE is modelled using the equation:
࢖૛ + ૛࢖ࢗ+ ࢗ૛ = ૚
were p2= AA genotype, 2pq=Aa genotype and q2=aa genotype.
Genotype data was investigated for variance from HWE using a Chi-squared test,
comparing population observed frequencies against expected frequencies. Genotype
values were taken from only unrelated individuals (parents) tested. No SNP was found
to deviate from HWE in any of the populations genotyped in this thesis (P<0.05).
2.6.3 HAPLOTYPE ANALYSES
Linkage Disequilibrium (LD) identifies the degree of non-random association between
SNPs across a region, providing a greater insight of DNA regional architecture.
Discovery of regions with extensive LD, encompassing a sentinel SNP, identifies
alternate polymorphisms that could be the underlying cause of any detected
association. This is since SNPs occurring together in a region of high LD are said to
occur together in a population at a greater degree than by chance, i.e. are inherited
together. Importantly, this form of analysis is therefore able to increase the scope of
genotyping experiments through the identification of alternate SNP genotypes that
were not included in the original genotyping design.
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Haploview7 (Barrett et al., 2005) was used to provide haplotype data, i.e. LD data, for
the population. Here, LD was defined using the R2 measure. The R2 value can vary
between 0 and 1, where R2=0 denotes linkage equilibrium and R2=1 denotes a perfect
correlation between the two alleles at the two SNP markers. Presence of high R2 values
between polymorphisms with similar allele frequencies will therefore identify good
tagging SNPs.
Briefly, Haplotype input data was generated using data from the HapMap Project
(Frazer et al., 2007, The_International_HapMap_Consortium, 2003) using the
procedure outlined below:
1. HapMap Download was selected from the drop down box
2. Genome version 3 build, release 27 was selected, followed by the
chromosome of interest
3. The areas of interest adjacent to the SNP of interest was selected
4. The CEU (Caucasian European Population) from the analyses panel was
selected.
5. The HapMap show info track was selected.
6. The LD Plot colour scheme was chosen from the display panel.
7. The show R2 tab was selected from the display panel
Blocks of linkage disequilibrium were defined as set up by Gabriel et al. through the
analyses panel (Gabriel et al., 2002).
7 Available at http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/downloads
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2.7 STATISTICAL ANALYSES
While two-way ANOVAs were carried out in PRISM v5.04, all remaining statistical
analyses were carried out in SPSS v16.
2.7.1 GENETIC ASSOCIATION ANALYSES
2.7.1.1 POWER CALCULATIONS
Power calculations were carried out in QUANTO8 for association studies of continual
traits in the cohorts of non-related individuals. Power calculations were carried out
using the following steps:
x Continuous data (change in scPLAUR levels) was selected for outcome/design
and gene only was selected as the hypothesis data
x SNP minor allele frequency was inserted for the SNP under investigation and
the additive model selected
x The cohorts population mean and standard deviation for the trait analysed
were introduced
x The tab main effect was selected and the beta value for the trait (degree of
change expected) was also introduced
x Sample size was inputted and an acceptable error rate of 0.05 set
x The calculator button was pressed to run the calculation
8 Available at - http://hydra.usc.edu/gxe/
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SNP MAF
COPD cohort
Power Calculation
rs9480227 0.32 >99%
rs7666900 0.14 >99%
rs6988339 0.40 >99%
rs6467459 0.33 >99%
rs4253238 0.48 >99%
rs341119 0.38 >99%
rs2731672 0.29 >99%
rs12200614 0.23 >99%
Table 2.16: Power calculations for genotyping carried out in the COPD cohort based on
variation is log10scPLAUR levels, identifies a >99% power statistic for all SNPs
genotyped. This identifies that all the quality controlled genotyping data is powered to detect
variation in log10scPLAUR levels due to changes in SNP genotype via association tests.
MAF=Minor Allele Frequency for the analysed population.
2.7.2 TESTS OF NORMALITY
Tests of normality were used in order to determine whether an outcome measure is
normally distributed or not and therefore determines which statistical tests can be run
on the data. However, in datasets with a small sample size (n<20), normality tests are
not powered to give confident results on Gaussian distribution. Therefore, as one
cannot be sure whether the assumption of normality has been violated and considering
that all the analyses in which these datasets were involved in were repeated
measurements (data taken from cell culture), all statistical tests in these datasets were
carried out using parametric tests.
In datasets where n ? ? ? ?ǡ
in SPSS, which identified whether the data fit a normal bell-shaped distribution.
Kolomogorov-Smirnov and Shapiro-Wilk tests of normality were also carried out,
where the cumulative distribution of the data is compared to an expected cumulative
normal distribution. A P-value of <0.05 indicates a non-normal distribution.
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2.7.3 LINEAR OUTCOME ANALYSES
2.7.3.1 LINEAR REGRESSION
This thesis is concerned with simple linear regression, where only one continuous
exposure variable is considered. Linear regression utilises the equation of a straight
line which would best describe how the outcome under investigation (usually plotted
on the y axis) changes with an increase in the exposure variable (value on the x axis).
The statistic attempts to plot the best straight line using the method of least squares,
with the equation of the regression line being:
࢟ = ࢼ࢕ + ࢼ૚࢞ȾȾ1 is the slope of the line. This statistical tool therefore
functions on the assumption that the relationship between variables is linear apart
from other assumptions including that:
x The outcome variable is normally distributed
x Standard deviation is identical for all points around the regression line
x All data points are independent
Briefly, analysis was carried out in SPSS as described previously (Stewart and Sayers,
2009), by selecting the Univariate analyses drop down menu. The phenotype under
investigation (scPLAUR) was placed in the dependant variable box while the exposure
variable and further known effectors of the phenotype variable (covariates) were
placed either in the covariates box if it was continuous or the Fixed Factor(s) box if
they were ordinal, following appropriate coding. The model was specified as Custom
and Main effects with factors and co-variates manually moved into the model.
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2.7.3.2 CORRELATION ANALYSIS
Correlation analysis estimates the degree of linear association between outcome and
exposure variables measured by the correlation coefficient r, which can be defined as
the number of standard deviations that the outcome y changes for a standard
deviation change in the exposure x. The correlation coefficient is always a number
between -1 and +1 were r=0 when variables are not associated. Negative values reflect
inverse relationships while positive values indicate that the outcome and association
variables increase or decrease together. Correlations presented in this thesis are
limited to a non-normal (non-parametric) dataset and therefore the non-parametric
version of the statistical tool (Pearsons Correlation) was used.
In SPSS, the bivariate button was selected from the Correlations bar in the analyse drop
downmenu. Pearsons correlation was selected.
2.7.4 CATEGORICAL ANALYSES
2.7.4.1 ANALYSES OF VARIANCE BETWEEN GROUPS
Tests carried out to identify variance in the mean (parametric) or median (non-
parametric) occurring between groups can be stratified based on the number of groups
analysed. When comparing two groups either a Students t-test (parametric) or Mann-
Whitney test (non-parametric) was used. When variance was investigated across 3 or
more groups either a one-way ANOVA (parametric) or a Kruskal-Wallis test (non-
parametric) was carried out. Post-hoc tests were carried out in one-way ANOVAs in
order to identify the groups that power the significant variance within the analysed
population. These consisted of either Tukeys post-hoc test, where all columns were
compared to each other or Dunnets when columns were compared to a selected
control column.
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All tests were carried out as two-tailed, were the null hypothesis is rejected when the
value of the test statistic is either sufficiently small or sufficiently large, as opposed to
one-tailed were only one of the rejection regions "sufficiently small" or "sufficiently
large" is preselected.
In SPSS, the required test was selected from either the Non-Parametric bar or the
Compare Means bar in the analyse drop downmenu.
2.7.4.2 TWO-WAY ANOVA
A two-way ANOVA is a similar test to the one-way ANOVA used when data can be
classified in two ways such as time and effect. This test is useful as it is able to not only
determine the main contributory effect of each independent variable but also identify
whether there is a significant interaction effect between the independent variables.
Briefly in Prism the two-way ANOVA test was selected from the analyse button and
the Bonferroni post-hoc test selected from the post-hoc drop-down bar.
CHAPTER 3:
SOLUBLE CLEAVED PLAUR AS A
BIOMARKER OF OBSTRUCTIVE
RESPIRATORY DISEASE
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CHAPTER 3: SOLUBLE CLEAVED PLAUR AS A BIOMARKER
OF OBSTRUCTIVE RESPIRATORY DISEASE
3.1 INTRODUCTION
As discussed in Chapter 1, scPLAUR is the remaining structure of the membrane bound
receptor, which is formed once cleavage has occurred at the receptors GPI anchor.
Previous studies have identified scPLAUR as a marker of human disease, with
elevations in the levels of the expressed protein determined in patients with various
types of cancer, including prostate (Almasi et al., 2011), pancreatic (Sorio et al., 2011),
colorectal (Halamkova et al., 2011) and lung cancers (Langkilde et al., 2011), as well as
other diseases such as liver cirrhosis (Zimmermann et al., 2012), sepsis (Savva et al.,
2011), cardiovascular disease (Persson et al., 2012) and other disease with low grade
inflammation (Eugen-Olsen et al., 2010a).
Apart from being a biomarker for disease per se, disease progression and disease
associated mortality, there has been some recent evidence that scPLAUR may act as a
direct modulator of disease. High serum levels of scPLAUR have been significantly
associated with short overall survival for patients suffering from prostate cancer,
(Almasi et al., 2011), while Zimmerman et al. have concluded that scPLAUR levels have
a high diagnostic power to identify established cirrhosis in chronic liver diseases with a
strong prediction of mortality or need for liver transplantation (Zimmermann et al.,
2012). Interestingly, a recent study by Shankland et al. has gone one step further by
identifying that scPLAUR not only acts as a disease biomarker in focal segmental
glomerulosclerosis, but also plays a direct role in the development and progression of    ǯ    Ⱦ3 integrin (Shankland and
Pollak, 2011).
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Interest in scPLAUR in obstructive lung disease stems from work in the same group
reported by Barton et al. in 2009, where PLAUR was identified as an asthma
susceptibility gene (Barton et al., 2009). In this study, single nucleotide polymorphisms
(SNPs) present in the genes intron 3 and 5`UTR, which were associated with asthma,
bronchial hyper-responsiveness (BHR) and decline in FEV1, were also associated with
differential serum scPLAUR expression (Barton et al., 2009). Here the presence of the
SNP risk allele was associated with elevations in serum scPLAUR.
Other studies provide further evidence of an association between scPLAUR and
respiratory disease. Elevated scPLAUR levels were identified in the induced sputum of
asthmatics when compared with healthy controls (Jiang et al., 2010, Xiao et al., 2005)
and in COPD subjects when compared to both asthmatics and healthy controls (Xiao et
al., 2005). Levels of scPLAUR in induced sputum were also found to be associated with
the degree of disease severity, with elevations discovered in the sputum of COPD
patients with a GOLD classification of III + IV when compared with COPD patients with
a classification of I + II (Jiang et al., 2010). Elevated levels of PLAUR were also identified
in the airways of patients who had died in status asthmaticus when compared to
airways from whole lung donors (Chu et al., 2006) and in the bronchial epithelial cells
of asthmatic subjects when compared to healthy controls (Stewart et al., 2012).
Therefore it was hypothesised that serum scPLAUR may be elevated in both asthma
and COPD, having a potential contribution to disease modulation. In addition it was
also hypothesised that serum scPLAUR may be associated with lung function based on
the known relationship between PLAUR and lung-function associated PLAUR SNPs
(Barton et al., 2009).
Identification of a novel serum molecule associated with obstructive airway disease
that could reflect changes in the airway, such as airway remodelling and changes in
lung function, may be utilised in conjunction with lung function tests to help determine
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the degree of asthma/COPD severity and to monitor disease progression. Although
previous work has already identified that elevated scPLAUR is associated with asthma
and COPD, this has been carried out in the induced sputum of diseased individuals.
Procurement of induced sputum is more stressful for the patient than procurement of a
simple blood sample. Therefore targeting scPLAUR in serum would be an easier and
therefore more clinically relevant medium to use for clinical diagnostics.
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3.2 AIMS
1. To determine whether the levels of scPLAUR in serum are elevated in
obstructive lung disease and reflect PLAUR driven mechanisms.
2. To determine whether the levels of scPLAUR in patient serum are related to
disease severity, lung function and/or bronchial hyper-responsiveness.
3. To replicate associations between a selection of PLAUR SNPs and serum
scPLAUR levels.
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3.3 METHODS
For general methods including population descriptives and demographics refer to
Chapter 2: General Materials and Methods.
3.3.1 ENZYME LINKED IMMUNOSORBENT ASSAY
Before quantifying serum scPLAUR levels, datasets were quality controlled. Related
subjects and controls with a percentage predicted FEV1 of <80% were removed from
the dataset. Serum scPLAUR levels were then determined in the Dutch asthma/control
(n=514 asthmatics; 96 controls), and Leicester COPD cohorts (n=381) via a Duoset
ELISA for scPLAUR (R&D Systems), with absorbance recorded using a Flexstation 3
microplate reader. A detailed description of this method is found in Section 2.3.3.
3.3.2 GENOTYPING AND QUALITY CONTROL
Genotyping data generation and quality control analysis were carried out by Dr Ian
Sayers (University of Nottingham) using procedures as described in Section 2.6.2.
Controls from the original dataset were quality controlled by excluding any subjects
with a FEV1 predicted <80%.
3.3.3 STATISTICAL ANALYSES
3.3.3.1 POPULATION STATISTICS
Tests for normality were initially carried out on scPLAUR levels in both datasets using
the Kolomogorov-Smirnov and Shapiro-Wilk tests. A detailed description of these tests
is available in Section 2.7.2.
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3.3.3.2 CORRELATION ANALYSES
As the distribution of scPLAUR levels in both datasets was determined to be non-
normalised, Pearsons Correlation was used in this chapter for all the correlation
analyses. Correlation was carried out on a number of potential co-variates for scPLAUR
levels in serum, namely height, weight, age and smoking pack/years.
Correlation analyses were also carried out on scPLAUR levels with the lung function
parameters FEV1 (L), FEV1(%Pred), FEV1/FVC, BHR (assessed through PC20 [the
provocative concentration of a substance such as methacholine required to cause a
20% fall in FEV1]) and the mean percentage change in FEV1 post-bronchodilator
(reversibility). Analyses were carried out separately in each population. A detailed
description of the procedure used is available in Section 2.7.3.2.
3.3.3.3 LINEAR REGRESSION
Linear regression (Univariate analyses of variance test) was used to identify
associations between PLAUR SNPs and serum scPLAUR levels. Analyses were carried
out separately in each population using the additive model. Age, height, weight and
smoking pack/years were used as covariates. A detailed description of the procedure
used to carry out the test is available in Section 2.7.3.1.
3.3.3.4 COLUMN STATISTICS
As serum scPLAUR levels were defined as non-normally distributed, Mann-Whitney
and Kruskal-Wallis tests were utilised to investigate differences in scPLAUR levels
between controls, asthmatics, COPD subjects and COPD subjects with a co-morbidity of
asthma, as well as differences between COPD severity, nocturnal asthma awakenings
and asthma atopic status. The Mann-Whitney test was also utilised to determine
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whether gender was a co-variate in the populations. A detailed description of the
procedure used to carry out this test is available in Section 2.7.4.
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3.4 RESULTS
3.4.1 POPULATION DESCRIPTIVES
For details of the populations used in this study see Sections 2.6.1.1 & 2.6.1.2.
Population descriptives identified significant differences between the different sub-
populations used in this study (Table 3.1).
Control Asthma COPD COPD & Asthma
Number 96 514 220 161
Percentage
Male
37.5% 44.9% 62.7% 49.1%
Mean Age*
(Years)
50 ±8.16 40 ±12.3 68 ±9.11 66 ±7.65
Mean Height*
(Metres)
1.71 ±0.08 1.74 ±0.09 1.67 ±0.09 1.66 ±0.10
MeanWeight*
(kg)
76.35 ±12.08 78.12 ±15.67 70.76 ±18.16 73.35 ±16.82
Percentage
Never Smokers
29.2 48.7 0 0
Mean Smoking*
pack years
10.50 ±11.69 4.95 ±9.58 45.95 ±26.69 41.53 ±24.09
FEV1 pre*
(%Pred)
100.94±11.00 80.71±20.70 40.50±16.99 39.51±16.27
FEV1 post*
(%Pred)
104.78±11.33 92.42±18.73 47.53±19.39 43.56±16.83
FEV
1
/VC pre* 0.80 ±0.05 0.70 ±0.14 0.46 ±0.13 0.44 ±0.12
FEV
1
/VC post* 0.82 ±0.04 0.76 ±0.12 0.45 ±0.13 0.44 ±0.13
Percentage
Reversibility*
(% change in
FEV1post bd)
3.91 ±4.43 11.72 ±7.16 6.64 ±3.29 3.59 ±0.56
BHR
(PC20mg/ml)
>32 <32 n/a n/a
Table 3.1: Population desciptives for cohorts used in this analysis. A star symbol defines
parameters that are statistically different across the groups as defined by Kruskal-Wallis tests.
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3.4.2 PLAUR SERUM LEVELS ARE NOT NORMALLY DISTRIBUTED
In the combined population of controls, asthmatics, COPD and COPD & asthma subjects
(n=991), the Kolmogorov-Smirnov and Shapiro-Wilk tests for normality result in
P-values of P<0.001. Since a significant P-value negates the null hypothesis of normal
distribution this identifies that serum scPLAUR levels are non-normally distributed.
This can also be confirmed by eye (Fig. 3.1), where a population curve presents a right-
handed skew. This result is also apparent for the control (n=96), asthmatic (n=514),
COPD (n=220) and COPD & asthma (n=161) populations, when these were analysed
separately (P<0.01) (Fig. 3.2). Conversion of the data to log10, x2 and square root values
did not alter the distribution of the data (Table 3.2) and so all analyses were carried
out on the non-transformed scPLAUR data using non-normally distributed tests.
Figure 3.1: The normality curve for the combined population of controls, asthmatics,
COPD patients and COPD patients. The curve presents with a right-handed skew, identifying
a non-normally distributed population. Analyses of the dataset using Kolmogorov-Smirnov and
Shapiro-Wilk tests confirm this finding (P<0.001).
PLAUR
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Figure 3.2: Population curves for the individually analysed cohorts. When analysed
separately, controls (A), asthmatics (B), COPD patients (C) and COPD patients with a co-
morbidity of asthma (D) are also found to produce right-skewed population curves and are
therefore considered to be non-normally distributed. Analyses of the datasets using
Kolmogorov-Smirnov and Shapiro-Wilk tests confirm this finding P<0.01.
PLAUR values Kolmogorov-Smirnov Shapiro-Wilk
Raw <0.001 <0.001
log 0.04 <0.001
x2 <0.001 <0.001
Square Root <0.001 <0.001
Table 3.2: Conversion of serum PLAUR data (n=991) to log, squared and square root
values does not alter significance for the Kolmogorov-Smirnov and Shapiro-Wilk tests of
normality. Therefore raw serum PLAUR levels were used and analysed using non-parametric
statistical tests.
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3.4.3 IDENTIFYING CO-VARIATES THAT INFLUENCE SCPLAUR LEVELS
In the combined population of controls, asthmatics, COPD and COPD & asthma subjects,
patient height and weight were both negatively correlated with serum scPLAUR levels,
while age and smoking pack/years were positively correlated with serum scPLAUR
levels (Table 3.3; Fig. 3.3). Gender was not associated with serum scPLAUR levels
(P=0.304). These associations were replicated in the individual datasets (data not
shown). Therefore in this chapter, age, height, weight and smoking pack/years were
considered as co-variates and included in the tests of association.
Factor p-Value Correlated? R2
Height 0.001 Yes 0.012
Weight <0.001 Yes 0.014
Smoking pack/years <0.001 Yes 0.059
Age <0.001 Yes 0.036
Table 3.3: Age, height weight and smoking pack/years were defined as covariates for
this study. Association was based on significant positive (Smoking & Age) and negative
(Height & Weight) correlations with serum scPLAUR levels.
Figure 3.3: Dot plots for the linear variants tested for correlation. In the combined
population negative correlations for height (R2=-0.012) and weight (R2=0.014) and positive
correlations for smoking pack/years (R2=0.059) and age (R2=0.036) are identified (P<0.001).
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3.4.4 SERUM SCPLAUR LEVELS ARE ELEVATED IN ASTHMA AND COPD
Median levels of serum scPLAUR in asthmatics (3306pg/ml) were elevated when
compared to healthy controls (2538pg/ml) (P<1x10-5) (Fig. 3.4). Serum scPLAUR levels
in COPD patients (5836pg/ml) and COPD with a co-diagnosis of asthma (5870pg/ml)
were also elevated when compared to healthy controls, but were also elevated when
compared to asthmatics (P<1x10-5) (Fig. 3.4). Serum scPLAUR levels did not vary
between the COPD patients and the COPD patients with a co-diagnosis of asthma
(P=0.66) (Fig. 3.4). However, a large distribution of data can be identified in each
population, with a significant degree of overlap occurring between them.
Figure 3.4: A scatter plot of serum scPLAUR levels based on disease phenotype identifies
a relationship between receptor levels and disease status. Median levels, indicated by the
red horizontal line, are elevated in asthmatics (3306pg/ml), COPD patients (5836pg/ml) and
COPD with a co-diagnosis of asthma (5870pg/ml) when compared to controls (2538pg/ml).
Levels were also elevated in the COPD patients (with and without asthma) when compared to
asthmatics. No difference was identified between the different COPD populations.
*** = P<1x10-5; *= P<0.05.
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3.4.5 COPD SEVERITY IS NOT ASSOCIATED WITH SERUM SCPLAUR
Due to the large range of data distribution present in the COPD and COPD+asthma
cohorts, it was hypothesised that serum scPLAUR is modulated according to COPD
disease severity as defined by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) (GOLD, 2011). Analysis identified that when stratified based on GOLD
criteria, no difference exists between median levels of serum scPLAUR in a population
consisting of all subjects with COPD (P=0.54) (Fig. 3.5a). This lack of association was
replicated in the COPD only (P=0.99) and COPD+asthma (P=0.33) cohorts (Fig. 3.5b&c).
Figure 3.5: A scatter plot of serum scPLAUR levels in the combined COPD (A), COPD only
(B)and COPD+asthma (C) populations. Stratification of the total COPD population according
to the GOLD criteria for COPD severity identifies no discernible difference in median serum
scPLAUR levels (A: P=0.54; B: P=0.99; C: P=0.33).
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3.4.6 ELEVATED SCPLAUR IS A FEATURE OF NON-ATOPIC ASTHMA
As data points within the asthmatic population demonstrate a wide distribution, the
possibility that the elevation in serum scPLAUR was driven by a specific asthmatic sub-
phenotype was investigated. Individuals determined to be atopic (n=324; serum
PLAUR=3217pg/ml) or non-atopic (n=124; serum PLAUR=4215pg/ml) were compared
(Table 3.4). Atopic status was defined by the Phadiatop̻ test, a commercially available
variant of serum specific IgE assay (Merrett and Merrett, 1987). Both presented with
elevated serum scPLAUR when compared to controls (n=96; serum
PLAUR=2538pg/ml) (Fig. 3.6). However, the non-atopic asthmatic population had
elevated levels of serum scPLAUR when compared to both atopic asthmatics and
controls (P<1x10-4), identifying that atopic status may be a driving force behind asthma
serum scPLAUR elevation (Fig. 3.6).
Atopic Asthma
(n=324)
Non-Atopic Asthma
(n=124)
Percentage Male 52.5 31.6
Age
(Years)
41±11.68 43±13.70
Height*
(Metres)
1.75±0.09 1.70±0.08
Weight*
(kg)
79.00±15.06 74.63±14.36
Smoking pack/years 5.11±10.17 5.38±9.35
FEV1 pre
(%Pred)
80.41±19.98 78.87±25.52
FEV
1
/VC pre 0.68±0.13 0.68±0.17
Reversibility*
(% change in FEV1)
18.81±16.80 16.38±15.51
BHR*
(PC20 mg/ml)
6.23±8.45 11.58±11.64
Table 3.4: Population desciptives for asthma cohort stratified on atopy identify mean
values and standard deviation. A star symbol defines statistically different parameters
across groups as defined by Mann-Whitney tests.
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Figure 3.6: Serum scPLAUR levels are associated with atopic status in asthma.
Stratification of the asthmatic population according to atopy, identifies that while serum
scPLAUR is elevated in both atopic (3217pg/ml) and non-atopic asthmatics (4215pg/ml) when
compared to controls (2538pg/ml) (P=1x10-4), the elevation in asthmatics is strongly driven
by the non-atopic phenotype (P=1x10-4).
3.4.7 SERUM SCPLAUR IS NOT RELATED TO THE DEGREE OF
NOCTURNAL AWAKENINGS IN ASTHMA
Due to the absence of asthma severity scores in the dataset, nocturnal awakening
occurring due to asthma was used as a substitute to define poorly controlled asthma.
Patient demographics confirm that asthmatics who reported nocturnal awakenings due
to an asthma exacerbation within the last 12 months had worse lung function, as
defined by pre-bronchodilator percentage predicted FEV1 and FEV1/VC, confirming
overall less well controlled asthma in this sub-set (Table 3.5).
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No Nocturnal Awakenings
(n=55)
Nocturnal Awakenings
(n=125)
Percentage Male 69.1 56.6
Age
(Years)
52 ±9.52 52 ±7.89
Height*
(Metres)
1.75 ±0.09 1.73 ±0.09
Weight*
(kg)
81.38 ±13.55 78.12 ±13.59
Percentage
Never Smokers*
25.5 40.3
Smoking pack/years* 13.11 ±15.88 7.86 ±11.52
FEV1 pre*
(%Pred)
78.02 ±23.74 66.83 ±25.52
FEV
1
/VC pre* 0.64 ±0.15 0.60 ±0.14
Reversibility*
(% change in FEV1)
10.82 ±5.87 14.07 ±7.76
Table 3.5: Population desciptives for the asthma cohort once stratified on reported
nocturnal awakenings due to an asthma exacerbation within the last 12 months. Values
identify mean values and standard deviation. A star symbol defines statistically different
parameters across groups as defined by Mann-Whitney tests.
Serum scPLAUR levels in asthmatics who reported a nocturnal awakening (n=125;
2495pg/ml) were not statistically different to the levels present in asthmatics who
reported no nocturnal awakenings (n=55; 2908pg/ml). Therefore serum scPLAUR
levels were not associated with the degree of nocturnal awakenings in asthma in a sub-
set of the asthma population (n=180) (P=0.11) (Fig. 3.7) and by association with
asthma severity.
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Figure 3.7: Serum scPLAUR levels are not associated with asthma severity as defined by
the presence of nocturnal awakenings. A scatter plot diagram identifies that the serum
scPLAUR levels in asthmatics who reported no Nocturnal awakenings over 12 months
(2908pg/ml) were not statistically significant from those who reported at least one awakening
over the past 12 months (2495pg/ml) (P=0.11).
3.4.8 SMOKING IS ASSOCIATED WITH ELEVATIONS OF SERUM
SCPLAUR IN NON-ATOPIC ASTHMATICS
Building on the identified correlation between smoking pack/years and serum
scPLAUR levels (see Section 3.4.3), as well as recent data obtained by colleagues
(unpublished) which identified that PLAUR SNPs are differentially associated with
various lung function parameters according to ever/never smoking history, it was
decided to stratify the results already presented based on smoking history. Analyses
identified that smoking history did not alter serum scPLAUR levels based on the
control, asthma, COPD and COPD+asthma phenotypes (Fig. 3.8). However, when
asthma was separated based on the atopic phenotype, although a slight elevation in
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serum scPLAUR levels is still found in never smokers; it is current smokers that are
found to drive the majority of the elevation of serum scPLAUR in non-atopic asthmatics
(Fig. 3.9a). Interestingly, ex-smokers show no change in serum scPLAUR compared to
non-diseased controls, as is the case with all smokers in the atopic phenotype
(Fig. 3.9b).
Figure 3.8: Stratification of serum scPLAUR based on smoking status. Median serum
scPLAUR levels in the control (A), asthma (B), COPD (C) and COPD+asthma (D) populations, as
identified by the red horizontal lines, identify that no difference in the expressed levels of
scPLAUR occurs when based on smoking status.. Controls (2628pg/ml VS 2463pg/ml; P=0.63);
Asthmatics (4547pg/ml vs. 4819pg/ml; P=0.42); COPD (5258pg/ml vs. 7071pg/ml P=0.07);
COPD+asthma (5838pg/ml vs. 5952pg/ml P=0.90).
Asthma
COPD COPD+Asthma
Control
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Figure 3.9: Median serum scPLAUR levels stratified based on IgE defined atopy and
smoking status. In non-atopic individuals (A), the elevation of serum scPLAUR previously
identified in the non-atopic phenotype is shown to be mainly driven by current smokers
(2538pg/ml vs. 3975pg/ml vs. 2457pg/ml vs. 5932pg/ml; P<0.001). In atopic individuals (B)
the slight elevation previously identified is driven by individuals who have never smoked
(2538pg/ml vs. 3365pg/ml vs. 2867pg/ml vs. 3478pg/ml; P=0.03).
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3.4.9 SERUM SCPLAUR LEVELS ARE NOT ASSOCIATED WITH LUNG
FUNCTION
In each individual population an overall lack of correlation was identified between
serum scPLAUR levels and lung function as defined by the following spirometry values:
i) FEV1 percentage predicted pre-Salbutamol
ii) FEV1 percentage predicted post-Salbutamol
iii) FEV1/VC pre-Salbutamol
iv) FEV1/VC post-Salbutamol
Suggestive evidence could be identified between serum scPLAUR and FEV1/VC in the
asthma cohort and for percentage change in FEV1 in the COPD cohort. However, these
did not hold once the P-value was corrected for multiple testing using Bonferronis
correction, where the corrected P-value was defined as P=2.50x10-3 (Table 3.6).
FEV1pp
prbd
FEV1pp
pobd
FEV1/VC
prbd
FEV1/VC
pobd
Change in
FEV1
Control
-0.146 -0.093 -0.154 -0.151 0.150
0.157 0.367 0.133 0.142 0.144
Asthma
0.044 0.024 0.115 0.119 -0.066
0.321 0.582 0.009 0.007 0.139
COPD
0.031 -0.005 0.027 -0.003 -0.161
0.654 0.939 0.691 0.970 0.017
COPD +
Asthma
-0.146 -0.180 0.029 -0.029 -0.016
0.080 0.081 0.723 0.738 0.848
Table 3.6: Serum scPLAUR is not correlated with spirometry defined lung function in any
of the studied populations. Using a P-value of P=2.50X10-3 as defined by Bonferronis
correction for multiple testing, analyses identify that serum levels of scPLAUR are not
associated with lung function parameters. In each cohort top values indicate the Z-value while
italic values identify the P-value. FEV1=forced expiratory volume in 1 second; VC= forced vital
capacity; pp= percentage predicted; prbd = pre-bronchodilator; pobd=post-bronchodilator.
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3.4.10 SERUM SCPLAUR LEVELS ARE NOT ASSOCIATED WITH BHR IN
ASTHMA
In the asthmatic population, no association was identified between serum scPLAUR
levels and bronchial hyper-responsiveness as defined by a bronchial challenge test
where the amount of histamine required to cause a 20% decline in FEV1 (P=0.727;
Z=0.061).
3.4.11 THE PLAUR 5` REGION SNP rs4493171 IS ASSOCIATED WITH
SERUM SCPLAUR LEVELS IN COPD PATIENTS
Investigations into whether 6 5`UTR SNPs were associated with serum scPLAUR levels
in the asthma and COPD cohort allowed for replication of the association identified by
Barton et al. between the 6 PLAUR SNPs and serum scPLAUR levels (Barton et al.,
2009). A seventh important Lys200Arg asthma associated SNP (rs2302524) located in
the genes Exon 6 was also investigated to identify whether this was also related to
levels of serum scPLAUR.
Quality control identified that one SNP in the asthma dataset, two SNPs in the COPD
dataset and one SNP in the COPD with asthma dataset were not in Hardy Weinberg
equilibrium (P<0.05). Although, due to the high number of comparisons (n=42), it is
possible that the significant P-values are due to chance alone, this cannot be
distinguished from alleles that are truly out of Hardy Weinberg equilibrium. Therefore
none of these highlighted SNPs were used in the analyses (Table 3.7).
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SNP Location
MAF
Asthma
Asthma
(n=514)
MAF
COPD
COPD
(n=220)
MAF
COPD +
Asthma
COPD
+Asthma
(n=161)
rs346043 5`UTR 0.24 0.18 0.16 0.78 0.22 0.72
rs1994417 5`UTR 0.29 0.04 0.22 0.2 0.22 0.77
rs4493171 5`UTR 0.21 0.81 0.17 0.89 0.16 0.58
rs344779 5`UTR 0.31 0.77 0.27 0.03 0.26 0.27
rs2356338 5`UTR 0.26 0.3 0.17 0.04 0.23 0.05
rs2239372 5`UTR 0.45 0.25 0.35 0.75 0.36 0.85
rs2302524 Exon 6 0.15 0.14 0.12 0.32 0.12 0.37
Table 3.7: Identifying whether SNP genotyping lies within Hardy-Weinberg Equilibrium.
Analyses identify that a number of SNPs provide significant P-values indicating that they are
not in Hardy-Weinberg Equilibrium (HWE). SNP rs1994417 is not in HWE in the asthma
cohort, while SNP rs344779 is not in HWE in the COPD cohort. SNP rs2356338 is not in HWE
in either the COPD or the COPD+Asthma cohorts. These SNPS will therefore not be used in the
association analyses in their respective cohorts.
Analyses of the remaining SNPs identified that in the asthma population no association
exists between any of the PLAUR SNPs and expressed levels of scPLAUR in serum. In
the COPD and COPD+asthma populations however, one SNP (rs4493171) was
significantly associated with serum scPLAUR levels (Table 3.8). However, the
association in the COPD+asthma population did not survive correction for multiple
testing, where the Bonferroni corrected Pvalue was calculated at P=0.007. The
F-statistic of the surviving association identifies that the major allele (C) is associated
with an elevation of serum scPLAUR over five times the expected value at the null
hypothesis. All analyses were corrected to the identified co-variates for serum
scPLAUR (Section 3.4.3). No analysis was carried out in the control population due to
the lack of genotyping data in this cohort.
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SNP
Asthma
(n=514)
COPD
(n=220)
COPD +Asthma
(n=161)
rs346043
0.828 0.300 0.043
0.438 0.741 0.958
rs1994417 n/a
0.267 2.471
0.766 0.089
rs4493171 0.161 5.339 3.529
0.851 0.005 0.032
rs344779
1.596
n/a
0.195
0.204 0.823
rs2356338
0.186
n/a n/a
0.83
rs2239372
2.341 0.190 0.073
0.097 0.828 0.929
rs2302524 0.0812 1.507 2.361
0.445 0.225 0.099
Table 3.8: SNP rs4493171 is significantly associated with serum scPLAUR levels in the
COPD cohort. Presence of the major allele (C) of rs4493171 was associated with elevated
levels of serum scPLAUR. Although the same SNP was associated with the COPD+asthma
cohort at the P<0.05, this did not survive Bonferroni correction for multiple testing (P=0.007)
Top values indicate the F statistic, while italic values identify the associated P-values.
3.4.12 A PLAUR EXON 6 SNP (RS2302524) IS ASSOCIATED WITH
SERUM SCPLAUR IN ASTHMATICS
PLAUR 5`UTR and gene SNPs investigated in section 3.4.11, were separated based on
smoking status in the asthma population. One SNP (rs2302524) located in exon 6 of the
PLAUR gene, changes a lysine (K) amino acid to arginine (R) at position 220 of the
PLAUR protein structure, was found to be significantly associated with serum scPLAUR
levels in the never smokers (Table 3.9). This association survived correction for
multiple testing, where the Bonferroni corrected Pvalue was calculated at P=7x10-3.
The F-statistic identifies that the major allele (T) is associated with an elevation of
serum scPLAUR over 5 times the expected value at the null hypothesis. Analyses were
not carried out in the COPD cohort, as all subjects were smokers, or in the control
cohort, as genotype data was not available.
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SNP Direction of Effect P-value
Ever Smoke Never Smoke Ever Smoke Never Smoke
rs346043 0.072 0.152 0.789 0.697
rs1994417 0.252 0.742 0.616 0.39
rs4493171 0.101 0.002 0.751 0.966
rs344779 3.27 0.599 0.072 0.44
rs2356338 0.812 0.124 0.134 0.14
rs2239372 1.644 3.28 0.201 0.071
rs2302524 1.924 5.342 0.167 0.002
Table 3.9: SNP rs2302524 was associated with serum scPLAUR in asthmatics who were
never smokers. Presence of the major allele (T) was associated with elevated levels of serum
scPLAUR fivefold above the expected value as outlined by the F-statistic.
3.4.13 SMOKING STRATIFICATION IDENTIFIES AN ASSOCIATION
BETWEEN SERUM SCPLAUR AND LUNG FUNCTION BUT NOT BHR IN
ASTHMATICS
When separated based on smoking status, serum scPLAUR levels were found to be
negatively associated with lung function as defined through the FEV1/VC ratio in ever
smokers. The association held with FEV1/VC ratios taken both pre and post treatment
with a bronchodilator (Salbutamol). Serum scPLAUR levels were also associated with
percentage airway reversibility post-bronchodilator in the smoking asthma population
(Table 3.10). No association was found between serum scPLAUR and BHR regardless of
smoking status. There were no associations between serum scPLAUR levels and lung
function as defined by spirometry in the control population regardless of smoking
status (Table 3.11). All analyses in this section were corrected for the previously
identified confounders of age, height and weight.
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Ever Smoke Never Smoke
R2 P-value R2 P-value
FEV1 pre 0.003 0.324 0.005 0.255
FEV1 post 0.001 0.550 0.007 0.203
FVC pre 1.96x10-4 0.824 1x10-6 0.986
FVC post 0.002 0.483 1x10-6 0.993
FEV1/VC pre 0.017 0.034 0.010 0.117
FEV1/VC post 0.015 0.050 0.014 0.059
BHR 0.005 0.310 0.006 0.263
FEV1 reversibility 0.018 0.029 9x10-6 0.961
Table 3.10: Serum scPLAUR levels are associated with lung function in asthmatic
smokers but not in asthmatic never smokers. An association exists between serum scPLAUR
and FEV1 reversibility and lung function measured using the FEV1/VC test both pre and post
Bronchodilator (Salbutamol) were determined in the asthmatic population. No association
could be identified between scPLAUR and BHR.
Ever Smoke Never Smoke
R2 P-value R2 P-value
FEV1 pre 1.21x10-4 0.926 0.002 0.836
FVC pre 7.84x10-4 0.818 0.007 0.662
FEV1/VC pre 0.020 0.250 0.045 0.279
Table 3.11: Serum scPLAUR levels are not associated with lung function or BHR in a
control population regardless of smoking status. Serum scPLAUR levels were also
independent of the degree of airway reversibility in controls.
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3.5 DISCUSSION
The aims of this chapter were to determine whether serum scPLAUR is elevated in
asthma and/or COPD per se and whether it is associated with lung function, airway
reversibility and/or bronchial hyper-responsiveness. This chapter also attempted i) to
replicate the associations between a selection of PLAUR SNPs identified by Barton et al.
to be associated with serum scPLAUR levels in other subjects, ii) to investigate whether
an important exon 6 SNP was associated with changes in serum scPLAUR levels and iii)
to extend the study into COPD. In order to correct for multiple testing throughout this
chapter, significance thresholds were modified using Bonferronis Correction to
account for false positive results.
Initial findings identified that serum scPLAUR was associated with the obstructive lung
diseases asthma and COPD (regardless of asthma co-morbidities), in a relationship
pattern similar to the sputum based results reported by Xiao et al., corroborating the
hypothesis that scPLAUR has a role in these diseases. The novel identification that
circulating levels of scPLAUR are related to obstructive lung diseases mirrors
previously reported relationships in other diseases, such as prostate cancer, diabetes
Type II and chronic liver disease, where scPLAUR has been defined as a marker of
disease progression and disease related mortality (Almasi et al., 2011, Zimmermann et
al., 2012, Eugen-Olsen et al., 2010a). Correction of the statistical analyses to identified
co-variates gives confidence that the identified associations are true associations
rather than an artefact driven by non-related variation within the studied population.
Association between scPLAUR and obstructive lung disease highlights a possible role
for this molecule in the development and/or maintenance of asthma and COPD. As
previously discussed in Chapter 1, recent developments have identified that scPLAURȾ3 integrin leading to the modulation of the kidney disease, FSGS (Wei et
al., 2011). Therefore it is possible that serum scPLAUR elevations in asthma and COPD
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are reflective of modulation of the development and/or progression of these diseasesǦǡȾ3 integrin family.
An alternate hypothesis for the observed elevation in serum scPLAUR is that elevation
is not associated with the presence of asthma and COPD per se but rather acts as a
marker of low-grade inflammation, given that, as described in Chapter 1, inflammation
is an important factor in both asthma and COPD development. Indeed scPLAUR has
previously been associated with a number of general inflammatory diseases (Eugen-
Olsen et al., 2010a), while a number of other studies have reported positive correlation
between scPLAUR and pro-inflammatory biomarkers such as leukocyte numbers,	ȽǡǦȋȌȋǦǤǡ ? ? ? ?ǡ
al., 2009, Andersen et al., 2008). It is however unlikely that this is the underlying
reason for the observed association in this study based on lack of association with
disease severity, with increasing asthma and COPD severity specifically known to be
associated with increasing inflammation in the lung (Turato et al., 2002, Louis et al.,
2000). However, investigations into the relationship between serum scPLAUR and
asthma severity must be considered in light of the lack of clinical data such as GINA
scores and medical history, from which asthma severity is usually defined. This study
was limited to using the nocturnal awakening phenotype as a surrogate phenotype for
asthma severity based on the National Heart, Lung, and Blood Institute (NHLBI)
definition that asthma severity is determined on the basis of both impairment and risk,
with impairment defined as a function of the frequency of daytime and nocturnal
symptoms (NHLBI, 2007). As subjects in this dataset that reported nocturnal
awakenings due to asthma have lower lung function than subjects who had no
nocturnal awakenings this increases confidence in the use of this phenotype as a
marker of disease severity.
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As mentioned in Chapter 1, asthma is not a single homogenous disease but is a group of
diseases based on the presence and absence of various phenotypes, including atopy
(Lotvall et al., 2011). Atopic asthmatics differ from non-atopics in their triggering
mechanism; atopic asthma is triggered by allergens originating from pollen and house
dust mite among others, while non-atopic asthma is not directly triggered by any
known allergen, but rather through the activation of innate receptors such as those for
IL-33 and GM-CSF (Barnes PJ, 2002, Willart et al., 2012). Non-atopic asthma is also
regarded as generally manifesting later in life and is often more severe than atopic
asthma (Rochat, 2005) as reflected in this dataset where non-atopic asthmatics have
less airway reversibility (P=0.042) and less BHR (P<1x10-3). Based on these
differences, it was decided to investigate whether association with scPLAUR was
driven by atopic status as defined by the Phadiatop̻ test, a commercially available
variant of serum specific IgE assay that was introduced for the screening of allergic
sensitization in 1987 (Merrett and Merrett, 1987). Elevated serum scPLAUR levels in
non-atopic asthmatics suggest that serum scPLAUR is associated with changes in the
airway rather than asthma per se, an idea supported by the increased levels of scPLAUR
present in COPD, which is by definition an irreversible airway obstructive disease,
vastly different from asthma in respect of airway reversibility.
Based on the above data, it is therefore likely that serum scPLAUR may be involved in
airway remodelling, causing irreversible changes such as smooth muscle hypertrophy,
mucous gland hyperplasia, increased cell proliferation and thickening of the basement
membrane (Wilson, 1998, Busse et al., 1999). This hypothesis is supported by the
association of serum scPLAUR levels to spirometry defined lung function (FEV1/VC)
and airway reversibility post-bronchodilator treatment in an ever smoking population.
A serum scPLAUR associated change in the degree of airway remodelling could lead to
the progression and/or modulation of airway obstructive disease, especially COPD and
non-atopic asthma, identifying an active role for scPLAUR in these disease states.
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As a strong positive correlation between serum scPLAUR and smoking pack/years was
identified in this chapter and recent data from colleagues in the department
(unpublished) identified PLAUR SNPs as being differentially associated with various
lung function parameters according to ever/never smoking history, it was decided to
investigate whether smoking history was a driving force in any of our phenotype
associations. Smoking status did not appear to have any role in the elevation of serum
scPLAUR in asthma or COPD, but seems to be the driving force elevating serum
scPLAUR in non-atopic asthma. Lack of a role for smoking status in asthma and COPD
may be explained due to our grouping of all asthmatics into one single disease state
and the uniform high rate of smoking in COPD. A role for smoking in regulating
scPLAUR in non-atopic asthma, lends further credence to the hypothesis that serum
scPLAUR plays a role in airway remodelling as cigarette smoke has a well-established
role in causing structural changes to the airways (Niewoehner et al., 1974, Floreani and
Rennard, 1999, Churg et al., 2006).
The second focus of this chapter was to identify whether serum scPLAUR was
associated with lung function as defined by spirometry, percentage reversibility of
FEV1 and BHR. A lack of association between serum scPLAUR and lung function was
contrary to what was anticipated based on the identification by Barton et al. of an
association between serum scPLAUR associated SNPs and lung function, albeit in a
family based design. The previously derived conclusion that serum scPLAUR plays a
role in airway remodelling, would also lead one to expect a relationship between serum
scPLAUR and lung function. However, this study was limited in its ability to relate
airway remodelling to lung function since airway remodelling is more closely
associated with longitudinal FEV1 (Mahut et al., 2010, Rasmussen et al., 2002), while
this study has investigated cross sectional changes. Therefore, the identified lack of
association with lung function does not preclude the hypothesis that serum scPLAUR
plays a role in airway remodelling. Indeed unpublished work in the same group
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associated various PLAUR SNPs with a number of airway remodelling parameters such
as epithelial proliferation rates and the rate of Collagen III deposition. Failure to
associate with lung function tests may also be explained by the possible masking effect
of cigarette smoke on any scPLAUR driven effect on the airways. This is suggested
based on the well-established role of cigarette smoke in causing changes in the airways
(Niewoehner et al., 1974, Floreani and Rennard, 1999, Churg et al., 2006). Indeed,
when stratified according to smoking status, an association with lung function and
airway reversibility were identified. Elevations of serum scPLAUR corresponded with a
lower FEV1/VC ratio and a lesser degree of airway reversibility, complimenting the
hypothesis that the association of serum scPLAUR with asthma and COPD occurs via an
effect on airway obstruction. Although difficult to define, airway remodelling can be
thought of as a collective term that encompasses the alterations in structural cells and
tissues resulting in airway wall thickening, sub-epithelial fibrosis, increased myocyte
muscle mass, as well as myofibroblast and mucus hypersecretion (Elias et al., 1999).
Therefore, through possible scPLAUR influenced thickening and fibrosis of the airway,
changes should occur in the airway resulting in a lesser degree of airway reversibility
and a lower FEV1/VC ratio, as identified.
The third focus of this chapter was to attempt to replicate the association between the
7 SNPs identified by Barton et al. (rs2356338, rs4493171, rs2239372, rs346043,
rs344779 and rs1994417) and serum scPLAUR, and to identify any association with
the exon 6 SNP rs2302524. Replication and extension of the findings was largely
unsuccessful with only a single 5`UTR SNP (rs4493171) found to be associated with
serum scPLAUR levels. However, rs4493171, which is located in the genes 5`UTR
(~10kb upstream of the TSS) was associated with serum scPLAUR in the same
directional effect as that reported by Barton et al., where presence of the major allele
(C) resulted in elevated serum scPLAUR (Barton et al., 2009). This is of interest as
Barton et al. identify this SNP (T allele) as being protective to asthma. Therefore,
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confirmation of the link between the risk genotype and serum scPLAUR levels ties in
well with our assertion that elevated serum scPLAUR is associated with the disease.
Failure to replicate the remaining SNPs may be due to differences in our populations
from the populations used in the Barton et al. study. This study was therefore limited
by not being a true replication of the original study with regards to patient
characteristics, disease and study design. In Barton et al., association was defined using
Family Based association tests. These tests are based on analysis of a linear
combination of observed offspring genotypes and phenotypes, which is appreciably
different from analysing the effect of SNPs on cross-sectional lung function data in a
population of non-related adults. Also, lack of association may be due to the low power
of association for these datasets. Power calculations identify the probability at which a
test will reject the null hypothesis when the null hypothesis is false. In this dataset
power ranged from 70% to 45%, identifying that low power of detection exists for
some of the associations and may explain why such associations did not achieve a
significant P-value in these analyses.
Another possible mask for SNP activity would be smoking history. As one can expect,
smoking was not present in the child population in the original study where the 7
PLAUR SNPs were associated with serum scPLAUR levels. This may explain why no
positive association was evident in the remaining 6 non-significant SNPs. However this
hypothesis was proved false when the dataset was stratified along the smoking history
phenotype and none of serum scPLAUR associated SNPs were found to deviate from
the null hypothesis of no association.
Interestingly, the association of rs2302524 with serum scPLAUR in a never smoker
population of asthmatics and a combined population of controls and asthmatics
identified a novel exon 6 SNP associated with serum scPLAUR. Failure to associate this
SNP when not stratifying for smoking status may be explained due to the strong
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correlation of cigarette smoke on serum scPLAUR expression. Elevations of serum
scPLAUR driven by cigarette smoke are so strongly correlated that they in all likelihood
are still able to confound the data and mask the effect of rs2302524, a non-
synonymous SNP that alters the PLAUR protein structure by changing a lysine amino
acid to arginine within the receptors Domain III.
In conclusion, this chapter identifies that serum scPLAUR may be involved in the
obstructive lung diseases asthma and COPD, with an important effector role played by
cigarette smoke, especially in the alteration of lung function and reversibility. This
suggests that circulating levels of scPLAUR may either be involved in these disease
states via airway remodelling, an effect known to be augmented on exposure to
cigarette smoke, or be a marker of processes occurring in the asthmatic/COPD lung
associated with cigarette smoke. This study also identifies rs2302524 as a novel
regulatory SNP for serum scPLAUR, which however appears to be masked by cigarette
smoke but has investigative potential due to its association with asthma and lung
function as defined by FEV1, which may be due to its up-regulation of serum scPLAUR.
Replication and extension of the results presented by Barton et al. associating 6 SNPs
with serum scPLAUR levels were however largely unsuccessful. This however, does not
necessarily disprove the authors results. One must consider that the authors replicated
their own results in two separate cohorts (Barton et al., 2009), while this study was
severely limited in that the population (unrelated control/diseased adults) differed
from the cohorts used in the study (affected sibling pairs). Therefore while this study
highlights a significant association between rs4493171 and serum scPLAUR in COPD
one cannot either truly define this as a true replication or reject Barton et al.s results.
CHAPTER 4:
IDENTIFICATION OF A NOVEL
GENETIC MECHANISM
DETERMINING SOLUBLE CLEAVED
PLAUR LEVELS USING A GENOME-
WIDE ANALYSES
148
CHAPTER 4: IDENTIFICATION OF A NOVEL GENETIC
MECHANISM DETERMINING SOLUBLE CLEAVED PLAUR
LEVELS USING A GENOME-WIDE ANALYSES
4.1 INTRODUCTION
As discussed in Chapter 3, scPLAUR is a molecule that is known to be elevated in a
number of diseases including various cancers (Eugen-Olsen et al., 2010b),
cardiovascular disease (Eugen-Olsen et al., 2010b), HIV (Savva et al., 2011) and kidney
disease (Wei et al., 2011). Elevations of the soluble cleaved receptor were associated
with increased disease risk and elevated mortality rates in these diseases (Savva et al.,
2011, Eugen-Olsen et al., 2010b), while in breast cancer elevated scPLAUR was
associated with lower survival rates (Andres et al., 2012). In Chapter 3, results identify
that levels of serum scPLAUR are elevated in both asthma (driven by the non-atopic
phenotype) and COPD, with a relationship between scPLAUR serum levels to smoking
history also identified. Therefore the soluble cleaved form of the receptor may be
considered to be an important driver of disease and disease associated mortality,
including in the obstructive lung diseases asthma and COPD through possibleȾ3 integrins, such as has been described in
kidney disease (Wei et al., 2011). It is consequently important that the regulatory
processes for the expression of this soluble form of the receptor in human serum is
fully understood as this would provide a better understanding of the mechanism of
disease and any potential therapeutic targets within. The work in this chapter has
attempted to address this question through identification of genetic regulators for
serum scPLAUR using a genome-wide association study (GWAS). Although a number of
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studies (Stewart et al., 2012, Xiao et al., 2005) have investigated scPLAUR expression
and function, such as in the airway epithelium and in induced sputum while other
studies have identified associations between PLAUR SNPs and serum scPLAUR levels
(Barton et al., 2009), there has been to date no genetic based investigation into the
underlying genetic mechanism of regulation of scPLAUR levels in serum.
GWAS involves the statistical determination of association of a large number of single
nucleotide polymorphisms (SNPs) (7300k) spanning the human genome, with a known
outcome or trait, in this case the identified level of scPLAUR in serum. Due to the
association of elevated serum scPLAUR in asthma (Chapter 3), analyses were carried
out on two distinct pools of individuals, namely a control population with no asthma or
obstructive lung disease and a population of doctor diagnosed asthmatics. Using these
cohorts the twofold aim of identifying novel genetic mechanisms that regulate serum
scPLAUR and determining if this regulation is specific or more relevant in obstructive
lung disease were approached. The same sample pool as in Chapter 3, namely the
Dutch asthma case and control cohort, was utilised for these analyses.
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4.2 AIMS
1. To identify novel genetic mechanisms determining scPLAUR levels in serum
using a genome-wide approach.
2. To identify the mechanism of regulation driven by these novel genetic
determinants.
3. To identify the functional effects of scPLAUR in primary human bronchial
epithelial cells.
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4.3 METHODS -GENETICS
For general methods including population descriptives and demographics kindly refer to
Chapter 2: General Materials and Methods.
4.3.1 ENZYME LINKED IMMUNOSORBENT ASSAY
Serum scPLAUR levels were determined in the Dutch asthma/control cohort (see
Section 2.6.1.1) in 514 asthmatics and 104 controls via a Duoset ELISA for scPLAUR
(R&D Systems), with absorbance recorded using a Flexstation 3 microplate reader. A
detailed description of this method is found in Section 2.3.3.
4.3.2 GENOME WIDE ASSOCIATION STUDY
A GWAS was carried out by the Dutch collaborators (Dr Martin Siedinski and Dr Gerard
Koppelmann; University of Groningen, the Netherlands) using the Illumina 300 and
370 chips. The control and asthma study populations used in the GWAS analyses were
obtained from the same pool of subjects as used in Chapter 3 and outlined in Section
2.6.1.1. Serum scPLAUR levels were log10 transformed prior to the analyses. Quality
control of the population dataset led to the exclusion of related subjects using a PI HAT
cut off of 0.1875 and the exclusion of ethnic outliers and cryptically related subjects
using smartpca software. This resulted in two final datasets of 104 controls and 480
asthma cases. Quality Control on SNP data carried out in both asthma subjects and
controls identified a SNP call rate of 0.95 and indicated that the population was in
Hardy Weinberg equilibrium with regards to the SNPs (P >1x10-7). A total of 295,196
SNPs were analysed for each of the 584 individuals and analyses carried out in either
cohorts separately and in a combined case/control cohort. Analyses was carried out in
PLINK using the additive model (Purcell et al., 2007).
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4.3.3 STATISTICAL SIGNIFICANCE TESTING
As a large number of tests of association, such as those carried out in a GWAS, are likely
to result in the generation of a number of false positives, the level of significance
(significant P-values) needs to be corrected for multiple testing. Corrections for
multiple testing are based on the requirement of a stronger level of evidence to be
observed in order for an individual comparison to be deemed significant, compensating
for positive results occurring by chance due to the number of inferences being made.
For the multiple testing carried out in the GWA datasets, Bonferroni Correction was
used. The Bonferroni correction is derived by observing Boole's inequality (Miller ? ? ? ?Ȍǡ        ǡ    Ⱦȋ Ⱦ  Ȍǡ            ?ȾǤȽǢȾǡȾ ?ȽȀǤ
Using the Bonferroni Correction at the 5% significance level, and considering that
295196 SNP associations were made per sample, genome-wide significance was
defined using a P-value ȋȾȌ  P ? ?Ǥ ? ? ? ?-7ǡ  Ƚ ? ?Ǥ ? ?   ? ? ? ?ǡ ? ? ?Ǥ 	
suggestive regions of interest were identified based on the detection of a sentinel SNP
showing association at a threshold of P=1x10-4 or smaller with at least one additional
SNP within 100Kb also reaching a threshold of P=1x10-4 or smaller.
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4.3.4 VISUALISATION OF ASSOCIATED REGIONS
To identify whether SNPs in the regions adjacent to the GWA selected regions provide
supporting evidence for association through elevated log10 P-values, the regions
500Kb upstream and downstream of all the SNPs identified in Section 4.3.2, were
investigated. Investigations were carried out in silico using the online software tool
LocusZoom version 1.19with the original GWAS dataset (Pruim RJ et al. 2010).
4.3.5 SNP GENOTYPING IN ADDITIONAL COHORTS AND ANALYSES OF
DATA FOR QUALITY CONTROL
In order to be able to carry out experiments to attempt duplication of the association
results obtained from the GWAS, the selected GWA SNPs were genotyped in an
additional disease cohort. Genotyping was carried out by KBiosciences (Hoddesdon,
Hertfordshire, UK) on DNA samples from the COPD cohort (n=368). A detailed
description of this methodology is available in Section 2.6.2.
4.3.6 HAPLOTYPE ANALYSES
Linkage disequilibrium maps for the combined control and asthma population used in
the GWA study were generated by the Dutch collaborators (Dr Martin Siedinski and Dr
Gerard Koppelmann; University of Groningen, the Netherlands) using Haploview
version 4.224 (Barrett et al., 2005). Linkage disequilibrium maps were also generated
for the SNP rs4253238 using HapMap (version 3, release 27 on CEU population; region
4:18737100-18741700) and 1000 genome (Release 9, on the CEU population; KLKB1
gene build ENSG00000164344, region 4:187130133-18717962525) populations. The
CEU population is defined as residents of the state of Utah with ancestry from northern
9 http://csg.sph.umich.edu/locuszoom
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and western Europe (n=180 & 100 respectively). A detailed description of the method
is available in Section 2.6.3.
4.3.7 DETERMINING GENOME-WIDE REGULATORS OF PLAUR MRNA
In order to identify whether the results from the protein based GWAS mirrored
association data for PLAUR expression in an mRNA based GWAS, associations for
PLAUR expression were identified in silico using the mRNA by SNP browser v 1.0.110.
The software incorporates a generic eQTL database and provides a graphic interface
for browsing association between 54,675 transcript levels and 406,912 SNPs. For each
transcript, the browser provides association test statistics (P<0.001), estimates of
effect size and allele information across the genome. Data is obtained from Epstein-
Barr virustransformed lymphoblastoid cell lines taken from 206 families of British
descent selected through a proband of childhood asthma, with cells taken from affected
subjects and their sibling pairs regardless of whether the sibling pair had asthma
(n=397 sibling pairs; 11 half sibling pairs) (Dixon et al., 2007).
Using the software program, the PLAUR gene was selected and the mean transcript
level for all 3 independent probes (210845_s_at; 211924_s_at; 214866_at) was
selected.
10 Available at http://www.sph.umich.edu/csg/liang/asthma/
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4.4 METHODS  PROTEIN ASSAYS & ANALYSES
4.4.1 HUMAN PLASMA KALLIKREIN ACTIVITY ASSAY
Since SNP rs4253238 lies within the promoter region of the gene for Human Plasma
Kallikrein (KLKB1), it is of interest to determine whether the SNP genotype affects
KLKB1 activity. KLKB1 activity in serum was therefore determined using an in house
designed activity assay. The assay is based on the commercially available substrate
H-Pro-Phe-Arg-AMC, which is cleaved by KLKB1, releasing the 7-amino-4-
methylcoumarin (AMC) fluorogenic moiety. Fluorescent intensity can then be related
to the degree of KLKB1 activity. 10 serum samples from each rs4253238 homozygote
genotype were randomly chosen from the COPD, Asthma and Control cohorts. 5µl of
each serum sample was added, in duplicate, to 50µl of H-Pro-Phe-Arg-AMC substrate in
activity buffer. After a 5 minute incubation at room temperature, fluorescence then was
recorded using a Flexstation 3 microplate reader for a period of 5 minutes using an
excitation wavelength of 380nm and absorbance wavelength of 460nm. Prior to use the         ? ? ?ɊȀ   Ǧ  ȋ
Section 2.3.1).
4.4.2 DEFINING THE RELATIONSHIP BETWEEN KLKB1 AND SCPLAUR
IN EPITHELIAL CELLS USING ELISA AND WESTERN BLOTTING
NHBECs were exposed to commercially obtained human derived KLKB1 at a  ? ?ɊȀǤ
while total protein levels of PLAUR were determined via Western blotting using the
monoclonal antibody IIIF10, correcting for changes in protein levels by staining forȾǦǤ ?Ǥ ?Ǥ ?Ƭ ?Ǥ ?Ǥ ?Ǥ
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4.5 METHODS  CELLULAR BASED WORK
4.5.1 CULTURING OF NHBECS
Cell based experiments in this chapter were carried out on passage 4 NHBECs cultured
in 6-well plates. A detailed description of this method is found in Section 2.4.2.1.
4.5.2 DETERMINING WHETHER KLKB1 DRIVES A CHANGE IN PLAUR
mRNA EXPRESSION
Quantitative PCR (qPCR) was used to determine whether PLAUR total mRNA levels are     ?Ǥ    ? ?ɊȀ  ?   
HBECs cultured in 6-well plates for a period of 4 or 24 hours. Cells were collected by
mechanical scraping and RNA extracted using the Qiagen RNeasy Kit as described in
Section 2.2.10. RNA stocks were reverse transcribed to form complimentary DNA
(cDNA), using the SuperScript̻ First-Strand Synthesis System for RT-PCR as outlined
in Section 2.2.11. The resulting cDNA, diluted to 1:10, was used in a qPCR as outlined in
Section 2.2.12, using HPRT Pre-Developed TaqMan Assay Reagent (PDAR) as the
housekeeping gene and the primers and probes for total PLAUR outlined in Tables 2.9
& 2.10.
These primers and probe were designed and validated by Dr Ceri Stewart (University
of Nottingham) and the assay had a 65.3% efficiency rate. Analyses were carried out
using the MxPro software and Microsoft Excel. Further details and cycling parameters
are available in Section 2.2.12.
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4.5.3 DETERMINING THE RELATIONSHIP BETWEEN KLKB1 AND
PLASMIN ACTIVITY IN AN EPITHELIAL CELL MODEL
The plasmin activity assay kit (Cambridge Bioscience; ANA72124) determines the rate
of activation of plasminogen into plasmin, a process that occurs in the presence of ?Ǥȋ ? ?ɊȌ ?Ǥ ?Ǥ ? ? ?Ɋ

as a negative control. The plate was pre-incubated for 10 minutes at 37oC in a hotbox ? ?ɊǦǤ
The reagents were mixed completely by shaking the plate gently for 30 seconds,
followed by incubation at 37oC for 90 minutes, keeping the plate away from direct light.
Fluorescence was then read using an excitation wavelength of 380nm and an emission
wavelength of 500nm using a Flexstation 3 microplate reader for a period of 5 minutes.
4.5.4 USING A CELL-FREE SYSTEM TO IDENTIFY A PLAUR
PROTEOLYTIC ROLE FOR KLKB1
        ?    Ǧ ǡ  ? ?Ɋ ȋȌȋƬ ? ? ?Ǧȏ ? ?ɊȀȐȌ ?Ɋ       ? ȋ ? ɊȀȌ   ? ? ?Ɋ  
water at 37oC for 24 hours,. The following controls were used; rPLAUR onlyȏ ? ?Ɋ ? ? ? ?Ɋ ȐǢ   ?  ȋ  ? ? ? ? ? ? ? ? ? ? ?ǡ   ? ?ȀȌȏ ? ?Ɋ ? ? ? ?ɊȐǢ ? ? ?ȋ ? ? ? ? ? ? ? ? ? ? ?Ȍȏ ? ?Ɋ ? ?Ɋ ? ? ? ?Ɋ ? ? ?Ɋ ȐǤ 	 ǡ   
via ELISA andWestern Blotting, the latter using the mAB IIIF10 and the pAB BAF807. A
detailed description of both methods is found in Sections 2.3.2 and 2.3.3.
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4.5.5 DETERMINING THE SITE OF KLKB1 MEDIATED CLEAVAGE VIA
N-TERMINAL SEQUENCING
N-terminal sequencing was carried out from a digested sample (Section 4.5.4) by
Cambridge Peptides, Birmingham UK, using the Edman degradation technique. In this
technique, phenylisothiocyanate reacts with the sequences terminal uncharged amino
group under mildly alkaline conditions, forming a cyclical phenylthiocarbamoyl
derivative. This terminal amino acid derivative is then cleaved to form a thiazolinone
derivative, under acidic conditions, which is then selectively extracted into an organic
solvent and treated with acid to form the more stable phenylthiohydantoin-amino acid
derivative. This final derivative can then be identified by using chromatography or
electrophoresis (Edman, 1949). Using this technique the first 5 terminal amino acids at
the site of KLKB1 mediated cleavage in the large remaining PLAUR fragment were
identified. The amino acid sequence was compared to the PLAUR protein sequence on
http://www.uniprot.org/, protein reference Q03405.
4.5.6 MANUFACTURING AN OVER-EXPRESSING VECTOR FOR SCPLAUR
In order to be able to investigate the role of scPLAUR in NHBECs, an over-expressing
vector for scPLAUR was manufactured. The open reading frame of membrane PLAUR
(NM_002659.3) minus the sequence coding for the GPI anchor, i.e. amino acids 1 to 293
of the mPLAUR protein structure, was amplified as described in Section 2.2.1, using
primers including a consensus Kozak sequence and restriction enzyme sites:
x 5`primer: ACTTGAATTCGCCACCATGGGTCACCCGCCGCT; spacer-EcoRI-Kozak-ATG.
x 3primer: ACTTCTCGAGTTAACAGCCACTTTTAGTACAGC; spacer-XhoI-stop (TAA).
The resulting PCR product was gel extracted (Sections 2.2.2 and 2.2.3), ligated into
pCR4-TOPO (see Section 2.2.4) and then subcloned into pcDNA3 using the EcoRI and
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XhoI restriction enzymes and T4 ligase (Section 2.2.9). The plasmid was then purified
(Section 2.2.6.2) and sequence verified (Section 2.2.7) prior to transfection.
4.5.7 TRANSFECTING NORMAL BRONCHIAL EPITHELIAL CELLS
In order to investigate the role of scPLAUR in the processes of cellular migration,
mitochondrial activity and apoptosis in comparison to the role played by mPLAUR and
to identify whether any effects are reversible in the presence of KLKB1, a cell system
over-expressing scPLAUR and mPLAUR is required. NHBECs cultured in 6-well plates
were transfected as described in Section 2.4.5 with the over-expression vector pcDNA3
(empty vector), a pcDNA3 construct for the over-expression of mPLAUR (Designed and
tested by Dr Ceri Stewart (Stewart et al., 2012)) and a pcDNA3 construct for the over-
expression of scPLAUR (Section 4.5.6). Cells over-expressing scPLAUR were also
treated with 2µl KLKB1.
4.5.8 DETERMING THE CHANGES IN BRONCHIAL EPITHELIAL CELL
MIGRATION ON OVER-EXPRESSION OF SCPLAUR WITH AND WITHOUT
THE PRESENCE OF KLKB1
Cells transfected as described in Section 4.5.7, were investigated using a scratch-wound
assay (Section 2.51). Here cells were wounded 24 hours post-transfection and the
wound measured at 0, 4, 8 and 24 hours post-wounding. Data analysis was carried out
in Cellprofiler̻ using a pipeline designed by Mr Benjamin Wilson (University of
Nottingham).
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4.5.9 DETERMING CHANGES IN BRONCHIAL EPITHELIAL CELL
MITOCHONDRIAL ACTIVITY ON OVER-EXPRESSION OF SCPLAUR IN
THE PRESENCE AND ABSENCE OF KLKB1
A sterile solution of 0.5mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was added to a cell population 24 hours post-
transfection as described in Section 4.5.7. The cells were then incubated at 37oC for 4 Ǥ  ? ? ?Ɋ  
well, absorbance at a wavelength of 570nm was recorded using a Flexstation 3
microplate reader. A detailed description of the MTT method is found in Section 2.5.2.
4.5.10 DETERMING CHANGES IN THE RATE OF APOPTOSIS OF
BRONCHIAL EPITHELIAL CELLS ON OVER-EXPRESSION OF SCPLAUR
WITH AND WITHOUT THE PRESENCE OF KLKB1
 ?Ǥ ?Ǥ ?Ǥ ? ? ?Ɋ ? ? ?Ɋ 2O2 in BEGM was then added to one set of transfections (a concentration  ȋǤǡ  ? ? ? ?ȌȌǡ  ? ? ?Ɋ

was added to an identical set of transfections. The solutions were left to incubate at
37oC for 8 hours and then frozen overnight at -80oC. Using the Apo-ONEHomogenous
Caspase 3/7 assay the rate of apoptosis was determined after an 8 hour incubation at
37oC, through fluorescence readings taken using the Flexstation 3 microplate reader. A
detailed description of the method is found in Section 2.5.3.
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4.6. STATISTICAL ANALYSES.
4.6.1 LINEAR REGRESSION
Analysis of the COPD cohort was carried out using linear regression. The additive
model (outlined in Section 2.7.3.1) and log10 values of serum scPLAUR were used in
order to replicate the methodology used in the original GWAS (Section 4.3.2). Although
a number of co-variates for serum scPLAUR have been identified in this thesis (Section
3.4.3), since the GWAS was carried out without the inclusion of co-variates, initial
analyses were also carried out in this way. Following initial analyses, the statistical
analyses were repeated using the known co-variates for serum scPLAUR levels; age,
height, weight and smoking pack/years (Section 3.4.3) in order to confirm any positive
associations. A detailed description of the method is available in Section 2.7.3.1.
4.6.2 CORRELATION ANALYSES
Spearmans Correlation was used to determine association between KLKB1 activity
levels and scPLAUR levels in serum. A detailed description of the procedure used is
available in Section 2.7.3.2.
4.6.3 COLUMN STATISTICS
Paired two-tailed Student t-tests and Repeated Measures ANOVA were utilised to
investigate differences in scPLAUR supernatant levels, total intracellular PLAUR levels
and NHBEC mitochondrial activity rates in this chapter. Pairing was used to address
inter-experimental variation. A detailed description of the procedure used to carry out
these tests is available in Section 2.7.4.1.
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4.6.4 TWO-WAY ANOVA
A two way ANOVA was used to investigate the effect of different categorical variables,
i.e. over-expression have on the rate of wound repair as presented by a scratch-wound
model in NHBECs and to concurrently determine whether this effect was modulated
over time. A detailed description of the procedure used to carry out these tests is
available in Section 2.7.4.2.
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4.7 RESULTS
4.7.1 LOCI IDENTIFIED BY THE GENOME WIDE ASSOCIATION STUDY
Quantile-Quantile plots for the observed P-values in controls (n=104) and asthmatics
(n=480) identified a modest deviation from the expected P-values (Fig. 4.1). In these
individual datasets, no SNP achieved a genome-wide significant P-value of P<1.69x10-7
(Bonferroni Correction). Quantile-Quantile plots for the combined analysis carried out
on the control/asthma dataset (n=584) identified a stronger deviation from the
expected P-values (Fig. 4.2), identifying an increase in effect in the combined
asthma/control population.
Figure 4.1: QQ-Plot for genome-wide analyses in control (n=104) (Panel A) and asthma (n=480)
(Panel B) populations. The QQ-plots identify that measured SNP log10 P-values do not deviate from the
expected trend in the control population, while there is a modest deviation in the disease (asthma)
population suggesting a greater role for genetic regulation.
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Figure 4.2: QQ-Plot for the combined asthma and control populations (n=584). The QQ-plot
identifies that measured SNP log P-values deviate significantly from the expected trend denoted by the
black trendline. This identifies that potential regulatory SNPs for soluble PLAUR exist within the
combined dataset.
Statistical analyses in PLINK, using the additive method identified 2 genome-wide
significant SNPs (rs4253238 and rs1912826) located at 4q35 (P=1.13x10-7, B=0.0733)
(Fig. 4.3). As the 2 SNPs in this region are in near complete linkage disequilibrium (LD)
(LOD=99; R2=94) (Fig. 4.4) they were consequently considered as a single genome-
wide significant locus. SNP rs4253238 was selected to act as the sentinel SNP for this
locus. The 4q35 region corresponds to the promoter/coding region of the gene for
human plasma kallikrein (KLKB1; previously known as KLK3).
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Figure 4.3: Manhattan plot identifies a single chromosome 4 region as genome-wide significant in a combined asthma/control population. This region
(identified by a red box) consists of two SNPs; rs4253238 and rs1912826, which achieve a genome-wide significance with a P-value of <1.69x10 -7. These SNPs lie
in the promoter and coding region of the Human Plasma Kallikrein (KLKB1) gene.
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Figure 4.4: Linkage disequilibrium map of the region determined to be Genome-wide
significant. Using SNP data from the GWA study the SNPs rs425328 and rs1912826 are shown
to be in high linkage disequilibrium (LOD=99; R2=94). Therefore these SNPs are considered to
be a single scPLAUR associated region.
4.7.2 ADDITIONAL POTENTIAL SCPLAUR ASSOCIATED LOCI
Using the less stringent criteria of a P-value threshold of 1x10 ? ? or less with an
additional SNP with a P-value of 1x10-4 or less within 100kb to identify potential loci
with P-values below the Bonferroni corrected P-value threshold in the combined GWAS
dataset, 7 further regions with potential scPLAUR regulatory SNPs were identified
(Table 4.1). Region plots identified supporting evidence in the form of surrounding
SNPs with low P-values in LD with the sentinel SNP for 6 of the 7 selected loci (Fig.
4.5c-h) similar to the layout for the genome wide significant loci (Fig. 4.5a). Although
no supporting evidence was identified for SNP rs2731672, this region was still
considered based on its P-value being close to the significance threshold (P=7.83x10-7;
Fig. 4.5b).
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SNP Chromosome Position MAF Beta P-value Gene
rs4253238
rs1912826
4 187148387 (C) 0.37 0.0733 1.13E07 KLKB1/FXI/CYP4VA2
rs2731672 5 176842474 (T) 0.43 0.0782 7.83E07 FXII
rs12200614 6 96544414 (C) 0.14 -0.0764 2.25E06 FUT9
rs6988339 8 32545916 (G) 0.35 -0.06757 2.92E05 NRG1
rs6467459 7 132692468 (T) 0.29 -0.0658 7.58E06 CHCHD3
rs9480227 6 156198945 (C) 0.47 -0.06615 5.75E05 mIR1202
rs7666900 4 146414333 (T) 0.18 -0.08533 8.39E05 RAB33B / SETD7
rs341119 6 158861618 (A) 0.23 -0.0601 2.19E05 TULP4
Table 4.1: 8 SNPs selected from the GWA study. SNPs were selected using less stringent
criteria than achieving a genome wide significant P-value of possessing a P-value of 1x10-4 or
smaller with at least 1 other SNP with a P-value of 1x10-4 in the 100kb flanking region and
supporting evidence from region plots visualised using the LocusZoom software. MAF = Minor
Allele Frequency; OR = Odds Ratio (Minor Allele); KLKB1 = Human Plasma Kallikrein gene; FXI
= Factor XI gene; CYP4VA2 = Cytochrome 4VA2; FXII = Factor XII gene; FUT9 =
Fucosyltransferase 9 gene; NRG1 = Neuregulin 1 gene; CHCHD3 = Coiled-coil-helix-coiled-coil-
helix domain containing 3 gene; mIR1202 = microRNA 1202; RAB33B = Ras-related protein
Rab-33B gene; SETD7 = SET domain containing (lysine methyltransferase) 7 gene; TULP4 =
Tubby like protein 4 gene. Genome positions refer to Genome Assembly GRCh37.p5, Genome
Build 37.3.
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Figure 4.5: Region plots for potential scPLAUR associated SNPs from the GWAS
dataset. Statistical significance of each SNP on the log10 scale is shown as a function
of chromosome position (NCBI build 37). The sentinel SNP is shown in purple and the
correlation (R2) of each of the surrounding SNPs shown by their colour (see key). Fine
scale recombination rate is plotted in blue. The red line denotes the lower stringency
cut off point of P=1x10-4. All SNPs had one SNP P>1x10-4 with one other SNP in 100kb
at P=1x10-4 apart from rs2731672 which was selected as it nearly achieved genome-
wide significance with P=7.83x10-7.
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4.7.3 IN SILICO MRNA GWAS RESULTS DO NOT MIRROR THE PROTEIN
BASED GWAS
In the mRNA by SNP Browser, no SNP achieved genome-wide significance. The top 10
associated SNPs (Table 4.2) did not match the 8 selected SNPs from the protein based
GWAS. A comparison of the tagged SNPs in the in silico mRNA study and the protein
GWAS identified only 9 associations that were present in both studies and had the
same direction of effect on PLAUR expression (Table 4.3). Of these associations one
(RAB9B) belonged to a pseudo gene.
Marker Chromosome Position MAF Beta P-value Gene
rs2528650 7 107194508 (T) 0.34 0.150 1.3x10-6 LAMB1
rs3766027 1 87518821 (G) 0.12 -0.203 4.8 x10-6 LMO4
rs1375317 2 168407701 (T) 0.14 0.146 8.9x10-6 B3GALT1
rs1014766 9 75504442 (G) 0.37 -0.138 1.4 x10-5 PCSK5
rs10241241 7 98176534 (T) 0.34 -0.162 1.8 x10-5 TRAAP
rs3774700 3 62291434 (G) 0.13 0.217 1.9 x10-5 C3orf14
rs2147351 13 4235769 (T) 0.29 0.132 2.2 x10-5 EPSTI1
rs2969998 18 46284902 (T) 0.08 0.173 2.3 x10-5 MAPK4
rs4814111 20 1240988 (T) 0.04 0.233 2.3 x10-5 SDCBP2
rs3850590 12 66484825 (C) 0.16 -0.132 2.4 x10-5 DYRK2
Table 4.2: Top 10 hits from the in silico mRNA GWAS. These hits do not relate to the hits
identified in the protein based GWAS. LAMB1 = Human laminin beta 1 precursor; LMO4 = LIM
domain only 4; B3GALT1 = Galactosylgalactosylxylosyl protein 3-beta-glucuronosyltransferase
1 Gene; PCSK5 = Proprotein convertase subtilisin/kexin type 5; C3orf14 = hypothetical protein
LOC57415; EPSTI1 = epithelial stromal interaction 1; SDCBP2 = Syndecan binding protein 2;
MAPK4 = Mitogen-activated protein kinase 4; DYRK2 = dual-specificity tyrosine-(Y)-
phosphorylation.
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SNP Chr Position MAF
Beta
GWAS
P-value
GWAS
Beta
mRNA
P-Value
mRNA
Gene
rs11894671 2 10100000 (T) 0.17 0.059 9.52x10-4 0.109 9.10x10-4 NPAS2
rs1430043 2 16557593 (C) 0.36 -0.078 3.10x10-3 0.172 7.6x10-4 FAM49A
rs7598792 2 23355914 (T) 0.48 0.027 4.00x10-3 -0.106 6.60x10-4 KLHL29
rs2675301 3 2717999 (A) 0.23 -0.040 0.008543 -0.128 8.5x10-4 CNTN4
rs1217461 5 104214088 (G) 0.13 -0.030 5.27x10-3 -0.131 1.40x10-4 RAB9B
rs3860938 9 83337581 (T) 0.20 0.060 4.94x10-3 0.146 6.70x10-4 FRMD3
rs10842777 12 26737511 (A) 0.49 0.031 5.32x10-3 0.105 7.30x10-4 ITPR2
rs1012004 16 22819248 (A) 0.48 -0.044 2.71x10-3 0.106 3.6x10-4 HS3ST2
rs371500 19 45172763 (A) 0.20 0.013 7.42x10-3 -0.210 6.80x10-4 PSMC4
Table 4.3: 9 regions were found to be associated with both the mRNA GWAS and the
protein based GWAS and had the same effect on PLAUR expression. None of the
associations were genome wide significant in either GWAS. NPAS2: neuronal PAS domain
protein 2; FAM49A: Family with sequence similarity 49, member A; KLHL29: kelch-like protein
29; CNTN4: contactin 4; RAB9B: ras-related protein Rab-9B; FRMD3: FERM domain containing
3; ITPR2: inositol 1,4,5-trisphosphate receptor, type 2; HS3ST2: heparan sulfate
(glucosamine) 3-O-sulfotransferase 2; PSMC4: proteasome (prosome, macropain) 26S subunit,
ATPase, 4.
4.7.4 ASSOCIATION BETWEEN GWAS IDENTIFIED SNPS AND SCPLAUR
IN A COPD COHORT
Analysis of the COPD cohort identified that the KLKB1 promoter SNP rs4253238 was
associated with serum scPLAUR levels when analysed without the inclusion of any
covariates (P<1.00x10-3). This association held when corrected for age, height, weight
and smoking pack/years (P<1.00x10-3) (Table 4.4). The association displayed the same
direction of effect on median scPLAUR levels as that identified in the genome-wide
association study with the presence of a positive F-value. The F-value also identifies a
large change in scPLAUR levels dependant on scPLAUR genotype with over 11 fold
difference in scPLAUR levels identified in the uncorrected analyses and nearly 10 fold
difference in the corrected analyses in the presence of the minor allele (C) (Table 4.4).
This can also be appreciated by eye in a scatter dot diagram where presence of the
minor allele (C) was also associated with higher scPLAUR levels
(C:C(6654pg/ml)>T:C(5435pg/ml)>T:T(4412pg/ml)) (Fig. 4.6). The scatter dot
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diagram identifies however that a degree of overlap between the genotyping groups is
present. None of the other 7 SNPs were found to be associated with serum scPLAUR
levels in this cohort.
Later analyses of the data using PLINK by Dr Mateusz Siedlinski (University of
Groningen, The Netherlands) reproduced the association in the COPD cohort with
rs4253238 (P=5.34x10-07; B=0.16812 for log10-transformed PLAUR levels and additive
allele coding). A meta-analysis including the control, asthma and COPD populations
(n=803) further confirmed the association between rs4253238 and serum scPLAUR
(P=5.037x10-12; B=0.0879). A significant degree of heterogeneity of the effect between
the studies (P=0.02) was observed and reflected a more pronounced effect by
rs4253238 on serum scPLAUR in COPD (B=0.16812) than in asthmatics (B=0.06972)
or controls (B=0.09129).
SNP F-value
Uncorrected
P-value
F-value
Corrected
P-value
rs4253238 11.348 <0.001 9.687 <0.001
rs12200614 1.026 0.301 N/A N/A
rs6988339 0.884 0.414 N/A N/A
rs9480227 0.255 0.775 N/A N/A
rs7666900 0.149 0.861 N/A N/A
rs2731672 0.069 0.934 N/A N/A
rs6467459 0.724 0.486 N/A N/A
rs341119 2.248 0.107 N/A N/A
Table 4.4: A significant association between the GWAS identified SNP rs4253238 and
serum scPLAUR levels in the COPD Cohort. This significance holds both when the analyses is
carried out with (Corrected) and without (Uncorrected) correction for the known covariates,
age, height, weight and smoking pack/years.
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Figure 4.6: The Chromosome 4 SNP rs4253238 significantly alters serum scPLAUR levels
in a COPD cohort (n=368). The scatter diagram identifies that the same direction of effect as
reported in the GWAS exists, i.e. C:C(6654pg/ml)>T:C(5435pg/ml)>T:T(4412pg/ml), were C is
the Minor allele (R2=0.056). These differences were determined to be statistically significant
(P<0.001) even when corrected to age, height, weight and smoking pack/years.
4.7.5 rs4253238 IS IN LINKAGE DISEQUILIBRIUM WITH KLKB1 SNPS
Two blocks of linkage disequilibrium including the KLKB1 gene and 5`UTR regions
were identified when LD was defined by the association R2 values. The first block of LD,
which encompassed the KLKB1 5`UTR and gene regions, included the GWAS identified
SNP rs4253238. Inclusion of SNP rs4253238 in this block of LD, identified that this SNP
is inherited with 4 other KLKB1 5`UTR SNPs and 10 KLKB1 gene SNPs. Specific R2
values for LD for rs4253238 range from R2=9 to R2=98, with the majority having an
R2>55, therefore identifying that the GWAS tagged SNP is itself in high LD with KLKB1
gene and 5`UTR SNPs independently of the identified block of LD (Fig. 4.7).
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Figure 4.7: SNP rs4253238 is in linkage disequilibrium (LD) with SNPs in the KLKB1 gene and promoter regions. The LD heat map identified LD according
to colour which in turn represents D values as identified by the key. Values define LD based on R 2 data. SNP rs4253238 is present in a strong block of LD that
spans 4 other 5`UTR and 10 gene SNPs.
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4.7.6 KLKB1 ACTIVITY IS REGULATED BY rs4253238 GENOTYPE, IS
DECREASED IN ASTHMA AND COPD AND IS INVERSLY CORRELATED
TO SERUM SCPLAUR LEVELS
The KLKB1 activity assay identified that human plasma kallikrein (KLKB1) protein
activity is related to the rs4253238 genotype in serum, i.e. presence of the major allele
(T) was associated with increased KLKB1 activity. Presence of the T allele resulted in
increased activity in the control (P<0.01), asthma (P<0.01) and COPD populations
(P<0.001) (Fig. 4.8). KLKB1 activity was also found to be lower in both asthmatic and
COPD patients when compared to the control population per se (P<0.001) regardless of
SNP genotype (Fig. 4.8). This suggests a negative relationship between KLKB1 and
scPLAUR and potential regulation of scPLAUR function in disease. Correlation analyses
of the KLKB1 activity data from all 3 cohorts, with previously determined scPLAUR
levels (see Section 3.3.1), confirmed that KLKB1 activity is inversely correlated to
serum scPLAUR (P<1x10-4; R2=-0.5277) (Fig. 4.9).
Figure 4.8: KLKB1 activity is related to rs4253238 genotype and disease phenotype.
KLKB1 activity was elevated in with the T:T genotype in the control (P<0.01), asthma (P<0.01)
and COPD populations (P<0.001). KLKB1 activity is also elevated in controls when compared
to asthma and COPD subjects, regardless of the genotype (P<0.001). Each column represents
data obtained from10 randomly selected subjects. RFU = Relative Fluorescent units.
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Figure 4.9: KLKB1 activity is correlated to serum scPLAUR levels. In the combined
control/asthma/COPD population, increased KLKB1 activity is associated with a decrease in
scPLAUR levels (P<1x10-4; R2=0.278) suggesting a relationship between KLKB1 activity and
circulating levels of scPLAUR in serum exists.
4.7.7 KLKB1 DETERMINES SCPLAUR LEVELS IN A CELL-BASED
SYSTEM
In normal human bronchial epithelial cells (NHBECs) cultured in vitro (n=3 in Donor
7F3158; n=3 in Donor 7F3206), the addition of human derived KLKB1 under normal
growth conditions leads to a decrease in the detectable levels of scPLAUR in the cell
supernatant after both the 4 (P=0.015) and 24 hour (P=0.029) incubations (Fig. 4.10).
At 4 hours levels decreased to 141pg/ml from a basal level of 236pg/ml (40%) while at
24 hours levels decreased to 148pg/ml from a basal level of 268pg/ml (45%). Although
no changes could be detected in the levels of total intracellular PLAUR after a 4 hour
incubation with KLKB1, a 21% decrease in the levels of total PLAUR intracellular
protein was apparent following a 24 hour incubation (P=0.05) (Fig. 4.11), suggesting
that KLKB1 is more efficient at targeting soluble/extracellular protein.
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Figure 4.10: KLKB1 decreases levels of scPLAUR in NHBEC cell supernatants. Exposure of ? ?ɊȀ  ?             ?   ? ?
hour incubation. HBECs were grown under normal conditions. Graphs represent mean values,
bars represents the standard error of the mean, n=6 carried out in 2 Donors.
Figure 4.11: KLKB1 decreases levels of total PLAUR whole cell protein. Exposure of KLKB1
to HBECs resulted in a modest decrease in the levels of total intracellular PLAUR only after a
24 hour incubation identifying that the major mechanism of KLKB1 does not involve
suppression of PLAUR expression and/or production. HBECs were grown under normal
conditions. Graphs represent mean values of DI specific staining corrected to beta-actin
expression, bars represent the standard error of the mean, n=6 carried out in 2 Donors.
PLAUR
Beta-Actin
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4.7.8 KLKB1 DOES NOT ALTER PLAUR mRNA EXPRESSION IN
BRONCHIAL EPITHELIAL CELLS
As KLKB1 was found to reduce the detectable levels of scPLAUR, but not modify total
intracellular PLAUR to a high degree, a qPCR assay was carried out on total PLAUR
expression to investigate the hypothesis that KLKB1 affects scPLAUR levels
independently of both PLAUR protein and mRNA levels.
Quantitative PCR carried out in a population of normal human bronchial epithelial cells
(HBECs), was successful, with clean results obtained from the RT negative controls. On
correction of sample readings to the house keeping gene (HPRT), PLAUR mRNA
expression was found to be unaltered on exposure of the cell monolayer to KLKB1 after
both a 4 (P=0.449) and a 24 hour (P=0.089) incubation period (Fig. 4.12). Unaltered
PLAUR mRNA levels confirm the total intracellular protein results and thereby validate
the hypothesis that KLKB1 alters scPLAUR levels using a mechanism that is
independent of cell driven gene expression and does not target novel gene expression.
Therefore it was hypothesised that KLKB1 either directly interacts with scPLAUR
altering its circulating levels or drives the expression of an alternate intermediate that
itself directly alters the circulating levels of scPLAUR.
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Figure 4.12: Total PLAUR mRNA expression is unaltered on addition of KLKB1. Data from
NHBECs corrected to the housekeeping gene HPRT identifies that while total PLAUR mRNA is
elevated unilaterally at 24 hours there is no change in expression on exposure to KLKB1 at
either time point (P=0.449 (4hrs), P=0.084 (24hrs), n=6 carried out in 2 Donors.
4.7.9 KLKB1 ALTERS THE RATE OF CONVERSION OF PLASMINOGEN
TO PLASMIN IN BRONCHIAL EPITHELIAL CELLS
Since KLKB1 is known to increase the rate of plasmin activation from plasminogen in
vivo (Miles, L. A. et al. 1983), and activated plasmin is known to cleave PLAUR in the
DI/DII linker region, disrupting the PLAUR structure (Hoyer-Hansen et al., 1992), it was
hypothesised that plasmin may be acting as an intermediary molecule in the observed
KLKB1 driven changes in scPLAUR expression. Therefore experimentation was carried
out to determine whether KLKB1 dependant plasmin activation was present in the cell
(NHBEC)-based system for investigating KLKB1 effects on scPLAUR. A plasmin activity           ? ?ɊȀ  ?
(see Section 4.5.2), identified that plasmin activity triples within the first 4 hours of
addition of KLKB1 (P=3x10-3; n=6 in two donors), with levels returning back to
baseline after 24 hours (Fig.4.13). This identifies that KLKB1 mediated effects in the
cell-based experiments may be due to KLKB1 regulated activation of plasmin.
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Figure 4.13: Plasmin activity is elevated on addition of KLKB1 but later returns to
baseline. Levels of activated plasmin triple following a 4 hour incubation in the presence of
KLKB1 (P=3x10-3), returning back to baseline at 24 hours, identifying that KLKB1 mediated
activity may be due to plasmin activation. Bars represent relative fluorescent units normalised
to basal activity at 4 hours, with error bars representing the standard error of the mean.
(n=3), RFU=Relative Fluorescent units.
4.7.10 KLKB1 IS FOUND TO PROTEOLYTICALLY CLEAVE SCPLAUR IN
A CELL FREE SYSTEM
Since it has been identified in Section 4.7.9 that KLKB1 may be driving changes in the
expressed levels of scPLAUR through plasmin activation (Fig.4.13), experiments in a
cell-free system were carried out so as to identify whether KLKB1 has an as yet
unknown direct effect on PLAUR. This experiment utilised commercial recombinant
PLAUR (rPLAUR), which mimics scPLAUR in that it is a soluble form of the full lengthǤ     ?ɊȀ        ?Ǥ ? ?ɊȀ
solution of KLKB1 formed cell-free system independent of other cellular processes that
might influence scPLAUR release, formation or degradation, such as activated plasmin.
Analysis of the rPLAUR+KLKB1 solution versus the equivalently diluted rPLAUR
solution identified that addition of KLKB1 results in complete loss of PLAUR detection
(3307pg/ml vs. 0pg/ml) (Fig. 4.14). This identifies that KLKB1 has a direct effect on
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PLAUR, altering expression levels through probable disruption of protein integrity,
preventing the ELISA capture/detection antibodies from binding.
Figure 4.14: Recombinant PLAUR is rendered undetectable by ELISA on exposure to
KLKB1.    ?Ǥ ? ?ɊȀ  ?   ?ɊȀ     
complete loss of detection of the recombinant protein, identifying that a direct interaction
with KLKB1 is the likely reason for the association between KLKB1 and scPLAUR levels. Bars
represent mean data of 3 experiments with error bars identifying the standard error of the
mean.
Using western blotting, both the DI specific (Fig. 4.15A) and polyclonal (Fig. 4.15B)
antibodies rPLAUR formed a band at 40-45kDa which identified the rPLAUR protein.
On addition of KLKB1 to rPLAUR, no rPLAUR was detected with the mAB IIIF10,
indicating that KLKB1 disrupts scPLAURs Domain I. A smaller fragment (around
30kDa in size) was detected with the pAB BAF807. This identifies that while KLKB1
causes major degradation of rPLAUR, it leaves behind a protein big enough to still be
detected using a pAB. No smaller fragments were visualised on either blot. Addition of
the known PLAUR proteolytic enzyme Chymotrypsin to the rPLAUR solution did not
result in any change in protein composition as defined by the DI mAB, while staining
with the pAB identified that while a rPLAUR representative band remained at 40-
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45kDa, a small amount of a smaller ~30kDa fragment was also formed. Importantly,
addition of the protease inhibitor mix to the PLAUR/KLKB1 incubation solution
resulted in identical results to that formed with untreated rPLAUR, identifying that the
effects of KLKB1 can be inhibited. Results were fully replicated in 3 independent
experiments.
A B
(kDa) (kDa)
Figure 4.15: Western Blotting identifies a direct proteolytic role for human plasma
kallikrein on PLAUR. Staining of recombinant human PLAUR (rPLAUR) digested with human
plasma kallikrein (KLKB1) at 37oC for 24 hours with the DI specific mAB IIIF10 (Panel A) and
the pAB BAF 807 (Panel B) identifies that KLKB1 proteolytically cleaves the rPLAUR molecule
at the DI region (Panel A) leaving behind a fragment of around 30kDa in weight, comparable to
that formed following digestion with the known PLAUR proteolytic enzyme, chymotrypsin. The
~30kDa region subsequently sequenced is highlighted in the red box. kDa = kiloDalton.
4.7.11 KLKB1 CLEAVES SCPLAUR IN THE VICINITY OF DOMAIN 3
So as to determine the site of cleavage for the identified large ~30kDa fragment formed
following incubation of rPLAUR with KLKB1 (Fig.4.15B), N-terminal sequencing was
carried out by Cambridge Peptides, directly from solution, on the ~30kDa fragment
identified in Fig. 4.15 (n=2). This identified that the first 5 amino acids at the cleavage
site of this ~30kDa fragment were: Aspartic Acid (D)  Threonine (T)  Histidine (H) 
Glutamic Acid (E)  Proline (P). The protein sequence THEP is unique to amino acids
250-253 of the mPLAUR (and ergo the scPLAUR) protein, which lies within DIII of the
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receptor (Fig. 4.16). The amino acid next to Threonine however is not Aspartic Acid,
but rather Glycine (G), which does not correspond to the sequencing results.
1 mghppllpll lllhtcvpas wgLRcmgckt ngdcrveeca lggdlcrtti vrlweegeel
61 elvekscths ektnrtlsyr tglkitslte vvcgldlcng gnsgravtys RSrylecisc
121 gssdmscerg rhqslgRSp eeqcldvvth wiqegeegrp kddrhLRgcg ylpgcpgsng
181 fhnndtfhfl kccnttkcne gpilelenlp gngrqcysck gnsthgcsse etflidcrgp
241 mnqclvatgt hepknqsymv rgcatasmcq hahlgdafsm nhidvscctk sgcnhpdldv
301 gyRSgaapgp gpahlsltit llmtarlwgg tllwt
Green: Domain 1
Blue: Domain 2
Yellow: Domain 3
Figure 4.16: PLAUR protein sequence. This sequence is identical for human mPLAUR and
scPLAUR. Green denotes the sequence that makes up DI, blue DII and yellow DIII. Intermittent
regions are the domain liker sequences while the area terminal to DIII makes up the GPI
anchor. Red areas mark potential proteolytic sites for human plasma kallikrein based on
known target sequences of the molecule. The red box denotes the DIII cleavage sites identified
through N-terminal sequencing.
4.7.12 SCPLAUR ATTENUATES WOUND REPAIR AND INDUCES
MITOCHONDRIAL ACTIVITY IN NHBECS WHICH IS REVERSED ON
INCUBATION WITH KLKB1
Scratch-wound and MTT assays were carried out to identify whether both scPLAUR
and KLKB1 have a functional role in
i) airway epithelial wound repair, in which scPLAUR has been previously
implicated (Stewart et al., 2012), and
ii) proliferation, which would alter the rate of cellular respiration, based on
the previous hypothesis (Chapter 3) that scPLAUR is involved in airway
remodelling
Data from scratch-wound assays carried out on NHBECs over-expressing recombinant
scPLAUR and mPLAUR, was normalised to the reading from cells transfected with the
empty vector (pcDNA3) taken at 8 hours, in order to remove donor dependant
variation. Analysis of the data identified that scPLAUR attenuated the rate of wound
repair comparable to that caused by mPLAUR at 4 and 8 hours post-wounding
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(scPLAUR; 4hrs: P<0.001, 8hrs: P<0.05; mPLAUR; 4 and 8hrs P<0.01) (Fig. 4.17). ? ?ɊȀ ?ȋ	Ǥ ?Ǥ ? ?ȌǤ
Data from the MTT assay was normalised to the rate of mitochondrial activity of cells
transfected with the empty vector (pcDNA3). This removed donor dependant variation
and corrected for variation caused by differences in mitochondrial activity across
different groups (data not shown). Analysis of the combined dataset identified that
over-expression of scPLAUR by NHBECs resulted in a near doubling of the rate of
cellular mitochondrial activity (P=2x10-4Ȍ ȋ	Ǥ  ?Ǥ ? ?ȌǤ    ? ?ɊȀ  ?
resulted in complete loss of the scPLAUR driven effects (Fig. 4.18). Over-expression of
mPLAUR did not have a significant effect on NHBECmitochondrial activity.
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Figure 4.17: Elevated expression of both mPLAUR and scPLAUR attenuate epithelial
wound repair in a scratch wound model and is modulated by KLKB1. The rate of mPLAUR
driven attenuation appears to be equivalent to the rate driven by scPLAUR (scPLAUR; 4hrs:
P<0.001, 8hrs: P<0.05; mPLAUR; 4 and 8hrs P< ?Ǥ ? ?ȌǤ  ? ?ɊȀ ?
effect driven by scPLAUR, increasing the rate of wound repair equivalent to the empty vector
control, while KLKB1 on its own did not have and discernible effect on the rate of wound
healing. Data points represent the mean area healed normalised to cells transfected with the
empty pcDNA3 vector at 8 hours (n=4 carried out in two donors). Normalisation to the pcDNA
transfected cells was carried out since wound sizes were not constant across different groups.
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Figure 4.18: scPLAUR increases the rate of NHBEC mitochondrial activity independently
of mPLAUR and is modulated by KLKB1. The increase in mitochondrial activity is double
that of cells transfected with the empty vector (pcDNA3) at 24 hours post-transfection
(P=2x10-4ȌǤ    ? ?ɊȀ  ?         
activity back to background. KLKB1 has no independent effect on cellular mitochondrial
activity. Data points represent the mean rate of mitochondrial activity normalised to cells
transfected with the empty pcDNA3 vector (n=4 carried out in 2 donors).
4.7.13 SCPLAUR DOES NOT AFFECT THE DEGREE OF APOPTISIS IN
NHBECS
In order to identify whether both scPLAUR and KLKB1 have a functional role in airway
epithelial apoptosis, an important function in airway remodelling, in which scPLAUR
has been hypothesised to have a role (see Chapter 3), an Apo-ONE Homogenous
Caspase 3/7 assay was carried out.
Over-expression of scPLAUR did not alter the rate of apoptosis of NHBECs under either
basal conditions (P ? ?Ǥ ? ?Ȍ ȋ	Ǥ  ?Ǥ ? ?Ȍ  ? ? ?Ɋ
H2O2 (P=0.07) (Fig. 4.19B). Membrane PLAUR also had no effect on apoptosis in basal
cells and while showing a trend for a decrease in the rate of apoptosis in stimulated
cells, this was not statistically significant to the rate expressed by NHBECs transfected
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with just the empty vector (pcDNA3) (P ? ?Ǥ ? ?ȌǤ  ? ? ?Ɋ2O2 resulted in a
100 fold increase in the rate of apoptosis when compared to NHBECs at baseline.
Figure 4.19: Neither mPLAUR or scPLAUR affect the rate of epithelial apoptosis . No
change in the rate of apoptosis is discerned in basal NHBECs (P=0.75) or in a system were ? ? ?Ɋ  2O2 was added to the cell system to stimulate apoptosis (P=0.07). A trend
identifying a reduction in the rate of apoptosis on over-expression of mPLAUR is apparent in
the stimulated cells but this was not statistically different (P=0.29) from cells transfected with
the empty vector (pcDNA3). The rate of apoptosis in stimulated cells was a 100 fold higher
than that of basal cells (n=4 carried out in 2 donors).
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4.8 DISCUSSION
This chapter has successfully tackled its aims, i.e. i) to identify novel genetic
mechanisms determining scPLAUR levels in serum using a genome-wide approach; ii)
to identify the mechanism of regulation driven by these novel genetic determinants;
and iii) to identify the functional effects of scPLAUR in primary human bronchial
epithelial cells. In summary, KLKB1 has been identified as a novel regulator of
scPLAUR, cleaving the receptor at DI and in the vicinity of DII and thereby negating
scPLAUR driven effects on bronchial epithelial wound healing and mitochondrial
activity (Fig. 4.20).
Figure 4.20: The role of KLKB1 in regulating scPLAUR. Membrane bound PLAUR (mPLAUR)
is a 3 globular domain (DI, DII and DIII) protein attached to the cell membrane via a GPI anchor.
DI and DII bind to the ligand urokinase while DIII is known to interact with cell bound
integrins. The GPI anchor is susceptible to both glycolytic and lipolytic cleavage, resulting in
the release of a cleaved full-length soluble receptor, soluble cleaved PLAUR, in which all
Domains are intact. Proteolytic action carried out by KLKB1, which is elevated in carriers of
the rs4253238 T allele, disrupts the receptors globular domains inhibiting receptor driven
effects on bronchial epithelial cell mitochondrial activity (labelled as proliferation) and
wound-healing. GPI-PLD: Glycosylphosphatidylinisotol specific phospholipase D; KLKB1:
Human plasma kallikrein; mPLAUR: Membrane bound urokinase plasminogen activator
receptor; scPLAUR: soluble cleaved urokinase plasminogen activator receptor.
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This chapter set out to identify the underlying genetic regulation of elevated scPLAUR
in obstructive airway disease identified in Chapter 3 of this thesis, by carrying out two
separate GWA studies in asthma and control populations. When analysed separately,
no SNP was found to be genome-wide significant in either the populations using a
Bonferroni corrected P-value of 1.69x10-7. As this is likely due to the low number of
asthmatic (n=480) and control (n=104) subjects used, the number of analysed subjects
was increased in a meta-analysis of both populations (n=584). Although this gives the
advantage of a larger population increasing the power, combining both populations is
not without its limitations. As an association between scPLAUR and asthma has been
identified (see Chapter 3) it is possible that the presence of disease may act as a
confounder in the analysis. It was in order to increase confidence in the results from
the combined dataset that the GWAS results were investigated in an independent
dataset (COPD Cohort). Duplication of results in this cohort, where all subjects are
matched based on disease phenotype, increases confidence that the associations
identified in the combined dataset are due to changes in scPLAUR levels driven by
genotype rather than due to disease.
Quantile-Quantile plots identify the likelihood of detecting regulatory loci with
deviation of the plotted result from the predicted distribution of P-values occurring for
a small number of SNPs. Although only 1 region actually achieved a Bonferroni P-value
of 1.69x10-7 or smaller, the presence of a larger number of SNPs with effects above the
line in the QQ-plots, suggested further regions regulating scPLAUR expression in
serum. It is probable that these SNPS did not achieve genome-wide significance due to
population size, which remains small for a GWAS and may result in a number of false
negative results. Therefore less stringent selection criteria were employed, as used
previously (Wan et al., 2011), to capture SNPs that may have failed to achieve genome-
wide significance but may however be functionally relevant.
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Of the 8 loci identified using the protein based GWAS or secondary criteria, 3 are
present in regions associated with candidate genes previously identified with PLAUR
or its signalling pathways.
a. Human plasma Kallikrein (KLKB1) (Chr:4, rs4253238) and Factor XII
(Chr:6, rs2731672) are known to be involved in the
plasmin/plasminogen activation cycle (fibrinolytic pathway), which is
actively regulated by PLAURmediated PLAU activation(Crippa, 2007).
b. Neuregulin 1 (NRG1) (Chr:5, rs6988339), also known as transcript
variant HRG-beta1 (
Ⱦͷ) is known to decrease the activity of the
PLAUR associated PLAU and MMP 9 (Mazumdar et al., 2001, Puricelli et
al., 2002).
The presence of associations in regions associated with candidate genes previously
identified with PLAUR or its signalling pathways, further adds confidence to the use of
a combined case/control dataset to identify novel regulators for scPLAUR expression.
The remaining identified loci present in chromosomal regions 6q16, 6q25, 4q31.1,
7q33 and 6q25 are in novel regions, having no known association with scPLAUR or its
signalling pathways.
Interestingly, failure to replicate associations, especially the rs4253238 association, in
the in silicomRNA GWAS highlights that a dependence on mRNA levels to identify novel
genome wide regulators for gene expression is likely to miss a number of important
protein regulatory factors. This was further highlighted when exposure of KLKB1 to
NHBECs did not alter PLAUR mRNA levels. As of writing, all published GWA studies
have exclusively utilised mRNA levels as an output for gene expression. This identifies
that a number of potential gene expression regulators have been missed globally.
Although 9 genes had the same directional effect in both the in silico and protein GWAS,
none fell into our selection criteria and so were not investigated further. However,
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presence of the in silico associations in the protein GWAS, exhibiting the same
directional effect, suggests that although these associations are not significant they may
play a role in scPLAUR expression and should be investigated in future work. All of the
identified in silico regions are in novel regions, having no known association with
scPLAUR, however MAPK has been shown to be involved in PLAUR signalling pathways
(Baek et al., 2010, Park et al., 2011).
So as to confirm the association of the 8 regions detected by the protein based GWAS
and serum scPLAUR levels, an attempt was made to duplicate the results through the
genotyping of the 8 selected SNPs in a COPD population. Although SNP rs4253238 was
the only successfully replicated SNP, other SNPs were shown to have the same
directional effect on scPLAUR levels; namely rs9480227 (chr6:156198945), rs7666900
(chr4:140414333) and rs2731672 (chr5:176842474). This identifies the possibility
that failure to reach significance may be due to limited sample numbers, even though
the study was powered to detect these variations (see Table 2.16). However, since
these SNPs did not replicate, investigations were focussed to the KLKB1 SNP
rs4253238. Interestingly the degree of association between rs4253238 and serum
scPLAUR levels was stronger in COPD subjects than in asthmatic and/or controls,
which ties in well with deductions made in Chapter 3 of this thesis, where serum
scPLAUR was associated to a higher degree with COPD subjects than asthmatics and
control subjects.
SNP rs4253238 is a promoter polymorphism for the KLKB1 gene, a 31kb long gene
located on chromosome 4q34-35 that codes for the protein pre-kallikrein (Fink et al.,
2007). Pre-kallikrein is cleaved by activated Factor XII, with high molecular weight
kininogen as a co-factor, to form the activated protein human plasma kallikrein
(KLKB1)(Fink et al., 2007). KLKB1 is a 80kDa serine protease synthesised in the liver
that normally circulates in serum at a concentration of 50µg/ml(Lilla et al., 2009), and
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is known to participate in the contact activation system of coagulation through the
activation of high molecular weight kininogen into bradykinin (Baumgarten et al.,
1986, Motta et al., 1998, Schmaier et al., 1999, Rojkjaer and Schmaier, 1999). KLKB1
also activates plasminogen into plasmin in vitro at a less efficient rate than that
catalysed by either PLAU or tissue plasminogen activator (tPA) (Miles et al., 1983).
KLKB1 differs both structurally and catalytically from the large family of tissue
kallikreins, which activate both high and low weight kininogen into an alternate form
of bradykinin (Lima et al., 2008).
The presence of the rs4253238 minor (T) allele results in the loss of 3 transcription
factor binding domains, namely those for:
a)  ?ȋ ?ȌǡȾ ?
b) Binding domain for Kruppel-like C2H2 zinc finger transcription factors
c) Binding domain for the PAR/pZIP family of transcription factors
Haplotype analysis identified that rs4253238 is in strong LD with other SNPs that span
the entire KLKB1 gene, including but not exclusive to SNPs present in the gene exon
regions. The rs4253238 SNP has also previously been identified to be in LD with
rs3733402, which causes a Arginine to Serine amino acid change at position 124 of the
KLKB1 protein, which causes a in the catalytic effect of KLKB1 (Katsuda et al., 2007).
This identifies that although an association has been identified between this SNP and
scPLAUR expression, it may not be rs4253238 that is the driving force of the
association but rather may be a marker for an alternate KLKB1 SNP that regulates
KLKB1 activity.
An activity assay confirmed that changes in rs4253238 genotype also drove changes in
KLKB1 activity with the minor allele associated with a lower level of KLKB1 activity
(×C:C,ØT:T) therefore deducing, as confirmed by correlation analyses, that KLKB1 had
an inverse relationship to serum scPLAUR levels. Based on its detection in each cohort,
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the relationship between rs4253238 genotype, KLKB1 activity and serum scPLAUR
levels was deduced to be a universal relationship regardless of disease state. However,
closer inspection of the KLKB1 activity assay data identifies a striking difference in
KLKB1 activity between the control and obstructive lung disease populations,
suggesting that KLKB1 may, through scPLAUR regulation, play a role in the progression
of obstructive lung disease. This is based on the supposition that scPLAUR is a
functional molecule that affects cell function and may drive the disease phenotype as
has been previously described in FSGS (Wei et al., 2011). The validity of this
relationship, identified in an artificial set-up, was confirmed at the protein level using a
living in vitro system (NHBECs).
Quantitative PCR identified that the mechanism underlying the relationship between
KLKB1 activity and serum scPLAUR was independent of changes at the mRNA level of
mPLAUR, the progenitor of scPLAUR. This is suggestive of a protein based mechanism
of action. First to be investigated was plasmin, a known PLAUR DI/DII protease (Hoyer-
Hansen et al., 1992), based on published data showing an elevation of activated
plasmin through modulation of the plasminogen-plasmin pathway by KLKB1. Here,
KLKB1 activates PLAU (Ichinose et al., 1986) and plasminogen (Miles et al., 1983),
indirectly increasing the overall levels of circulating activated plasmin. However,
although elevations in activated plasmin levels were identified on addition of KLKB1 to
a NHBEC population, these returned to baseline at 24 hours, an effect not replicated
when measuring scPLAUR levels. This suggests that KLKB1 affects scPLAUR levels by
an alternate mechanism to that of plasmin activation.
Since KLKB1 has a known proteolytic role, it was hypothesised that KLKB1 affects
scPLAUR levels by proteolytically cleaving scPLAUR and so rendering it unable to carry
out any of its biological functions. A proteolytic role for KLKB1 ties in well with a
previously published investigation into relationships between a different kallikrein,
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human tissue kallikrein (hK4) and PLAUR (Beaufort et al., 2006). This study identified
that hK4 acts as a proteolytic enzyme on the PLAUR molecule in the DI-DII linker region
and within the carboxyl terminus of DIII. However such a proteolytic role for KLKB1
was not a certainty, based on the determination that KLKB1 is non-homologous to any
of the other members of the kallikrein family and therefore may not have the same
functional roles (Yousef and Diamandis, 2001).
Experimentation carried out in a cell-free based system to remove any influence of the
plasminogen-plasmin pathway, identified that exposure to KLKB1 resulted in the loss
of PLAURs DI epitope as well as loss of full length PLAUR forming a smaller ~30kDa
fragment, confirming a plasmin independent proteolytic role for KLKB1. Lack of PLAUR
detection by mAB IIIF10 identifies a cleavage site within DI of the receptor structure
while N-terminal sequencing suggests that the KLKB1 mediated cleavage of PLAUR
involves a site adjacent to DIII. However, the presence of a mismatched allele at position
249 of the rPLAUR protein structure does not allow for confident determination of the
DIII cleavagesite. This is since although this substitution of Glycine to Aspartic Acid at
position 249 has been previously described (Zhu, F. X., et al. 2000), no SNP has been
validated in this region. Also, this sequence does not match the sequence reported by
the manufacturing company (R&D Systems), leaving us unable to explain this
substitution. Therefore it is likely that KLKB1 regulates PLAUR levels by acting as a
proteolytic enzyme on the PLAUR protein, in a plasmin-independent regulatory system.
Although detected in the scPLAUR form of the receptor, this regulatory mechanism
should be equally valid for the membrane bound receptor, which has the same
molecular structure as scPLAUR.
The identification of a novel system of scPLAUR regulation by KLKB1 has important
implications for scPLAUR driven disease mechanisms, as regulation of scPLAUR
expression may be fundamental to disease progression and development. This
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argument is based on scPLAUR association with increased disease mortality rates
(Eugen-Olsen et al., 2010b) and recent publications identifying the receptor as having a
direct role in the modulation of kidney disease (FSGS) (Wei et al., 2011). Suggestion of
the importance of the KLKB1/scPLAUR interaction in disease is hinted at in this
chapter by the identification of greater association between rs4253238 and serum
scPLAUR in the COPD population and the presence of significantly lower KLKB1
activity in both asthmatics and COPD patients.
Since this thesis set out to investigate PLAUR as a gene/receptor involved in
obstructive lung disease, investigations of the role of KLKB1 in disease focussed on
scPLAUR driven changes in the lung. Since earlier on (see Section 3.5) it was argued
that scPLAUR may modulate disease directly by affecting airway remodelling and
mPLAUR has been shown to dyseregulate wound healing through attenuation of repair
in NHBECs partly due to the increased scPLAUR shedding (Stewart et al., 2012), it was
prudent to identify whether the KLKB1/scPLAUR mechanism effects the rate of
migration, proliferation and apoptosis in NHBECs. These outcomes were chosen as
dysregulation of epithelial cell turnover (defined by dysregulation of the rates of
cellular migration, proliferation and apoptosis) plays an important role in airway
remodelling in asthma (Chung, 2005). In this thesis, the MTT assay was used in order
to determine the effect of KLKB1/scPLAUR on cellular proliferation. However, one
must keep in mind that as previously discussed; results of the MTT assay only
indirectly measures cellular proliferation through the measure of cellular respiration
(mitochondrial activity). Therefore, while it is likely that changes detected in cellular
respiration in this chapter relate to changes in proliferation, a definte link to cellular
proliferation cannot be concluded.
Scratch-wound assay results confirm and extend previous suggestions that scPLAUR is
the active molecule driving mPLAUR attenuation of epithelial cell migration (Stewart et
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al., 2012). In addition scPLAUR increased the rate of NHBEC cellular respiration
independently of mPLAUR, lending weight to the argument, stemming from results in
Chapter 3, that scPLAUR modulates obstructive airway disease through airway
remodelling on over-expression by causing an alteration in normal bronchial epithelial
repair and through a possible modulation of cellular proliferation. Complete loss of the
effects caused by scPLAUR on addition of KLKB1 further consolidates the conclusion
that KLKB1 plays an important role through the regulation of scPLAUR. Therefore it
can be hypothesised that a loss of active KLKB1 in obstructive respiratory diseases
(asthma and COPD) results in a build-up of active scPLAUR, which in turn modulates
changes in the airway by causing a possible increase in epithelial proliferation, while
simultaneously inhibiting epithelial cell migration.
In summary, in this chapter, a GWAS study identified genetic determinants
(rs4253238) of serum scPLAUR. Importantly, this finding was also observed in an
independent population of COPD subjects with a meta-analysis including the control,
asthma and COPD populations further confirming the association and identifying a
more pronounced effect in COPD subjects than in asthmatics or controls (B=0.09129).
The rs4253238 associated protein KLKB1 regulates scPLAUR levels through
proteolytic cleavage at the proteins DI and DIII regions, which prevents scPLAUR
binding to either PLAU (Blasi and Carmeliet, 2002) or other membrane bound integrins
(Wilcox-Adelman et al., 2000, Wei et al., 2007). This renders scPLAUR inactive to its
known processes (Fig. 4.17 & Fig. 4.18). It must be noted however, that this process
may not be unique to scPLAUR as mPLAUR possesses an identical protein structure.
Although common to the general population, KLKB1 mediated regulation of PLAUR
may play a role in scPLAUR associated disease, where loss of scPLAUR interaction with
membrane bound integrins and its role in sequestering freely circulating PLAU will
have an effect in the modulation of associated diseases such as asthma and FSGS.
Indeed, this chapter confirmed that KLKB1 regulation of PLAUR is able to prevent
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scPLAUR mediated changes in bronchial epithelial cells, which may prevent changes in
the airway epithelium such as dysregulation in the process of wound repair and
cellular proliferation, which would have an effect on the process of airway remodelling.
SNP rs4253238 has a minor allele frequency (MAF) of 0.32 in a Caucasian population,
which identifies that the SNP is a relatively prevalent one in a general Caucasian
population, making it a potentially widespread regulator of scPLAUR with implications
for scPLAUR driven disease.
CHAPTER 5:
DEFINING MOLECULAR
MECHANISMS DETERMINING
PLAUR MRNA EXPRESSION
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CHAPTER 5: DEFINING MOLECULAR MECHANISMS
DETERMINING PLAUR MRNA EXPRESSION
5.1 INTRODUCTION
As previously discussed in Chapter 1, different forms of PLAUR exist. These different
forms exist via either receptor cleavage or through the presence of different gene
splicing. The most common of these and the ones tackled by this thesis are the
membrane bound PLAUR (mPLAUR), the soluble cleaved PLAUR (scPLAUR) and the
soluble spliced PLAUR (ssPLAUR), which arises from a splice form of the PLAUR gene
that results in an alternate terminal exon and the lack of a GPI anchor (Pyke et al., 1993,
Stewart and Sayers, 2009). A number of recent investigations have suggested that
changes in the level of PLAUR expression are important in obstructive lung disease.
Increases in the expression of total PLAUR were identified in the epithelium of
asthmatics (Stewart et al., 2012) and COPD patients (Wang et al., 2008) when
compared to non-diseased controls. In vitro increases in the level of expressed PLAUR
were associated with a reduction in the rate of epithelial cell migration and therefore
attenuation of wound repair in bronchial epithelial cells, as well as being up-regulated
at the epithelial wound edge (Stewart et al., 2012). This highlights that PLAUR has a
probable role in the modulation of tissue remodelling within the airways, through the
dysregulation of epithelial migration and wound repair, important constituents of
airway remodelling. Furthermore, results discussed in Chapter 3 of this thesis identify
an association between scPLAUR (and by its association mPLAUR) and the obstructive
lung diseases asthma and COPD, as well an association with the degree of reversibility
of fixed airway obstruction in never smokers.
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The specific association between scPLAUR and reversibility of fixed airway obstruction
in smokers highlights a probable relationship between exposure to cigarette smoke
and the role of PLAUR in obstructive lung disease. This hypothesis is further supported
by the high degree of correlation between serum levels of scPLAUR and smoking
pack/year history identified in Chapter 3 as well as the association defined in literature
and in Chapter 3 of this thesis between PLAUR and COPD, a disease whose main
causative factor is exposure to cigarette smoke. Therefore, considering the increased
expression of PLAUR in obstructive lung disease, its association with cigarette smoke
and its role in modulating the rate of wound repair, regulation of the rate of gene
expression both basally and under stimulation of wound repair and cigarette smoke,
with focus within the airway epithelium, could be an important determining factor for
the role of PLAUR in the regulation of cell functional effects.
Although a genome-wide regulator for scPLAUR has been identified (see Chapter 4),
the potential genetic regulatory elements within the PLAUR gene itself have not yet
been defined in bronchial epithelial cells, the key functional cell type identified in
previous work (Stewart et al., 2012, Stewart and Sayers, 2009). Initial genetic based
investigations have however identified the 5`UTR/promoter and 3` distal regions as
potential important regulatory regions for PLAUR. Colleagues within the same group
have determined that SNPs within the 5`UTR/promoter, which is identical for both
mPLAUR and ssPLAUR, regulate serum scPLAUR levels as well as asthma risk, the rate
of FEV1 decline in asthma, changes in baseline lung function and protection in COPD
(Barton et al., 2009, Stewart et al., 2009). SNPs within the 2 distinct 3 prime distal
regions, that give rise to the 2 different terminal exons for the 2 PLAUR isoforms
(mPLAUR and ssPLAUR), were also associated with an increased risk in asthma as well
as the rate of FEV1decline in asthma (Stewart et al., 2009).
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Literature on PLAUR 5`UTR driven transcription has generally been limited to the
discovery and further understanding of the minimal basal gene promoter.
Investigations in colon cancer and U937 lymphoma cells have identified that the
minimal PLAUR promoter lies within the first 200bp of the TSS (Wang et al., 1994,
Soravia et al., 1995) and that while this minimal promoter lacks both TATA and CAAT
boxes, it contains a GC-rich proximal sequence that contains multiple Sp-1 consensus
elements that regulate basal gene expression (Soravia et al., 1995). This 200bp minimal
promoter was also found to contain a number of transcriptional elements including but
not limited to AP-1, c-Jun, c-Fos and Fra-1, which contributed to PLAUR transcriptional
regulation (Okan et al., 2001). Investigations into other regulatory areas outside the
minimal promoter region have been minimal. A region between 398 and 197 base pairs
upstream of the TSS was identified to be essential for PLAUR gene silencing occurring  Ⱦ3 integrin in conjunction with the PEA3 motif at 248bp (Laufs et al.,
2006), while a study in transgenic mice has identified that the 1.5kb region upstream of
the TSS to be required for optimal expression, with a region spanning between 1295
and 1192 base pairs upstream of the TSS proposed as a novel regulatory region (Wang
et al., 2003).
Investigations into PLAUR post-transcriptional regulation by the genes 3`UTR have
also been limited to a few studies to the 3`UTR of the membrane bound receptor.
However, these studies highlight that the 3`UTR has an important role in PLAUR     Ǥ ǡ 
	Ⱦ ? 
hnRNPC have been defined as stabilisers of PLAUR mRNA (Lund et al., 1995, Shetty et
al., 2005), while a cis-acting AU-rich region present in the 3`UTR of the gene (Wang et
al., 1998) was defined as an important 3`UTR regulatory region for mRNA stability. A
destabilising agent for PLAURmRNA (p53) was also discovered (Shetty et al., 2007a).
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Therefore, there remains scope for further investigation into PLAUR regulation, not
only to understand gene regulation in bronchial epithelial cells (the key functional cell
type identified in previous work (Stewart et al., 2012, Stewart and Sayers, 2009)) but
also to better understand general regulation of this disease important receptor.
Specifically it is important to understand how the extended 5 prime distal region,
which contains disease associated polymorphisms (see above), affects gene
transcription and how 3`UTR regulation of the soluble spliced receptor, which has not
yet been investigated, differs from that of the membrane bound receptor. How PLAUR
transcriptional regulation alters under conditions known to affect PLAUR expression,
i.e. smoking and scratch-wounding, will help further our understanding of the driving
force behind the changes in receptor expression (including the as yet uninvestigated
ssPLAUR). This may highlight potential targets for future manipulation of receptor
expression such as micro RNAs, regulators that bind to complementary sequences on
3`UTR transcripts resulting in translational repression or target degradation and gene
silencing (Bartel, 2009, Kusenda et al., 2006).
In this chapter, the regulatory potential of the immediate 3`UTR and 5`UTR was
investigated using in silico identification of regions with high inter-species homology
and ergo a high potential for gene regulation and in silico prediction of the regions
potential gene regulatory elements. These gene regulatory elements were specific to
the region investigated, with transcription factors affecting the 5` region and micro
RNAs (miRNAs) affecting the 3` region. Transcription factors promote or inhibit the
recruitment of the RNA polymerase enzyme to the 5`UTR/promoter regulating the
levels of gene transcription to mRNA. Micro RNAs on the other hand are short (~22
nucleotides) RNAs that bind to and act on mRNA transcripts that regulate gene
expression through translational repression, mRNA degradation, gene silencing or a
degree of each.
205
These investigations were then followed by experimental investigations into the role
of the untranslated regions in regulating PLAUR expression in bronchial epithelial cells.
This built upon previous investigations which identified the minimal PLAUR promoter
within the first 200 base pairs from the ATG in a number of oncogenic cell lines (Dang
et al., 1999, Soravia et al., 1995). To this aim transcriptional regulation by the 5`UTR
and 3`UTR was investigated under basal conditions and under stimulation by cigarette
smoke extract and scratch-wounding, based on the relationship between PLAUR and
cigarette smoke previously identified in this thesis (see Chapter 3) and the previously
identified role of mPLAUR and scPLAUR on the rate of scratch-wound repair (see
Chapter 4) (Stewart et al., 2012).
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5.2 AIMS
1. To investigate the potential regulatory motifs and regions of the PLAUR genes
3` distal region and 5`UTR in silico.
2. To determine the relative contribution of the immediate PLAUR 5`UTR in
transcriptional regulation of the gene.
3. To determine the role of the PLAUR 3`UTR in the regulation of PLAUR isoform
specific expression.
4. To determine the contribution of core PLAUR 5`UTR and 3` distal regions to
cigarette smoke extract and scratch wound induction of PLAUR.
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5.3 METHODS - BIOINFORMATICS
5.3.1 IN SILICO PREDICTION OF INTER-SPECIES VARIATION
The use of inter-species homology reports allows for the identification of conserved
regions across different species. A high degree of conservation across different species
identifies that that region has been conserved through evolution and therefore has a
higher probability of containing gene regulatory elements. The further down the
evolutionary tree that the conservation is maintained, the higher the probability that
gene regulatory elements are present. Inter-species homology reports were set-up
using the following databases:
a) VISualization Tools for Alignments, using the Human February 2009 build of
the Human genome - http://genome.lbl.gov/vista/index.shtml (Mayor et al.,
2000).
b) USCS Genome Browser, using the Human February 2009 build of the human
genome - http://genome.ucsc.edu/cgi-bin/hgGateway (Kent et al., 2002).
Analyses were carried out with respect to the genetic sequence in higher Primates
(Orang-utan, Chimp, Rhesus Monkey and Gorilla) and Mouse by selected their
respective boxes in each software package. The region of interest, encompassing the
PLAUR gene its 5`UTR and 3` distal regions (chr19:44,145,247-44,179,498 of the
February 2009 gene build) were placed into the gene region box and the select button
was pressed in order to analyse the region.
In order to determine whether the gene inter-species also occurs at the amino acid
level the human (Q03405) protein was aligned with the Mouse (P35456), Rat (P49616)
and Chimpanzee (Q9GK80) protein at http://www.uniprot.org/align.
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5.3.2 IN SILICO PREDICITION OF 5`UTR TRANSCRIPTION FACTORS
Transcription factors (TF) are proteins which bind to complimentary DNA sequences
either alone or in a complex. Through binding, transcription factors control gene
transcription by activating or repressing the recruitment of RNA polymerase
(Latchman, 1997, Nikolov and Burley, 1997, Lee and Young, 2000). Therefore in order
to fully understand the 5`UTR and promoter driven transcription of the gene it is
important to identify putative transcription factor binding motifs for this region.
As investigations were carried out in silico, TF calls are prone to database dependant
errors. Therefore, TFs were only selected if they were present in at least two of the
databases used to carry out TF calling.
The sequence up to 2584bp upstream of the PLAUR TSS (NC_000019.9: c44184671-
44174298) which corresponds to the region investigated later on in this chapter, was
analysed as a FASTA sequence, in 3 separate transcription factor databases:
a) MatInspector TF Mining tool  available at: www.genomatix.de (Cartharius et
al., 2005).
b) Transcription Element Search System (TESS)  available at:
www.cbil.upenn.edu/cgi-bin/tess/tess (Schug, 2008).
c) PROMO - available at: http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 (Messeguer et al., 2002).
Analyses were done exclusively for human transcription factors. Data were transferred
to a Microsoft Excel spread sheet and common transcription factors were identified.
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5.3.3 IN SILICO PREDICITION OF POTENTIAL 3`UTR EFFECT
MODIFYING miRNAS
In order to identify possible miRNA binding sites the online database
http://www.microrna.org/microrna/home.do (Betel et al., 2008) containing a
16228619 predicted microRNA target sites in 34911 distinct 3'UTR from isoforms of
19898 human genes, was used. Target predictions are based on a development of the
miRanda algorithm, incorporating miRNA target rules and a compendium of
mammalian microRNAs and scored for likelihood of mRNA down-regulation using
mirSVR, a regression model that is trained on sequence and contextual features of the
predicted miRNA-mRNA duplex.
Under the target mRNA tab, the PLAUR gene was entered into the target mRNA field
and Homo sapiens selected from the species drop down menu. By selecting the go
button links to the alignment details of both PLAUR 3`UTRs, originating from the genes
alternate terminal exon and coding for mPLAUR or ssPLAUR, were made available.
Calling of miRNAs was done by selecting miRNAs with good miRSRV values from the
drop downmenu of the display options bar.
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5.4 METHODS  MOLECULAR BIOLOGY
5.4.1 DETERMINING CHANGES IN PLAUR MRNA EXPRESSION
Quantitative PCR (qPCR) was used to determine changes in PLAUR mRNA expression
levels. NHBECs in culture were collected by mechanical scraping and total cellular RNA
was extracted using the Qiagen RNeasy Kit as described in Section 2.2.10. and used to
form complimentary DNA (cDNA) as outlined in Section 2.2.11. The resulting cDNA,
diluted to 1:10, was used in qPCR analysis as outlined in Section 2.2.12, using the HPRT
gene targeting Pre-Developed TaqMan Assay Reagent (PDAR) as the housekeeping
gene and the primers and probes for total or specific forms of PLAUR as described in
Tables 2.9 and 2.10 (see Section 2.2.12). All primers and probes were designed and
validated by Dr Ceri Stewart (University of Nottingham). Analyses were carried out
using the MxPro software and Microsoft Excel. Further details and cycling parameters
are available in Section 2.2.12.
When correcting stimulated mRNA expression across donors, data were normalised to
a 100%with respect to the mRNA values expressed by the cells at baseline.
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5.4.2 CONSTRUCTION OF A PLASMID LIBRARY FOR 5`UTR AND 3`UTR
TRANSCRIPTIONAL ACTIVITY STUDIES.
5.4.2.1 IDENTIFICATION OF A SUBJECT CARRYING PLAUR SNP COMMON
ALLELES WHOSE DNAWILL BE USED AS A CONSTRUCT TEMPLATE
DNA from a number of asthmatics from the Nottingham asthma cohort (n=37) was
considered as a template to construct the plasmid vectors. The genotype of 17 5`UTR
SNPS (reported (Stewart et al., 2009)and unreported), for each of these samples were
placed in Excel 2010 and colour coded according to overall genotype. The DNA from
the individual (A073) containing the most common haplotype was selected as a
template for promoter constructs.
5.4.2.2 GENERATION OF 5`UTR AND 3`UTR CONSTRUCTS FOR USE IN
TRANSCRIPTIONAL ACTIVITY STUDIES.
General methods used in plasmid construction through molecular cloning can be found
in Sections 2.2.4, 2.2.8 & 2.2.9. The steps involved in the construct of this particular
plasmid library are outlined in Fig. 5.1. Where relevant, the concentration and purity of
PCR products and plasmid DNA were measured using a NanoDrop Technologies
NanoDrop® ND-1000 Spectrophotometer, as outlined in Section 2.2.10. Additional
details specific to the construct of plasmids used in this chapter are provided below.
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Figure 5.1: Process of plasmid construction. PCR constructs (5`UTR and 3`UTR) were ligated to the
pCR®4-TOPOXL®/pCR®4-TOPO® vector (A). Following bulking up in Top10 E.coli cells inserts were
removed via restriction digest and ligated into the pGL4.10 (5`UTR) and psiCHECK-2 (3`UTR) vectors (B).
In brief, constructs of increasing length from the PLAUR TSS (Fig. 5.2) and relating to
the two 3`UTR isoforms (mPLAUR and ssPLAUR) were created using PCR (see Section
2.2.1) using the primers outlined in Table 5.1.
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Figure 5.2: PLAUR 5`UTR fragments cloned into the luciferase expressing vectors . All
fragments originate from the genes transcriptional start site and so should drive PLAUR
transcription.
Variant
Product
Length
Primer Pair
5`UTR Forward CTGAGCTAGCGGGTCCCTGCAGTCTT
(200) 199 CTGAGGTACCCGAGCCAGCCCCTTCAC
(500) 490 CTGAGGTACCGAAGCAAAGCAAGGGTTAAGT
(900) 887 CTGAGGTACCTCCCACCTAAGCATACAGCC
(1500) 1484 CTGAGGTACCCCCACAGAAAAGGAGACAGAATGGCA
(2500) 2584 CTGAGGTACCCAGGCATGCATGAGAATC
3`UTR
(Exon 7a)
Forward ATAGTCGAGACCTGAAATCCCCCTCTCT
419bp ATAGCGGCCGCGCAGGGGCCTCAAACATGACCC
3`UTR
(Exon 7b)
Forward ATAGTCGAGAGAGCCCCAGATGTTTCAGCCA
314bp ATAGCGGCCGCGAGGTCTCACTGTGTTGCCCAGG
Table 5.1: Primers used for the construction of plasmid vectors used in this chapter.
Restriction enzyme sites were introduced to the primers (red characters; 5`UTR FWD: Nhe1;
5`UTR REV: Kpn1; 3`UTR FWD: Xho1; 3`UTR REV: Not1). 4 nonsense base pairs were added to
the end to prevent loss of required sequence through cloning. Primers for fragments larger
than 2586bp are for reference only as their resulting product failed to form a usable vector
construct. FWD=Forward Primers; REV=Reverse Primers.
Transcription
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The gel-purified PCR constructs were then inserted into the Invitrogen vector
pCR®4-TOPO XL® (1.5bp and 2.5kp constructs)/pCR®4TOPO® (200bp  900bp
constructs) for sequence verification (see Section 2.2.4 for details), generating the
required pCR®4-TOPOXL®/pCR®4-TOPO® constructs (Figure 5.1A). The required
sequence was then extracted by restriction digestion and inserted into either the
pGL4.10 (5`UTR) or psiCHECK2 (3`UTR) vector (Fig.5.3), so as to produce the
respective luciferase expressing constructs (Fig.5.1B). Presence of the correct
sequence/insert was confirmed by dideoxynucleotide triphosphate chain terminator
sequencing (see Section 2.2.7). Multiple attempts to construct an Isoform 2 psiCHECK-2
construct were unsuccessful and therefore a commercial firefly luciferase expression
vector (PLAUR 3UTR_01) was purchased (PLAUR 3UTR_01).
Figure 5.3: Plasmid vector backbones used in this chapter. The pGL4.10 vector is used for
5`UTR promoter studies, with 5`UTR constructs driving the expression of Firefly Luciferase.
The psiCHECK-2 vector is used for 3`UTR analyses, where the influence of 3`UTR constructs on
Renilla Luciferase expression driven by the T7 promoter was investigated. Firefly luciferase is
transiently expressed by the psiCHECK-2 vector and acts as a transfection control. Restriction
enzymes used in each vector are highlighted in red.
A B
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5.5 METHODS  CELL BASED
5.5.1 CULTURING OF BRONCHIAL EPITHELIAL CELLS AND
FIBROBLASTS
For the purpose of this chapter the bronchial epithelial cell line Beas2BR1, the
fibroblast cell line MRC-5 and primary normal human bronchial epithelial cells (Donors
7F3158 and 7F3206) were cultured. For a detailed description of the culturing
procedures see Sections 2.4.1 & 2.4.2.
5.5.2 TRANSIENT TRANSFECTION OF PLASMID CONSTRUCTS
Plasmids were transfected into NHBECs using the FuGENE®6 transfection reagent as
described in Section 2.4.5. In this chapter a transfection ratio of FuGENE®6 to DNA of
3:2 was used. Vectors expressing only Firefly Luciferase (pGL4.10; PLAUR 3UTR_01)
were co-transfected with the Renilla Luciferase expressing control vector pRL-TK at a
ratio of Firefly:Renilla of 1:5. The SV40 promoter driven pGL4 vector pGL4.13, was also
transfected as a positive control in each experiment. For a detailed description of the
transfection procedure refer to Section 2.4.5.
5.5.3 IMMUNOFLUORESCENCE
Methods detailed below deal with this specific chapter, for a detailed description of the
immunofluorescence technique refer to Section 2.5.4.
5.5.3.1 CONFIRMATION OF THE EPITHELIAL CELL PHENOTYPE
In order to confirm the phenotype of the commercially obtained (Lonza) NHBECs used
in this chapter, cell populations from donors 7F3158 and 7F3206 were cultured in 4
well chamber well slides and stained both for epithelial cell markers as well as
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contamination by fibroblasts. A control fibroblast cell line (Normal Human Foetal Lung
Fibroblast: MRC-5) was also stained for the same proteins in parallel. To this aim the
following primary antibodies were used:
a) Mouse Anti-Cytokeratin 14 IgG monoclonal Antibody (Millipore MAB3232)
b) Mouse Fibroblast Surface Protein IgM monoclonal Antibody 1B10 (Abcam
AB11333)
Anti-cytokeratin 14 (CK-14) was used based on the knowledge that cytokeratins are
proteins of keratin-containing intermediate filaments found in the intracytoplasmic
cytoskeleton of epithelial tissue, specific to basal epithelial cells, which has previously
been used before to identify NHBECs (Wetzels et al., 1992). Anti-1B10 was used to
determine whether any fibroblast contamination was present in any of the NHBEC
populations.
Fluorescence was driven by the use of the following secondary antibody visualised on
the Improvision spinning disk confocal microscope:
a) Fluorescein isothiocyanate (FITC) anti-mouse monoclonal secondary antibody
(Sigma F0257) visualised using green filters.
While the following isotype controls were used as controls:
a) Mouse IgG1 from MOPC-21 isotype control (Sigma M7894).
b) Mouse IgM from MM-30 isotype control (Abcam AB18400).
Primary antibodies originating from different species were mixed together to allow for
dual staining of the population, while controls were set for the non-specificity of
secondary antibodies, all isotypes and cell auto fluorescence, using a layout as outlined
in Fig. 5.4A&B.
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A
CK-14 + CC26 CK-14 + 1B10 TRITC 2o Cont. FITC 2o Control
1:200 + 1:500 1:200 + 1:500 1:100 1:100
B
Cells Only Mouse IgM Iso Mouse IgG Iso Rabbit IgG Iso
1:2500 1:1250 1:1
(Pre-dilute Add Neat)
5.5.3.2 IDENTIFYING CELLULAR TRANSFECTION EFFICIENCY
In order to determine the rate of transfection of DNA into Beas2BR1 cells and NHBECs,
immunostaining was carried out on cells cultured in 4 well chamber well slides and
transiently transfected with either the pGL4.10+500bp truncation, pisCHECK-
2+Isoform 1 or the commercial PLAUR 3UTR_01. Cells were stained with the pAb anti-
firefly luciferase antibody (Abcam AB21176) with secondary staining carried out using
the Goat anti Rabbit IgG Rhodamine TRITC (Stratech 111-025-0003) with Rabbit
polyclonal IgG (Abcam AB27472) used as the isotype control. Total number of cells and
number of stained cells were counted in five fields of a Neubauer Haemocytometer.
Transfection efficiency was calculated by dividing total number of fluorescent cells by
total number of cells.
Chamber Well Slide A
Chamber Well Slide B
Figure 5.4: Layout of the 8-well chamber slide used to confirm the
epithelial cell phenotype by immunofluorescence . This layout includes
secondary (2o) antibody controls, isotype controls as well as a cells only
well to identify autofluoresence. This layout was replicated for both NHBEC
donors and the MRC-5 population.
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5.5.4 DUAL LUCIFERASE ASSAY
Dual Luciferase assays (DL) (Promega UK - E1960) make use of plasmid vectors that
express Firefly or/and Renilla luciferase to infer the role of 5` or 3` untranslated region
determined effects on gene expression. As Firefly and Renilla luciferase proteins are
not expressed by mammalian cells, it is possible to specifically determine the effect of
the fragment of interest on gene expression independently of baseline cell expression
by measuring luciferase activity. Corrections for differences in cell density and
transfection efficiency are tackled by measuring and normalising to alternate luciferase
gene expression driven by an independent promoter. In this thesis, the Firefly
luciferase expressing pGL4 vector constructs and the commercial Isoform 2 vector
were normalised using the Renilla expressing pRL-TK vector (Fig. 5.5). In the
psiCHECK̻-2 vector, Renilla luciferase levels were normalised using HSV-TK promoter
driven Firefly luciferase expressed by the same plasmid vector (Fig. 5.3B).
Figure 5.5: The pRL-TK vector. This vector was used as the control vector for the pGL4 and
PLAUR 3UTR_01vectors through its expression of Renilla luciferase driven by the HSV TK
promoter. This control vector was chosen as it had a different promoter to the positive control
vector and therefore would have minimal interaction in the control plates.
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Briefly, at 24 hours post transfection, the DLR assay was carried out as follows:
1.  ?ȋ ? ?ǣ ? ?ɊǢ ? ?ǣ ? ?ɊȌǦ ? ?oC.
2.  ? ?Ɋ ? ?ǦǤ
3. 	ǡ  ? ?ɊȋǢ
Luciferase Assay Substrate + Luciferase Assay Buffer II) was added to each well
4. Luminescence was read for 10 seconds following a 2 second delay.
5. To measure Renilla ǡ  ? ?Ɋ
 were then added
to the same wells and luminescence read again for 10 seconds following a 2
second delay.
All readings were taken using a Luminoskan Ascent Microplate Luminometer. Data
were then corrected to the pRL-TK Renilla readings (pGL4.10; PLAUR 3UTR_01) or
Firefly readings (psiCHECK̻-2) so as to normalise for variation in transfection
efficiency and differences in cell number using the following equation:
ݔ = ܩ݁݊݁ܴ݁݃ݑ݈ܽݐ݁݀ܮݑ݂ܿ݅݁ݎܽݏ݁ ÷ ܥ݋݊ݐݎ݋݈ܮݑ݂ܿ݅݁ݎܽݏ݁
Expression values were not normalised to the empty pGL4.10 vector (internal control)
as transfection of the internal control into Beas2BR1 and NHBECs resulted in negligible
luciferase activity values (~0.1-0.2) when compared to those expressed by the
experimental constructs. Therefore correcting the large experimental value to the
minute control value resulted in artificially variable results. Successful transient
transfection was confirmed in each experiment by the internal positive control
pGL4.13 (pGL4- SV40).
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5.5.5 SCRATCH-WOUND ASSAY
In order to identify the role of mechanical injury on modifying PLAUR expression
through 5`UTR and 3`UTR mechanisms, NHBECs were wounded with 4 wounds in a
cross-hatch pattern (Fig. 5.6) 16 hours post-transfection in bronchial epithelial
wounding media (BEWM) (see Section 2.5.1). Changes in gene expression were
investigated using a Dual Luciferase assay at 8 and 24 hours post-wounding (Section
5.5.4).
In order to investigate the role of ssPLAUR on the rate of scratch wound healing,
NHBECs recombinantly over-expressing mPLAUR and ssPLAUR were investigated
using the scratch wound assay as outlined in Section 2.5.1.
5.5.6 IDENTIFYING HOW EXPOSURE TO CIGARETTE SMOKE EXTRACT
EFFECTS 5`UTR AND 3`UTR DRIVEN CHANGES IN PLAUR EXPRESSION
In order to identify the role of cigarette smoke extract on modifying PLAUR expression
through 5`UTR and 3`UTR regulation, NHBECs were treated with freshly made 5% v/v
Cigarette Smoke Extract (CSE) (see Section 2.4.6) at 24 hours post transfection. BEBM
was used for the control wells. Changes in gene expression were investigated using a
Dual Luciferase assay at 8 and 24 hours post-wounding (see Section 5.5.4).
Figure 5.6: Example of a well layout used in
the DLR scratch wound assay. Wounds were
formed using a sterile P200 tip on a confluent
well of a 6 well plate in a cross hatch pattern.
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5.5.7 WESTERN BLOTTING
In this chapter, western blotting was utilised to confirm qPCR results on changes in
PLAURmRNA expression on the addition of 5% v/v CSE to NHBECs. Following culture,
protein was harvested by mechanical scraping (see Section 2.3.2.1) and protein levels
of total, soluble spliced and membrane PLAUR were determined using the mAB IIIF10ȋ ?Ǥ ? ? ?ȀȌȾǦȋ ?Ǥ ? ?ȀȌȋ ?Ǥ ?Ǥ ?Ǥ ?ȌǤ
5.5.8 MTT ASSAY
In order to identify a role for ssPLAUR in NHBECs, the effect of ssPLAUR on the rate of
epithelial proliferation was investigated through the determination of the rate of
cellular respiration. NHBECs, recombinantly over-expressing ssPLAUR and mPLAUR
were allowed to reach 50% confluence before the rate of cellular respiration was
investigated using the MTT assay as described in Section 2.5.2. Data from the MTT
assay was normalised to the rate of cells transfected with the empty vector (pcDNA3)
in order to remove donor dependant variation.
5.5.9 APO-ONE® HOMOGENEOUS CASPASE-3/7 ASSAY
In order to further identify a role for ssPLAUR in NHBECs, the effect of ssPLAUR on the
rate of epithelial apoptosis was investigated. NHBECs recombinantly over-expressing
ssPLAUR and mPLAUR were investigated using an Apo-ONE® Homogeneous Caspase-
3/7 Assay as described in Section 2.5.3. Data from the apoptosis assay was normalised
to the rate of apoptosis in cells transfected with just the empty vector (pcDNA3) in
order to remove donor dependant variation.
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5.6 RESULTS - BIOINFORMATICS
5.6.1 GENERATING PLAUR 5`UTR AND 3`UTR FRAGMENTS BY PCR
In order to form the required fragments for plasmid construction (see Section 5.4.2) a
series of PCRs were carried out using genomic DNA from subject A073. PCR
successfully generated fragments up to 2584bp upstream of the genes TSS and form
both 3`UTR isoforms (Fig. 5.7).
Figure 5.7: 5`UTR Products (A&B) and 3`UTR products (C) formed via PCR using
Invitrogen Platinum Taq and compared to the Invitrogen 1kB (A&B) and 100bp (C) DNA
ladders. Products from these gels were gel purified and ligated to their respective plasmid
vectors. 200  2500: Base Pair fragment size; Iso1: mPLAUR 3`UTR (419bp); iso2: ssPLAUR
3`UTR (314bp).
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5.6.2 THE PLAUR GENE, 5`UTR AND 3`UTR SHOW A HIGH DEGREE OF
INTER-SPECIES HOMOLOGY.
Alignment plots generated by VISTA (Fig. 5.8) and the USCS genome browser (Fig. 5.9)
identify that the PLAUR gene, its 5`UTR and 3`UTR are highly conserved between
humans and the higher primates (Orang-utan, Chimp, Rhesus and Gorilla), with
conservation generally reaching values of >90%. However, significantly less
conservation is present in the lower mammals, as defined by the mouse genome. Here
conservation was sparse and mainly limited to the gene exon regions, where
conservation at maximum reached 54%. The data replicates well between the both
databases. The untranslated regions are especially well conserved in the higher
primates achieving close to 100% conservation in Chimps and Rhesus monkeys.
At the amino acid level, the human PLAUR protein shows 99% homology with the
Chimpanzee protein but only 43% homology when compared to both the mouse and
the rat protein sequence. This homology was also highly fragmented and did not show
any preference for domain coding regions (Fig. 5.10). This mirrors well with the data
generated by the gene homology report.
The H3K27AC track available on the USCS genome browser utilises ENCODE data and
identifies regulatory elements within the genome. This identifies that active regulatory
elements are present in the intronic regions between exons 1 and 2, between exons 3
and 4 and in exon 6. Interestingly, active regulatory elements are identified within the
first 500bp upstream of the TSS, with the peak present at around 250bp upstream of
the TSS. This identifies that the regions present within the reporter vector constructs,
may be important in gene transcriptional regulation. However, the presence of a strong
regulatory region at ~5000bp upstream of the TSS identifies that certain important
regulatory elements may be missed in the dual luciferase assay experimental setup
(maximum fragment length analysed: 2584bp).
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Figure 5.8: VISTA alignment plot demonstrating peaks of conservation in the pairwise sequence alignment of the PLAUR gene and its 5`UTR and 3`UTR.
Conserved sequences are shown on the VISTA plot relative to their position on the human genome (Horizontal Axis) with the percentage identities shown on the
vertical axis. The horizontal line identifies the 50% conservation line. Exons are identified by dark blue bands while UTRs are identified with turquoise bands.
The location of validated SNPs across the region is identified by small black boxes. The gene runs from the 3`UTR on the left to the 5`UTR on the right.
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Figure 5.9: USCS alignment plot demonstrating areas of conservation in the pairwise sequence alignment of the Human PLAUR gene and its 5`UTR and
3`UTR . Conserved sequences are shown on the USCS plot relative to their position on the human genome (Horizontal Axis). The location of validated SNPs across
the region is identified by small black boxes at the bottom of the plot. Layered H3K27AC values identify that probable regulatory elements are restricted within
the gene and partially in the 3`UTR. The gene runs from the 3`UTR on the left to the 5`UTR on the right.
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Figure 5.10: UniProt alignment of Human PLAUR with Chimpanzee (PANTR), mouse and
rat protein . Alignment identifies that near complete homology (99%) occurs between the
Human and Chimpanzee protein. However, dissimilarities are present within receptor domain
1 (Green Line) and Domain II (Red Line), suggesting that these may have important functional
implications. Homology between the human and rodent proteins identifies a much lower
degree of homology (43%) which is fragmented across the entire protein structure. Domain I
is highlighted by a green line, Domain II a red line and Domain III a blue one.
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5.6.3 THE PLAUR 5`UTR IS POTENTIALLY REGULATED BY A NUMBER
OF TRANSCRIPTION FACTORS.
Bioinformatics were used to identify potential transcription factors that interact with
the region upstream of the PLAUR TSS up to a maximum of 2500 base pairs from the
TSS. A total of 23 individual transcription factors (TFs) were identified, with 7 TFsȋǦ ?ǡ Ǧ ?ǡ ǦȽǡ Ǧǡ 
Ǧ ?ǡ 	Ǧ ?   ?Ȍ     ? 
occasions in the upstream region (Table 5.2). This suggests that the genes 5`UTR has a
strong potential for regulation by a number of these TFs.
Transcription Factor Location (Base Pairs from TSS)
Ets-1 37
Elk-1 38
AP-1 94
c-Jun 95
Sp-1 123
Ets-1 163
E2F-1 175
c-Jun 208
AP-1 211
C/EBP-į 244
c-Jun 388
GATA-1 427
PEA3 438
Ets-2 554
YY1 572
C/EBP-Ȗ 600
YY1 622
NF-1 839
GATA-1 854
GR 970
TF11D 1047
NF-1 1110
IRF-2 1126
NF-1 1133
C/EBP-Ȗ 1182
MEF-2A 1197
NF-1 1258
C/EBP-į 1313
POU3F2 1368
NF-1 1408
YY1 1412
C/EBP-Ȗ 1589
C/EBP-į 1628
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AP-1 1653
c-Myb 1656
RXR-į 1684
YY1 1713
YY1 1725
ER-į 1732
ER-į 1754
c-Jun 1757
NF-1 1784
NF-1 1823
GATA-1 1864
C/EBP-į 1909
C/EBP-į 1925
YY1 1951
RBP--Ȝ 2056
Mzf-1 2076
GATA-1 2086
GATA-1 2096
c-Ets-2 2142
c-Ets-1 2153
GATA-1 2159
GR-į 2236
YY1 2271
NF-1 2287
c-Ets-1 2388
AP-1 2410
C/EBP-į 2520
Table 5.2: The upstream region of the PLAUR gene has a potential of being regulated by a
maximum of 23 transcription factors. Bioinformatic analysis of the 2.5kb region upstream
of the genes TSS identified 23 individual TFs that survived quality control. Of these 7 TFsȋǦ ?ǡ Ǧ ?ǡ ǦȽǡ Ǧǡ 
Ǧ ?ǡ 	Ǧ ?   ?Ȍ     	 ȋ ? ?
identifications). Each coloured section identifies transcription factors located in different
truncations of the vector constructs (see section 5.4.2).
5.6.4 BIOINFORMATICS IDENTIFIES ISOFORM SPECIFIC miRNAs,
THAT MAY REGULATE THE PLAUR 3`UTR AND MRNA STABILITY
Bioinformatics have allowed us to identify a number of potential regulators of 3`UTR
activity, i.e. miRNAs, that are specific to the two different 3` UTR isoforms of the PLAUR
gene (Table 5.3). Six miRNAs are specific to the 3`UTR of the membrane bound
receptor (Isoform 1) while 3 were specific to the 3`UTR of the soluble spliced receptor
(Isoform 2). The identified miRNAs all had negative mirSVR scores, which is a relatively
novel regression method for predicting the likelihood of target mRNA down-regulation
from sequence and structure features in microRNA/mRNA predicted target sites (Betel
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et al., 2010). This identifies that all miRNAs contribute to down regulation of the target
gene with miR-135 potentially having the strongest effect.
miRNA mirSVR value Isoform Present
Let-7a -0.295 Isoform 1
Let-7b -0.295 Isoform 1
Let-7c -0.295 Isoform 1
mIR-133a -0.145 Isoform 1
mIR-320 -0.305 Isoform 1
mIR-146b -0.124 Isoform 1
mIR-222 -0.105 Isoform 2
mIR-135 -0.716 Isoform 2
mIR-23b -0.295 Isoform 2
Table 5.3: Putative miRNAs which selectively target different isoforms of the PLAUR
3`UTR. Using the online database available at http://www.microrna.org/microrna/home.do
selected for all miRNAs with good miRSRV values, 6 miRNAs selective to the membrane bound
receptors 3`UTR and 3 to the 3`UTR of the soluble spliced receptors were identified. All
miRNAs present with a negative mirSVR values and therefore are predicted to contribute
towards the down-regulation of PLAUR with varying degrees of magnitude.
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5.7 RESULTS  MOLECULAR BIOLOGY
5.7.1 NHBEC POPULATIONS SHOW EPITHELIAL CELL MORPHOLOGY
NHBECs from both epithelial cell populations (donors 7F3158 and 7F3206) stained
positive for the epithelial cell marker CK-14 (Fig. 5.11). This identified that the cell
used experimentally throughout this thesis presented with epithelial cell morphology.
Importantly, both populations did not stain against the 1B10 fibroblast specific
antibody (Fig.5.11). This identified that there was no contamination of either cell
populations with fibroblast cells, which can occur during isolation.
The 1B10 antibody was validated through positive staining in a Fibroblast cell line
(MRC-5), while the specificity of the anti-CK14 antibody was confirmed through lack of
staining in the MRC-5 population (Fig.5.11). Isotype controls for the IgG Mouse and IgM
Mouse antibodies gave no visible background staining, indicating specific antibody
binding to its antigen (Fig.5.12). This therefore identifies that the staining observed
above is largely due to the primary antibodies binding to the protein of interest and the
secondary antibody binding to their primary antibody rather than due to non-specific
staining. All experiments were replicated 3 times.
For basic morphology of MRC-5 cells and NHBECs refer to Sections 2.4.1 and 2.4.2.
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Anti CK14 1B10
Figure 5.11: Immunofluorescence images of undifferentiated NHBECs and MRC-5
fibroblast cells using basal (CK14-green), non-ciliated (CC26-red) and fibroblast (1B10-
Green) cell markers. Cell cultures from donors 7F3158 and 7F3206 showed positive staining
for CK14 and CC26, but not 1B10. Fibroblast cells show positive staining for 1B10 (Green),
with no staining for the epithelial cell markers. Nuclei were counterstained with DAPI (blue).
Images are representative of n=3 experiments with random fields digitally captured.
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FITC Secondary Control IgM Mouse Isotype IgG Mouse Isotype
Figure 5.12: Immunofluorescence of undifferentiated NHBECs and MRC-5 cells
treated with isotype and secondary antibody controls. Negligible staining
occurs for the isotype (CK14: IgG Mouse CC26: IgG Rabbit; 1B10: IgM Mouse) or
secondary antibody controls. Nuclei were counterstained with DAPI (blue). Images
are random fields representative of n=3 experiments.
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5.7.2 PLAUR LEVELS ARE ALTERED IN NHBECS ABOVE PASSAGE 4.
Experiments were performed in order to determine the cell passage number at which
PLAUR expression changes from baseline and so identifies how PLAUR levels drift in
cell culture. This is important as cells must be used experimentally at a passage where
the cell phenotype is similar to that when it is freshly extracted from tissue (Passage 0
& 1). To determine this, PLAURmRNA levels were quantified from each NHBEC donor
that were cultured from passage 2 up to a passage where cells were no longer viable,
commonly passage 6, (n=6). Donor 7F3158 HBECs failed to proliferate beyond passage
6, with cells failing to achieve confluence above 60% after 20 days in culture as
opposed to normally achieving 90% confluence five days after seeding. Donor 7F3206
NHBECs were successfully cultured up to passage 10 at which time the experiment was
stopped. Determination of PLAUR mRNA expression was successful, with donor
7F3158 expressing half the amount of PLAUR mRNA as donor 7F3206 NHBECs
(P<1x10-4). PLAUR expression, dropped significantly at passage 5 (P<1x10-4), followed
by an elevation at passage 6 (P<1x10-4) (Fig. 5.13) identifying passage 4 as the maximal
passage at which cell gene expression follows that of cells at earlier passages.
Figure 5.13: PLAUR mRNA levels are altered from baseline above passage 4. PLAUR mRNA
levels remain constant from passage 2 up to and including passage 4. At passage 5 mRNA
levels drop by ~50% (P<0.01) while at passage 6 the mRNA levels increase by ~50% (P<0.01);
One-way ANOVA P:<1x10-4. Therefore passage 4 was the maximal passage at which cells were
used experimentally (n=3 over two donors).
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5.7.3 IDENTIFYING THE OPTIMAL TRANSFECTION PARAMETERS FOR
THE LUCIFERASE EXPRESSING VECTORS
In order to obtain optimal results from the DL assay, the best transfection ratio for the
luciferase expressing vectors with FuGENE®6 in NHBECs had to be determined. Also,
since DL assays may be affected by the trans effects that occur between promoters on
co-transfected plasmids (Farr and Roman, 1992), it is important to determine the
maximal Firefly:Renilla ratio that can be used in NHBECs when co-transfecting the pRL-
TK control vector and the Firefly luciferase expressing experimental vectors. Selection
of the correct ratio will ensure independent expression analyses between the
experimental and control reporter genes.
Using DL, the optimal FuGENE®6 to DNA ratio was determined to be 3:2 when the
control vector pGL4.13 and the largest pGL4.10 construct were transfected into both
NHBECs (n=6 over two donors) and Beas2BR1 cells (n=3) (Fig. 5.14). Using 3
Renilla:Firefly ratios of 1:5, 1:8 and 1:10, the ratio of 1 part pRL-TK to 5 parts of Firefly
expressing vector was determined to be the only viable ratio in NHBECs, with the 1:8
and 1:10 ratios resulting in no measurable Renilla Luciferase. All ratios presented with
measurable Renilla values in Beas2BR1 cells. Therefore throughout this chapter all
transfections were carried out with a FuGENE® 6 to DNA ratio of 3:2 and a
Renilla:Firefly ratios of 1:5.
NHBECs and Beas2BR1 cells transfected with the pGL4.10 vector, with the 2.5kb
construct or pRL-TK control vector alone, and NHBECs and Beas2BR1 cells co-
transfected with the pRL-TK vector and the pGL4.10 vector with the 2.5kb construct
did not show any variation in the Firefly luciferase readings (Fig. 5.15). Therefore no
trans effects can be said to be present when transfecting the pRL-TK promoter with the
experimental promoters when transfecting these vectors at a ratio of 1:5.
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Figure 5.14: Transfection optimisation experiments identify a FuGENE® 6:DNA ratio of
3:2 as optimal for transfection of the plasmid constructs. Readings were taken at 24, 48
and 72 hours using the largest pGL4.10 construct (A&C) and the positive control vector
pGL4.13 [pGL4SV40] (B&D) in Beas2BR1 (A&B) and NHBECs (C&D). Based on results showing
overall significantly pronounced results by 48 hours a ratio of 3:2 and readings at 24 and 48
hours were chosen.
Figure 5.15: No trans effect is discernible on co-transfecting pRL-TK and vectors
containing experimental promoters. Using the pGL4.10 vector containing the largest (2.5kb)
construct, no change in either Firefly or Renilla luciferase values could be identified when
vectors were transfected into Beas2BR1 and NHBECs on their own or when co-transfected at a
ratio of 1:5.
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5.7.4 IDENTIFYING TRANSFECTION EFFICIENCY OF PLASMID
CONSTRUCTS
Immunostaining carried out on both NHBEC donors and Beas2BR1 cells identify that a
high degree (>75%) of transfection exists (P>0.05) following transient transfection
with either the pGL4.10+500bp truncation vector, the pisCHECK-2+Isoform 1 vector or
the commercial PLAUR 3UTR_01 vector (Fig. 5.16A).
Lack of immunofluorescence in all isotype controls (Fig. 5.16B) identifies that
immunofluorescent readings taken in the transiently transfected cells are due to
specific binding of the antibodies to their target proteins rather than being due to non-
specific binding. This adds credibility to the results identified above (Fig.5.16A).
All experiments were replicated 3 times, with 5 counting fields taken per experiment.
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Figure 5.16: A high rate of transfection efficiency can be detected in Beas2BR1 cells and
NHBECs. Using the primary polyclonal anti-firefly luciferase antibody with secondary staining
carried out using the Goat anti Rabbit IgG Rhodamine TRITC and a Rabbit polyclonal IgG
isotype control, one can visually identify a high degree of transfected cells for all plasmids in
all cell types. Percentage transfection was determined by taking the number of transfected
cells from 5 randomly selected images per well per experiment. Images are representative of
n=3 independent experiments.
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5.7.5 THE MINIMAL PLAUR PROMOTER LIES WITHIN THE FIRST
199BP OF THE TSS AND IS AUGMENTED BY A REGION 291-688BP
UPSTREAM OF IT
A robust promoter element was observed within the first construct, which includes the
first 199bp upstream of the genes TSS (Fig. 5.17). This result was first identified in the
Beas2BR1 cells line and then replicated in both NHBEC donors. Although the same
effect can be identified in both NHBEC donors, the magnitude of effect of the promoter
in donor 7F3206 is double that identified in donor 7F3158, identifying donor specific
variation in PLAUR expression. This however follows well from qPCR data on donor
specific total PLAUR expression (see Section 5.7.2) adding credibility to the data and
suggesting that the relevant site has been cloned into the reporter vector.
While no change in gene transcription is identified in the 490bp construct, when
compared to the 199bp construct, the 397bp region between 490bp and 887bp
resulted in a near doubling of gene transcription in the Beas2BR1 cell line (P<1x10-3)
and in donor 7F3158 NHBECs (P=0.037) (Fig.5.17). Although this result was not fully
replicated in donor 7F3206 NHBECs (P=0.07), a trend in the data where the presence
of the 887bp construct results in the doubling of gene transcription can still be
identified. This suggests that a transcription regulatory element may be present in this
region which enhances the effect of the genes core promoter. Interestingly, increasing
the construct size beyond 887bp resulted in a decrease in gene expression. This is most
likely due to effects resulting from plasmid size rather than by the presence of a
transcriptional regulatory element although the possibility of reduction in
transcriptional activity by the larger fragments cannot be fully excluded.
At the 48 hour time point a similar pattern can be observed as at the 24 hour time
point for the first 4 truncations in Beas2BR1 cells and the 2 NHBEC donors. The
increased PLAUR transcription driven by the 397bp region between 490bp and 887bp
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upstream of the TSS and was found to be statistically significant by paired testing in
Beas2BR1 (P=0.03) and donor 7F3158 NHBECs (P<1x10-3). Although it appears that
the larger fragments (1.5kb and 2.5kb) achieve the same effect on the rate of
transcription as the 900bp fragment at 48 hours, this does not replicate in both NHBEC
donors and therefore no conclusions can be reached about these fragments.
Figure 5.17: The minimal PLAUR promoter lies within the first 199bp upstream from the
receptors TSS and is doubled by addition of the 397bp region between 490bp and 887bp
upstream of the TSS. A Dual Luciferase assay identified that PLAUR expression is strongly
induced by a region within the first 199bp (200) upstream of the TSS in Beas2BR1 cells (A)
and in two NHBEC donors (B&C) (Beas2BR1: P<1X10-3; 7F3158: P=0.037; 7F3206: P=0.07),
The region present in the 887bp construct (900) results in doubling of transcriptional activity
in all the populations, which is lost on subsequent enlarging of the promoter fragment to
include the 1500bp and 2500bp fragments. At 48 hours the same pattern of results can be seen
for the Beas2BR1 (D) and 2 NHBEC donors (E&F), with the elevation in the 900bp fragment
significant in Beas2BR1 (P=0.03) and NHBECs (P<1x10-3). Although the larger 1.5kb and 2.5kb
fragments appear to achieve the same effect as the 900bp fragment on transcription rate in
Beas2BR1 cells, this was not replicated in NHBECs. Each graph represents Firefly luciferase
values normalised to pRL-TK for differences in transfection and cell density (n=3).
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5.7.6 THE 3`UTR REGULATES PLAUR GENE LEVELS
Multiple attempts to construct a psiCHECK-2 vector for the Isoform 2 3`UTR were
unsuccessful. Therefore a commercial Firefly luciferase expressing vector containing
the Isoform 3`UTR (PLAUR 3UTR_01; Switchgear Genomics; S202937) and its
corresponding empty vector (EMPTY_3UTR; Switchgear Genomics; S290005) were
purchased and sequence verified (data not shown).
In the case of the 3`UTR vectors, DL data was first normalised to the vector-specific
control luciferase, i.e. Firefly for psiCHECK-2 and Renilla for the SWG_Vectors, followed
by normalisation to the empty vector. This was possible as the readings presented by
the empty vector controls were of values that did not introduce artificial variation to
the results as was experienced with the empty pGL4.10 vector (Section 5.7.5). As all
transfections were carried out in tandem with the pGL4 vectors, the internal positive
control (pGL4 SV40) was taken as a universal control to confirm successful transient
transfection.
The 3`UTR in both the membrane bound (Isoform 1) and soluble spliced (Isoform 2)
receptor were found to suppress luciferase gene expression (Fig. 5.18). In the
membrane bound receptor presence of the 3`UTR led to a decrease in detectable
luciferase of ~75% at 24 hours, which was replicated at 48 hours (Fig. 5.18a-c), this
was first detected in Beas2BR1 cells (P<0.001) (Fig.5.18A) and then replicated in donor
7F3158 (P<0.001) and 7F3206 (P<0.001) NHBECs (Fig.5.18B&C). In the soluble spiced
receptor, 3`UTR led to a decrease in detectable luciferase of ~30% at 24 hours in
Beas2BR1 (P=0.011) (Fig. 5.18D) and donor 7F3206 NHBECs (P<0.001) (Fig. 5.18F),
which remained at 48 hours. In donor 7F3158 NHBECs however, a significant decrease
in detectable luciferase levels was only detectable at 48 hours (P=7x10-4), with a slight
and non-significant decrease detected at 24 hours (Fig. 5.18E).
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Figure 5.18: Both of the PLAUR 3`UTR isoforms supress luciferase expression. Dual-
Luciferase analyses identified ~75% inhibition of gene expression at the 24 hour time point
for the membrane bound receptor in Beas2BR1 (A) and NHBECs (B&C) (P<0.001). In the
soluble spliced receptor the 3`UTR causes a ~30% reduction in gene expression at 24 hours in
Beas2B (D) (P<0.011) and one NHBEC donor (F) (P<0.001). Although a reduction in gene
expression was not evident at 24 hours in NHBEC donor 7F3158, this became evident at the 48
hour time point (E) (P=7X10-4). Each graph represents Firefly luciferase values normalised to
pRL-TK for differences in transfection and cell density (fold) which in turn was normalised to
the relevant empty vector (n=3).
5.7.7 THE 5`UTR OR 3`UTR ARE NOT MAJOR REGULATORS OF
SCRATCH-WOUND DRIVEN CHANGES IN PLAUR EXPRESSION
5.7.7.1 OPTIMISATION OF THEWOUND ASSAY
It was first necessary to determine the optimal time point post-wounding for
determining changes in gene expression using the luciferase vector system. Therefore a
time course was carried out on NHBECs transfected with the pGL4.10+887bp construct
with levels of expressed luciferase expression determined in wounded and unwounded
NHBECs at 0, 2, 4, 8, 12 and 24 hours post wounding.
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Differences could be determined between wounded and unwounded cells at 8 hours,
with the difference becoming statistically significant at 24 hours (mean RLuc
unwounded: 19.55, wounded: 31.03; P=0.041; n=3) (Fig.5.19A). Evidence previously
published by Dr Ceri Stewart (Stewart et al., 2012) confirmed the results of the DL
assay. In this study total PLAUR mRNA was up regulated in NHBECs at both the 8 and
24 hour time-point post-wounding (n=3) (Fig. 5.19B). Therefore for the purpose of this
thesis the 8 and 24 hour time points post NHBEC wounding were selected as the
optimal periods in which to investigate 5`UTR and 3` distal region regulation of gene
expression via a DL assay.
Figure 5.19: 8 and 24 hours post wounding in NHBECs are the optimal time-points to
investigate 5`UTR and 3` distal region regulation of gene expression. Differences in gene
expression as defined by the luciferase expression of the pGL4 vector with the 887bp 5`UTR
fragment (P=4x10-3) between wounded and unwounded NHBECs is evident from 8 hours post-
wounding but is only significant at the 24 hour time-point (A). PLAUR mRNA experiments
confirm dual luciferase experimental results identifying elevations in PLAUR mRNA at the 8
and 24 hour time point. The wound healing experiment was carried out in donor 7F3158
NHBECs (n=3) while mRNA levels data was provided from previously published data by Dr
Ceri Stewart (Stewart et al., 2012). Graphs represent means and standard error of the mean.
RLuc = Relative luciferase; *=P<0.05; **=P<0.01; ***=P<0.001.
5.7.7.2 DETERMINING THE EFFECT OF MECHANICAL DAMAGE ON PLAUR
5`UTR AND 3`UTR DRIVEN GENE REGULATION
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Results from the unwounded NHBECs confirm the results described in sections 5.7.5
and 5.7.6. For the 5`UTR, the basal promoter was once again determined to lie within
the first 199bp upstream of the PLAUR TSS and to be enhanced by a region between
490 to 887bp upstream of the TSS (P=0.0126 at 8 hours; P=0.025 at 24 hours) leading
to a doubling in the expression level. With regards to the 3`UTR, in mPLAUR the 3`UTR
drove a 75% decrease in gene expression (P=2x10-4 at 8 hours; P=1x10-4 at 24 hours)
while in ssPLAUR the 3`UTR drove a 30% decrease in gene expression (P=9x10-3 at 8
hours; P=9.3x10-3 at 24 hours). This therefore adds weight to the conclusions derived
in sections 5.7.5 and 5.7.6.
When investigating the role of scratch-wounding on PLAUR gene regulation, results in
this section identify that overall, mechanical damage caused by scratch-wounding did
not significantly regulate PLAUR expression as driven by the genes 5`UTR and 3`UTR
(Fig.5.20). Although a number of differences can be identified for the 5`UTR and the
soluble spliced receptors 3`UTR at both time-points, the only statistically significant
difference was identified for the 500bp fragment, which contains the region between
199bp and 490bp upstream from the TSS, at 24 hours (P=0.04). However, the change in
effect is small with wounding causing just a 25% decrease in gene expression when
compared to baseline. Therefore it is unlikely that this change is translated into
significant changes in the PLAUR protein levels.
Bearing in mind the positive association reported for the 887bp reporter construct in
section 5.7.7.1, it is worth noting that while donor 7F3158 NHBECs did once again
present with this finding, this was not replicated in donor 7F3206. Therefore this was
not considered a true effect.
Although not significant (P=0.06), differences identified at 8 hours between wounded
and unwounded NHBECs containing the 500bp truncation and at 24 hours in cells
transfected with the soluble spliced receptors 3`UTR remain interesting due to the
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presence of the same direction of effect in each separate experiment over 2 individual
donors (n=6). Failure of these changes to reach significance is probably due to changes
in gene expression being very slight, with replication in 4 experiments not being
enough to achieve statistical significance.
Figure 5.20: Mechanical injury caused by a scratch-wound assay does not play a major
role in altering 5`UTR (A&B) and 3`UTR (C&D) regulated gene expression. Significant
changes in gene expression can only be identified in cells containing the 500bp truncation
after an incubation of 24 hours post-wounding (B). Here, gene expression in wounded cells is
reduced by a factor of 0.25 when compared to cells at the baseline (P=0.04). Each graph
represents 4 independent experiments carried out in 2 NHBEC donors (n=4 over two donors).
RLuc = Relative luciferase, +=Wounded, -=Unwounded; *=P=0.04.
5.7.8 CIGARETTE SMOKE EXTRACT REGULATES SSPLAUR THROUGH
THE 3`UTR BUT DOES NOT MODIFY 5`UTR DRIVEN TRANSCRIPTION.
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Since cigarette smoke is a known causative factor for both asthma and COPD, while the
smoking pack/year phenotype has been strongly correlated with scPLAUR levels in
human serum (see Section 3.4.3), it was of interest to investigate whether cigarette
smoke has a direct effect on PLAUR expression.
As in section 5.7.7.2, results from the basal NHBECs confirm the results described in
sections 5.7.5 and 5.7.6. with regards to basal 5`UTR and 3`UTR driven regulation of
gene expression.
In this assay, data was collected at the 8 and 24 hour time points in order to be
comparable to the scratch wound assay. Interestingly, exposure of NHBECs to 5% v/v
CSE did not alter the level of gene expression driven by the 5`UTR. However, exposure
to 5% v/v CSE did selectively affect 3`UTR driven regulation of gene expression for the
soluble spliced receptor. Here, gene expression doubled back to baseline, identifying a
CSE dependant loss of 3`UTR driven inhibitory effects on gene expression (P=0.039)
(Fig. 5.21).
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Figure 5.21: 5%v/v cigarette smoke extract exclusively modifies effects on gene
expression in the soluble spliced receptor 3`UTR. NHBECs cultured in the presence of
5%v/v cigarette smoke extract do not have altered 5`UTR driven transcription when compared
to basal NHBECs (A&B). Similarly exposure to 5%v/v cigarette smoke extract did not modify
3`UTR regulation of gene expression for the membrane bound receptor (C). However,
expression levels of the gene for the soluble spliced receptor were modified, where the
expression suppressing effect of the 3`UTR appears to be completely reversed (P=0.039) (D)
(n=4 over two donors). RLuc = Relative luciferase; *=P=0.039.
5.7.9 NHBEC SSPLAUR MRNA LEVELS ARE ELEVATED ON ADDITION
OF 5%V/V CSE
Expression of specific forms of PLAUR, as defined by mRNA expression, was shown to
follow the same pattern as suggested by 3 prime reporter work on exposure to 5%v/v
CSE (Section 5.7.8) (Fig. 5.22). PLAURmRNA levels were found to increase from 4 to 24
hours for the total, membrane bound and soluble spliced PLAUR mRNAs. At 4 hours
post exposure to 5%v/v CSE no marked change in mRNA levels were identified for any
of the qPCR assays, while total PLAUR also had no identifiable change in mRNA levels
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from the baseline at 24 hours. Although a slight decrease in mRNA for membrane
PLAUR was observed at 24 hours and was replicated in all 6 experiments over 2
donors, this did not achieve statistical significance by paired testing (P=0.384; n=6 over
2 donors). However, soluble spliced PLAUR mRNA levels were increased by 76.4%
compared to baseline, following a 24 hour stimulation with 5% v/v CSE (P<1x10-4).
This confirms that mRNA levels are regulated by CSE as suggested by the 3`UTR model
system described in Section 5.7.8).
Figure 5.22: 5%v/v cigarette smoke extract selectively elevates intracellular soluble
spliced mRNA levels. While total (A) and membrane (B) PLAUR mRNA levels are not
significantly affected by the addition of cigarette smoke extract, ssPLAUR mRNA levels are
elevated by ~1.5 fold when compared to cells grown at baseline (P<1x10-4)at the 24 hour time
point (C) (n=6 over 2 donors).
Total PLAUR Membrane PLAUR
Soluble Spliced PLAUR
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5.7.10 5%V/V CSE ELEVATES SSPLAUR PROTEIN LEVELS
The protein expression pattern of soluble spliced PLAUR on exposure to 5%v/v CSE
emulated the qPCR results described in Section 5.7.9, where it was shown that
exposure to 5%v/v CSE did not alter total and mPLAUR mRNA levels (Fig. 5.23A&B)
but selectively elevated intracellular ssPLAURmRNA levels (Fig. 5.24A).
When stained with the monoclonal antibody for PLAUR DI (IIIF10), the soluble spliced
form of the receptor forms a band at circa 45kDa which is separate and distinct from
the band for membrane bound and soluble cleaved PLAUR (circa 55kDa) (Fig. 5.24B).
This allows for the specific probing of the ssPLAUR form of the receptor. While at 4
hours post CSE stimulation no significant difference in expressed ssPLAUR protein can
be identified between basal and stimulated cells (Fig. 5.24A&B), at 24 hours post-
stimulation, ssPLAUR protein levels increase by 35% when compared to baseline
protein levels (Fig. 5.24A). This was determined to be statistically significant
(P=3.2x10-3). This data therefore confirms that data obtained from i) the DLR assay and
ii) mRNA, are translated to protein levels.
Figure 5.23: 5%v/v cigarette smoke extract does not affect intracellular levels of total
and membrane bound PLAUR. When probed with the DI specific antibody IIIF10, no
difference can be seen between basal and stimulated NHBECs. Data from n=4 experiments.
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Figure 5.24: 5%v/v cigarette smoke extract elevates intracellular soluble spliced PLAUR
protein levels. When probed with the DI specific antibody IIIF10, soluble spliced PLAUR
protein levels were shown to increase by 35% after a 24 hour stimulation with 5%v/v CSE (A)
(P=3.2x10-3). Western Blots (B) identify the band representative of ssPLAUR within the blot
for total PLAUR. The 2 larger distinct bands are known to represent mPLAUR (Stewart et al.,
2012). Blots are representative of 2 separate blots, each displaying data of n=3 cell-basedǤȾǦǮǯǤ
ssPLAUR
4 hours 24 hours 24 hours4 hours
mPLAUR
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5.7.11 THE EFFECT OF SELECTIVE OVER-EXPRESSION OF MPLAUR OR
SSPLAUR ON NHBEC FUNCTION
5.7.11.1 QUALITY CONTROL OF NHBECS RECOMBINANTLY EXPRESSING
VARIOUS FORMS OF PLAUR
In order to determine whether the cells were successfully transfected with the pcDNA3
vectors for the recombinant over-expression of mPLAUR and ssPLAUR, levels of total
intracellular PLAUR protein were investigated. Elevated levels of PLAUR protein in
NHBECs transiently transfected to over-express either mPLAUR or ssPLAUR were
identified when compared to cells transiently transfected with the empty pcDNA3
vector (P=2x10-4) (Fig. 5.25). This identifies successful transfection of the cell
populations and successful over-expression of the protein of interest in these
populations.
Figure 5.25: Intracellular PLAUR protein expression is elevated in NHBECs transiently
transfected with pcDNA3 vectors for mPLAUR and ssPLAUR. Using the D I specific antibody
IIIF10, levels of intracellular PLAUR protein are found to be ~2.5 fold higher in NHBECs
recombinantly expressing either mPLAUR or ssPLAUR when compared to cells transiently ?ǤȾǦ
normalised to cells cultured in media only. This corrected for inter-experimental variation
(n=4 over 2 donors). ***=P:2x10-4.
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5.7.11.2 SSPLAUR INDUCES MITOCHONDRIAL ACTIVITY IN NHBECS
The rate of mitochondrial activity was not altered in NHBECs recombinantly over-
expressing mPLAUR, identifying that mPLAUR does not alter the rate of NHBEC cellular
respiration. However, recombinant over-expression of ssPLAUR by NHBECs resulted in
an 88% increase in the rate of NHBEC respiration, which was identified to be
statistically significant when analysed using a paired t-test (P=2x10-4) (Fig. 5.26).
Figure 5.26: Soluble spliced PLAUR increases NHBEC mitochondrial activity
independently of mPLAUR. Analysis identifies that over expression of the soluble spliced
form of PLAUR increases cellular respiration by 88% when compared to NHBECs
recombinantly over-expressing both the empty vector and the membrane form of the receptor
(P=2x10-4)(n=4 over 2 donors).
5.7.11.3 SSPLAUR DOES NOT ALTER THE RATE OF APOPTISIS OR THE RATE OF
WOUND REPAIR IN NHBECS
Recombinant over-expression of mPLAUR in NHBECs was found to attenuate wound
healing at 4, 8 and 24 hours post-wounding (P<0.01), replicating data previously
published by researchers from the same group (Stewart et al., 2012). However, over-
expression of the ssPLAUR variant was found to not significantly alter the rate of
wound healing from the baseline (P=0.17) (Fig. 5.27).
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Over-expression of ssPLAUR also did not alter the rate of apoptosis of NHBECs either
under basal conditions (P ? ?Ǥ ? ?Ȍ ȋ	Ǥ  ?Ǥ ? ?Ȍ       ? ? ?Ɋ
solution of H2O2 (P=0.49) (Fig.5.28B) previously shown to stimulate NHBEC apoptosis
(Bucchieri et al., 2002). Membrane PLAUR also had no effect on apoptosis in basal cells
and while showing a trend for a decrease in the rate of apoptosis in H2O2 stimulated
cells, this was not statistically significant to the rate expressed by NHBECs transfected
with just the empty vector (pcDNA3) (P=0.77).
Figure 5.27: Investigating the effect of soluble spliced PLAUR (ssPLAUR) on the rate of
cell migration. The rate of wound repair as defined by the rate of wound-healing of NHBECs
over expressing the soluble spliced form of the receptor does not vary significantly from cells
transfected with the empty vector (EV) (P=0.17). NHBECs over expressing membrane PLAUR
(mPLAUR) were used as a positive control, attenuating the rate of wound-repair at the 4, 8 and
24 hour time point (P<0.01). The graph represents data from 4 individual experiments carried
out over 2 individual donors, with data normalised to the wound area of cells transfected with
the empty vector at 8 hours.
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Figure 5.28: Investigating the effect of ssPLAUR on the rate of epithelial apoptosis. When
compared to baseline cells transfected with the empty pcDNA3 vector, both mPLAUR and
ssPLAUR over-expressing cells do not appear to alter the rate of epithelial cell apoptosis. The
rate was unaltered both when cells were cultured at baseline and when cultured in the ? ? ?Ɋ2O2 (P>0.05; n=4 over 2 individual donors).
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5.8 DISCUSSION
The aims of this chapter were to characterise the PLAUR 3`UTR and core 5`UTR
through bioinformatics followed by experimentally determining these regions role in
regulating PLAUR expression under both basal and stimulated (scratch wound & CSE)
conditions, which are both relevant to airway disease. This work subsequently
developed these aims further and characterised a role for the CSE elevated ssPLAUR in
NHBEC functions.
In silico investigations identified the degree of gene interspecies homology as well as
the location of putative transcription factor binding sites and putative miRNA binding
sites. A high degree of conservation between higher primates (including Homo sapiens)
for all UTRs identifies a high probability for the presence of gene regulatory elements.
Indeed, this chapter predicts a large number of 5`UTR transcription factors, of which 7  ? ?Ǥǡ  ?Ǧ
the asthmatic and/or COPD airway; namely ETs-1 (McKinlay et al., 1998, Nakamura etǤǡ ? ? ? ?Ȍǡ ?ȋǤǡ ? ? ? ?ȌǡȽȋǤǡ ? ? ? ?ǡǤǡ ? ? ? ?Ȍ
AP-1 (Desmet et al., 2005), while elevated levels of AP-1 have also been reported in
mice lungs following cigarette smoke exposure (Li et al., 2009b). Moreover, AP-1 (Park
et al., 2011, Bhattacharya et al., 2001), SP-1 (Bhattacharya et al., 2001) and Ets-1
(Mylona et al., 2006) have previously been shown to regulate PLAUR, while c/EBP, SP-
1, AP-1 and GATA have also been previously predicted in silico to regulate PLAUR
expression (Stewart and Sayers, 2009). This highlights that regions regulated by these
transcription factors are potentially important in regulating 5`UTR driven regulation of
gene transcription. Interestingly the 199bp construct is rich in AP-1, Sp-1 and Ets-1
sites, highlighting a potential reason for the recorded strong gene regulatory function
of this 5`UTR construct.
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At the 3`UTR a number of isotype specific miRNAs were detected, of which a number
have been previously associated with airway disease. Expression levels of the Isoform
1 specific miRNA miR-133a, were found to be supressed in the bronchial smooth
muscle in a mouse model of allergic bronchial asthma when compared to healthy
controls (Chiba and Misawa, 2010). Other Isoform 1 unique miRNAs were also
associated with the airway; mir-320 was found to be significantly down regulated in
human airway smooth muscle cells by a pro-inflammatory stimulus of IL-1beta, TNF-
alpha, and IFN-gamma (Kuhn et al., 2010) and miR-146b was determined to be a        
	Ⱦ   
epithelial cell differentiation. Let-7b has been found to be highly over expressed in
human airway tissue, with levels 70 fold higher than the average miRNA (Williams et
al., 2009). The Isoform 2 specific miRNA miR-222 has been implicated in the regulation
of non-small cell lung cancer (Acunzo et al., 2012) and general lung cancer (Zhang et al.,
2011). Therefore bioinformatics identifies a strong regulatory potential for the PLAUR
3`UTR, for the mPLAUR and ssPLAUR forms, as well as the 5`UTR in respiratory
disease. This confirms that investigating both the 5`UTR and 3`UTR is pertinent to this
work.
This provided a platform for further experimental studies to study the role of the
5`UTR and 3`UTR in vitro. Although previous studies on the putative PLAUR promoter
have been published, these are limited by their use of cancerous cell lines, namely the
colon cancer cell lines HCT116 and DEO (Dang et al., 1999) and the cervical epithelial
tumour cell line HeLa (Soravia et al., 1995). Therefore, prior to this investigation,
PLAUR 5`UTR driven regulation had not been investigated in primary cells per se or in
airway cells, which are pertinent based on elevations of PLAUR detected in NHBECs in
asthma (Stewart et al., 2012). In this chapter, experimental studies have located the
minimal PLAUR promoter within the first 199bp upstream from the TSS, confirming
previously published results in colon cancer and U937 lymphoma cells (Dang et al.,
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1999, Soravia et al., 1995). This minimal promoter was determined to be robust, based
on luciferase reading well above those normally published for similar promoters (~ 1to
5 fold elevation) (Bonello and Khachigian, 2004, Takeuchi et al., 2002) confirming a
high level of regulation by the baseline promoter. The importance of this region is
further emphasised by the gene regulation associated transcription factors AP-1 and
Sp-1. Increased gene transcription driven by the region between 490 and 887 base
pairs upstream of the TSS suggests that transcriptional regulatory elements that are
relevant to the modulation of PLAUR regulation are also present in this region, a
finding that has not been previously reported. Potential gene regulatory elements ?ȀȾǡ
to be deregulated in COPD (Natanek et al., 2011) and asthma (Roth et al., 2004).
Interestingly this region also contains the lung function and asthma associated SNP
rs2356338, which has been previously associated with changes in circulating PLAUR
levels and so provides further evidence that this region is important in regulating gene
expression. Therefore, although the effect of this region is modest (it does not cause a
doubling of the rate of gene expression), it is still relevant to gene regulation and it may
be of increased importance in obstructive lung disease through possible disease driven
effects by these gene regulatory elements. A decrease in transcriptional activity by the
1.5kb and 2.5kb fragments is unexpected and is likely to be due to changes in the
conformation of the plasmid brought about by large inserts which could affect plasmid
driven promoter activity. Therefore, effects driven by these large fragments were
difficult to interpret.
Identification that gene expression is strongly suppressed by alternate gene regulatory
elements within the individual 3`UTRs of the membrane bound and soluble splice
variant of the receptor (see Fig. 1.8 Chapter 1) highlights that these regions also play an
important role in modulating PLAUR expression by probable post-translational
mechanisms. The membrane bound receptor 3` distal region has already been shown
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to effect PLAUR expression through the interaction of phosphoglycerate kinase (PGK)
with PLAUR mRNA in vivo and in cell free systems. Stability of PLAUR mRNA was
reported to occur through mRNA phosphorylation (Shetty et al., 2004), mediated by
PGK binding to a 37 mRNA nucleotide sequence (nucleotides 1051 to 1088) (Shetty et
al., 2004). Other investigations identified that heterogeneous nuclear ribonucleic
protein C1 (hnRNPC), binds to a 110 mRNA nucleotide sequence (Shetty, 2005)
preventing mRNA degradation, an effect increased by the presence of PLAU (Velusamy
et al., 2008). Therefore the 3`UTR directed work described in this chapter builds on this
data, focusing on the mRNA coding 3`UTR. Results confirm previously published
inferences that the mPLAUR 3`UTR is an important gene regulatory element under
basal conditions and have identified that the 3`UTR is also an important regulatory
region for the soluble spliced receptor, limiting gene expression of both receptor forms
via a repressive mechanism as yet undefined in NHBECs.
Interestingly, recent publication by the Encyclopaedia of DNA Elements (ENCODE)
Consortium (Rosenbloom et al., 2012) of a now completed ENCODE dataset identifying
markers for promoter and enhancer elements, has provided supporting evidence for
the conclusions arrived at in this chapter (Fig. 5.29).
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Figure 5.29: ENCODE identifies important gene regulatory elements within the PLAUR gene and its 5`UTR. Strong gene regulatory elements present in the
gene 5UTR and replicated in both the H3K4Me1 and H3K4Me3 tracks identifies important regions of gene transcriptional regulation. A particularly strong
association in the region that corresponds to the 199bp fragment supports the finding presented in this thesis that the PLAUR gene is strongly regulated by its
minimal promoter present in this region. A region associated with promoter/enhancer activity towards the end of the 2.5kb fragment studied in this thesis is
only present in the H3K4Me1 track and does not reflect dual luciferase assay results presented. This adds weight to the conclusion derived in this chapter that
dual luciferase assay results for the larger 1.5kb and 2.5kb are difficult to interpret. A strong tag for a promoter/enhancer region in the region ~5kb upstream of
the gene suggests that further regulatory regions exist for PLAUR which have not been tackled by this thesis. Low degrees of tagging for promoter/enhancer
elements at the 3`UTR for mPLAUR (top fragment) and ssPLAUR (second fragment from the bottom), suggests that the changes in gene expression that were
experimentally discovered in this chapter are more likely to be driven by post-translational effects.
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Markers identify important regulatory elements within the 2.5kb fragments analysed,
especially within the first 300bp upstream from the TSS, supporting previously
published results, confirmed by this work, that the region corresponding to the first
200bp upstream of the TSS are important in gene transcriptional regulation. The
presence of another peak towards the end of the 2.5kb fragment however does not
match with results presented in this thesis. This may suggest that, as previously
concluded, results obtained by the larger fragments may not be skewed due to vector
size dependant effects and are therefore difficult to interpret. However this
promoter/enhancer marker is absent in ENCODEs H3K4Me3 track, making a correct
interpretation of the data difficult. The appearance of another strong
promoter/enhancer region further upstream of the region investigated in this thesis,
present in both the H3K4Me1 and H3K4Me3 ENCODE tracks, identifies that an
important regulatory region may exist ~5kb upstream of the gene. This therefore
suggests that further gene regulatory mechanisms remain uninvestigated, which may
be important in basal gene regulation or in altering gene expression on epithelial cell
stimulation. This is of importance when considering that the mechanism of alteration
of PLAUR expression on scratch-wounding has still not been conclusively determined
(see below). The low degrees of tagging for promoter/enhancer elements present in
the 3`UTR for mPLAUR and ssPLAUR suggests that the changes in gene expression
described in this chapter are more likely to be driven by post-translational effects, as
expected.
Once regulation of gene expression in NHBECs had been investigated, it was pertinent
to investigate changes in gene expression following cellular stimulation by scratch-
wounding and CSE exposure. These outcomes were selected based on previous
evidence from the same research group identifying an elevation of PLAUR at the wound
edge of a scratch wound (Stewart et al., 2012), the association of PLAUR SNPs with lung
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function in smokers (Stewart et al., 2009) and the correlation between ssPLAUR and
smoking pack/years described in Section 3.4.3.
Scratch-wounding stimulation of NHBECs appears to only effect gene expression
through the 5`UTR region between 490 and 887 base pairs upstream of the TSS. While
this is of interest due to the presence of SNP rs344781 within this fragment (466bp),
which has previously shown borderline significant association with baseline lung
function as defined by the FEV1/VC ratio in smokers (Stewart, Hall et al. 2009), the
increase is not large enough (0.25 fold) to translate to a significant change in gene
expression. Therefore, overall epithelial cell damage can be said not to alter expression
driven by the investigated 5`UTR regions or the either isoform specific 3`UTR,
suggesting that neither the 3`UTR nor the studied 2.5kb region of the 5`UTR are key
regulatory regions for PLAUR regulation on mechanical damage. Therefore the
causative mechanism for the reported increase in PLAUR levels at the NHBEC wound
edge (Stewart et al., 2012) has not been identified with the gene regulatory elements
likely present further upstream of the gene or within the PLAUR gene.
As above, the regulatory region for changes in PLAUR expression driven by 5%v/v CSE
is independent of the 2.5kb 5`UTR as well as the 3`UTR of the membrane bound
receptor. Therefore, as in the scratch wound model, no causative mechanism has been
identified for CSE modulation of mPLAUR and its associated soluble form (scPLAUR).
Again however, one must take into consideration that lack of regulation simply
identifies that no regulatory region is present in the studied areas and that regulatory
elements may be present further upstream of the gene or within the PLAUR gene
structure itself. However with regards to ssPLAUR, inhibition by CSE of the 3`UTR
driven suppression of gene expression suggests that CSE selectively elevates ssPLAUR,
a finding confirmed at the mRNA and protein level. This is of special interest as
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investigations into the soluble spliced form of the receptor are severely lacking in the
field, with a role for ssPLAUR not yet defined.
Cell migration, MTT and apoptosis assays identified that the role of ssPLAUR in
NHBECs is limited to the modulation of cellular respiration, similar to that identified
for scPLAUR (see Section 4.7.12/3). Similarity in effect between scPLAUR and ssPLAUR
independent of mPLAUR allows for the hypothesis that the presence of a free-floating
intact domain 1 (the only domain which is identical between the two forms) is the
essential structure that regulates PLAUR activity on epithelial cell respiration. As
previously discussed, changes in cellular respiration can be due to changes n the rate of
cellular proliferation. As increased cell proliferation is a known constituent of airway
remodelling (Wilson, 1998, Busse et al., 1999), it is natural to suppose that elevated
ssPLAUR may play a detrimental effect in the process of airway remodelling, leading to
changes in obstructive airway disease. This ties in well with the known role of cigarette
smoke in affecting airway remodelling (Niewoehner et al., 1974, Floreani and Rennard,
1999, Churg et al., 2006) and may potentially be one of the factors driving this effect.
Interestingly, ssPLAUR does not mimic scPLAURs role in modifying epithelial wound
repair in a scratch wound model (see Section 4.7.12), suggesting that a mechanism
involving the full length receptors DIII is involved.
In conclusion, this chapter identifies, through bioinformatics, that the genes 5`UTR and
3`UTR do have regulatory potential that is conserved through different species.
Experimental investigations in a bronchial epithelial cell line (Beas2BR1) and in
primary bronchial epithelial cells (NHBECs) identify a role for the 5`UTR and 3`UTR
under basal and stimulated (scratch wound & CSE) conditions. PLAUR transcription
was found to be strongly influenced by the minimal promoter region present in the
first 199bp upstream of the TSS as previously reported. Transcription was found to be
augmented by a region between 490bp and 887bp upstream of the TSS. This chapter
262
also confirms a role for the 3`UTR in the regulation of mPLAUR and ssPLAUR
expression via gene suppression. While the regulatory mechanism for changes in
PLAUR expression on mechanical damage as defined by a scratch-wound model still
remain to be identified, CSE was found to selectively elevate ssPLAUR through
inhibition of 3`UTR driven gene suppression. This led to an increase in the rate of
NHBEC respiration, indicating a possible effect on cellular proliferation and so
identifying a possible role for ssPLAUR in airway remodelling. Therefore this thesis, for
the first time, identifies a biological effect for this specific gene isoform.
CHAPTER 6:
IDENTIFYING COMMON AND RARE
VARIANTS ACROSS THE PLAUR
GENE USING NEXT-GENERATION
SEQUENCING
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CHAPTER 6: IDENTIFYING COMMON AND RARE VARIANTS
ACROSS THE PLAUR GENE USING NEXT-GENERATION
SEQUENCING
6.1 INTRODUCTION
Significant evidence is present in the literature which highlights the importance of the
urokinase plasminogen activator receptor in the progression and modulation of a
variety of disease states (Eugen-Olsen et al., 2010b, Haupt et al., 2012, Langkilde et al.,
2011, Sidenius et al., 2000, Barton et al., 2009), while work in this thesis has identified
a link between PLAUR and the obstructive lung diseases, asthma and COPD (Section
3.4.4) as well as smoking (Sections 3.4.3 & 5.7.8). At the cellular level, work in this
thesis suggests a role for the different forms of the receptor in airway remodelling
(Sections 4.7.12 & 5.7.11), an important process in obstructive airway disease
(O'Donnell et al., 2002). Therefore, variation in receptor expression or function may
play an important role in the modulation of disease.
Variation in the genetic code in the form of SNPs or insertion/deletions (indels) can
result in changes in the rate of gene expression or, in the case of non-synonymous
SNPs, changes in the amino acid sequence that may affect protein structure and any
role the protein may have on disease risk and/or progression. Indeed work by
colleagues in the same group has identified variants within the gene to either have a
regulatory effect on PLAUR expression, elevating the levels of scPLAUR in serum
(Barton et al., 2009), to be associated with an increase in the decline of lung function in
asthma and smokers (Barton et al., 2009, Stewart et al., 2009) or the development of a
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number of disease states (Tee et al., 2012, Manetti et al., 2011, Shih et al., 2011,
Turkmen et al., 1997).
Work on the effect of variance within the PLAUR gene and its untranslated regions
through the tagging of SNPs spanning the PLAUR gene (Barton et al., 2009), has been
limited to work on common variants, defined as SNPs with a MAF >1% (Lemire, 2011).
The importance of discovering novel variants is highlighted by previous work on
PLAUR where the gene was identified as an asthma susceptibility gene, yet the
causative polymorphism(s) behind the association remained as yet undetermined
(Barton et al., 2009).
Further scope to identify novel rare variants that may be involved in the regulation of
PLAUR gene expression and/or asthma is based on the long-standing idea that rare
variants, over common variants, could be the driving force behind a number of
common diseases such as asthma (Schork et al., 2009, Pritchard, 2001, Bodmer and
Bonilla, 2008). This idea was expanded upon by a recent study by Cirulli and Goldstein
where the authors hypothesised that much of the genetic control of common diseases
occurs via rare variants, which are usually deleterious in nature (Cirulli and Goldstein,
2010). The authors go on to describe the effect of rare variants on the risk of common
diseases such as autism, mental retardation, epilepsy and schizophrenia as being
strong in individual patients (Cirulli and Goldstein, 2010).
The 1000 genome project (1000_Genome_Project, 2010) identified over eight million
novel variants (SNPs and insertion/deletions) by 2010, a large percentage of which
were rare genome variants. The presence of so many novel variants highlights that
many may still remain to be discovered genome wide, including a large number of
PLAUR variants, which may regulate PLAUR expression and activity.
Therefore, detection of rare variants will increase understanding of the PLAUR gene
structure with regards to polymorphisms spanning the gene and its untranslated
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regions. Stratification of results based on asthma disease status will help identify which
of the novel and other detected variants have an impact on disease risk and/or
susceptibility. Recent advances in next-generation sequencing (NGS) has improved
sequence coverage for most genes as well as the onset of more cost-efficient
processes, providing the opportunity to be able to identify rare variants within the
total pool of identified variants.
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6.2 AIMS
1. To carry out next-generation sequencing on the chromosome 19q13 locus
relating to the PLAUR gene and its untranslated regions (8317bp at the 3`UTR
and 34971bp at the 5`UTR) in order to identify novel variants using 200 severe
asthma cases and 200 non-wheeze, non-atopic controls.
2. To identify whether these novel variants are unique to either the asthma or
control populations.
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6.3 METHODS
The experimental processes described in this chapter were carried out for the PLAUR gene in
conjunction with next generation sequencing for the IL1RL1 and IL18R1 genes.
6.3.1 STUDY POPULATIONS
Next-generation sequencing was carried out on DNA from 200 severe asthma cases
and 200 non-asthmatic, non-atopic, non-wheeze controls. Case subjects were obtained
from the Genome-Wide Association Study To Identify Genetic Determinants Of Severe
Asthma (AUGOSA) study cohort (Wan et al., 2012), while a subset of general population
controls from the Nottingham Gedling cohort (McKeever et al., 2001), were selected to
be the non-asthmatic, non-wheeze and non-atopic controls (Table 6.1). Attempts were
made to sex match the cases and controls, but controls were chosen to be slightly older
than the asthmatics in order to provide further assurance of their non-asthmatic status.
Therefore the resulting samples were made of cases with a population of 69.4% female
with an average age of 48 years (±15) and controls with a population of 73.0% female
with an average age of 57 years (±13).
AUGOSA Cohort Gedling Cohort
Age (Yrs) 48 ±14.88 57 ±12.64
Percentage Male 30.6 27.0
Height (M) 1.64 ±0.08 1.66 ±9.06
FEV1 (L) 2.17 ±0.84 2.77 ±0.79
Smoking pack/years 11.82 ±20.25 8.40 ±18.61
Percentage Never Smokers 52.0 53.5
Table 6.1: Demographics comparing the case (AUGOSA) and control subjects (Gedling)
sequenced in this chapter.
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6.3.2 REGION SELECTION
The untranslated regions, included in the experimental design due to their potential in
regulating gene expression as suggested by previously published work (Barton et al.,
2009), and the gene region of PLAUR (chromosome 19q13) were selected for
sequencing. This gave a total selected region of Chr19: 44,141,930-44,209,469
(Fig. 6.1). This included the region 8317 base pairs downstream of the 3`UTR and
34971 base pairs upstream of the TSS. The length of the 3`UTR investigated was
limited by the location of the cell adhesion molecule 4 (CADM4) gene
(Chr19:44126522-44143991). The region encompassing the 5`UTR was selected to
capture SNP rs346054, previously associated with bronchial hyper-responsiveness,
located at 30147 base pairs downstream of the genes transcriptional start site (Barton
et al., 2009). All co-ordinates are reported in the Genome Reference Consortium
GRCh37.p9 Primary Assembly.
270
Figure 6.1: Region selected for next-generation sequencing. The region selected for next generation sequencing, located within chromosome 19(q13.31), is
highlighted by the black band within the above diagram that represents the region of Chr19:44131930-44219469 (Feb 2009 build). This includes the 3`
untranslated region up to and including part of the cell adhesion molecule 4 (CADM4) gene and the 5` untranslated region up to ~35kb upstream of the
transcriptional start site.
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6.3.3 BAIT DESIGN
Baits are 120bp oligonucleotides used to carry out sample target enrichment. Bait
design was carried out in silico using the SureSelect̻ e-array design software11. In this
software, the following protocol was used:
x The Illumina Chip was selected from the Sequencing Technology bar
x From the Design option tab Paired-End long read was selected. This allows for
the design of a library targeted towards paired-end sequencing (shotgun
sequencing), where long DNA fragments are broken down into shorter
fragments and sequenced from both ends before being re-arranged together to
form a sequence of the original DNA strand
x The default parameters were thenmodified as follows:
o The amount of bait tiling was increased to X5; this results in each
nucleotide being selected by five individual baits, increasing coverage
o A justified design was selected; this allowed design of baits with a good
degree of overlap allowing for repeated sequencing of the DNA regions
o An overlap of 40 was selected for inclusion into avoided regions; this
allows for optimised anchoring of the baits to the required regions
x Both of the avoid standard repeat masked regions tabs was selected. This
selected the repeat and the windows masker algorithms. This minimises the
degree of masking of the sequencing areas and so increases the number of baits
designed for the region of interest
11 available at https://earray.chem.agilent.com/earray
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Following the submission of the design and the online generation of the bait library, the
following files were formed:
1. A .zip file containing a .summary file describing both the design and the results
2. A .fate file listing the number of baits generated in the target region
3. A .bed file that mapped the location of each individual bait and
4. A .tdt file which provided the sequence and target position of each of the baits
The .bed files were then loaded as custom tracks on the USCS genome browser on
which the custom MAP readability track12, designed by Mr Richard Capper (Agilent
UK), had been activated to allow visualisation of the baits mapped onto the region of
interest.
12 Available at http://genome.ucsc.edu/cgi-
bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=Richard%20Capper&hgS_otherUserS
essionName=Ian%20Sayers
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6.3.4 NEXT-GENERATION SEQUENCING
The experimental process of re-sequencing in terms of library preparation, target
enrichment (Fig. 6.2), cluster generation, cluster sequencing and base calling (Fig. 6.3)
were carried out by SourceBioscience (Nottingham, UK). Next-generation sequencing
was carried out on two separate lanes, one for cases and the other for controls, using
the Illumina HiSeq2000̻ systems pipeline (San Diego, USA). Sequencing used a paired-
end design using 100bp reads.
Since generation of data on an individual level can be costly, multiplexing was carried
out on the sample pool, with the case and control subjects split into 3 randomly
indexed pools of 66, 66 and 68 individuals (Cases=Pools 1, 2, 3; Controls=Pools 4, 5, 6).
To ensure that relatively identical DNA concentrations were present for each sample
prior to pooling, DNA concentrations were determined using an Agilent BioAnalyzer.
DNA samples in each pool were then sheared and target sequence enrichment carried
out using the Agilent SureSelect Custom Capture kit, built with the bait library designed
in Section 6.3.3; this had a capture size range of 500Kb to 1.5Mb. These biotinylated
RNA baits hybridise to the regions of interest in the now fragmented DNA allowing
Streptavidin coated beads to select out the regions of interest in order to focus the area
for amplification prior to the cluster generation and sequencing steps (Mamanova et
al., 2010, Leproust, 2012). Prior to sample library preparation each of the 6 sample
pools were indexed by bar-coding with unique adaptor sequences (Harismendy and
Frazer, 2009, Meldrum et al., 2011, Kenny et al., 2011).
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Figure 6.2: Sureselect̻ library preparation and target enrichment. Genomic DNA samples
are prepped using the Sureselect̻ Kit, where the DNA is sheared, repaired, indexed and
selected via PCR using SureSelect̻ Primer and SureSelect̻ Pre-capture Reverse PCR primers.
Following hybridisation with the SureSelect̻ capture library, regions of interest are captured
using streptavidin magnetic beads. DNA sequences are then washed off the magnetic beads
and RNA contamination removed. The samples are then ready for sequencing. Diagram
adapted from (Agilent, 2012).
Illumina sequencing utilises cBot for automated cluster generation, followed by a
sequencing by synthesis (SBS) reversible terminator technology, to generate data for
the region of interest (Shendure and Ji, 2008, Metzker, 2010, Ansorge, 2009).
Fragmented genomic DNA is bound to two unique adapter oligonucleotides at both
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ends resulting in fragments between 150 and 200bp in size. These fragments are then
immobilised on a flow-cell surface that facilitates the access to DNA polymerase
enzymes, reducing the degree of fluorescently labelled dNTP non-specific binding and
therefore resulting in a highly stable surface template. This immobilization occurs
through the hybridisation of the adapter oligonucleotides to a lawn of corresponding
oligonucleotides present on the surface of the flow-cell. As the free distal end of the
DNA fragments is complimentary to nearby surface bound oligonuceotides, a dense
cluster of fragments (circa. 2000 per cluster) of the original DNA template is able to
form via 3 prime replication using solid phase bridge amplification (Fig. 6.3a).
Sequencing is then carried out by the addition of a single fluorescently labelled dNTP to
the DNA chain followed by the capture of fluorescence following laser excitation. The
dNTP is enzymatically cleaved and the next dNTP incorporated. In this way bases are
identified sequentially (Fig. 6.3b).
Figure 6.3: Solid phase bridge amplification, cluster formation (A) followed by Illumina
sequencing (B). Adaptor sequences bound to fragmented genomic DNA are immobilised on a
flow-cell. Binding to adjacent free adaptors allow for 3 prime directed bridge amplification,
forming a dense cluster of the same sequence. Fluorescent based sequencing is then carried
out followed by data alignment.
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As the total region sequenced was 67539bp (Chr19:44,141,930-44,209,469) the total
region size sequenced in a single lane was 4.5Mb (67539bp x 66) for each indexed
sample. The Illumina product specifications identify that approximately 10GB of data is
generated for each lane of sequencing with 60% on target efficiency expected using the
HiSeq2000 systems pipeline. Therefore, considering that sequencing for PLAUR was
carried out in tandem with sequencing for IL33 and IL1RL1/IL18R1 locus to a total
sequence of 54MB, the estimated average coverage per individual was 37-fold
calculated from: 10GB data/3 pools/54MB region x 0.60 efficiency.
6.3.5 DATA ANALYSIS
6.3.5.1 QUALITY CONTROL
All data analysis was carried out in collaboration with Mr Nick Shrine (University of
Leicester) using the UNIX operating system. Data was converted into a Sequence
Alignment/Map (SAM) Output format using the Burroughs-Wheeler transform
construction algorithm (Burroughs and Wheeler, 1994). SAM files are TAB-delimited
text files consisting of an optional header section and an alignment section. Each
alignment line has 11 mandatory fields for essential alignment information such as
mapping position, and variable number of optional fields for flexible or aligner specific
information. Data was then run using the software package SAM Tools (Li et al., 2009a)
which provides various utilities for manipulating alignments in the SAM format,
including sorting, merging, indexing and generating alignments in a per-position
format. Briefly, using SAM Tools, any unmapped reads and duplicate reads were
removed and mapped reads sorted. Base quality was then re-calibrated, which
assigned a score to each read reflecting the degree of confidence of the base-calling
algorithm. This score operates within an effective dynamic range of 2-40, where 40
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indicates that there is a 1 in 10,000 chance that the called base is incorrect (99.99%
accurate) and is currently the highest effective score that a single base can receive
under normal conditions.
6.3.5.2 VARIANT CALLING ANDMAPPING
Data was then transformed in a Variant Call Format (VCF) output. VCF files are a text
files format that contains meta-information lines, a header line, and data lines, each
containing information about a position in the human genome. Conversion to VCF
format allowed mapping of the reads to the NCBI GRCh37 genome template using the
command: /human_glk_v37.fasta/ and alignment of called variations to the NCBIs SNP
database (dbSNP) in order to identify already known variants, using the command
dbSNP_132_b37.vcf. Realignment around insertion deletions and recalibration of
quality scores was carried out using the freeware software programme GATK (DePristo
et al., 2011), while variant detection was carried out using the freeware software
program Syzgy (Rivas et al., 2011), both run on the UNIX platform, forming tables
identifying total and novel variations. Variants were called using a cut-off quality score
of 10 which corresponds to a P-value of Pd0.1, below which the accuracy of the called
SNPs cannot be confidently established. Using this cut off point reduced the number of
false calls in this analysis.
Novel variants were differentiated from the total number of variants called using data
from the 1000 Genomes Project. The 1000 Genomes Project is a continuously updating
sequencing and genotyping project with data being freely deposited online. The latest
data releases, which contains calls based on 629 individuals, for the full project
genotype release (16 December 2010) and indel release (16 February 2011) were
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analysed using VCF version 4.0 files. These were extracted from the EBI FTP site13
using the following commands in UNIX via tabix (Li, 2011):
tabix -h
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/ALL.2of4intersectoin.20
100804.genotypes.vcf.gz
19:44,141,930-44,209,469
6.3.6 IDENTIFYING WHETHER IDENTIFIED NON-SYNONYMOUS SNPS
ALTER PLAUR STRUCTURE
In order to identify whether any identified novel non-synonymous SNPs caused a
change in PLAUR structure and therefore whether these SNPs had potential biological
reference, SNPs were analysed in silico, using PolyPhen-214.
Briefly, the protein FASTA sequence for full length PLAUR was pasted into the required
field, the position within the protein sequence of the amino acid altered by the
identified non-synonymous SNP was entered into the required field and the type of
amino-acid change selected before the query was submitted.
13 Available at - ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
14 Available at - http://genetics.bwh.harvard.edu/pph2/index.shtml
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6.4 RESULTS
6.4.1 BAIT DESIGN
Sureselect̻ run statistics identified that 39270 base pairs of the total selected target
length of 67540 base pairs were covered by the bait design, i.e. a total of 58.14% of the
targeted base pairs being covered. Visualisation of the bait design on the USCS genome
browser (Fig. 6.4) highlights that the areas not targeted by baits have been strongly
masked by both the windows and repeat maskers identifying that these regions (>40%
of the selected region) were unreadable using current technology. This is due to the
presence of a large number of repeats and runs in the genetic sequence in these
regions. Therefore these regions were not integrated into the analyses. Unreadable
regions were present throughout the whole region of interest in both the untranslated
ends and in the gene intron structure. The largest unreadable region is present in the
intronic region between exons 6 and 7 with other large unreadable regions present in
the regions between exons 2 and 3 and 3 and 4 as well as in the 5`UTR. The 3`UTR is
relatively well covered by the baits. However, gene exon regions were fully covered by
the designed baits and therefore have the potential to be completely sequenced.
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Figure 6.4: A screenshot from the USCS genome browser identifying regions on chromosome 19 covered by the designed baits. Loading of .bed files into
the UCSC browser along with the custom track designed by Mr Richard Capper (see Section 6.3.3) displays tracks identifying areas masked by the windows and
repeat masker, locations of known SNPs and the location of the PLAUR gene. This identifies that a large section of the gene and its untranslated regions are
unreadable using current technology and therefore will not be integrated into the current analyses. Baits at the 3 prime end overlap with the gene for cell
adhesion molecule 4 (CADM4) which is in close proximity to the PLAUR gene. Although present within an alternate gene these baits were included in the final
library used for sequencing as they may still affect PLAUR expression through their close proximity to PLAUR .
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6.4.2 DETERMINING SEQUENCING DATA ENRICHMENT EFFICIENCY
Bait mapping quality was significantly low, with data generated for the region of
interest being only marginally elevated when compared to non-targeted sequencing
throughout the human genome (Fig. 6.5). The percentage mapped reads for the
individual pools for the region of interest averaged at 3.49% compared to a non-
specific mapping of ~1.5% on other non-specific chromosomes.
282
Figure 6.5: Mapping distribution of reads across the human genome. Reads obtained from the next generation sequencing targeted to PLAUR (Chromosome
19), which was run in conjunction with targets in Chromosomes 2 and 9, identify that mapping to targeted areas was only modestly enriched for Chromosomes 2,
9 and 19 using SureSelect enrichment. This identifies that the sequencing procedure is not optimal and may therefore not produce accurate variant calling
results.
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Overall percentage mapped reads for individual pools for all 3 regions sequenced
averaged at just 9.15% (Table 6.2).
Pool
Percentage Mapped
(PLAUR only)
Pool 1 7.5%
Pool 2 9.7%
Pool 3 10.5%
Pool 4 9.5%
Pool 5 9.1%
Pool 6 8.6%
Table 6.2: Percentage mapped reads per sample pool. A uniform
degree of low mappability for the PLAUR gene is present across all pools.
This therefore affected coverage of the targeted region, limiting the overall and specific
(PLAUR) gene coverage as identified in Table 6.3.
Min. 1st Qu. Median Mean 3rd Qu. Max
POOL1 0 3.39 5.38 4.93 6.5 11.36
POOL2 0 4.74 8.41 7.82 10.77 17.42
POOL3 0 4.09 7.29 6.83 9.4 14.74
POOL4 0 2.5 4.38 4.03 5.52 9.53
POOL5 0 2.62 4.55 4.17 5.67 8.88
POOL6 0.01 2.82 4.71 4.41 5.88 9.59
Table 6.3: Coverage statistics for the PLAUR region (67.5Kb) based on sample coverage.
As indicated by the low mapping specificity of the sequencing reaction, coverage for the
targeted area is low. Values define fold coverage per sample in the PLAUR targeted region.
Min = Minimal coverage detected; 1st Qu. = First Quartile (25% of values are below this
value); 3rd Qu. = Third Quartile (75% of values are below this value); Max = Maximal coverage
detected.
Importantly 75% of all subjects had a coverage of <11% with the control population
(Pools 4-6) having the lowest coverage (<6%). This highlights the limitation of this
study in that poor coverage has reduced overall quantity of sequencing data as well as
its quality as there is a) around 50% less coverage and therefore data in the control
population and b) there are a number of samples with no coverage, reducing pool
numbers. This results in the next-generation sequencing being unable to reliably call
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rare variants. However, despite this limitation, some analyses could be performed and
these are summarised in the next section.
6.4.3 IDENTIFICATION OF VARIANTS PRESENT IN THE COMBINED
POPULATION
Variant detection was carried out through the alignment of the genomic position of
each identified variant (SNPs or insertion/deletions) to the reference genome in order
to identify positions at which differences between read and reference occur in a
significant degree. Using a number of criteria including read depth and mapping
quality, a quality threshold (indicating the probability of error in the variant call) was
determined for the data. This helps identify false calls within the dataset and therefore
allows for subsequent removal of the false call data from the dataset. Standard quality
score thresholds for next-generation sequencing, such as that carried out in the 1000
Genomes Project, is <30 which corresponds to Pd0.001 error, i.e. a 1 in 1000
probability that the base call is wrong (99.9% accuracy of base calling). However, this
was not utilised in this dataset due to the high level of false negatives called at this
level, with a quality threshold for exclusion set to <10 instead. This corresponds to a
Pd0.100 error, i.e. a 1 in 10 probability that the base call is wrong (90% accuracy of
base calling). Using a quality threshold of <10, 398 variants including 15 SNPs
validated by the 1000 Genomes Project that would have been excluded at a quality
threshold level of <30 were included in list of variants called. This was equivalent to
42.66% of all called variants.
Called variants mapped to data from the 1000 genome project identified a total of 933
variants of which 597 were defined as novel, present in the combined population but
not in the 1000 Genome Project mapped to the GRCh37/hg19 build of the human
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assembly. Of the novel variants, 62 (10%) had a frequency of less than 1% (Table 6.4)
and can therefore be defined as rare variants (Lemire, 2011).
Variants Called Number of variants
Variants called by the
1000 Genomes Project
Total 933
1498 (total)
329 (common [>5%])
Novel and Quality Controlled 597 n/a
Novel, Quality Controlled
and Rare (<1%)
62 n/a
Table 6.4: Variant calling results for the PLAUR gene and its surrounding areas. Variant
calling identified a total of 933 variants that satisfied quality control criteria of which the
majority (64%) were novel variants. Of these novel SNPs, 62 (10% of total) were identified as
rare variants. Although only ~23% of the total number of called variants by the 1000 genomes
project in the same region have been identified in this analysis, when only common variants
were selected in both datasets ~81% (267 variants) of the total common variants defined by
the 1000 genome project were identified .
Of the 597 novel variants identified, 7 novel SNPs were identified within PLAUR exons
regions (Table 6.5), specifically within exons 1, 5, 6 and the terminal exon (7a), which
is unique to the membrane bound receptor. All of these exon SNPs were, at the time of
detection, novel variants; however by the time of writing all variants except that at
position 44156419 were reported by the 1000 Genome Project.
Position
(Chr 19)
Exon Type A.A Major/Minor
Alleles
Frequency
(Cases)
Frequency
(Controls)
44174249 1 Synonymous SNP C|T 0.0033 0.0149
44159722 5 Non-synonymous SNP
Change from [R] to [H]
159 C|T 0.0056 2.00E-04
44156419 6 Synonymous SNP G|A 0.005 1.00E-04
44156472 6 Non-synonymous SNP
Change from [K] to [R]
191 T|C 0.1926 0.1751
44153100 7a Non-Synonymous SNP
Change from [L] to [P]
274 A|G 0.1528 0.1415
44153248 7a Non-synonymous SNP
Change from [M] to [V]
268 T|C 0.0014 0.0054
44153255 7a Synonymous SNP G|A 0.0154 0.0246
Table 6.5: Identification of novel variants located in the PLAUR exons. Through re-
sequencing 7 SNPs located in the genes exon regions were identified 4 of which cause a
change in the genes amino acid backbone. These changes are located at amino acid positions
159 and 175 (Domain II) and at positions 268 and 272 (Domain III). 4 of these SNPs are rare
variants occurring in <1% of the population. A.A. = Amino acid.
286
However this analysis, as suggested by the quality control results, was highly limited.
In the first instance a total of 24 SNPs documented in database SNP and the 1000
Genomes Project were excluded in the final dataset as they did not achieve a quality
score of >10. Secondly, only 336 previously known variants for the entire region
analysed were identified (for full list of called variants see Appendices). Considering
that as of writing the 1000 Genomes Project has identified 1498 variants with the same
region, it would suggest that a large number of variants have not been called in this
analysis. However, when only common variants were selected in both datasets ~81%
(267 variants) of the total common variants defined by the 1000 genome project (329
variants) were identified. This therefore suggests, as indicated by the low coverage
generated for this analyses (see Table 6.3) that this analysis while being able to pick up
most common variants, is unable to reliably call rare variation. Therefore a number of
false negative calls have, especially with regards to rare variants, likely been made and
subsequently a large number of variants have been missed by this experimental
procedure.
6.4.4 ONE NON-SYNONYMOUS SNP ALTERS PLAUR STRUCTURE
Using PolyPhen-2, the polymorphism at position chr19:44153100, produced a high
PolPhen-2 score and was therefore deduced to be damaging to the PLAUR protein
structure (Table 6.6) and therefore potentially results in a biologically relevant role. All
other non-synonymous polymorphisms were identified as benign, causing no change to
PLAUR protein structure.
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SNP Position Amino Acid Amino Acid
change
Score Result
44159722 159 [R] to [H] 0.002 Benign
44156472 191 [K] to [R] 0.000 Benign
44153100 274 [L] to [P] 0.999 Probably Damaging
44153248 268 [M] to [V] 0.346 Benign
Table 6.6: Only one of the novel non-synonymous SNPs causes an amino acid change that
is potentially damaging to PLAUR structure. This identifies that this SNP has a potential
biological role through alteration of PLAUR function. All other non-synonymous SNPs cause
amino acid changes that do not significantly alter the PLAUR protein structure.
6.4.5 IDENTIFICATION OF ASTHMA SPECIFIC VARIANTS
Variant calling was split based on pools, with data from pools 1, 2 and 3, (pools
containing samples from the asthma population) compared to data from pools 4,5 and
6, (pools containing data for the control population). Analyses of the split data
identified that a total of 4 novel variants were exclusive to Pools 1, 2 and 3 and
therefore exclusive to the asthma population (Table 6.7). No unique SNPs were
identified for pools 4, 5 and 6, i.e. the control population. All of these identified asthma
specific SNPs were novel and rare variants.
Mapping of the asthma specific variants to the human genome identified that the SNP
at position 44167227 is located within the gene region for PLAUR (chr19:44,150,271-
44,174,502; Build 37). Closer investigation identified that this SNP lies in intron 3. The
remaining variants (one insertion and two SNPs) were respectively located in the
genes 5UTR at 9206bp, 20634bp and 30138bp upstream from the genes TSS.
Position
(Chr19)
Type
Major/Minor
Alleles
Frequency
(Cases)
Frequency
(Controls)
44167227 SNP C|T 0.0085 0
44183708 Insertion G|GAT 0.0034 0
44195136 SNP C|T 0.0056 0
44204640 SNP G|T 0.0058 0
Table 6.7: Identification of rare variants unique to the disease population. An analysis
has identified 4 variants unique to asthmatics of which one lies in the genes intronic region
between exons 3 and 4. The remaining variants were found to lie in the genes 5`UTR up to a
maximum of 30138 base pairs upstream of the transcriptional start site.
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6.5 DISCUSSION
The aim of this chapter was to identify novel variants, including both SNPs and
insertion-deletions, present within the PLAUR gene and its 3`UTR and 5`UTRs, with a
special interest in the detection of rare variants. Secondary to that any novel variants
that were unique to either 200 severe asthma patients or the control population of 200
non-asthmatic, non-atopic and non-wheeze individuals would also be identified.
Although attempts to tackle these aims can be considered to be successful based on the
calling of a number of variants, one must take into consideration that limitations in the
dataset exist. Firstly, the bait design protocol has, due to restraints of current
technology, been unable to map more than 58.14% of the targeted base pairs, meaning
that potential variation in >40% of the targeted region has been missed. Secondly,
results were obtained from an experimental dataset with poor mapping and limited
target enrichment/coverage. Poor target enrichment and coverage suggests that the
resulting sequencing would be unreliable in the calling of rare variants within the
region. This was confirmed by the identification that while ~81% of the common
variants known to be present within the region were successfully identified by this
analysis, only 69 of the 1169 rare variants called by the 1000 Genomes Project (~6%)
were called. Therefore although this work has confidently presented novel variants and
meaningful data on variant distribution in a combined and separated asthma and
control cohort, it is not a complete picture of PLAUR variation as it has been identified
that the analyses were severely underpowered in the detection of rare variants.
However, due to the high degree of detection for common variants one is able to
confidently exclude the existence of any common novel variants present just in the
asthma population.
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Using pooled data, a number of novel variants have been detected to be present in the
combined case and control population and a number of SNPs (n=4) unique to the
diseased population have been identified. These identified variants included a number
of rare variants, which the re-sequencing was able to detect due to the high depth of
coverage that results from process of next-generation sequencing (37 fold expected).
Although only a small number of SNPs (n=4) were identified as unique to the disease
cohort, these were all classified as rare variants, i.e. present in less than 1% of the
studied population. Rare variants have been hypothesised to play an important role in
both common and complex disease (Pritchard, 2001, Iyengar and Elston, 2007) where,
unlike common associated variants which usually generate small effect sizes, rare
variants have been hypothesised to be the primary drivers of common disease (Cirulli
and Goldstein, 2010). With reference to respiratory disease and in keeping with the
common disease/rare variant hypothesis, where it is supposed that rare allelic
variation has an impact on clinical applications such as the design of prognostic assays
and the planning of therapeutic investigations (Iyengar and Elston, 2007), rare variants
have been associated with asthma susceptibility (Torgerson et al., 2012, Haller et al.,
2009). This adds significance to the identification of PLAUR rare variants in the asthma
population, where presence of the risk alleles of these rare variants may be
contributing significantly to the development and/or modulation of asthma.
Of the 4 rare variants unique to the asthma cohort, one was also present within the
gene itself. Although one may at first dismiss this variant due to its presence in one of
the genes intronic regions, meaning that this SNP does not alter the PLAUR protein
structure, there is still potential that it may play a role in the modulation of asthma.
This argument is based on recent work by Torgerson et al. that have identified non-
coding rare variants in gene intronic regions to be significant contributing factors
towards asthma susceptibility (Torgerson et al., 2012).
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Detection of 7 novel variants within several exon regions of the PLAUR gene has
identified novel regions that may cause potential structural changes in the receptor.
This was confirmed by the identification of 4 of these variants as non-synonymous,
causing a change in the amino acid backbone of the protein within the receptors
Domains II and III. In silico analysis identified that one of these variants, which is
present in the region coding for Domain III, has the potential to alter receptor domain
structure and therefore domain driven receptor effects, such as binding to integrins,
marking this variant as of possible biological importance. The location of this SNP
within domain III is of special importance considering the conclusions derived in
Chapter 5, that Domain III is the essential region driving PLAUR effects on scratch-
wound healing.
All the 7 novel variants within several exon regions of the PLAUR gene were classified
as SNPs, with half defined as rare variants. Therefore when one considers the rare
variant hypothesis, it can be supposed that these SNPs might play a greater role in
PLAUR regulation, an important observation when considering their potential in
affecting receptor structure. By the time of writing, 7 of these identified variants had
been validated by the 1000 genome study, with the synonymous SNP at position
44156419 being the only one currently unreported.
Therefore, in conclusion, this work has added to the knowledge of PLAUR gene and
untranslated region variation, identifying a number of novel common and rare
variants. Identification of novel disease specific rare variants provide possible new
targets for further study of disease specific gene regulation, while identification of
novel rare variants within the genes exon structure relating to Domains II and III
identifies variants that have a potential effect on PLAUR driven biological functions and
PLAUR associated diseases.
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Overall, these results add weight to the hypothesis that rare variation explains some of
the genetic heritability that still needs to be identified in asthma. Further work will
need to be conducted to determine the functional implications of both the disease
specific variants and the exon region variants. Also it would be interesting to
investigate the relationship between common PLAUR SNPs previously associated with
asthma, lung function and gene expression (Barton et al., 2009, Stewart et al., 2009)
and the newly identified rare variants.
CHAPTER 7:
GENERAL DISCUSSION
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CHAPTER 7: GENERAL DISCUSSION
7.1 HYPOTHESIS AND AIMS
The basis of this work is the hypothesis that the urokinase plasminogen activator
receptor plays an important role as a marker and modulator of disease in asthma and
COPD. This hypothesis is based on two observations. Firstly there has been ample
evidence that the coagulation/fibrinolytic pathways, in which PLAUR plays an
important role, are important in the development and progression of both asthma and
COPD (Polosa et al., 2011, de Boer et al., 2012). Here increased deposition of fibrin in
the airways significantly contributed to airway hyper-responsiveness (Wagers et al.,
2004) while elevated levels of plasmin had a direct role in modulating the degree of
airway remodelling (Kucharewicz et al., 2003). Secondly, at the genetic level, studies
carried out by colleagues in the same research group have identified an association
between PLAUR SNPs and asthma susceptibility, lung function decline and serum
PLAUR levels (Barton et al., 2009). In addition, PLAUR SNPs were found to determine
baseline lung function in smokers (Stewart et al., 2009), while PLAUR protein levels
were found to be elevated in the airways of asthma patient particularly in the
epithelium. Similar findings were also described by others in COPD (Wang et al., 2008).
Therefore, it was hypothesised that differential regulation of the expression of different
forms of the receptor (full length membrane, soluble cleaved and soluble spliced),
which potentially have their own specialised functions, would play an important role in
the development of PLAUR mediated airway disease through the alteration of lung-
expressed and circulating PLAUR levels.
Although there have been multiple publications tackling the transcriptional regulation
and post-transcriptional modification of PLAUR mRNA (Allgayer et al., 1999, Buchler et
al., 2009, Dang et al., 1999, Soravia et al., 1995, Bhandary et al., 2009, Shetty and Idell,
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1999, Velusamy et al., 2008), these have been limited to cancer cell lines which, by their
very definition, are different from the cells normally present in the body. Also a lack of
studies investigating how the regulation of PLAUR differs under stimulus pertinent to
respiratory disease made the study of PLAUR regulation an important aim.
Interestingly, there has also been no attempt to discern the regulation of the soluble
spliced form of the receptor or whether this structurally different molecule has a role
similar to that of full-length PLAUR, a question this thesis has also undertaken to
answer.
The aims of this thesis were:
1. To investigate the relationship between scPLAUR and obstructive lung
disease (asthma & COPD) diagnosis and clinical parameters
2. To identify novel genetic mechanisms regulating scPLAUR levels
3. To define the relative contribution of proximal PLAUR regulatory regions in
determining gene expression
4. To determine the functional role of different PLAUR forms in primary
bronchial epithelial cells
5. To identify both rare and common genetic variants spanning PLAUR and to
identify which of these are relevant to asthma
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7.2 MAIN FINDINGS
Levels of scPLAUR in serum were found to be elevated in COPD subjects in relation to
asthmatics and controls and in asthmatics when compared to controls. The elevation
identified in the asthmatic phenotype was particularly driven by the non-atopic sub-
population, which presents with a different clinical picture to atopic asthma in the
study population. In general non-atopic asthmatics have a greater degree of
macrophage dysfunction with inflammatory processes having a less significant role in
the pathophysiology of the disease (Humbert et al., 1999, Rackemann, 1947). Non-
atopics also tend to be older and develop a more severe form of the disease
(Rackemann, 1947, Humbert et al., 1999). Indeed recent data (unpublished) suggests
an association between PLAUR SNPs and age of onset of asthma. In the studied cohort,
non-atopic asthmatics had a lower degree of fixed airway obstruction than atopic
asthmatics, to a degree approaching that of COPD. Further evidence linking PLAUR to
changes occurring in the airway is provided by the identified strong correlation
between smoking and PLAUR expression, which indicates that cigarette smoke, which
is an important causative factor for the airway changes occurring in both asthma and
COPD (Wang et al., 2005), has a role in modulating PLAUR driven effects.
As serum scPLAUR levels did not change when subjects were stratified based on the
GOLD defined score of COPD severity or asthma severity as defined by nocturnal
awakenings, it suggests that while scPLAUR may be associated with the disease per se,
it is not involved in disease progression leading to a more severe disease state in the
analysed datasets. However, previous association of scPLAUR with COPD severity in
induced sputum (Jiang et al., 2010) suggests that the soluble receptor is in fact
associated with disease progression, but only locally at the airways with the changes
not translated to changes in scPLAUR levels in the periphery. Association with disease
severity would correspond to the later deduction that PLAUR has an active role in
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modulating changes in the airway (see below). Association with disease follows from
previously published literature, where in general elevated scPLAUR levels have been
associated with other inflammatory diseases as a marker of disease-related mortality,
while specifically elevated scPLAUR has been identified in the asthmatic and COPD
lungs and in the induced sputum of asthmatics and COPD patients (Stewart et al., 2012,
Wang et al., 2008, Xiao et al., 2005, Jiang et al., 2010). Strong associations with non-
atopic asthma and COPD potentially suggest that scPLAUR may be related to the more
severe changes occurring in these airways (lower degree of airway
reversibility/greater degree of airway obstruction), supported by the reported
association between PLAUR SNPs and FEV1/VC in smokers (Stewart et al., 2009).
Therefore it is likely that scPLAUR is involved in airway remodelling, even though this
process can vary significantly between asthma and COPD (Dournes and Laurent, 2012).
The hypothesis that scPLAUR plays a role in the process of airway remodelling follows
on well from published work that suggests that PLAUR and the plasminogen activator
system have active roles in airway remodelling (Stewart et al., 2012, Kucharewicz et al.,
2003, Stewart and Sayers, 2013), with the effects of full-length PLAUR potentially
explained by the soluble cleaved form of the receptor (Stewart et al., 2012). A recent
study by Zhang et al. has also associated changes in PLAUR and its related molecules
(PLAU and PAI-1) to airway remodelling (Zhang et al., 2012). An in vitro study using
NHBECs where mechanical stimulation of cells in order to mimic the process that
occurs in the lung during bronchoconstriction resulted in a 16.2 fold increase in the
expression of PLAUR (Chu et al., 2006), added further weight to this hypothesis. This is
of importance when considering that this repeated contraction of the airways has been
shown to be a driving force of airway remodelling in the absence of inflammation
through progressive extracellular matrix deposition (Holgate et al., 2010). More direct
evidence of a role for PLAUR in airway remodelling has been recently made available
by colleagues from the same group (unpublished work). Here PLAUR SNPs have been
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associated with a number of pro-airway remodelling outcomes such as thickening of
the basement membrane, increased collagen III deposition and airway epithelial
proliferation, all hallmarks of remodelling in asthma, while other PLAUR SNPs have
been associated with lung function decline (Barton et al., 2009, Koppelman and Sayers,
2011).
Over-expression studies involving mPLAUR and scPLAUR, confirmed a role for the
receptor in bronchial epithelial cells with PLAUR and scPLAUR attenuating wound
repair and scPLAUR independently doubling the rate of cellular respiration. This
therefore identified a role for scPLAUR in the bronchial epithelium independently of
the membrane-bound receptor such as that recently described by Wei et al. in the
kidney disease, focal segmental glomerulosclerosis (FSGS) (Wei et al., 2011, Wei et al.,
2008). Here the authors describe how circulating levels of scPLAUR independentlyȾ3 integrin, resulting in the modulation of the disease and therefore
suggesting that scPLAUR is essential for disease development and not simply a by-
product of disease. The migration and cellular respiration results obtained on cultured
NHBECs presented in this thesis, combined with data identifying an elevation of
scPLAUR in disease with pronounced airway remodelling, allows one to hypothesise
that scPLAUR may act in a similar way in asthma and COPD. Here scPLAUR may
directly modulate the changes occurring in the airway, such as dysregulation of the rate
of wound repair and the rate of proliferation, which are reflective of airway
remodelling, independently of other forms of PLAUR. This in turn is at least in part
driven by effects of specific PLAUR SNPs on expression levels.
Failure, in the same dataset, to associate lung function and bronchial hyper-
responsiveness to circulating levels of scPLAUR may seem surprising in light of the
originating studies that identified the PLAUR gene as a gene involved in BHR and lung
function (Barton et al., 2009, Stewart et al., 2009). However, this may be explained if
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one considers that SNPs may regulate any of the different forms of PLAUR and ergo, the
reported gene-based effect on lung function decline may not be due to scPLAUR. Also,
there are fundamental differences between the analysed datasets. Firstly, while the
original analysis identified the main genetic evidence in children with asthma, the
dataset analysed in this thesis dealt with a general population. Secondly, this work has
looked at a cross-sectional measurement of lung function, which differs from the
measurements originally reported both by Barton et al and Stewart et al., which were
longitudinal in nature. Therefore, if the effects of PLAUR on lung function are exclusive
to changes in decline of lung function over a period of time, it would be unsurprising
that an association would not be detected by investigating scPLAUR levels at only one
time point.
In order to identify novel regulatory networks, a genome-wide association approach
was used. This method allows for the examination of genetic variants over multiple
individuals identifying, in a hypothesis-free environment, novel variants associated
with a trait. Using this method, potential obscure regulatory pathways for scPLAUR
expression could be identified, that would otherwise not be identified by traditional
methods of detection for novel regulatory pathways, such as familial inheritance
studies using genetic linkage. In this thesis, GWAS identified a novel scPLAUR
regulatory protein, Human Plasma Kallikrein (KLKB1). KLKB1 was found to regulate
scPLAUR through a novel mechanism, that is, proteolytic cleavage in the DI region of
PLAUR and lateral to the DIII region. Although this novel regulatory mechanism was
present in the general population, KLKB1 activity was significantly attenuated in both
asthmatics and COPD subjects. Alteration in KLKB1 function may therefore go some
way in explaining the elevations of scPLAUR identified in the asthmatic and COPD
populations and therefore may also be an important part of the cellular dysfunction
process regulated by PLAUR. Importantly, the process of determining this novel
regulatory mechanism was, at the time of writing, the first procedure by which a hit
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from a GWAS was followed on and confirmed at the protein level. This has highlighted
the limitations of attempting to define regulatory procedures solely through changes in
mRNA levels. Indeed, attempts to replicate the protein-based association on an mRNA-
based bioinformatics platform and on total cellular mRNA both failed to highlight
association. Also, recent investigations to determine genetic variants affecting gene
expression in human lung tissue did not highlight the KLKB1 locus as a expression
quantitative trait locus (eQTL)(Hao et al., 2012).
Transcription regulation studies have confirmed that in primary normal human
bronchial epithelial cells, the minimal promoter region lies in the first 199bp
downstream of the TSS, as previously reported (Dang et al., 1999, Soravia et al., 1995).
However, this work is the first to report a region between 490bp and 887bp
downstream of the TSS as being an additional PLAUR 5`UTR regulatory region. Also the
3`UTRs of the PLAUR gene for both full length and soluble spliced were determined to
have an overall suppressor role on PLAUR mRNA expression, which is also novel, being
the first description of 3`UTR directed gene suppression for PLAUR. This therefore
confirms the general outlook on PLAUR expression in that it is a balance between
5`UTR (transcriptional) and 3`UTR (post-transcriptional) events. Investigations into
how stimulations relevant to the asthmatic and COPD lung affected PLAUR gene
expression identified that changes in PLAUR expression driven by scratch wounding
(Stewart et al., 2012) were not driven by either 5`UTR (corresponding to the limited
5`UTR investigated) or 3`UTR driven regulatory effects. This suggests that changes in
PLAUR expression levels in NHBECs, driven by wounding of the bronchial epithelium,
probably occur distally to those includeg in the reporter constructs (see Section 7.3).
These could include intragenic regions, as well as lateral regions to the 5`UTR and
3`UTR constructs used. Stimulation by cigarette smoke extract similarly has no effect
on expression of the PLAUR gene driven by the investigated 5`UTR. However, it does
appear to fully negate the 3`UTR driven suppression of the PLAUR gene that encodes
300
the soluble spliced form of the receptor. Protein and mRNA-based experiments
confirmed that cigarette smoke extract specifically elevates ssPLAUR but does not
affect the expression of full length PLAUR. This is of special interest when considering
that ssPLAUR over-expression experiments identified a substantial increase in the rate
of NHBEC cellular respiration driven by ssPLAUR independently of the full length
membrane bound receptor. Using the hypothesis that the rate of cellular respiration
indicates a change in the rate of cellular proliferation, one is able to putatively link
ssPLAUR to one of the mechanisms by which cigarette smoke affects the airways. This
suggests that ssPLAUR may also have a role in airway remodelling and more
importantly it could be the significantly contributing molecule behind PLAUR driven
changes in the airways caused through smoke inhalation, i.e. changes occurring in
COPD. This work is the first to identify a role for ssPLAUR and is also the first to
identify the way by which this form of the receptor is transcriptionally regulated under
both basal and stimulated conditions.
PLAUR is known to be an extensively polymorphic gene with 1315 polymorphisms
identified by the 1000 genomes project within the gene region (Chr 19:44150247-
44174498). The highly polymorphic nature of the gene makes it likely that further
undefined variation is present within the gene and its untranslated regions that could
affect general and disease-specific gene expression. Next generation sequencing of the
PLAUR gene and its lateral regions has identified a number of novel variants and novel
rare variants, substantially increasing the knowledge on variation for this gene and its
regulatory regions. A number of variants were determined to lie within the genes
coding region and result in changes to the amino acid structure of the receptor, which
makes these variants likely to have a role in affecting receptor gene structure and
function. This analysis has also identified a number of variants that are exclusively
present in the pool of severe asthma subjects. These may therefore contain gene
regulatory elements that drive altered gene expression in disease.
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7.3 LIMITATIONS
The work in this thesis however has not been without its limitations. In the first results
chapter experimentation was carried out in a cohort of unrelated asthmatic individuals.
However, the study by Barton et al., from which this study has progressed, consisted of
a study in a family cohort of two disease affected sibling pairs. Therefore, results of
PLAUR SNP association studies must be considered in the light of:
a) The use of a different population in the original study, in which it is likely that
the disease phenotype is altered (children tend to express atopic asthma with
higher reversibility and are expected to be non-smokers) and
b) Analyses carried out in a cross sectional format (FEV1 and FEV1/VC at one time-
point) as opposed to the longitudinal study (decline in FEV1) carried out in the
original study.
This may therefore in part explain the lack of replication for the association between
lung function and PLAUR SNPs/scPLAUR levels occurring in this thesis.
In the second chapter a GWAS was undertaken; generally GWA studies require large
populations in order to have the power to detect positive associations. The populations
used in this chapter however were relatively small, with a control population of 104
and an asthma population of 480. Therefore it is highly probable that a number of
regions that are in actual fact associated with scPLAUR serum levels did not achieve
genome-wide significance in this study due to a low power of detection driven by small
population sizes. This is highlighted by the detection of a number of other associated
regions when using less stringent criteria that made biological sense such as Factor XII
and NRG1, which are either known to directly interact with PLAUR or the PLAUR
associated pathways. A true replication of the GWAS in an alternate population, which
could have confirmed the association, was also not available at the time. The only
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attempt at duplication was carried out in the COPD population, however this was also
limited through small population numbers and by not being a true GWAS replication.
Finally, further limitations in this experimental design are that GWAS itself is only
powered to detect common variants (>5%), thereby missing potentially important
regulatory rare variants, and that the investigation was carried out using a first
generation platform containing ~300,000 SNPs, which gives significantly less coverage
than the platforms currently on the market (e.g. the Illumina Infinium Human
OmniExpress Exome BeadChip Kit that has over 700,000 genome-wide markers).
Therefore, it is highly probable that other serum scPLAUR regulatory regions,
describing other novel regulatory pathways, have been missed by this work.
In the third results chapter, successful introduction of a maximal length of 2584bp of
the 5`UTR meant that known polymorphisms in the 5`UTR that had been associated
with lung function and asthma (Table 7.1) were not investigated and therefore their
effect on PLAUR expression was not quantifiable.
SNP Location upstream of TSS
rs344779 3666bp
rs7259340 12331bp
rs11668247 20040bp
rs346043 20459bp
rs740587 22346bp
rs346043 20459bp
rs346054 30147bp
Table 7.1: Disease and lung function associated PLAUR SNPs not included in the Dual
Luciferase reporter assay. As these SNPs have been shown to be associated with disease and
changes in lung function it is likely that they may have an effect on PLAUR expression.
Inability to include these SNPs into the dual reporter assay serves as a limitation when
investigating 5`UTR driven changes in PLAUR expression.
Recent developments by ENCODE have confirmed this limitation in the approach
utilised in this thesis to determine 5`UTR driven transcriptional regulation.
Visualisation of the untranslated regions in the UCSC genome browser (Rosenbloom et
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al., 2012) (see Section 5.5, Figure 5.29) identifies a transcriptionally relevant region, as
defined by the ENCODE dataset, ~5kb upstream of the transcriptional start site
confirming that experimentally an important regulatory region has been missed in the
dual-luciferase assay. Also, ENCODE has determined that gene promoters are strongly
regulated by long-range distal elements interacting with the promoter via a looping
mechanism, most of which (>93%) do not interact with their closest gene (Sanyal et al.,
2012). This suggests that gene promoter regulation is more complex than the model
assumed in a dual-luciferase assay, i.e. a linear promoter region distal to the gene it
regulates which extends to a certain distance upstream of the TSS and independently
regulates gene expression.
Finally in the fourth results chapter, next-generation sequencing analysis has been
limited through low capture due to bait design and lack of enrichment, especially with
regards to rare variants. Therefore, while it is unlikely that the dataset has generated a
set of false positive results, it is highly probable that a large number of false negatives
have been generated and so a large number of PLAUR variants have not been detected
by this analysis, especially when considering rare variants.
However, although it is appreciated that the work presented in this thesis has its
limitations, these limitations are concerned with the generation of false negatives, and
so do not detract from any of the findings presented.
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7.4 PROPOSED FURTHER WORK
While this work has attempted to investigate the regulation of PLAUR gene expression,
further work is still necessary to fully define the regulatory mechanisms involved in
determining both mRNA and protein levels in health and respiratory disease. Full
understanding of the regulatory process of PLAUR would require the inclusion of
techniques such as the Chromosome Conformation Capture technique, DNase
footprinting assay and the ChIP-on-chip method. These methods allow for
determination of the structural properties and spatial organization of chromosomes
important to the regulation of gene expression and the determination of interactions
between proteins such as histones and transcription factors with DNA in vivo,
respectively.
Suggested future work more closely related to the presented work would include
investigation into the effect of PLAUR 5`UTR SNPs on gene regulation. Using the
plasmid constructs built in this thesis, site-directed mutagenesis could be used to
introduce mutations translating to SNPs rs4251805 and rs2356338. These are located
at the 119bp and 649bp regions downstream of the TSS respectively, regions
determined to be important to basal gene transcription. Other work involving the
5`UTR SNPs could be carried out by introducing small fragments containing asthma
and lung function SNPs up to 10kb downstream of the TSS, to investigate whether gene
folding, which may bring the SNPs in close proximity to the core promoter region, has
any effect on basal PLAUR transcription. Although this work has successfully identified
regulatory effect of the 3`UTR in mPLAUR and ssPLAUR expression, the mechanism is
still not fully understood. In silico based analysis has identified a number of potential
miRNA regulators and therefore experiments using these miRNAmimics and inhibitors
would be useful in determining whether these molecules play a role in 3`UTR driven
PLAUR regulation. Recent publications have also identified a number of miRNAs whose
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expression in the airways is driven by the exposure of cigarette smoke (Pottelberge et
al., 2011, Schembri et al., 2009, Izzotti et al., 2009), which putatively bind to the
ssPLAUR 3`UTR. Inclusion of these miRNAs into a future study would also be of interest
in light of the cigarette smoke extract driven changes in ssPLAUR 3`UTR regulation.
Results presented in this thesis also present scope for further work by presenting new
questions about the role and regulation of PLAUR. The identification of KLKB1 as a
novel regulator of scPLAUR expression raises the question whether this novel
mechanism is relevant in scPLAUR associated disease such as focal segmental
glomerulosclerosis and obstructive lung disease. This is especially relevant when
considering the statistically significant difference in KLKB1 activity determined
between control and asthma/COPD populations (see Chapter 4). This could be
addressed through quantification of KLKB1 expression in the plasma of disease
populations. Identification of a role for scPLAUR and ssPLAUR raises the question of
what further processes these molecules are involved in. In order to obtain a complete
understanding of the potential role of PLAUR it would be pertinent to use animal
models. Animal studies using knockout and overexpressing mouse models would allow
investigation of either scPLAUR or ssPLAUR driven effects in a complex living model
rather than in simple single cell in vitromodels.
Finally, although a number of novel variants have been determined through next
generation sequencing for the PLAUR gene and its untranslated regions, the
experimental set-up used in this thesis has not allowed for the direct identification of
common and rare variants that drive the expression levels of PLAUR. Identification of
such variants can achieved through the design of a novel next generation sequencing
experiment where the frequency of detected variants across pools of subjects stratified
according to plasma scPLAUR expression levels are compared.
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7.5 CONCLUSIONS
In conclusion, this work has identified an association between scPLAUR levels in serum
and the obstructive lung diseases asthma and COPD. Regulation of serum scPLAUR has
been determined to involve proteolytic cleavage by KLKB1 at the PLAURs DI region
and adjacent to the DIII region and scPLAUR having a probable role in modifying
epithelial functions independently of the membrane bound receptor. Transcriptional
regulatory studies have confirmed that the PLAUR minimal promoter in bronchial
epithelial cells lies in the first 199bp downstream of the TSS and identified that PLAUR
regulation is additionally driven by a region between 490 and 887bp downstream of
the TSS as well as the 3`UTR (both membrane and soluble spliced forms). While scratch
wounding did not alter PLAUR regulation, exposure to cigarette smoke extract nullified
the suppressor role of the soluble spliced receptors 3`UTR, resulting in an elevation of
ssPLAUR, which this work has identified, has a probable role in modulating changes in
the airway through a possible effect on epithelial cell proliferation rates. Various novel
variants have been detected for PLAUR, including a number of rare variants and coding
region SNPs as well as disease specific variants that substantially add to knowledge
about variation in the PLAUR gene and its untranslated regions.
Apart from furthering the general understanding of the urokinase plasminogen
activator receptor, these data have also confirmed a role for the receptor as a marker
and modulator of asthma and COPD. In this way, these data have also addressed the
originating hypothesis for this work, increasing the volume of evidence identifying that
the various forms of PLAUR are important molecules that drive and maintain the
asthma and COPD phenotype.
APPENDICES
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APPENDIX I - BUFFERS AND SOLUTIONS
1. 50x TAE buffer: Add 57.1ml glacial acetic acid to 242g Tris base and 100ml
0.5M EDTA at pH 8. Make up to 1l with deionised WATER. Dilute 1 in 50 to
make 1x TAE buffer when required.
2. 6x Orange G loading dye:Make up 30% glycerol (v/v) in deionised water. Add
Orange G dye to make a solution of 0.25%w/v.
3. 1Kb and 100bp DNA ladders (ready to use):  ? ? ?Ɋ ?ǡ ? ?Ɋ  ? ? ?  ǡ   ? ? ?Ɋ  ? ?  ?   ? ? ?Ɋ   ?  
   Ǥ     ? ? ? ?Ɋ   ? ? ?Ɋ  
sterile water. Store in aliquots at -20°C.
4. LB (Lysogeny Broth) Agar: Add 400ml sterile water to 16g Miller LB agar.
Autoclave immediately and store at room temperature.
5. LB agar plates with antibiotics: Melt the LB agar (see above) slowly until
melted and starting to boil. Allow to cool to approximately 32°C. Add ampicillin         ? ? ?ɊȀ   ? ?ɊȀ
respectively, and mix quickly. Pour 25ml agar per plate and allow to set for 30
minutes. Store upside down, to prevent condensation dripping onto the agar, at
4°C.
6. LB broth: Add 500ml sterile water to 12.5g Miller LB broth powder. Autoclave
immediately and store at room temperature.
7. 5x Reducing gel loading buffer: Add 5.2ml 1M Tris (pH 6.8) to 1g DTT and  Ǥ   ?Ǥ ?   Ǥ   ?Ǥ ?   ? ? ?Ɋ  ? ? ?
bromophenol blue. Mix by linear oscillation for at least 30 minutes. Divide into ? ? ?ɊǦ ? ?Ǥ
8. 10x Tris-Glycine-SDS running buffer (250mM Tris base, 1.92M glycine, 1%
SDS): Add 800ml sterile water to 30.3g Tris base, 144g Glycine and 100ml 10%
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SDS. Stir to dissolve. Add sterile water to a final volume of 1l. Do not adjust pH
and store at room temperature. Dilute 1:10 to make 1x Tris-Glycine-SDS
running buffer when required.
9. 10x Tris-Glycine transfer buffer (250mM Tris base, 1.92M glycine): Add
800ml sterile water to 30.3g Tris base and 144g Glycine. Stir to dissolve. Add
sterile water to a final volume of 1l. Do not adjust pH and store at room
temperature. Dilute 1:10 to make 1x Tris-Glycine transfer buffer when
required. Do not adjust pH and store at 4°C.
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APPENDIX II  DETAILS OF LONZA NHBECS
Donor 7F3158 7F3206
Age 56 50
Sex Male Male
Race Caucasian Caucasian
Seeding Efficiency 31% 45%
Viability Blue Exclusion 70 75
Doubling Time 24 21
Drinks Alcohol Yes Yes
Smoker Yes Yes
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APPENDIX III - RESEARCH CIGARETTE 3R4F ANALYSIS
Cigarette Design Criteria
Cigarette Length 84 mm
Tobacco Rod Circumference 24.8 mm
Tobacco rod Length 57 mm
Filter Length 27 mm
Total Resistance to Draw (RTD) 128 mm H2O
Tar 9.5 mg/cigarette
Cigarette Rod Cigarette Filter
Filter 3R4F Blend Tow
Cellulose
Acetate
2.9/41,000
Cuts per Inch 30 Plasticizer 9% Triacetin
Paper Permeability 24 CORESTA
units
4-upResistance
toDraw
115 mm H2O
Paper Citrate 0.60 % Circumference 24.45 mm
TobaccoWeight
(13%OV)
0.783 mg Length 27 mm
Length 57 mm
Target Total Cigarette
Tipping Paper Length 32 mm, white
Dilution 30 +/- 5%
Circumference 24.8 mm
Length 84 mm
Resistance to Draw 128 mm H2O
Weight 1.06 g
Pack Moisture 13%Oven Volatiles
Final Total Cigarette Measurements (n = 11)
Dilution 29 (4.2) %
Circumference 24.9 (0.07) mm
Total Resistance to Draw 133.5 (4.45) mmH2O
CigaretteWeight 1.05 (0.002) g
Tobacco Weight 0.775 (0.001) g
Pack Moisture 12.9 (0.33)%Oven Volatiles
Firmness 2.43 (0.113) mm
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Preliminary FTC Smoking Results Average
Butt Length 35 mm
Puff Count 9.0 (0.112)
Total Particulate Matter, TPM 10.9 (0.168) mg/cigarette
Tar 9.4 (0.142) mg/cigarette
Nicotine 0.726 (0.009) mg/cigarette
CarbonMonoxide 11.9 (0.208) mg/cigarette
Final FTC Smoking Results Average (n=12)
Puff Count 9.0 (0.15)
Total Particulate Matter, TPM 11.0 (0.33) mg/cigarette
Tar 9.4 (0.30) mg/cigarette
Nicotine 0.73 (0.013) mg/cigarette
CarbonMonoxide 12.0 (0.48) mg/cigarette
Preliminary Filler Analysis
Total Alkaloids 1.98% (.04) at 13%Oven
Volatiles
Reducing Sugars 8.4 % (0.4) at 13%Oven Volatiles
Glycerin 2.7 % (0.1) at 13%Oven Volatiles
Final Filler Analysis (n=23)
Total Alkaloids (as-is) 2.05% (0.04) at 11.6%Oven
Volatiles
Reducing Sugars (as-is) 8.7% (0.3) at 11.6%Oven
Volatiles
Glycerin (as-is) 2.36% (0.05) at 11.6%Oven
Volatiles
Blend Summary 2R4F 3RF4
Flue Cured 32.51 % 35.41%
Burley 19.94 % 21.62%
Maryland 1.24 % 1.35%
Oriental 11.08 % 12.07%
Reconstituted (Schweitzer
Process)
27.13 % 29.55%
Glycerin (dry-weight basis @ 11.6% OV) 2.80 % 2.67%
Isosweet (Sugar) 5.30 % 6.41%
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APPENDIX IV - FULL LIST OF VARIANTS CALLED BY NEXT-
GENERATION SEQUENCING IN A COMBINED ASTHMA AND
CONTOL COHORT
Position Type
Major/Minor
Alleles
Frequency
(Cases)
Frequency
(Controls)
44196927 SNP C|A 0.0041 1.00E-04
44156419 SNP G|A 0.005 1.00E-04
44188641 SNP A|T 0.0061 1.00E-04
44200795 SNP G|A 0.0087 1.00E-04
44167224 SNP T|A 0.0091 1.00E-04
44202308 SNP T|C 0.0111 1.00E-04
44177686 Insertion C|CT 0.004 2.00E-04
44177685 SNP G|T 0.0041 2.00E-04
44159722 SNP C|T 0.0056 2.00E-04
44184816 SNP G|A 0.0065 2.00E-04
44204928 SNP G|T 0.0045 3.00E-04
44173484 SNP G|T 0.0055 3.00E-04
44149992 SNP G|A 0.0067 5.00E-04
44148884 SNP G|C 0.0061 8.00E-04
44149557 SNP C|G 0.0064 0.0012
44195188 SNP C|T 0.0069 0.0021
44186622 SNP G|A 0.0055 0.0024
44157254 Deletion TG|T 0.0058 0.0029
44159198 SNP C|G 0.0088 0.0031
44150085 SNP G|T 2.00E-04 0.0033
44155605 SNP G|T 0.0106 0.0036
44180769 SNP T|G 0.0023 0.0038
44191490 Insertion G|GCC 0.0064 0.0039
44206434 SNP C|G 1.00E-04 0.0041
44163558 SNP G|A 0.0017 0.0041
44168210 SNP T|C 0.0159 0.0042
44145481 SNP C|T 2.00E-04 0.0043
44196517 SNP G|A 1.00E-04 0.0047
44166621 SNP G|T 0.0013 0.0047
44184671 SNP G|A 0.004 0.0047
44208803 SNP G|T 1.00E-04 0.0048
44159200 SNP G|T 0.0147 0.0048
44159201 SNP A|C 0.0149 0.0049
44168870 SNP G|A 1.00E-04 0.005
44187178 SNP C|T 0.0099 0.005
44197509 SNP G|C 4.00E-04 0.0053
44153248 SNP T|C 0.0014 0.0054
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44192726 SNP G|A 0.0181 0.0059
44182729 SNP A|C 0.004 0.006
44207022 SNP G|A 0.0124 0.006
44145626 SNP G|A 0.0172 0.006
44204952 SNP T|C 0.0043 0.0063
44148866 Insertion A|AC 0.0117 0.0066
44180322 SNP T|G 0.0018 0.0068
44173227 SNP G|A 0.0073 0.0068
44159202 SNP C|T 0.0148 0.0074
44202687 SNP C|T 0.0139 0.0077
44165924 SNP C|T 0.0031 0.008
44191724 SNP G|T 0.0106 0.008
44193332 SNP C|T 0.0017 0.0082
44189517 Insertion A|AC 0.0153 0.0082
44194305 SNP G|A 0.0084 0.0083
44202100 SNP C|T 0.0106 0.0086
44149651 SNP G|T 0.0182 0.0089
44172130 SNP T|C 0.0101 0.009
44191545 SNP G|A 0.0086 0.0091
44191726 SNP C|T 0.0057 0.0092
44180328 Deletion GCC|G 0.0071 0.0093
44180424 SNP G|A 0.0092 0.0093
44184981 SNP A|T 0.0132 0.0093
44179442 SNP C|G 0.0173 0.0095
44149326 SNP G|A 0.0073 0.0096
44193668 Deletion AT|A 0.0149 0.0097
44143205 Deletion CAG|C 0.0017 0.0099
44199474 Deletion AG|A 0.0144 0.01
44186061 SNP G|A 0.0138 0.0101
44197488 Deletion GTA|G 0.0107 0.0106
44196433 SNP G|A 0.0142 0.0109
44167962 SNP C|A 0.0068 0.0114
44160393 SNP C|A 0.005 0.0116
44149289 SNP T|A 0.0033 0.0119
44190172 Deletion GT|G 0.0082 0.012
44202978 SNP A|G 0.0147 0.0121
44158630 SNP C|G 0.006 0.0123
44197478 SNP G|T 0.0142 0.0124
44202840 SNP A|T 0.0093 0.0125
44191629 SNP T|C 0.0034 0.0128
44186575 SNP C|A 0.0151 0.0129
44166075 SNP G|A 0.0013 0.0132
44190034 Insertion C|CA 0.019 0.0133
44182396 SNP T|C 0.0191 0.0135
44188204 Insertion C|CA 0.0195 0.0136
44170629 SNP C|T 0.0043 0.0137
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44205241 Insertion T|TG 0.0096 0.0137
44201075 SNP G|T 0.0183 0.0137
44153799 SNP G|A 0.0121 0.0139
44175090 SNP C|G 0.0133 0.0139
44190252 Insertion G|GC 0.0153 0.014
44202146 Deletion ATG|A 0.0185 0.0145
44191681 SNP T|G 0.0193 0.0145
44176880 Insertion T|TC 0.0162 0.0148
44190237 Deletion CA|C 0.029 0.0148
44174249 SNP C|T 0.0033 0.0149
44144997 SNP SNP G|A 0.02 0.015
44186619 SNP A|T 0.022 0.0152
44187496 SNP T|C 0.008 0.0154
44206930 SNP T|C 0.0267 0.0154
44149281 Insertion T|TA 0.0182 0.0156
44153794 SNP A|G 0.0163 0.0157
44192091 SNP C|T 0.0136 0.0159
44142740 SNP C|T 0.0044 0.0166
44160401 SNP T|C 0.0125 0.0166
44205257 SNP G|C 0.0146 0.0166
44160412 Deletion AT|A 0.0145 0.0167
44206242 SNP A|G 0.0135 0.0169
44160383 SNP T|C 0.013 0.017
44166565 Insertion A|AC 0.0107 0.0173
44147348 SNP T|A 0.0137 0.0175
44180267 SNP T|C 0.0112 0.0176
44205063 Deletion CT|C 0.016 0.018
44184984 SNP T|A 0.023 0.018
44189749 SNP C|T 0.0133 0.0182
44200549 SNP T|C 0.0137 0.0182
44155607 SNP G|A 0.0087 0.0183
44159456 Deletion TG|T 0.0177 0.0184
44177861 SNP C|T 0.0039 0.0186
44206036 SNP C|T 0.0411 0.0192
44169465 SNP C|T 0.0189 0.0196
44202833 Deletion GA|G 0.0189 0.0196
44197479 Deletion TG|T 0.0263 0.0197
44186263 SNP C|A 0.0184 0.0198
44161111 SNP C|T 0.0241 0.0199
44164336 Insertion G|GTTTTGTTTTA 0.0195 0.02
44146296 Deletion CCA|C 0.0171 0.0202
44160421 SNP T|A 0.0191 0.0205
44161618 SNP G|A 0.0358 0.0205
44165566 SNP T|G 0.0282 0.021
44182160 SNP G|C 0.0197 0.0212
44164338 SNP G|T 0.0205 0.0212
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44154319 SNP T|C 0.0157 0.0213
44187802 SNP G|A 0.0192 0.0213
44195183 SNP A|G 0.0083 0.0214
44185006 SNP T|G 0.0198 0.0214
44197477 Deletion TG|T 0.0286 0.0215
44197460 SNP G|C 0.0128 0.0218
44154950 Insertion G|GC 0.0204 0.0219
44191720 SNP C|G 0.0208 0.0223
44170973 SNP A|G 0.0173 0.0224
44154324 SNP A|G 0.0181 0.0229
44197430 Insertion T|TA 0.0228 0.0229
44152286 SNP T|A 0.0373 0.0232
44194459 SNP T|C 0.0244 0.0236
44184987 SNP T|C 0.0289 0.0237
44197657 Deletion AT|A 0.0179 0.0239
44152426 SNP G|C 0.0138 0.0241
44153255 SNP G|A 0.0154 0.0246
44190229 Insertion C|CA 0.0287 0.0246
44150963 SNP T|G 0.0214 0.0248
44202643 SNP T|C 0.008 0.0256
44203307 SNP G|A 0.0209 0.0257
44153824 Deletion AGAAG|A 0.0208 0.026
44144598 Insertion A|AG 0.0186 0.0261
44176882 Insertion G|GC 0.0283 0.0262
44190191 Deletion GC|G 0.0256 0.0267
44168134 SNP C|G 0.0319 0.0273
44173987 Deletion CA|C 0.0258 0.0274
44192552 Deletion CTCTG|C 0.0182 0.0276
44151687 SNP G|A 0.0143 0.028
44152151 SNP C|T 0.0226 0.0285
44161149 SNP G|A 0.0237 0.0286
44190241 Insertion A|AC 0.0337 0.029
44180333 SNP T|C 0.0378 0.029
44164483 SNP A|G 0.027 0.0291
44179027 Deletion TTTG|T 0.0283 0.0295
44209414 Insertion G|GA 0.032 0.0298
44179646 Deletion GAC|G 0.0326 0.0298
44175982 SNP C|T 0.0298 0.0303
44207790 SNP C|T 0.0222 0.0305
44151987 SNP G|A 0.0253 0.0306
44209364 Insertion T|TCC 0.033 0.0307
44153785 SNP A|G 0.0247 0.031
44152495 SNP A|G 0.0184 0.0313
44190582 SNP G|A 0.0349 0.0319
44152414 SNP A|G 0.0194 0.0321
44185010 SNP T|G 0.0329 0.0323
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44190230 Insertion A|AGG 0.0419 0.0324
44151183 SNP C|T 0.0221 0.0326
44184216 SNP T|A 0.0386 0.0326
44180290 SNP A|G 0.0374 0.0327
44152367 SNP A|G 0.0157 0.0331
44185005 SNP A|T 0.033 0.0331
44173984 Deletion AAG|A 0.0285 0.0333
44202979 SNP G|A 0.0403 0.0337
44154341 SNP C|T 0.0266 0.0341
44164533 SNP G|A 0.057 0.0343
44152091 SNP T|C 0.042 0.0346
44179910 Deletion CAG|C 0.04 0.0347
44176884 Deletion TA|T 0.0316 0.0351
44174441 SNP C|T 0.0291 0.0352
44150095 Deletion GT|G 0.033 0.0353
44152585 SNP A|T 0.0228 0.0357
44183623 Insertion C|CTCAAAAA 0.0388 0.0364
44191719 SNP T|G 0.0425 0.0365
44180334 SNP G|C 0.0506 0.0365
44166187 SNP A|C 0.0542 0.0366
44146462 SNP T|A 0.0394 0.037
44176871 Insertion A|ATGCATCAGCT 0.0423 0.0374
44162297 SNP A|G 0.0371 0.038
44153003 SNP C|T 0.0187 0.0392
44151770 SNP A|C 0.0218 0.0392
44149900 SNP C|T 0.0318 0.0398
44153898 Deletions GA|G 0.0366 0.041
44157857 SNP T|C 0.0473 0.0412
44200203 Insertion T|TA 0.0335 0.0414
44206074 Insertion C|CA 0.0483 0.0416
44170593 SNP C|T 0.0265 0.0422
44167949 SNP C|A 0.0563 0.0427
44202961 SNP G|A 0.0297 0.0431
44209334 SNP C|A 0.0398 0.0442
44186618 Deletion A|AT 0.0446 0.0453
44198172 SNP G|T 0.0489 0.0459
44193729 SNP C|T 0.053 0.0476
44146459 SNP G|A 0.043 0.0479
44157612 SNP C|G 0.0532 0.048
44150864 SNP G|T 0.0502 0.0485
44162194 Deletion TA|T 0.0453 0.0486
44160133 SNP G|A 0.0464 0.0502
44206291 SNP T|C 0.041 0.0506
44189348 Insertion A|AC 0.053 0.0506
44164337 SNP A|T 0.0455 0.051
44185009 SNP A|T 0.0556 0.0514
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44160868 SNP A|G 0.0374 0.0515
44202660 SNP A|G 0.048 0.0516
44155868 SNP G|A 0.0539 0.0521
44201206 Deletion AATTTT|A 0.0338 0.0524
44159377 SNP G|A 0.0537 0.0529
44159365 SNP T|G 0.0553 0.0535
44187494 SNP C|T 0.0482 0.054
44176935 Deletion AG|A 0.0668 0.0542
44161498 SNP C|G 0.0428 0.0549
44159280 SNP T|C 0.0543 0.0554
44176883 Deletion C|CTAT 0.0637 0.0557
44189286 SNP A|T 0.0471 0.0558
44158528 SNP G|T 0.0575 0.0558
44206278 SNP A|C 0.041 0.0559
44161573 SNP G|C 0.0467 0.0559
44154218 SNP C|T 0.0506 0.0561
44157776 SNP C|A 0.064 0.0563
44143612 SNP T|C 0.0586 0.0564
44189160 SNP C|T 0.0397 0.0567
44147349 SNP A|T 0.06 0.0567
44161486 SNP T|A 0.0427 0.0569
44162115 SNP G|T 0.0618 0.0569
44197788 Deletion AG|A 0.0395 0.057
44161081 SNP A|T 0.0467 0.0573
44184997 Deletion A|AC 0.0613 0.0574
44158016 SNP G|A 0.0561 0.0578
44156600 SNP G|A 0.0559 0.058
44151698 SNP C|T 0.0657 0.058
44180332 SNP G|C 0.0627 0.0586
44156741 SNP C|T 0.0561 0.0591
44201920 SNP T|C 0.057 0.0593
44162199 Insertion A|AC 0.0492 0.0596
44196889 SNP G|T 0.0416 0.0601
44162144 SNP T|C 0.0714 0.0603
44159489 SNP G|A 0.0733 0.0608
44156118 SNP C|T 0.0813 0.0609
44200667 SNP C|A 0.0561 0.061
44186820 Insertion C|CA 0.0616 0.0618
44206883 SNP C|T 0.0423 0.0619
44162145 SNP G|A 0.0708 0.0625
44201167 SNP C|T 0.0481 0.0626
44161781 SNP T|C 0.0464 0.0634
44209348 SNP T|G 0.0476 0.0641
44162233 SNP A|G 0.0762 0.0641
44184990 SNP T|A 0.0702 0.0643
44158004 SNP G|A 0.0619 0.0651
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44159876 SNP G|A 0.0414 0.0654
44202704 SNP T|C 0.0701 0.0655
44198947 Deletion AAC|A 0.0424 0.0658
44198884 SNP G|A 0.0457 0.0664
44186617 SNP G|A 0.0752 0.0673
44202701 SNP A|G 0.0716 0.068
44198377 SNP G|A 0.0758 0.0683
44153775 Deletion AAAAG|A 0.0791 0.0688
44161050 SNP C|A 0.0576 0.0698
44157156 SNP A|G 0.0648 0.0698
44187577 SNP A|G 0.0484 0.0709
44151525 SNP C|T 0.0567 0.0709
44159819 SNP T|C 0.0626 0.0709
44186577 Insertion A|AGTC 0.0508 0.0724
44200928 SNP G|C 0.0556 0.0726
44206375 SNP G|A 0.0415 0.0727
44202920 SNP A|C 0.0618 0.0732
44205852 SNP G|A 0.0555 0.0739
44199523 SNP C|T 0.0512 0.0745
44177700 SNP C|T 0.1073 0.075
44198376 SNP C|G 0.0638 0.0757
44206922 Insertion C|CTT 0.0644 0.0757
44198020 Insertion AG|A 0.0753 0.0757
44184996 SNP T|A 0.0822 0.0761
44184993 Insertion A|AC 0.0746 0.0765
44209093 Deletion AT|A 0.0859 0.0766
44163471 SNP G|A 0.0794 0.077
44197098 Insertion C|CA 0.0727 0.0773
44155355 SNP C|T 0.082 0.079
44180292 SNP G|T 0.0873 0.0791
44163594 SNP G|A 0.1172 0.0792
44200246 Insertion C|CA 0.0522 0.0795
44167978 Deletion CA|C 0.0889 0.0804
44197490 SNP A|G 0.0863 0.0824
44188104 SNP C|T 0.0854 0.0826
44200812 SNP C|T 0.0522 0.0839
44188002 SNP C|G 0.0552 0.0843
44182486 SNP G|A 0.0798 0.0854
44188485 SNP C|T 0.0768 0.0864
44202855 SNP A|T 0.0519 0.0868
44201312 SNP C|T 0.0564 0.0877
44176124 Deletion GT|G 0.0909 0.0897
44164271 Insertion T|TGCG 0.0883 0.09
44199926 SNP G|A 0.0611 0.0908
44149661 SNP G|T 0.1071 0.0919
44164305 Insertion C|CGTTTT 0.0879 0.0936
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44183635 SNP G|A 0.0883 0.0942
44149322 SNP G|A 0.0902 0.0948
44149283 SNP T|A 0.0969 0.0965
44160417 SNP T|A 0.0937 0.0973
44186616 Deletion TGA|T 0.1117 0.0979
44197458 SNP G|C 0.0958 0.0981
44176869 SNP T|A 0.1075 0.0986
44197440 Deletion CTGTGTGTG|C 0.0926 0.0992
44207318 SNP C|T 0.0786 0.1011
44158277 Deletion GA|G 0.1099 0.1042
44149275 Deletion AGT|A 0.0983 0.1067
44184986 SNP T|A 0.1002 0.1072
44209257 Insertion T|TGGTC 0.1249 0.1082
44176867 Deletion TC|T 0.1255 0.1089
44167953 SNP A|C 0.1089 0.1098
44202101 Insertion A|AAC 0.1134 0.1098
44176872 SNP T|G 0.1087 0.1105
44176946 SNP A|G 0.1305 0.1123
44165783 SNP G|A 0.115 0.1127
44177028 Deletion GCATTCTCCAC|G 0.105 0.1129
44149660 Deletion TG|T 0.1207 0.1134
44151621 SNP T|C 0.1306 0.115
44154472 SNP T|G 0.1295 0.1165
44197452 SNP G|C 0.1117 0.1176
44197454 SNP G|C 0.1122 0.1182
44206241 Deletion GA|G 0.1131 0.1194
44149324 SNP A|G 0.1161 0.12
44197456 SNP G|C 0.1147 0.1207
44164478 SNP C|T 0.1236 0.1216
44184992 SNP T|A 0.118 0.1225
44176947 SNP C|T 0.1435 0.1242
44202965 Deletion CA|C 0.1171 0.1255
44154170 Deletion GT|G 0.1133 0.1257
44159252 Insertion A|AC 0.1517 0.1259
44154473 SNP G|T 0.1418 0.1294
44201064 Deletion CTGT|C 0.1421 0.1325
44205337 SNP T|A 0.1632 0.1329
44142882 SNP T|C 0.144 0.1333
44205082 SNP G|A 0.1415 0.1339
44147333 Insertion C|CCTT 0.1478 0.1339
44164437 SNP T|C 0.176 0.1356
44164609 SNP G|A 0.1511 0.1368
44207803 SNP C|T 0.1717 0.1381
44177666 SNP A|T 0.1828 0.1393
44186621 SNP A|T 0.1514 0.1401
44164386 SNP C|T 0.156 0.1405
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44153100 SNP A|G 0.1528 0.1415
44163954 SNP C|T 0.1335 0.1433
44177049 SNP G|T 0.1417 0.144
44163994 SNP A|C 0.1354 0.1461
44155589 Deletion GT|G 0.1457 0.1486
44184977 Deletion TTTTATTTATTTATTTA|T 0.1519 0.1487
44183618 SNP C|T 0.1719 0.1502
44183619 SNP A|G 0.1711 0.1525
44165454 SNP G|A 0.1578 0.1527
44177057 TGCA|T 0.1521 0.1557
44165091 SNP G|A 0.1458 0.1558
44209418 SNP A|G 0.1603 0.1561
44178928 SNP C|T 0.1888 0.1576
44191717 SNP G|T 0.1559 0.1582
44163033 SNP T|G 0.1719 0.159
44183464 SNP A|C 0.1744 0.1598
44165065 SNP T|C 0.1427 0.1599
44178272 SNP A|G 0.1618 0.1606
44167452 Deletion TACACACAC|T 0.1569 0.1613
44183469 Insertion C|CA 0.1681 0.1613
44197450 SNP G|C 0.1496 0.1635
44163314 SNP C|T 0.1403 0.164
44163061 SNP T|C 0.1699 0.1659
44209319 SNP C|T 0.1756 0.1664
44146930 SNP C|A 0.1766 0.1665
44198146 Insertion A|ACTT 0.1597 0.1687
44191682 Insertion C|CATCGTG 0.1673 0.1692
44183605 SNP C|T 0.1836 0.1733
44156472 SNP T|C 0.1926 0.1751
44183603 SNP G|A 0.1893 0.1784
44205026 SNP A|G 0.185 0.1793
44209388 Deletion CT|C 0.185 0.184
44183642 SNP G|A 0.2233 0.1901
44205851 SNP T|C 0.2125 0.1904
44145282 SNP A|G 0.2111 0.1913
44202983 Insertion A|AACC 0.208 0.1925
44209323 SNP G|C 0.1992 0.1932
44183602 SNP T|C 0.2042 0.1938
44150940 Deletion CT|C 0.1715 0.1941
44197448 SNP G|C 0.2041 0.195
44176885 Insertion A|AC 0.2108 0.196
44164627 Deletion GT|G 0.1878 0.1963
44150012 SNP T|A 0.2027 0.1981
44204339 Deletion GTTC|G 0.2244 0.1991
44190195 Deletion ATT|A 0.1853 0.1992
44161093 Deletion CT|C 0.2049 0.1994
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44176971 SNP G|A 0.2179 0.2011
44174971 SNP G|T 0.2305 0.2015
44145543 SNP T|A 0.1891 0.2021
44173267 Insertion T|TA 0.2267 0.2026
44183594 SNP G|A 0.2249 0.2034
44153729 SNP G|A 0.168 0.2059
44183577 SNP C|T 0.2249 0.2061
44142771 SNP A|G 0.204 0.2075
44197480 SNP G|T 0.2286 0.2086
44175100 Insertion G|GA 0.2144 0.2091
44186627 SNP A|G 0.2253 0.2091
44198771 Deletion CAT|C 0.2093 0.2114
44183556 Deletion A|G 0.2119 0.2148
44149479 Deletion AT|A 0.2397 0.2156
44152090 Deletion CT|C 0.2205 0.2171
44149449 SNP A|G 0.2318 0.2173
44160202 SNP T|C 0.2361 0.2177
44186628 SNP G|A 0.236 0.2194
44209246 SNP G|A 0.2262 0.2209
44189107 SNP G|A 0.2409 0.223
44160413 SNP T|A 0.2501 0.2242
44202748 SNP C|T 0.2248 0.2243
44196531 SNP C|T 0.258 0.2272
44209019 SNP C|T 0.2464 0.228
44168281 SNP C|T 0.2201 0.2292
44146463 Insertion A|AAATAATAGT 0.2526 0.2301
44197446 SNP G|C 0.2347 0.2317
44184856 SNP C|T 0.2382 0.2319
44180595 SNP G|A 0.2531 0.2374
44148315 Deletion GT|G 0.2424 0.2375
44178815 SNP C|T 0.2036 0.2376
44176970 SNP T|C 0.2583 0.2401
44183541 SNP T|C 0.2396 0.2409
44202819 SNP G|A 0.2591 0.2409
44180254 SNP G|A 0.3195 0.2427
44173961 Deletion CAAAA|C 0.2457 0.2445
44179004 Deletion CTT|C 0.2323 0.2455
44192580 SNP T|C 0.2463 0.2459
44163781 SNP A|T 0.2598 0.2459
44171283 SNP C|T 0.2686 0.2473
44209457 SNP A|G 0.2713 0.2501
44159428 Deletion CA|C 0.2482 0.255
44191505 Deletion CT|C 0.2333 0.2573
44181125 SNP T|C 0.2628 0.2585
44183651 SNP C|T 0.2963 0.2586
44190834 SNP C|T 0.2426 0.2614
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44181952 Insertion T|TAGAG 0.2701 0.2622
44172025 SNP C|T 0.2748 0.264
44183538 SNP C|T 0.2714 0.2674
44186623 Deletion AAAAAG|A 0.2637 0.2713
44164484 Deletion AT|A 0.2963 0.2782
44201669 SNP G|A 0.2665 0.2788
44184068 SNP T|C 0.2622 0.2801
44207848 Deletion CA|C 0.2839 0.2805
44176995 SNP C|A 0.3007 0.2847
44148867 Deletion CT|C 0.2799 0.2905
44163319 Insertion C|CTTTTGTT 0.31 0.2914
44176989 SNP G|A 0.303 0.2918
44204384 SNP A|G 0.2845 0.2922
44180539 SNP T|A 0.3374 0.2928
44176999 SNP C|A 0.3106 0.2951
44209232 SNP T|A 0.2902 0.2973
44177005 SNP C|T 0.3138 0.2983
44176987 SNP A|G 0.3201 0.3002
44183632 SNP G|A 0.3281 0.3003
44195633 Deletion CAA|C 0.3146 0.3085
44177016 SNP C|T 0.3245 0.3091
44165552 Deletion CTTTTTTT|C 0.3191 0.3139
44183518 SNP G|T 0.2979 0.314
44200052 Insertion C|CA 0.3194 0.318
44197444 SNP G|C 0.3074 0.3181
44177019 SNP A|G 0.3503 0.3227
44146297 CA|C 0.3049 0.3245
44180282 Deletion TTGTGTGCATG|T 0.3515 0.3267
44201512 SNP C|G 0.3013 0.3278
44187506 SNP C|T 0.2999 0.3282
44184051 SNP A|C 0.3339 0.3332
44166872 Deletion GT|G 0.3489 0.3332
44204519 SNP G|A 0.3125 0.3358
44188073 SNP C|T 0.354 0.3369
44183481 SNP A|G 0.3664 0.339
44189244 SNP T|C 0.3405 0.3469
44203408 SNP T|A 0.3477 0.3474
44190626 SNP C|A 0.3205 0.3482
44185753 SNP G|A 0.3514 0.3485
44203256 SNP G|C 0.329 0.3506
44180407 Deletion CGT|C 0.354 0.3521
44186592 SNP T|C 0.3528 0.3546
44203093 SNP G|A 0.3296 0.3551
44183699 SNP T|C 0.3724 0.3555
44184046 SNP C|T 0.3573 0.3626
44186653 SNP C|A 0.3758 0.3718
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44188128 SNP C|T 0.4016 0.3724
44183505 SNP A|T 0.3583 0.3732
44189349 Insertion C|CA 0.3619 0.3749
44191567 SNP C|G 0.3598 0.3799
44197442 SNP G|C 0.3659 0.3888
44194362 SNP C|T 0.4075 0.3905
44192556 SNP G|C 0.3988 0.394
44192554 Deletion CTG|C 0.3879 0.3947
44190371 SNP C|T 0.4367 0.3971
44180330 Deleltion CTG|C 0.4113 0.3989
44183485 SNP G|A 0.4318 0.4017
44177874 Deletion GA|G 0.431 0.4048
44184031 SNP A|G 0.4008 0.406
44169854 SNP T|C 0.415 0.4075
44198021 SNP G|A 0.4262 0.4183
44183728 SNP G|A 0.4386 0.4187
44184213 Deletion AAATAATAATAAT|A 0.4271 0.4207
44183771 SNP T|A 0.4188 0.4208
44190662 SNP G|A 0.4451 0.424
44183776 SNP G|T 0.419 0.4251
44163746 SNP G|A 0.389 0.4287
44169855 SNP G|A 0.4421 0.4302
44183494 SNP C|T 0.4039 0.4349
44193731 SNP C|T 0.4444 0.4351
44192475 SNP G|A 0.4593 0.4352
44197805 SNP G|A 0.465 0.445
44199977 SNP C|T 0.492 0.4513
44196668 SNP T|C 0.4381 0.4515
44183800 SNP A|C 0.4448 0.4559
44199905 SNP T|C 0.4865 0.4643
44184007 SNP T|A 0.4752 0.4647
44198241 SNP C|T 0.5054 0.4681
44162954 SNP A|G 0.481 0.4686
44182301 Insertion T|TGGGG 0.4747 0.4704
44183838 SNP A|G 0.4501 0.4737
44172890 SNP A|C 0.4898 0.4852
44172188 SNP T|C 0.4948 0.5042
44166375 SNP C|T 0.4877 0.5062
44197545 SNP C|T 0.4773 0.508
44196994 SNP A|G 0.5094 0.5102
44170586 SNP A|T 0.492 0.5117
44180550 SNP A|C 0.4832 0.5126
44171349 SNP C|T 0.5346 0.5135
44198526 SNP G|T 0.5756 0.5174
44182142 SNP C|T 0.515 0.5212
44204469 SNP G|C 0.5315 0.5308
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44183886 SNP T|A 0.5481 0.5331
44164560 SNP T|C 0.5275 0.5399
44208102 SNP T|C 0.5449 0.542
44171582 SNP T|A 0.5321 0.5449
44198242 SNP A|G 0.5783 0.5476
44198577 SNP G|A 0.5714 0.5493
44169865 SNP C|T 0.5693 0.5666
44202776 SNP G|A 0.5762 0.5745
44179956 SNP C|T 0.6156 0.5875
44177988 SNP T|G 0.6251 0.616
44166424 SNP T|C 0.6534 0.6648
44166888 SNP G|A 0.6614 0.6652
44177867 SNP T|C 0.7674 0.7361
44197840 SNP A|G 0.751 0.7395
44169738 SNP G|C 0.7502 0.7415
44178649 SNP A|G 0.7936 0.7436
44178630 SNP G|C 0.7988 0.7438
44178137 SNP T|C 0.7731 0.7457
44176333 SNP C|A 0.7943 0.7667
44174788 SNP C|T 0.7977 0.7724
44194781 SNP C|T 0.7517 0.7744
44178437 SNP T|C 0.82 0.7861
44171142 SNP T|C 0.8109 0.7906
44179760 SNP G|A 0.8125 0.7908
44181195 SNP C|T 0.8245 0.7954
44181531 SNP C|T 0.8208 0.7988
44193244 SNP A|C 0.7791 0.7998
44193644 SNP T|C 0.7856 0.8035
44182554 SNP T|A 0.8883 0.879
44182291 SNP T|C 0.8841 0.8875
44185202 SNP A|T 0.8988 0.8899
44185926 SNP G|A 0.9227 0.8986
44185752 SNP T|C 0.8991 0.9028
44186073 SNP A|G 0.9177 0.9061
44185724 SNP G|A 0.9051 0.9087
44186072 SNP T|C 0.9058 0.9092
44185352 SNP T|A 0.9124 0.9098
44182695 SNP A|G 0.9228 0.9121
44182805 SNP T|C 0.9174 0.9151
44184962 SNP A|T 0.932 0.9173
44185710 SNP C|A 0.9102 0.919
44186501 SNP G|A 0.9196 0.9246
44183698 SNP G|C 0.9518 0.9452
44169897 SNP G|C 0.9714 0.9678
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